BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed trial readouts (industry Phase 2/3)
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:308ca677c7dc06da30b8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261119
DTEND;VALUE=DATE:20261120
SUMMARY:Hoffmann-La Roche P2 readout (est.): A Study to Evaluate the Safety
  and Biomarker Effects of RO7269162 in Participants at Risk for or at the 
 Prodromal Stage of Alzheimer's Disease (AD)
DESCRIPTION:A Study to Evaluate the Safety and Biomarker Effects of RO72691
 62 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Di
 sease (AD)\nNCT06402838 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Hoffma
 nn-La Roche\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nSource: https://clinicaltrials.gov/study/NCT06402838\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06402838
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9ffa6da518f9f4d1703e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261119
DTEND;VALUE=DATE:20261120
SUMMARY:Janssen Research & Development\, LLC P2 readout (est.): READY-AD
DESCRIPTION:A Study of JNJ-95597528 in Participants With Moderate to Severe
  Atopic Dermatitis\nNCT07230860 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor
 : Janssen Research & Development\, LLC\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nSource: https://clinicaltrials
 .gov/study/NCT07230860\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07230860
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e4f78a1429f6367d6e4a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261120
DTEND;VALUE=DATE:20261121
SUMMARY:MRK P3 readout (est.): Study of Pembrolizumab (MK-3475) in Combinat
 ion With Adjuvant Chemotherapy With or Without Radiotherapy in Participant
 s With Newly Diagnosed Endometrial Cancer After Surgery With Curative Inte
 nt (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
DESCRIPTION:Study of Pembrolizumab (MK-3475) in Combination With Adjuvant C
 hemotherapy With or Without Radiotherapy in Participants With Newly Diagno
 sed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / K
 EYNOTE-B21 / ENGOT-en11 / GOG-3053)\nNCT04634877 | PHASE3 | ACTIVE_NOT_REC
 RUITING | sponsor: Merck Sharp & Dohme LLC\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nTicker MRK (confidence 0.6
 )\nSource: https://clinicaltrials.gov/study/NCT04634877\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04634877
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b6472b9a42c9cec6b342@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261120
DTEND;VALUE=DATE:20261121
SUMMARY:INCY P2 readout (est.): A Study to Evaluate the Efficacy and Safety
  Study of Povorcitinib in Participants With Inadequately Controlled Modera
 te to Severe Asthma
DESCRIPTION:A Study to Evaluate the Efficacy and Safety Study of Povorcitin
 ib in Participants With Inadequately Controlled Moderate to Severe Asthma\
 nNCT05851443 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Incyte Corporatio
 n\nPrimary completion date (ESTIMATED)\; top-line results usually follow l
 ater.\nTicker INCY (confidence 0.9)\nSource: https://clinicaltrials.gov/st
 udy/NCT05851443\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05851443
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:354ee87d26e55664e8ac@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261120
DTEND;VALUE=DATE:20261121
SUMMARY:SKYE P2 readout (est.): CBeyond
DESCRIPTION:Study to Evaluate the Effect on Obesity of QW Nimacimab and QW 
 Nimacimab Co-administered With Semaglutide vs Placebo\nNCT06577090 | PHASE
 2 | ACTIVE_NOT_RECRUITING | sponsor: Skye Bioscience\, Inc.\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nTicker SK
 YE (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06577090\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06577090
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:897e7378611a479bf513@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261121
DTEND;VALUE=DATE:20261122
SUMMARY:Changchun GeneScience Pharmaceutical Co.\, Ltd. P3 readout (est.): 
 A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocript
 ine Mesylate Tablets
DESCRIPTION:A Phase III Clinical Study of Cabergoline Tablets Compared With
  Bromocriptine Mesylate Tablets\nNCT07124221 | PHASE3 | RECRUITING | spons
 or: Changchun GeneScience Pharmaceutical Co.\, Ltd.\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nSource: https://c
 linicaltrials.gov/study/NCT07124221\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07124221
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fdcb04e9fd9e045ac108@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:Resverlogix Corp P1/P2 readout (est.): A Two-Part Phase 2a Study of
  RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialy
 sis
DESCRIPTION:A Two-Part Phase 2a Study of RVX000222 in Patients With End-Sta
 ge Renal Disease Treated With Hemodialysis\nNCT03160430 | PHASE1/PHASE2 | 
 NOT_YET_RECRUITING | sponsor: Resverlogix Corp\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nSource: https://clinic
 altrials.gov/study/NCT03160430\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03160430
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a25c00bc723259211cab@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:Shanghai Henlius Biotech P2 readout (est.): A Phase II Study to Eva
 luate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma
  Failed or Intolerance to Second-line Therapy
DESCRIPTION:A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/M
 etastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Th
 erapy\nNCT06839066 | PHASE2 | RECRUITING | sponsor: Shanghai Henlius Biote
 ch\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nSource: https://clinicaltrials.gov/study/NCT06839066\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06839066
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7a9e911ad54f505cd2c6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:Haisco Pharmaceutical Group Co.\, Ltd. P2 readout (est.): A Clinica
 l Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Pos
 toperative Pain Treatment in Abdominal Surgery
DESCRIPTION:A Clinical Trial Evaluating the Efficacy and Safety of HSK55718
  in Patients for Postoperative Pain Treatment in Abdominal Surgery\nNCT075
 33786 | PHASE2 | RECRUITING | sponsor: Haisco Pharmaceutical Group Co.\, L
 td.\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nSource: https://clinicaltrials.gov/study/NCT07533786\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07533786
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0ad846e137752a389804@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261123
DTEND;VALUE=DATE:20261124
SUMMARY:GlaxoSmithKline P2 readout (est.): AZUR-4
DESCRIPTION:A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxali
 platin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mism
 atch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer\nNC
 T06567782 | PHASE2 | RECRUITING | sponsor: GlaxoSmithKline\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nSource: ht
 tps://clinicaltrials.gov/study/NCT06567782\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06567782
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b6749322b306430b390a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261123
DTEND;VALUE=DATE:20261124
SUMMARY:GlaxoSmithKline P3 readout (est.): A Study on the Safety of an Inve
 stigational Chickenpox Vaccine\, When Given to Healthy Children\, 12 to 15
  Months of Age
DESCRIPTION:A Study on the Safety of an Investigational Chickenpox Vaccine\
 , When Given to Healthy Children\, 12 to 15 Months of Age\nNCT06693895 | P
 HASE3 | RECRUITING | sponsor: GlaxoSmithKline\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nSource: https://clinica
 ltrials.gov/study/NCT06693895\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06693895
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:512ca5f0e01d3f875a9a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261123
DTEND;VALUE=DATE:20261124
SUMMARY:GlaxoSmithKline P3 readout (est.): A Study on the Immune Response a
 nd Safety of a Combined Vaccine Against Diphtheria\, Tetanus and Acellular
  Pertussis (dTpa) in Japanese Healthy Pregnant Women
DESCRIPTION:A Study on the Immune Response and Safety of a Combined Vaccine
  Against Diphtheria\, Tetanus and Acellular Pertussis (dTpa) in Japanese H
 ealthy Pregnant Women\nNCT07596199 | PHASE3 | ACTIVE_NOT_RECRUITING | spon
 sor: GlaxoSmithKline\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0759
 6199\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07596199
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0aab104b773d12f5204d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:EMD Serono Research & Development Institute\, Inc. P3 readout (est.
 ): Avelumab Program Rollover Study
DESCRIPTION:Avelumab Program Rollover Study\nNCT03815643 | PHASE3 | ACTIVE_
 NOT_RECRUITING | sponsor: EMD Serono Research & Development Institute\, In
 c.\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nSource: https://clinicaltrials.gov/study/NCT03815643\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03815643
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:626b3c69c12832289c04@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:AZN P1/P2 readout (est.): APOLLO
DESCRIPTION:Study of AZD0754 in Participants With Metastatic Prostate Cance
 r\nNCT06267729 | PHASE1/PHASE2 | RECRUITING | sponsor: AstraZeneca\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nTi
 cker AZN (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT062
 67729\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06267729
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d817c6b0d28fe7a7bc0b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:Karuna Therapeutics\, Inc.\, a Bristol Myers Squibb company P3 read
 out (est.): A Study to Evaluate KarXT as a Treatment for Psychosis Associa
 ted With Alzheimer's Disease (ADEPT-4)
DESCRIPTION:A Study to Evaluate KarXT as a Treatment for Psychosis Associat
 ed With Alzheimer's Disease (ADEPT-4)\nNCT06585787 | PHASE3 | RECRUITING |
  sponsor: Karuna Therapeutics\, Inc.\, a Bristol Myers Squibb company\nPri
 mary completion date (ESTIMATED)\; top-line results usually follow later.\
 nSource: https://clinicaltrials.gov/study/NCT06585787\nScheduling/referenc
 e data from public records\; dates can move. Not investment\, legal or med
 ical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06585787
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b98d6473fa2f9bdfdac3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:TECX P2 readout (est.): A Study of TX000045 in Patients With Pulmon
 ary Hypertension Secondary to Heart Failure With Preserved Ejection Fracti
 on (the APEX Study)
DESCRIPTION:A Study of TX000045 in Patients With Pulmonary Hypertension Sec
 ondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)\
 nNCT06616974 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Tectonic Therapeu
 tic\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nTicker TECX (confidence 0.9)\nSource: https://clinicaltrials.gov/
 study/NCT06616974\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06616974
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9b43ac3377893e289af2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:HTA Co.\, Ltd. P3 readout (est.): A Phase III Clinical Study to Com
 pare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting O
 xytrexine in Adult Patients With NETs
DESCRIPTION:A Phase III Clinical Study to Compare the Safety and Efficacy o
 f 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients Wi
 th NETs\nNCT07057622 | PHASE3 | RECRUITING | sponsor: HTA Co.\, Ltd.\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Source: https://clinicaltrials.gov/study/NCT07057622\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07057622
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2f82f9777ca0cd44ba8e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:CanSino Biologics Inc. P1/P2 readout (est.): Clinical Trial of the 
 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus To
 xoid)
DESCRIPTION:Clinical Trial of the 24-valent Pneumococcal Polysaccharide Con
 jugate Vaccine (CRM197/Tetanus Toxoid)\nNCT07600983 | PHASE1/PHASE2 | RECR
 UITING | sponsor: CanSino Biologics Inc.\nPrimary completion date (ESTIMAT
 ED)\; top-line results usually follow later.\nSource: https://clinicaltria
 ls.gov/study/NCT07600983\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07600983
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b45dfaa1119005039c3a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:Beijing InnoCare Pharma Tech Co.\, Ltd. P3 readout (est.): ICP-332 
 in Subjects With Moderate to Severe Atopic Dermatitis
DESCRIPTION:ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis\n
 NCT06775860 | PHASE3 | RECRUITING | sponsor: Beijing InnoCare Pharma Tech 
 Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nSource: https://clinicaltrials.gov/study/NCT06775860\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06775860
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:604e4bf714d2a397e82b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:SNY P3 readout (est.): Rilzabrutinib for the Adult Participants Wit
 h Chronic ITP Who Have Completed Phase 3 Study in Japan
DESCRIPTION:Rilzabrutinib for the Adult Participants With Chronic ITP Who H
 ave Completed Phase 3 Study in Japan\nNCT07216079 | PHASE3 | ACTIVE_NOT_RE
 CRUITING | sponsor: Sanofi\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nTicker SNY (confidence 0.9)\nSource: https
 ://clinicaltrials.gov/study/NCT07216079\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07216079
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fa83044e3736dca6ebc9@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:Tesaro\, Inc. P3 readout (est.): RUBY
DESCRIPTION:A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Ver
 sus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or 
 Primary Advanced Endometrial Cancer\nNCT03981796 | PHASE3 | ACTIVE_NOT_REC
 RUITING | sponsor: Tesaro\, Inc.\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nSource: https://clinicaltrials.gov/s
 tudy/NCT03981796\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03981796
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:67d01b664c02d1aba72f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:Shaanxi Micot Pharmaceutical Technology Co.\, Ltd. P3 readout (est.
 ): Study of MT1013 for the Treatment of Patients With Secondary Hyperparat
 hyroidism
DESCRIPTION:Study of MT1013 for the Treatment of Patients With Secondary Hy
 perparathyroidism\nNCT07122401 | PHASE3 | RECRUITING | sponsor: Shaanxi Mi
 cot Pharmaceutical Technology Co.\, Ltd.\nPrimary completion date (ESTIMAT
 ED)\; top-line results usually follow later.\nSource: https://clinicaltria
 ls.gov/study/NCT07122401\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07122401
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:30709060165fe06a330c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261128
DTEND;VALUE=DATE:20261129
SUMMARY:Haisco Pharmaceutical Group Co.\, Ltd. P3 readout (est.): A Study t
 o Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cyst
 ic Fibrosis Bronchiectasis
DESCRIPTION:A Study to Assess the Efficacy and Safety of HSK31858 in Partic
 ipants With Non-Cystic Fibrosis Bronchiectasis\nNCT06660992 | PHASE3 | REC
 RUITING | sponsor: Haisco Pharmaceutical Group Co.\, Ltd.\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nSource: htt
 ps://clinicaltrials.gov/study/NCT06660992\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06660992
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ed6097bfca233e6076aa@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261128
DTEND;VALUE=DATE:20261129
SUMMARY:TrueBinding\, Inc. P2 readout (est.): A Phase 2a Multicenter Clinic
 al Trial of TB006 in Participants With Parkinson's Disease
DESCRIPTION:A Phase 2a Multicenter Clinical Trial of TB006 in Participants 
 With Parkinson's Disease\nNCT06773962 | PHASE2 | ACTIVE_NOT_RECRUITING | s
 ponsor: TrueBinding\, Inc.\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nSource: https://clinicaltrials.gov/study/N
 CT06773962\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06773962
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d8be294892c00b45b0fb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261128
DTEND;VALUE=DATE:20261129
SUMMARY:SNY P3 readout (est.): A Phase III Control Study of the Safety and 
 Immunogenicity of vYF in Pediatric Population
DESCRIPTION:A Phase III Control Study of the Safety and Immunogenicity of v
 YF in Pediatric Population\nNCT07103148 | PHASE3 | ACTIVE_NOT_RECRUITING |
  sponsor: Sanofi\nPrimary completion date (ESTIMATED)\; top-line results u
 sually follow later.\nTicker SNY (confidence 0.9)\nSource: https://clinica
 ltrials.gov/study/NCT07103148\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07103148
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:22091366b46904a2a93c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261129
DTEND;VALUE=DATE:20261130
SUMMARY:PFE P3 readout (est.): A Study to Learn About the Study Medicine Ca
 lled Rimegepant in Women When Used for Intermittent Prevention of Menstrua
 l Migraine
DESCRIPTION:A Study to Learn About the Study Medicine Called Rimegepant in 
 Women When Used for Intermittent Prevention of Menstrual Migraine\nNCT0664
 1466 | PHASE3 | RECRUITING | sponsor: Pfizer\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker PFE (confidence 0
 .9)\nSource: https://clinicaltrials.gov/study/NCT06641466\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06641466
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:92563cdae9f8ffdf3b7c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:NTHI P1/P2 readout (est.): Safety and Efficacy Study in Recurrent o
 r Progressive Grade III or IV IDH1 Mutated Glioma
DESCRIPTION:Safety and Efficacy Study in Recurrent or Progressive Grade III
  or IV IDH1 Mutated Glioma\nNCT02704858 | PHASE1/PHASE2 | ACTIVE_NOT_RECRU
 ITING | sponsor: Neonc Technologies\, Inc.\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nTicker NTHI (confidence 0.
 9)\nSource: https://clinicaltrials.gov/study/NCT02704858\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT02704858
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6d6d5e0e4bbd90f59e59@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Hoffmann-La Roche P3 readout (est.): A Study in Participants Previo
 usly Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored At
 ezolizumab Study (IMbrella A)
DESCRIPTION:A Study in Participants Previously Enrolled in a Genentech- and
 /or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)\nNC
 T03148418 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Hoffmann-La Roche\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nSource: https://clinicaltrials.gov/study/NCT03148418\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03148418
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7c690f095304a93ae923@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:BeyondBio Inc. P1/P2 readout (est.): Evaluation of Safety and Effic
 acy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Panc
 reatic Cancer
DESCRIPTION:Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gem
 citabine Combination in Patient with Pancreatic Cancer\nNCT03579836 | PHAS
 E1/PHASE2 | RECRUITING | sponsor: BeyondBio Inc.\nPrimary completion date 
 (ESTIMATED)\; top-line results usually follow later.\nSource: https://clin
 icaltrials.gov/study/NCT03579836\nScheduling/reference data from public re
 cords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03579836
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a4a16dd86af4fafe1acb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Celgene P1/P2 readout (est.): A Study to Determine the Recommended 
 Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC
 -92480 in Combination With Standard Treatments in Participants With Relaps
 ed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myel
 oma (NDMM)
DESCRIPTION:A Study to Determine the Recommended Dose and Regimen and to Ev
 aluate the Safety and Preliminary Efficacy of CC-92480 in Combination With
  Standard Treatments in Participants With Relapsed or Refractory Multiple 
 Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)\nNCT03989414 | 
 PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Celgene\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nSource: http
 s://clinicaltrials.gov/study/NCT03989414\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03989414
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:97630b2d1ef802f7e4ad@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Genentech\, Inc. P2 readout (est.): NAUTIKA1
DESCRIPTION:A Study of Multiple Therapies in Biomarker-selected Participant
 s With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nNCT043
 02025 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Genentech\, Inc.\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nSo
 urce: https://clinicaltrials.gov/study/NCT04302025\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04302025
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e563a7a942ff0428c980@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:BeyondBio Inc. P1/P2 readout (est.): A Study to Evaluate Safety and
  Efficacy of BEY1107 in Combination with Capecitabine in Patients with Met
 astatic Colorectal Cancer
DESCRIPTION:A Study to Evaluate Safety and Efficacy of BEY1107 in Combinati
 on with Capecitabine in Patients with Metastatic Colorectal Cancer\nNCT050
 93907 | PHASE1/PHASE2 | RECRUITING | sponsor: BeyondBio Inc.\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nSource: 
 https://clinicaltrials.gov/study/NCT05093907\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05093907
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:23a9610247924b6ad4ed@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:AMGN P1/P2 readout (est.): MTAPESTRY 101
DESCRIPTION:A Study of Anvumetostat in Participants With Advanced MTAP-null
  Solid Tumors (MTAPESTRY 101)\nNCT05094336 | PHASE1/PHASE2 | ACTIVE_NOT_RE
 CRUITING | sponsor: Amgen\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nTicker AMGN (confidence 0.9)\nSource: https
 ://clinicaltrials.gov/study/NCT05094336\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05094336
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a599f7182b0a3e141f99@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:ModernaTX\, Inc. P1/P2 readout (est.): A Study of mRNA-3745 in Adul
 t and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
DESCRIPTION:A Study of mRNA-3745 in Adult and Pediatric Participants With G
 lycogen Storage Disease Type 1a (GSD1a)\nNCT05095727 | PHASE1/PHASE2 | ACT
 IVE_NOT_RECRUITING | sponsor: ModernaTX\, Inc.\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nSource: https://clinic
 altrials.gov/study/NCT05095727\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05095727
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8d58991657cb1ced8275@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:NPCE P2 readout (est.): RNS System LGS Feasibility Study
DESCRIPTION:RNS System LGS Feasibility Study\nNCT05339126 | PHASE2 | ACTIVE
 _NOT_RECRUITING | sponsor: NeuroPace\nPrimary completion date (ESTIMATED)\
 ; top-line results usually follow later.\nTicker NPCE (confidence 0.9)\nSo
 urce: https://clinicaltrials.gov/study/NCT05339126\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05339126
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ef6352b71eab813dca64@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:PHAR P3 readout (est.): Pediatric Patients Aged 4 to 11 Years With 
 APDS
DESCRIPTION:Pediatric Patients Aged 4 to 11 Years With APDS\nNCT05438407 | 
 PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Pharming Technologies B.V.\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Ticker PHAR (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT
 05438407\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05438407
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:bc63143d15bbbc7d7c62@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:AUG Therapeutics P3 readout (est.): A Study to Evaluate Efficacy an
 d Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type I
 I
DESCRIPTION:A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients
  With Leukocyte Adhesion Deficiency Type II\nNCT05462587 | PHASE3 | RECRUI
 TING | sponsor: AUG Therapeutics\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nSource: https://clinicaltrials.gov/s
 tudy/NCT05462587\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05462587
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3a7489f119d215b1fc72@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:OncoC4\, Inc. P1/P2 readout (est.): PRESERVE-006
DESCRIPTION:ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients 
 With mCRPC\nNCT05682443 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor:
  OncoC4\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nSource: https://clinicaltrials.gov/study/NCT05682443\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05682443
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:52d412c522411d819cc9@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Xentria\, Inc. P1/P2 readout (est.): Study of Multiple-Ascending-Do
 se Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Withou
 t Extrapulmonary Manifestations
DESCRIPTION:Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients 
 With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations\n
 NCT05890729 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Xentria\, I
 nc.\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nSource: https://clinicaltrials.gov/study/NCT05890729\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05890729
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:99f002449aab0501552b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:CAS Lamvac (Guangzhou) Biomedical Technology Co.\, Ltd. P2/P3 reado
 ut (est.): Plasmodium Immunotherapy for Advanced Ovarian Cancer
DESCRIPTION:Plasmodium Immunotherapy for Advanced Ovarian Cancer\nNCT059247
 76 | PHASE2/PHASE3 | NOT_YET_RECRUITING | sponsor: CAS Lamvac (Guangzhou) 
 Biomedical Technology Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nSource: https://clinicaltrials.gov/s
 tudy/NCT05924776\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05924776
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:440c0d91eef2c24bb770@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:QURE P1/P2 readout (est.): GenTLE
DESCRIPTION:AMT-260 Gene Therapy Study in Adults With Unilateral Refractory
  Mesial Temporal Lobe Epilepsy\nNCT06063850 | PHASE1/PHASE2 | RECRUITING |
  sponsor: UniQure Biopharma B.V.\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nTicker QURE (confidence 0.6)\nSource
 : https://clinicaltrials.gov/study/NCT06063850\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06063850
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2991402b6b6b6c5d07d0@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cytopeutics Sdn. Bhd. P2/P3 readout (est.): UCMSCs as Treatment for
  Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)
DESCRIPTION:UCMSCs as Treatment for Patients With Acute Ischemic Stroke (St
 roke Neuroncell-EX)\nNCT06129175 | PHASE2/PHASE3 | RECRUITING | sponsor: C
 ytopeutics Sdn. Bhd.\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0612
 9175\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06129175
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:10a90c3973cb4b2efb7c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:OriCell Therapeutics Co.\, Ltd. P1/P2 readout (est.): OriCAR-017 Ch
 imeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
DESCRIPTION:OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for
  the Treatment of R/RMM\nNCT06182696 | PHASE1/PHASE2 | RECRUITING | sponso
 r: OriCell Therapeutics Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; 
 top-line results usually follow later.\nSource: https://clinicaltrials.gov
 /study/NCT06182696\nScheduling/reference data from public records\; dates 
 can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06182696
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f1a1d57004bf62f6e820@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bio-Thera Solutions P1/P2 readout (est.): A Clinical Study Evaluati
 ng the Safety\, Tolerability\, Pharmacokinetic Characteristics\, and Preli
 minary Efficacy of the Combination of BAT8008 With BAT1308 in Patients Wit
 h Advanced Solid Tumors
DESCRIPTION:A Clinical Study Evaluating the Safety\, Tolerability\, Pharmac
 okinetic Characteristics\, and Preliminary Efficacy of the Combination of 
 BAT8008 With BAT1308 in Patients With Advanced Solid Tumors\nNCT06341114 |
  PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Bio-Thera Solutions\nPri
 mary completion date (ESTIMATED)\; top-line results usually follow later.\
 nSource: https://clinicaltrials.gov/study/NCT06341114\nScheduling/referenc
 e data from public records\; dates can move. Not investment\, legal or med
 ical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06341114
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f00e899e65d5d962f645@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:AURA P2 readout (est.): Suprachoroidal Administration in Subjects W
 ith Metastases to the Choroid
DESCRIPTION:Suprachoroidal Administration in Subjects With Metastases to th
 e Choroid\nNCT06643884 | PHASE2 | RECRUITING | sponsor: Aura Biosciences\n
 Primary completion date (ESTIMATED)\; top-line results usually follow late
 r.\nTicker AURA (confidence 0.9)\nSource: https://clinicaltrials.gov/study
 /NCT06643884\nScheduling/reference data from public records\; dates can mo
 ve. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06643884
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b621786531c4e20ecea8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nuwacell Biotechnologies Co.\, Ltd. P1/P2 readout (est.): A Study o
 f NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA）
DESCRIPTION:A Study of NCR100 Injection for the Treatment of Knee Osteoarth
 ritis（ KOA）\nNCT06741098 | PHASE1/PHASE2 | NOT_YET_RECRUITING | sponso
 r: Nuwacell Biotechnologies Co.\, Ltd.\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nSource: https://clinicaltrials
 .gov/study/NCT06741098\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06741098
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7b39f35c89cc6c08c2ce@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Mundipharma Research Limited P2 readout (est.): Rezafungin for Trea
 tment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Trea
 tment Options
DESCRIPTION:Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CP
 A) in Adults With Limited Treatment Options\nNCT06794554 | PHASE2 | ACTIVE
 _NOT_RECRUITING | sponsor: Mundipharma Research Limited\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nSource: https
 ://clinicaltrials.gov/study/NCT06794554\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06794554
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:93ae2e1696fefea94c3a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:TAK P2 readout (est.): A Study of TAK-360 in Adults With Idiopathic
  Hypersomnia
DESCRIPTION:A Study of TAK-360 in Adults With Idiopathic Hypersomnia\nNCT06
 812078 | PHASE2 | RECRUITING | sponsor: Takeda\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nTicker TAK (confidence
  0.9)\nSource: https://clinicaltrials.gov/study/NCT06812078\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06812078
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5de9e8d381d9e713c80a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Gritgen Therapeutics Co.\, Ltd. P3 readout (est.): To Evaluate the 
 Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
DESCRIPTION:To Evaluate the Clinical Study of GS1191-0445 Injection in the 
 Treatment of Hemophilia A\nNCT06833983 | PHASE3 | RECRUITING | sponsor: Gr
 itgen Therapeutics Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nSource: https://clinicaltrials.gov/stud
 y/NCT06833983\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06833983
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d192934d53fcab58ea22@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:IMCR P1/P2 readout (est.): Phase 1/2 Study of IMC-R117C in Selected
  Advanced Cancers
DESCRIPTION:Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers\nNCT0
 6840119 | PHASE1/PHASE2 | RECRUITING | sponsor: Immunocore Ltd\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nTicker
  IMCR (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT068401
 19\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06840119
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3b255bf0ca27963550bf@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:TAK P2 readout (est.): A Study of TAK-360 in Adults With Narcolepsy
  Without Cataplexy (NT2)
DESCRIPTION:A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy 
 (NT2)\nNCT06952699 | PHASE2 | RECRUITING | sponsor: Takeda\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nTicker TAK
  (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06952699\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06952699
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f4fbbc740a2a919ef353@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:InventisBio Co.\, Ltd P3 readout (est.): A Study to Evaluate D-0502
  in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
DESCRIPTION:A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally A
 dvanced or Metastatic Breast Cancer\nNCT06954961 | PHASE3 | RECRUITING | s
 ponsor: InventisBio Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nSource: https://clinicaltrials.gov/stud
 y/NCT06954961\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06954961
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fea132d82a235f875270@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:SKBBY P3 readout (est.): A166
DESCRIPTION:A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patient
 s With HER2-Positive Unresectable or Metastatic Breast Cancer Previously T
 reated With Trastuzumab and Taxane Therapy\nNCT06968585 | PHASE3 | ACTIVE_
 NOT_RECRUITING | sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co.\, Lt
 d.\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nTicker SKBBY (confidence 0.6)\nSource: https://clinicaltrials.gov/
 study/NCT06968585\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06968585
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2da761a8c245c2a1c55a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Akeso P2 readout (est.): A Phase II Study of AK104 Combination With
  Lenvatinib Versus Lenvatinib for Second-line HCC
DESCRIPTION:A Phase II Study of AK104 Combination With Lenvatinib Versus Le
 nvatinib for Second-line HCC\nNCT06984718 | PHASE2 | NOT_YET_RECRUITING | 
 sponsor: Akeso\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nSource: https://clinicaltrials.gov/study/NCT06984718\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06984718
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c1c142320d2f5e02f2cb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:AZN P2 readout (est.): TREMENDOUS-2
DESCRIPTION:Durvalumab and Tremelimumab With Lenvatinib as First-line Treat
 ment in Patients With Unresectable Hepatocellular Carcinoma\nNCT07081633 |
  PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: AstraZeneca\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nTicker AZN (co
 nfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07081633\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07081633
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:10048ebcc14a697c2d32@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. P2 readout (est.): IBI363 Comb
 ined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoa
 djuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lun
 g Cancer
DESCRIPTION:IBI363 Combined With Chemotherapy or Pembrolizumab Combined Wit
 h Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squam
 ous Non-Small Cell Lung Cancer\nNCT07122687 | PHASE2 | RECRUITING | sponso
 r: Innovent Biologics (Suzhou) Co. Ltd.\nPrimary completion date (ESTIMATE
 D)\; top-line results usually follow later.\nSource: https://clinicaltrial
 s.gov/study/NCT07122687\nScheduling/reference data from public records\; d
 ates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07122687
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e12cb22f994c88a854dc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bavarian Nordic P2 readout (est.): Comparability Trial of the MVA-B
 N Vaccine Manufactured in Different Production Cells
DESCRIPTION:Comparability Trial of the MVA-BN Vaccine Manufactured in Diffe
 rent Production Cells\nNCT07199569 | PHASE2 | ACTIVE_NOT_RECRUITING | spon
 sor: Bavarian Nordic\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0719
 9569\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07199569
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:30616306bde5bde1e678@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Saol Therapeutics Inc P3 readout (est.): Phase III Study to Assess 
 the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain
DESCRIPTION:Phase III Study to Assess the Safety and Efficacy of SL1002 for
  Osteoarthritis Knee Pain\nNCT07226258 | PHASE3 | ACTIVE_NOT_RECRUITING | 
 sponsor: Saol Therapeutics Inc\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nSource: https://clinicaltrials.gov/stu
 dy/NCT07226258\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07226258
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0c5264f90a7694840acc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:CSPC Megalith Biopharmaceutical Co.\,Ltd. P2 readout (est.): A Stud
 y of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadju
 vant Therapy for Patients With EGFR Mutation-positive Resectable Non-squam
 ous Non-small Cell Lung Cancer
DESCRIPTION:A Study of SYS6010 Combined With Osimertinib Versus Osimertinib
  Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Res
 ectable Non-squamous Non-small Cell Lung Cancer\nNCT07256509 | PHASE2 | NO
 T_YET_RECRUITING | sponsor: CSPC Megalith Biopharmaceutical Co.\,Ltd.\nPri
 mary completion date (ESTIMATED)\; top-line results usually follow later.\
 nSource: https://clinicaltrials.gov/study/NCT07256509\nScheduling/referenc
 e data from public records\; dates can move. Not investment\, legal or med
 ical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07256509
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1b712f11511252ac04e8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Shanghai JMT-Bio Inc. P1/P2 readout (est.): Phase I/II Clinical Stu
 dy of JMT108 Injection for the Treatment of Advanced Malignant Melanoma an
 d Urinary Tract Tumors
DESCRIPTION:Phase I/II Clinical Study of JMT108 Injection for the Treatment
  of Advanced Malignant Melanoma and Urinary Tract Tumors\nNCT07280832 | PH
 ASE1/PHASE2 | RECRUITING | sponsor: Shanghai JMT-Bio Inc.\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nSource: htt
 ps://clinicaltrials.gov/study/NCT07280832\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07280832
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9257d26e1817c392025d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Ranok Therapeutics (Hangzhou) Co.\, Ltd. P2 readout (est.): To Eval
 uate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancr
 eatic Ductal Adenocarcinoma.
DESCRIPTION:To Evaluate the Safety and Efficacy of RNK08954 in Patients Wit
 h Metastatic Pancreatic Ductal Adenocarcinoma.\nNCT07303465 | PHASE2 | REC
 RUITING | sponsor: Ranok Therapeutics (Hangzhou) Co.\, Ltd.\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nSource: h
 ttps://clinicaltrials.gov/study/NCT07303465\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07303465
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3240eeea3377a4aa1301@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Mylan Pharmaceuticals Inc P2 readout (est.): Investigating Ovulatio
 n Inhibition for Use as a Contraceptive
DESCRIPTION:Investigating Ovulation Inhibition for Use as a Contraceptive\n
 NCT07365904 | PHASE2 | RECRUITING | sponsor: Mylan Pharmaceuticals Inc\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nSource: https://clinicaltrials.gov/study/NCT07365904\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07365904
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dd45aca67ad3f495e81a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Taisho Pharmaceutical Co.\, Ltd. P3 readout (est.): A Clinical Stud
 y of TS-172 in Hyperphosphatemia Patients on Hemodialysis
DESCRIPTION:A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hem
 odialysis\nNCT07548840 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Taisho 
 Pharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nSource: https://clinicaltrials.gov/study/NC
 T07548840\nScheduling/reference data from public records\; dates can move.
  Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07548840
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a639ae2030bd7f674c40@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:BIOA P2 readout (est.): QUELL-CV
DESCRIPTION:A Phase 2 Study to Evaluate the Pharmacodynamics\, Safety and T
 olerability of BGE-102 in Participants With Obesity and Cardiovascular Ris
 k Factors\nNCT07656727 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: BioAge 
 Labs\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nTicker BIOA (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT07656727\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07656727
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b1951de16231f52c6b3e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Zhejiang Wenda Pharma Technology LTD. P3 readout (est.): A Multicen
 ter\, Randomized\, Double-Blind\, Placebo-Controlled Phase Ⅲ Study to Ev
 aluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Mode
 rate to Severe Plaque Psoriasis
DESCRIPTION:A Multicenter\, Randomized\, Double-Blind\, Placebo-Controlled 
 Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for 
 the Treatment of Moderate to Severe Plaque Psoriasis\nNCT07672561 | PHASE3
  | RECRUITING | sponsor: Zhejiang Wenda Pharma Technology LTD.\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nSource
 : https://clinicaltrials.gov/study/NCT07672561\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07672561
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:827c9f5c5aa39aa175fa@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Italfarmaco P2 readout (est.): Long-term Study Evaluating the Effec
 t of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
DESCRIPTION:Long-term Study Evaluating the Effect of Givinostat in Patients
  With Chronic Myeloproliferative Neoplasms\nNCT01761968 | PHASE2 | ACTIVE_
 NOT_RECRUITING | sponsor: Italfarmaco\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nSource: https://clinicaltrials.gov/study/NCT01761968\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT01761968
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dea92532b0a8560075ad@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:KPTIQ P2 readout (est.): Selinexor (KPT-330) in Patients With Relap
 sed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
DESCRIPTION:Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffus
 e Large B-Cell Lymphoma (DLBCL)\nNCT02227251 | PHASE2 | ACTIVE_NOT_RECRUIT
 ING | sponsor: Karyopharm Therapeutics Inc\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nDate precision: month (sho
 wn on the first day)\nTicker KPTIQ (confidence 0.9)\nSource: https://clini
 caltrials.gov/study/NCT02227251\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT02227251
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e60db178778553f05ca5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SynerGene Therapeutics\, Inc. P2 readout (est.): Study of Combined 
 SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
DESCRIPTION:Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Me
 tastatic Pancreatic Cancer\nNCT02340117 | PHASE2 | ACTIVE_NOT_RECRUITING |
  sponsor: SynerGene Therapeutics\, Inc.\nPrimary completion date (ESTIMATE
 D)\; top-line results usually follow later.\nDate precision: month (shown 
 on the first day)\nSource: https://clinicaltrials.gov/study/NCT02340117\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT02340117
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:79fe13acb117a5bfac06@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SUPN P3 readout (est.): Open-label Study to Evaluate Long-term Safe
 ty and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
DESCRIPTION:Open-label Study to Evaluate Long-term Safety and Efficacy of S
 PN-812 (Viloxazine Extended-release Capsule)\nNCT02736656 | PHASE3 | ACTIV
 E_NOT_RECRUITING | sponsor: Supernus Pharmaceuticals\, Inc.\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nDate prec
 ision: month (shown on the first day)\nTicker SUPN (confidence 0.9)\nSourc
 e: https://clinicaltrials.gov/study/NCT02736656\nScheduling/reference data
  from public records\; dates can move. Not investment\, legal or medical a
 dvice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT02736656
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4c13d50d78787ec511e7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Cancer Vaccines Limited P1/P2 readout (est.): Investigation of a Th
 erapeutic Vaccine (ACIT-1) in Cancer
DESCRIPTION:Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer\nNCT0
 3096093 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Cancer Vaccines
  Limited\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nDate precision: month (shown on the first day)\nSource: http
 s://clinicaltrials.gov/study/NCT03096093\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03096093
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:84a3a364380273dc5fa5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:CivaTech Oncology P2 readout (est.): Feasibility Study to Treat Lun
 g Cancer With the Permanently Implantable LDR CivaSheet®
DESCRIPTION:Feasibility Study to Treat Lung Cancer With the Permanently Imp
 lantable LDR CivaSheet®\nNCT03290534 | PHASE2 | RECRUITING | sponsor: Civ
 aTech Oncology\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nDate precision: month (shown on the first day)\nSource
 : https://clinicaltrials.gov/study/NCT03290534\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03290534
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:88b7b9fce7aec5af3f95@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:CORT P2 readout (est.): Extension Study to Evaluate the Safety of L
 ong-Term Use of Relacorilant in Patients With Cushing Syndrome
DESCRIPTION:Extension Study to Evaluate the Safety of Long-Term Use of Rela
 corilant in Patients With Cushing Syndrome\nNCT03604198 | PHASE2 | ACTIVE_
 NOT_RECRUITING | sponsor: Corcept Therapeutics\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nDate precision: month 
 (shown on the first day)\nTicker CORT (confidence 0.9)\nSource: https://cl
 inicaltrials.gov/study/NCT03604198\nScheduling/reference data from public 
 records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03604198
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:24fb3e516013702bdb1f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:UTHR P3 readout (est.): A Study Evaluating the Long-Term Efficacy a
 nd Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
DESCRIPTION:A Study Evaluating the Long-Term Efficacy and Safety of Ralinep
 ag in Subjects With PAH Via an Open-Label Extension\nNCT03683186 | PHASE3 
 | ENROLLING_BY_INVITATION | sponsor: United Therapeutics\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nDate precisi
 on: month (shown on the first day)\nTicker UTHR (confidence 0.9)\nSource: 
 https://clinicaltrials.gov/study/NCT03683186\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03683186
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:028cae3b8c4be139d539@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Tasly Pharmaceuticals\, Inc. P3 readout (est.): Outcome Research to
  Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
DESCRIPTION:Outcome Research to Confirm the Anti-anginal Effect of T89 in P
 atients With Stable Angina\nNCT03789552 | PHASE3 | RECRUITING | sponsor: T
 asly Pharmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-lin
 e results usually follow later.\nDate precision: month (shown on the first
  day)\nSource: https://clinicaltrials.gov/study/NCT03789552\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03789552
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dc47249cc004481b80b7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:TLTFF P2 readout (est.): Intravesical Photodynamic Therapy ("PDT") 
 in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC"
 ) Patients
DESCRIPTION:Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/I
 ntolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients\nNCT039451
 62 | PHASE2 | RECRUITING | sponsor: Theralase® Technologies Inc.\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nDat
 e precision: month (shown on the first day)\nTicker TLTFF (confidence 0.6)
 \nSource: https://clinicaltrials.gov/study/NCT03945162\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03945162
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fc968862a138ccba30ca@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Iperboreal Pharma Srl P1/P2 readout (est.): PURE
DESCRIPTION:Peritoneal Ultrafiltration in Cardio Renal Syndrome.\nNCT039948
 74 | PHASE1/PHASE2 | RECRUITING | sponsor: Iperboreal Pharma Srl\nPrimary 
 completion date (ESTIMATED)\; top-line results usually follow later.\nDate
  precision: month (shown on the first day)\nSource: https://clinicaltrials
 .gov/study/NCT03994874\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03994874
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:88fb613407aa0023e1aa@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:BRTX P2 readout (est.): A Single Dose of BRTX 100 for Patients With
  Chronic Lumbar Disc Disease (cLDD)
DESCRIPTION:A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc
  Disease (cLDD)\nNCT04042844 | PHASE2 | RECRUITING | sponsor: BioRestorati
 ve Therapies\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nDate precision: month (shown on the first day)\nTicker B
 RTX (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT04042844
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04042844
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4f2d54bd2746f21c57da@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Phoenix Molecular Designs P1/P2 readout (est.): Dauntless-1
DESCRIPTION:Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic 
 Breast Cancer\nNCT04115306 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | spons
 or: Phoenix Molecular Designs\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nSource: https://clinicaltrials.gov/study/NCT04115306\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04115306
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c83e10026f75846b670a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. P3 readout (est.)
 : A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hy
 drochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocell
 ular Carcinoma (HCC)
DESCRIPTION:A Phase III Clinical Trial of AK105 Injection Combined With Anl
 otinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced H
 epatocellular Carcinoma (HCC)\nNCT04344158 | PHASE3 | ACTIVE_NOT_RECRUITIN
 G | sponsor: Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd.\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nDate p
 recision: month (shown on the first day)\nSource: https://clinicaltrials.g
 ov/study/NCT04344158\nScheduling/reference data from public records\; date
 s can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04344158
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9d0db61b2bbd906148b5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Inmunotek S.L. P3 readout (est.): MM09-SIT-023
DESCRIPTION:Efficacy and Safety Evaluation for the Treatment of Allergy Aga
 inst Mites\nNCT04435990 | PHASE3 | RECRUITING | sponsor: Inmunotek S.L.\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nDate precision: month (shown on the first day)\nSource: https://clinica
 ltrials.gov/study/NCT04435990\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04435990
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:18a7b528d038f3bff003@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:KPTIQ P2/P3 readout (est.): A Study of Rituximab-Gemcitabine-Dexame
 thasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relaps
 ed/Refractory Diffuse Large B-cell Lymphoma
DESCRIPTION:A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP)
  With or Without Selinexor in Patients With Relapsed/Refractory Diffuse La
 rge B-cell Lymphoma\nNCT04442022 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING |
  sponsor: Karyopharm Therapeutics Inc\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nTicker KPTIQ (confidence 0.9)\nSource: https://clinicaltr
 ials.gov/study/NCT04442022\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04442022
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:aeb331cd6d637533b2d3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sapience Therapeutics P1/P2 readout (est.): A Phase 1-2 Study of ST
 101 in Patients With Advanced Solid Tumors
DESCRIPTION:A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumo
 rs\nNCT04478279 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sapienc
 e Therapeutics\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nDate precision: month (shown on the first day)\nSource
 : https://clinicaltrials.gov/study/NCT04478279\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04478279
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cf5b7762215b1dbf5c6e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:GE Healthcare P1/P2 readout (est.): Rapiscan PIP
DESCRIPTION:A Study to Evaluate the Safety and Pharmacokinetics of Regadeno
 son in Pediatric Patients\nNCT04604782 | PHASE1/PHASE2 | RECRUITING | spon
 sor: GE Healthcare\nPrimary completion date (ESTIMATED)\; top-line results
  usually follow later.\nDate precision: month (shown on the first day)\nSo
 urce: https://clinicaltrials.gov/study/NCT04604782\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04604782
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1162ccf184da7abada18@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:GILD P3 readout (est.): Asian Study of Sacituzumab Govitecan (IMMU-
 132) in HR+/HER2- Metastatic Breast Cancer (MBC)
DESCRIPTION:Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Me
 tastatic Breast Cancer (MBC)\nNCT04639986 | PHASE3 | ACTIVE_NOT_RECRUITING
  | sponsor: Gilead Sciences\nPrimary completion date (ESTIMATED)\; top-lin
 e results usually follow later.\nDate precision: month (shown on the first
  day)\nTicker GILD (confidence 0.9)\nSource: https://clinicaltrials.gov/st
 udy/NCT04639986\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04639986
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:75f8452e85f5848e823f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ABBV P2/P3 readout (est.): ATMOSPHERE
DESCRIPTION:Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Th
 erapy Administered Via Subretinal Delivery One Time in Participants With n
 AMD\nNCT04704921 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: AbbVie
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nDate precision: month (shown on the first day)\nTicker ABBV (confide
 nce 0.9)\nSource: https://clinicaltrials.gov/study/NCT04704921\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04704921
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:87fe5d9e892e147acc63@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Ambrx\, Inc. P2 readout (est.): ARX788 in HER2-positive\, Metastati
 c Breast Cancer Subjects (ACE-Breast-03)
DESCRIPTION:ARX788 in HER2-positive\, Metastatic Breast Cancer Subjects (AC
 E-Breast-03)\nNCT04829604 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Ambr
 x\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nDate precision: month (shown on the first day)\nSource: http
 s://clinicaltrials.gov/study/NCT04829604\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04829604
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:931f705b98e2b394fd3b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Allist Pharmaceuticals\, Inc. P3 readout (est.): FORWARD
DESCRIPTION:To Assess the Efficacy and Safety of Furmonertinib Versus Place
 bo\, in Patients With Epidermal Growth Factor Receptor Mutation Positive S
 tage II-IIIA Non-small Cell Lung Carcinoma\, Following Complete Tumour Res
 ection With or Without Adjuvant Chemotherapy\nNCT04853342 | PHASE3 | RECRU
 ITING | sponsor: Allist Pharmaceuticals\, Inc.\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nDate precision: month 
 (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT0485
 3342\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04853342
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a27ff00990f33e8ca227@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Kedrion S.p.A. P3 readout (est.): KIDCARES10
DESCRIPTION:Clinical Assessment of Pharmacokinetics\, Efficacy\, and Safety
  of 10% IVIg in Pediatric PID Patients (KIDCARES10)\nNCT04944979 | PHASE3 
 | ACTIVE_NOT_RECRUITING | sponsor: Kedrion S.p.A.\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nDate precision: mon
 th (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT0
 4944979\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04944979
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1ebc5c01cfa54f613d96@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:GC Cell Corporation P3 readout (est.): Safety and Efficacy of Immun
 cell-LC With Gemcitabine in Resectable Pancreatic Cancer
DESCRIPTION:Safety and Efficacy of Immuncell-LC With Gemcitabine in Resecta
 ble Pancreatic Cancer\nNCT04969731 | PHASE3 | RECRUITING | sponsor: GC Cel
 l Corporation\nPrimary completion date (ESTIMATED)\; top-line results usua
 lly follow later.\nDate precision: month (shown on the first day)\nSource:
  https://clinicaltrials.gov/study/NCT04969731\nScheduling/reference data f
 rom public records\; dates can move. Not investment\, legal or medical adv
 ice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04969731
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:02f5c155a77ef592a715@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:UBP Greater China (Shanghai) Co.\, Ltd P2 readout (est.): A Proof o
 f Concept Study to Evaluate the Effect of UB-421 in Combination With Chida
 mide on HIV Viral Reservoir
DESCRIPTION:A Proof of Concept Study to Evaluate the Effect of UB-421 in Co
 mbination With Chidamide on HIV Viral Reservoir\nNCT04985890 | PHASE2 | NO
 T_YET_RECRUITING | sponsor: UBP Greater China (Shanghai) Co.\, Ltd\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nDa
 te precision: month (shown on the first day)\nSource: https://clinicaltria
 ls.gov/study/NCT04985890\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04985890
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c481320a011ebf20ce6b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Zenith Epigenetics P2 readout (est.): ZEN003694 and Enzalutamide Ve
 rsus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate 
 Cancer
DESCRIPTION:ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in M
 etastatic Castration-Resistant Prostate Cancer\nNCT04986423 | PHASE2 | REC
 RUITING | sponsor: Zenith Epigenetics\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nSource: https://clinicaltrials.gov/study/NCT04986423\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04986423
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:afda8401cf34926a0cae@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:3D Medicines (Sichuan) Co.\, Ltd. P1/P2 readout (est.): Phase Ib/II
  Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
DESCRIPTION:Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects W
 ith Solid Tumors\nNCT05024214 | PHASE1/PHASE2 | RECRUITING | sponsor: 3D M
 edicines (Sichuan) Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nSource: https://clinicaltrials.gov/study/NCT05024214\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05024214
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:186071a940763b62b3c9@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P2 readout (est.): A Clinic
 al Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatm
 ent of Recurrent and Metastatic HNSCC
DESCRIPTION:A Clinical Study of SI-B001 in Combination With Paclitaxel/Doce
 taxel in the Treatment of Recurrent and Metastatic HNSCC\nNCT05054439 | PH
 ASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sichuan Baili Pharmaceutical Co.\,
  Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nDate precision: month (shown on the first day)\nSource: https:/
 /clinicaltrials.gov/study/NCT05054439\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05054439
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d5b11ba778c65057963d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:DMAC P2/P3 readout (est.): ReMEDy2
DESCRIPTION:Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)\nNCT05065216
  | PHASE2/PHASE3 | RECRUITING | sponsor: DiaMedica Therapeutics Inc\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nD
 ate precision: month (shown on the first day)\nTicker DMAC (confidence 0.9
 )\nSource: https://clinicaltrials.gov/study/NCT05065216\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05065216
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c002ae4d69ccc2ec0195@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:3D Medicines (Sichuan) Co.\, Ltd. P2 readout (est.): Study of Envaf
 olimab Alone or With Lenvatinib in Patients With Advanced Endometrial Canc
 er
DESCRIPTION:Study of Envafolimab Alone or With Lenvatinib in Patients With 
 Advanced Endometrial Cancer\nNCT05112991 | PHASE2 | RECRUITING | sponsor: 
 3D Medicines (Sichuan) Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nDate precision: month (shown on the
  first day)\nSource: https://clinicaltrials.gov/study/NCT05112991\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05112991
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:738e352d10bddeacdb05@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SBFM P2 readout (est.): A Study to Explore the Therapeutic Effect o
 f HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in 
 Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
DESCRIPTION:A Study to Explore the Therapeutic Effect of HEC585 on Delaying
  Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosin
 g Interstitial Lung Disease (PF-ILD) Patients\nNCT05139719 | PHASE2 | RECR
 UITING | sponsor: Sunshine Lake Pharma Co.\, Ltd.\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nDate precision: mon
 th (shown on the first day)\nTicker SBFM (confidence 0.6)\nSource: https:/
 /clinicaltrials.gov/study/NCT05139719\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05139719
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3a3532053e64237b2503@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:AAPG P2 readout (est.): Study of APG-2575 in Patients With Relapsed
 /Refractory CLL/SLL
DESCRIPTION:Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL\
 nNCT05147467 | PHASE2 | RECRUITING | sponsor: Ascentage Pharma Group Inc.\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nDate precision: month (shown on the first day)\nTicker AAPG (confiden
 ce 0.9)\nSource: https://clinicaltrials.gov/study/NCT05147467\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05147467
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:42d731caa42aca8c6d61@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Nanjing Leads Biolabs Co.\,Ltd P1/P2 readout (est.): A Phase I/II C
 linical Study of LBL-024 in Patients With Advanced Malignant Tumors
DESCRIPTION:A Phase I/II Clinical Study of LBL-024 in Patients With Advance
 d Malignant Tumors\nNCT05170958 | PHASE1/PHASE2 | RECRUITING | sponsor: Na
 njing Leads Biolabs Co.\,Ltd\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nDate precision: month (shown on the firs
 t day)\nSource: https://clinicaltrials.gov/study/NCT05170958\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05170958
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f868f86bd7400b62e724@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Lion TCR Pte. Ltd. P2 readout (est.): Study of HBV-TCR T Cells (Lio
 Cyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HC
 C
DESCRIPTION:Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combin
 ation With Lenvatinib for HBV-related HCC\nNCT05195294 | PHASE2 | NOT_YET_
 RECRUITING | sponsor: Lion TCR Pte. Ltd.\nPrimary completion date (ESTIMAT
 ED)\; top-line results usually follow later.\nDate precision: month (shown
  on the first day)\nSource: https://clinicaltrials.gov/study/NCT05195294\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05195294
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8d37c28776f39aa67dca@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Rottapharm Biotech P1/P2 readout (est.): Vorbipiprant (CR6086) / Ba
 lstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC\, a
 nd Other Metastatic GI Cancers
DESCRIPTION:Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in S
 tage IV Refractory pMMR - MSS CRC\, and Other Metastatic GI Cancers\nNCT05
 205330 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Rottapharm Biote
 ch\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nDate precision: month (shown on the first day)\nSource: https://cl
 inicaltrials.gov/study/NCT05205330\nScheduling/reference data from public 
 records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05205330
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dcf46a5998ccd7024f7d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:DNLI P1/P2 readout (est.): A Study to Evaluate the Safety\, Tolerab
 ility\, Pharmacokinetics\, and Pharmacodynamics of DNL593 in Healthy Parti
 cipants and Participants With Frontotemporal Dementia (FTD-GRN)
DESCRIPTION:A Study to Evaluate the Safety\, Tolerability\, Pharmacokinetic
 s\, and Pharmacodynamics of DNL593 in Healthy Participants and Participant
 s With Frontotemporal Dementia (FTD-GRN)\nNCT05262023 | PHASE1/PHASE2 | AC
 TIVE_NOT_RECRUITING | sponsor: Denali Therapeutics Inc.\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nDate precisio
 n: month (shown on the first day)\nTicker DNLI (confidence 0.9)\nSource: h
 ttps://clinicaltrials.gov/study/NCT05262023\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05262023
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:da13f66022d604ed53b9@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:3D Medicines P2 readout (est.): 3D1002 in Combination With Oxycodon
 e Hydrochloride Sustained-release Tablets in Patients With Moderate to Sev
 ere Cancer Pain
DESCRIPTION:3D1002 in Combination With Oxycodone Hydrochloride Sustained-re
 lease Tablets in Patients With Moderate to Severe Cancer Pain\nNCT05265052
  | PHASE2 | NOT_YET_RECRUITING | sponsor: 3D Medicines\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nDate precision
 : month (shown on the first day)\nSource: https://clinicaltrials.gov/study
 /NCT05265052\nScheduling/reference data from public records\; dates can mo
 ve. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05265052
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b4769f6cb19d0227657f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:GNLX P3 readout (est.): Efficacy & Safety of Olvi-Vec and Platinum-
 doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and B
 evacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrim
 e\, GOG-3076)
DESCRIPTION:Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizuma
 b Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platin
 um-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime\, GOG-3076)\nNCT05
 281471 | PHASE3 | RECRUITING | sponsor: Genelux Corporation\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nDate prec
 ision: month (shown on the first day)\nTicker GNLX (confidence 0.9)\nSourc
 e: https://clinicaltrials.gov/study/NCT05281471\nScheduling/reference data
  from public records\; dates can move. Not investment\, legal or medical a
 dvice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05281471
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b3fbea6a54dd79d67a7e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Keymed Biosciences Co.Ltd P1/P2 readout (est.): A Study of CM336 in
  Patients With Relapsed or Refractory Multiple Myeloma
DESCRIPTION:A Study of CM336 in Patients With Relapsed or Refractory Multip
 le Myeloma\nNCT05299424 | PHASE1/PHASE2 | RECRUITING | sponsor: Keymed Bio
 sciences Co.Ltd\nPrimary completion date (ESTIMATED)\; top-line results us
 ually follow later.\nDate precision: month (shown on the first day)\nSourc
 e: https://clinicaltrials.gov/study/NCT05299424\nScheduling/reference data
  from public records\; dates can move. Not investment\, legal or medical a
 dvice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05299424
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:57387ca11e3dc1ed170a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Aveta Biomics\, Inc. P2 readout (est.): Safety and Efficacy of APG-
 157 in Head and Neck Cancer
DESCRIPTION:Safety and Efficacy of APG-157 in Head and Neck Cancer\nNCT0531
 2710 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Aveta Biomics\, Inc.\nPri
 mary completion date (ESTIMATED)\; top-line results usually follow later.\
 nDate precision: month (shown on the first day)\nSource: https://clinicalt
 rials.gov/study/NCT05312710\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05312710
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0e317de43fbbf5da8402@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:TolerogenixX GmbH P2 readout (est.): Clinical Trial With Donor Modi
 fied Immune Cells in Living Donor Kidney Transplantation
DESCRIPTION:Clinical Trial With Donor Modified Immune Cells in Living Donor
  Kidney Transplantation\nNCT05365672 | PHASE2 | RECRUITING | sponsor: Tole
 rogenixX GmbH\nPrimary completion date (ESTIMATED)\; top-line results usua
 lly follow later.\nDate precision: month (shown on the first day)\nSource:
  https://clinicaltrials.gov/study/NCT05365672\nScheduling/reference data f
 rom public records\; dates can move. Not investment\, legal or medical adv
 ice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05365672
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f1cbe99b4ef73882b619@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Stemline Therapeutics\, Inc. P1/P2 readout (est.): ELECTRA
DESCRIPTION:Study of Abemaciclib and Elacestrant in Participants With Brain
  Metastasis Due to ER+/HER-2- Breast Cancer\nNCT05386108 | PHASE1/PHASE2 |
  RECRUITING | sponsor: Stemline Therapeutics\, Inc.\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nDate precision: m
 onth (shown on the first day)\nSource: https://clinicaltrials.gov/study/NC
 T05386108\nScheduling/reference data from public records\; dates can move.
  Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05386108
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:02ddcd4e2ae006d5b15e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:IONS P3 readout (est.): A Study to Assess the Long-Term Safety and 
 Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angio
 edema (HAE)
DESCRIPTION:A Study to Assess the Long-Term Safety and Efficacy of Donidalo
 rsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)\nNCT0539
 2114 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Ionis Pharmaceuticals\, I
 nc.\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nDate precision: month (shown on the first day)\nTicker IONS (conf
 idence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05392114\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05392114
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4fb7236a737436259243@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Kite\, A Gilead Company P2 readout (est.): iMMagine-1
DESCRIPTION:Study of Anitocabtagene-autoleucel in Relapsed or Refractory Mu
 ltiple Myeloma (iMMagine-1)\nNCT05396885 | PHASE2 | ACTIVE_NOT_RECRUITING 
 | sponsor: Kite\, A Gilead Company\nPrimary completion date (ESTIMATED)\; 
 top-line results usually follow later.\nDate precision: month (shown on th
 e first day)\nSource: https://clinicaltrials.gov/study/NCT05396885\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05396885
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ca8189f179f9dc741dc1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Suven Life Sciences Limited P3 readout (est.): Masupirdine for the 
 Treatment of Agitation in Dementia of the Alzheimer's Type
DESCRIPTION:Masupirdine for the Treatment of Agitation in Dementia of the A
 lzheimer's Type\nNCT05397639 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: S
 uven Life Sciences Limited\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nDate precision: month (shown on the first 
 day)\nSource: https://clinicaltrials.gov/study/NCT05397639\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05397639
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1f57de98a95189c9c229@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SynDevRx\, Inc. P1/P2 readout (est.): Amelia-1
DESCRIPTION:Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patie
 nts With a PI3K Alteration and HR+/Her2- Breast Cancer\nNCT05455619 | PHAS
 E1/PHASE2 | RECRUITING | sponsor: SynDevRx\, Inc.\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nDate precision: mon
 th (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT0
 5455619\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05455619
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:86eb7339f91b1610d98e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:LTRN P2 readout (est.): HARMONIC
DESCRIPTION:A Study of LP-300 With Carboplatin and Pemetrexed in Never Smok
 ers With Advanced Lung Adenocarcinoma\nNCT05456256 | PHASE2 | RECRUITING |
  sponsor: Lantern Pharma Inc.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nTicker LTRN (confidence 0.9)\nSource: https://clinicaltrials.gov/
 study/NCT05456256\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05456256
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c170a02a219fedd3d4af@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Step Pharma\, SAS P1/P2 readout (est.): A Phase 1/2 Study of STP938
  (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Ce
 ll Lymphomas
DESCRIPTION:A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects Wi
 th Relapsed/Refractory B-Cell and T-Cell Lymphomas\nNCT05463263 | PHASE1/P
 HASE2 | RECRUITING | sponsor: Step Pharma\, SAS\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nDate precision: month
  (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT054
 63263\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05463263
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7c110d0f6e2fd4624090@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:AP Biosciences Inc. P1/P2 readout (est.): APT-CUBE
DESCRIPTION:A Study to Investigate the Safety\, Pharmacokinetics\, and Clin
 ical Activity of AP203 in Patients with Locally Advanced or Metastatic Sol
 id Tumors\, and Expansion to Selected Malignancies\nNCT05473156 | PHASE1/P
 HASE2 | RECRUITING | sponsor: AP Biosciences Inc.\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nDate precision: mon
 th (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT0
 5473156\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05473156
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8ad748499382f4236950@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dren Bio P1/P2 readout (est.): A Study of DR-01 in Subjects With La
 rge Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
DESCRIPTION:A Study of DR-01 in Subjects With Large Granular Lymphocytic Le
 ukemia or Cytotoxic Lymphomas\nNCT05475925 | PHASE1/PHASE2 | RECRUITING | 
 sponsor: Dren Bio\nPrimary completion date (ESTIMATED)\; top-line results 
 usually follow later.\nDate precision: month (shown on the first day)\nSou
 rce: https://clinicaltrials.gov/study/NCT05475925\nScheduling/reference da
 ta from public records\; dates can move. Not investment\, legal or medical
  advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05475925
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0eaea344fed856e9d3e5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:RayzeBio\, Inc. P3 readout (est.): ACTION-1
DESCRIPTION:Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Wel
 l-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy\n
 NCT05477576 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: RayzeBio\, Inc.\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nDate precision: month (shown on the first day)\nSource: https://clinica
 ltrials.gov/study/NCT05477576\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05477576
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a0847cc4b6e03e1956fe@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. P1/P2 readout (est.): A Trial o
 f Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjec
 ts With Advanced Non-small Cell Lung Cancer
DESCRIPTION:A Trial of Injectable SHR-A1811 in Combination With Pyrotinib o
 r SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer\nNCT054825
 68 | PHASE1/PHASE2 | RECRUITING | sponsor: Jiangsu HengRui Medicine Co.\, 
 Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually follo
 w later.\nDate precision: month (shown on the first day)\nSource: https://
 clinicaltrials.gov/study/NCT05482568\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05482568
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6cbd8d480fe792c38dce@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:MDGL P3 readout (est.): A Phase 3 Study to Evaluate the Effect of R
 esmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirr
 hosis (MAESTRO-NASH-OUTCOMES)
DESCRIPTION:A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinica
 l Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-
 OUTCOMES)\nNCT05500222 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Madriga
 l Pharmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nDate precision: month (shown on the first da
 y)\nTicker MDGL (confidence 0.95)\nSource: https://clinicaltrials.gov/stud
 y/NCT05500222\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05500222
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4167f98f6da76abe516a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:GLUE P1/P2 readout (est.): Study of Oral MRT-2359 in Selected Cance
 r Patients
DESCRIPTION:Study of Oral MRT-2359 in Selected Cancer Patients\nNCT05546268
  | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Monte Rosa Therapeutic
 s\, Inc\nPrimary completion date (ESTIMATED)\; top-line results usually fo
 llow later.\nDate precision: month (shown on the first day)\nTicker GLUE (
 confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05546268\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05546268
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:33981d18f4cd9eb92b47@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sinew Pharma Inc. P2 readout (est.): To Evaluate the Efficacy and S
 afety of TYNADOTE® in the Treatment of Acetaminophen Overdose
DESCRIPTION:To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatm
 ent of Acetaminophen Overdose\nNCT05557448 | PHASE2 | RECRUITING | sponsor
 : Sinew Pharma Inc.\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nS
 ource: https://clinicaltrials.gov/study/NCT05557448\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05557448
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f5f001440c4843f09f6c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:EPRX P1/P2 readout (est.): RESOLVE
DESCRIPTION:A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esopha
 gitis (EoE).\nNCT05608681 | PHASE1/PHASE2 | RECRUITING | sponsor: Eupraxia
  Pharmaceuticals Inc.\nPrimary completion date (ESTIMATED)\; top-line resu
 lts usually follow later.\nDate precision: month (shown on the first day)\
 nTicker EPRX (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NC
 T05608681\nScheduling/reference data from public records\; dates can move.
  Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05608681
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6b1c19d5ac3c0f6d5940@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P1/P2 readout (est.): A Stu
 dy of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgki
 n's Lymphoma
DESCRIPTION:A Study of GNC-038 Injection in Patients With Relapsed or Refra
 ctory Non-Hodgkin's Lymphoma\nNCT05623982 | PHASE1/PHASE2 | RECRUITING | s
 ponsor: Sichuan Baili Pharmaceutical Co.\, Ltd.\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nDate precision: month
  (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT056
 23982\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05623982
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1914862da5f824c5ef07@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:OriCell Therapeutics Co.\, Ltd. P1/P2 readout (est.): Ori-C101Chime
 ric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
DESCRIPTION:Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for th
 e Treatment of HCC\nNCT05652920 | PHASE1/PHASE2 | RECRUITING | sponsor: Or
 iCell Therapeutics Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nSource: https://clinicaltrials.gov/study/NCT05652920\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05652920
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0307786466852481726f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Mabscale\, LLC P3 readout (est.): A Safety and Efficacy Study of Be
 vacizumab\, Paclitaxel\, Carboplatin Compared to Avastin® in Non-Small Ce
 ll Lung Cancer
DESCRIPTION:A Safety and Efficacy Study of Bevacizumab\, Paclitaxel\, Carbo
 platin Compared to Avastin® in Non-Small Cell Lung Cancer\nNCT05654454 | 
 PHASE3 | RECRUITING | sponsor: Mabscale\, LLC\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nDate precision: month (
 shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT05654
 454\nScheduling/reference data from public records\; dates can move. Not i
 nvestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05654454
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:89149df8b8cbd3cc737e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:INAB P1/P2 readout (est.): A Phase 1b / 2 Drug Resistant Immunother
 apy With Activated\, Gene Modified Allogeneic or Autologous γδ T Cells (
 DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recu
 rrent or Newly Diagnosed Glioblastoma
DESCRIPTION:A Phase 1b / 2 Drug Resistant Immunotherapy With Activated\, Ge
 ne Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination 
 With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnose
 d Glioblastoma\nNCT05664243 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | spon
 sor: In8bio Inc.\nPrimary completion date (ESTIMATED)\; top-line results u
 sually follow later.\nDate precision: month (shown on the first day)\nTick
 er INAB (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0566
 4243\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05664243
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:37aad96843e402e691ac@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P1/P2 readout (est.): A Stu
 dy of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or 
 Metastatic Head and Neck Squamous Cell Carcinoma
DESCRIPTION:A Study of SI-B001+SI-B003± Chemotherapy in Patients With Loca
 lly Advanced or Metastatic Head and Neck Squamous Cell Carcinoma\nNCT05668
 858 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sichuan Baili Pharm
 aceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nDate precision: month (shown on the first day)\n
 Source: https://clinicaltrials.gov/study/NCT05668858\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05668858
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a240bb774fd6f5b76adc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Akeso P1/P2 readout (est.): Study of AK119 Combined With AK112 in P
 atients With Advanced Solid Tumors
DESCRIPTION:Study of AK119 Combined With AK112 in Patients With Advanced So
 lid Tumors\nNCT05689853 | PHASE1/PHASE2 | RECRUITING | sponsor: Akeso\nPri
 mary completion date (ESTIMATED)\; top-line results usually follow later.\
 nDate precision: month (shown on the first day)\nSource: https://clinicalt
 rials.gov/study/NCT05689853\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05689853
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:17ee3f2507a4fd132e7f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Amydis Inc. P2 readout (est.): A Study of AMDX-2011P in Participant
 s With CAA
DESCRIPTION:A Study of AMDX-2011P in Participants With CAA\nNCT05709314 | P
 HASE2 | RECRUITING | sponsor: Amydis Inc.\nPrimary completion date (ESTIMA
 TED)\; top-line results usually follow later.\nDate precision: month (show
 n on the first day)\nSource: https://clinicaltrials.gov/study/NCT05709314\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05709314
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dba8343261f8259a82b5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Taiho Oncology\, Inc. P2 readout (est.): FOENIX-CCA4
DESCRIPTION:Study of Futibatinib in Patients With Advanced Cholangiocarcino
 ma With FGFR2 Fusion or Rearrangement\nNCT05727176 | PHASE2 | RECRUITING |
  sponsor: Taiho Oncology\, Inc.\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nDate precision: month (shown on the f
 irst day)\nSource: https://clinicaltrials.gov/study/NCT05727176\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05727176
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9e8f3f50a4d9cebfa9fb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:A2 Biotherapeutics Inc. P1/P2 readout (est.): EVEREST-1
DESCRIPTION:A Study to Evaluate the Safety and Efficacy of A2B530\, a Logic
 -gated CAR T\, in Participants With Solid Tumors That Express CEA and Have
  Lost HLA-A*02 Expression\nNCT05736731 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUI
 TING | sponsor: A2 Biotherapeutics Inc.\nPrimary completion date (ESTIMATE
 D)\; top-line results usually follow later.\nDate precision: month (shown 
 on the first day)\nSource: https://clinicaltrials.gov/study/NCT05736731\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05736731
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:17e4a03ada496b7e97e2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Zucara Therapeutics Inc. P2 readout (est.): ZONE
DESCRIPTION:A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Ty
 pe 1 Diabetes\nNCT05762107 | PHASE2 | RECRUITING | sponsor: Zucara Therape
 utics Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nDate precision: month (shown on the first day)\nSource: ht
 tps://clinicaltrials.gov/study/NCT05762107\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05762107
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:52612a651f66e5500281@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Cook MyoSite P3 readout (est.): DigniFI
DESCRIPTION:Iltamiocel Compared to Placebo for Chronic Fecal Incontinence i
 n Females With Obstetric Injury\nNCT05776277 | PHASE3 | ACTIVE_NOT_RECRUIT
 ING | sponsor: Cook MyoSite\nPrimary completion date (ESTIMATED)\; top-lin
 e results usually follow later.\nDate precision: month (shown on the first
  day)\nSource: https://clinicaltrials.gov/study/NCT05776277\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05776277
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:de7b38a26acafd185961@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ReAlta Life Sciences\, Inc. P2/P3 readout (est.): STAR
DESCRIPTION:A Study to Evaluate the Safety\, Tolerability\, Pharmacokinetic
 s\, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-I
 schemic Encephalopathy Undergoing Therapeutic Hypothermia\nNCT05778188 | P
 HASE2/PHASE3 | RECRUITING | sponsor: ReAlta Life Sciences\, Inc.\nPrimary 
 completion date (ESTIMATED)\; top-line results usually follow later.\nDate
  precision: month (shown on the first day)\nSource: https://clinicaltrials
 .gov/study/NCT05778188\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05778188
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6a5862ce1c3066bf1ffa@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. P3 readout (est.)
 : Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Th
 erapy Compared With Placebo Combined With Endocrine Therapy in Patients Wi
 th Breast Cancer
DESCRIPTION:Clinical Study on Adjuvant Therapy of TQB3616 Combined With End
 ocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Pa
 tients With Breast Cancer\nNCT05780567 | PHASE3 | ACTIVE_NOT_RECRUITING | 
 sponsor: Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd.\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nDate preci
 sion: month (shown on the first day)\nSource: https://clinicaltrials.gov/s
 tudy/NCT05780567\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05780567
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:51390a24b2f841027ff3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:TiumBio Co.\, Ltd. P1/P2 readout (est.): Study of TU2218 in Combina
 tion With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
DESCRIPTION:Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) i
 n Patients With Advanced Solid Tumors\nNCT05784688 | PHASE1/PHASE2 | RECRU
 ITING | sponsor: TiumBio Co.\, Ltd.\nPrimary completion date (ESTIMATED)\;
  top-line results usually follow later.\nDate precision: month (shown on t
 he first day)\nSource: https://clinicaltrials.gov/study/NCT05784688\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05784688
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:194fb0e8203ab205877e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P2 readout (est.): A Study 
 of BL-B01D1 in Patients With Multiple Solid Tumors\, Including Locally Adv
 anced or Metastatic Urinary System Tumors
DESCRIPTION:A Study of BL-B01D1 in Patients With Multiple Solid Tumors\, In
 cluding Locally Advanced or Metastatic Urinary System Tumors\nNCT05785039 
 | PHASE2 | RECRUITING | sponsor: Sichuan Baili Pharmaceutical Co.\, Ltd.\n
 Primary completion date (ESTIMATED)\; top-line results usually follow late
 r.\nDate precision: month (shown on the first day)\nSource: https://clinic
 altrials.gov/study/NCT05785039\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05785039
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d1fc9674f50a825db93d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Tern Therapeutics\, LLC P1/P2 readout (est.): A Registrational Stud
 y of TTX-381 to Treat Vision Loss in CLN2 Disease
DESCRIPTION:A Registrational Study of TTX-381 to Treat Vision Loss in CLN2 
 Disease\nNCT05791864 | PHASE1/PHASE2 | RECRUITING | sponsor: Tern Therapeu
 tics\, LLC\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nDate precision: month (shown on the first day)\nSource: ht
 tps://clinicaltrials.gov/study/NCT05791864\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05791864
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5115245acd9f979d34f2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P1/P2 readout (est.): A Stu
 dy of BL-B01D1 in Patients With Multiple Solid Tumors\, Including Recurren
 t or Metastatic Gynecological Malignancies
DESCRIPTION:A Study of BL-B01D1 in Patients With Multiple Solid Tumors\, In
 cluding Recurrent or Metastatic Gynecological Malignancies\nNCT05803018 | 
 PHASE1/PHASE2 | RECRUITING | sponsor: Sichuan Baili Pharmaceutical Co.\, L
 td.\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nDate precision: month (shown on the first day)\nSource: https://c
 linicaltrials.gov/study/NCT05803018\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05803018
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8497a3f6879b965a005d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:GeneCradle Inc P1/P2 readout (est.): Evaluation of Safety and Effic
 acy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA)
  Type 1 Patients
DESCRIPTION:Evaluation of Safety and Efficacy of Gene Therapy Drug in the T
 reatment of Spinal Muscular Atrophy (SMA) Type 1 Patients\nNCT05824169 | P
 HASE1/PHASE2 | RECRUITING | sponsor: GeneCradle Inc\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nDate precision: m
 onth (shown on the first day)\nSource: https://clinicaltrials.gov/study/NC
 T05824169\nScheduling/reference data from public records\; dates can move.
  Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05824169
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ba335ad2f7a53a721d47@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:TARA P2 readout (est.): STARBORN-1
DESCRIPTION:Safety and Efficacy Study of Intracystic TARA-002 for the Treat
 ment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Y
 ears of Age\nNCT05871970 | PHASE2 | RECRUITING | sponsor: Protara Therapeu
 tics\nPrimary completion date (ESTIMATED)\; top-line results usually follo
 w later.\nDate precision: month (shown on the first day)\nTicker TARA (con
 fidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05871970\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05871970
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:718773a18e620e66aa70@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. P3 readout (est.): An Open-labe
 l Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects Wi
 th Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
DESCRIPTION:An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide I
 njection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocr
 ine Tumors.\nNCT05884255 | PHASE3 | RECRUITING | sponsor: Jiangsu HengRui 
 Medicine Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nS
 ource: https://clinicaltrials.gov/study/NCT05884255\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05884255
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e26bc499e3fe81bcae39@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:BEAM P1/P2 readout (est.): A Study Evaluating the Safety and Effica
 cy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia 
 (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
DESCRIPTION:A Study Evaluating the Safety and Efficacy of BEAM-201 in Relap
 sed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymph
 oblastic Lymphoma (T-LL)\nNCT05885464 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUIT
 ING | sponsor: Beam Therapeutics Inc.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nTicker BEAM (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT05885464\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05885464
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ef645ba1cdbdc916d2ae@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Guangzhou Gloria Biosciences Co.\, Ltd. P1/P2 readout (est.): Immun
 o-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Adva
 nced Patients Solid Tumors
DESCRIPTION:Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Tr
 eating With Advanced Patients Solid Tumors\nNCT05909436 | PHASE1/PHASE2 | 
 RECRUITING | sponsor: Guangzhou Gloria Biosciences Co.\, Ltd.\nPrimary com
 pletion date (ESTIMATED)\; top-line results usually follow later.\nDate pr
 ecision: month (shown on the first day)\nSource: https://clinicaltrials.go
 v/study/NCT05909436\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05909436
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f9de32c31085685d1888@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ANRO P2 readout (est.): Study of ALTO-300 in MDD
DESCRIPTION:Study of ALTO-300 in MDD\nNCT05922878 | PHASE2 | RECRUITING | s
 ponsor: Alto Neuroscience\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nDate precision: month (shown on the first d
 ay)\nTicker ANRO (confidence 0.9)\nSource: https://clinicaltrials.gov/stud
 y/NCT05922878\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05922878
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2ff44613efd96bcc3962@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P2 readout (est.): A Study 
 of BL-B01D1\, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stag
 e Small Cell Lung Cancer
DESCRIPTION:A Study of BL-B01D1\, SI-B003 and BL-B01D1+SI-B003 in Patients 
 With Extensive Stage Small Cell Lung Cancer\nNCT05924841 | PHASE2 | RECRUI
 TING | sponsor: Sichuan Baili Pharmaceutical Co.\, Ltd.\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nDate precisio
 n: month (shown on the first day)\nSource: https://clinicaltrials.gov/stud
 y/NCT05924841\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05924841
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:90a634d713bfab6d270d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:BCDA P1/P2 readout (est.): CardiALLO
DESCRIPTION:Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-
 derived Mesenchymal Stem Cells\nNCT05925608 | PHASE1/PHASE2 | ACTIVE_NOT_R
 ECRUITING | sponsor: BioCardia\, Inc.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nTicker BCDA (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT05925608\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05925608
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7de75d07992b3220a0d6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:TransThera Sciences (Nanjing)\, Inc. P3 readout (est.): FIRST-308
DESCRIPTION:Study of Tinengotinib VS. Physician's Choice a Treatment of Sub
 jects With FGFR-altered in Cholangiocarcinoma\nNCT05948475 | PHASE3 | ACTI
 VE_NOT_RECRUITING | sponsor: TransThera Sciences (Nanjing)\, Inc.\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nDat
 e precision: month (shown on the first day)\nSource: https://clinicaltrial
 s.gov/study/NCT05948475\nScheduling/reference data from public records\; d
 ates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05948475
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8d11378d2d75c87339f4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P1/P2 readout (est.): A Stu
 dy of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced 
 or Metastatic Non-small Cell Lung Cancer
DESCRIPTION:A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of L
 ocally Advanced or Metastatic Non-small Cell Lung Cancer\nNCT05949606 | PH
 ASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sichuan Baili Pharmaceutica
 l Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nDate precision: month (shown on the first day)\nSource: 
 https://clinicaltrials.gov/study/NCT05949606\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05949606
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6e01e88924183ebf12c6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P2 readout (est.): A Study 
 of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metas
 tatic Non-small Cell Lung Cancer\, Nasopharyngeal Carcinoma and Other Soli
 d Tumors
DESCRIPTION:A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locall
 y Advanced or Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Carci
 noma and Other Solid Tumors\nNCT05956587 | PHASE2 | RECRUITING | sponsor: 
 Sichuan Baili Pharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATE
 D)\; top-line results usually follow later.\nDate precision: month (shown 
 on the first day)\nSource: https://clinicaltrials.gov/study/NCT05956587\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05956587
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1aae95115a5e96f9114d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P2 readout (est.): A Study 
 of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metas
 tatic Urothelial Carcinoma and Other Solid Tumors
DESCRIPTION:A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locall
 y Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors\nNCT0
 5965856 | PHASE2 | RECRUITING | sponsor: Sichuan Baili Pharmaceutical Co.\
 , Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nDate precision: month (shown on the first day)\nSource: https:
 //clinicaltrials.gov/study/NCT05965856\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05965856
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7bfb2e26d7040510954f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. P3 readout (est.)
 : A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary
  Carcinoma.
DESCRIPTION:A Clinical Study of TQB3454 Tablets in the Treatment of Advance
 d Biliary Carcinoma.\nNCT05987358 | PHASE3 | ACTIVE_NOT_RECRUITING | spons
 or: Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd.\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nDate precision:
  month (shown on the first day)\nSource: https://clinicaltrials.gov/study/
 NCT05987358\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05987358
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3e736217d4dee9c03b77@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P2 readout (est.): A Study 
 of BL-B01D1\, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or M
 etastatic Cervical Cancer and Other Gynecological Malignancies
DESCRIPTION:A Study of BL-B01D1\, SI-B003 and BL-B01D1+SI-B003 in Patients 
 With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malig
 nancies\nNCT05990803 | PHASE2 | RECRUITING | sponsor: Sichuan Baili Pharma
 ceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nS
 ource: https://clinicaltrials.gov/study/NCT05990803\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05990803
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7a76a854a353075d549e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Aadi Bioscience\, Inc. P2 readout (est.): Trial of Nab-Sirolimus in
  Combination With Letrozole in Patients With Advanced or Recurrent Endomet
 rioid Endometrial Cancer
DESCRIPTION:Trial of Nab-Sirolimus in Combination With Letrozole in Patient
 s With Advanced or Recurrent Endometrioid Endometrial Cancer\nNCT05997017 
 | PHASE2 | RECRUITING | sponsor: Aadi Bioscience\, Inc.\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nDate precisio
 n: month (shown on the first day)\nSource: https://clinicaltrials.gov/stud
 y/NCT05997017\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05997017
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dc38aa06521d0d4ed166@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P2 readout (est.): A Study 
 of BL-B01D1\, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or M
 etastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
DESCRIPTION:A Study of BL-B01D1\, SI-B003 and BL-B01D1+SI-B003 in Patients 
 With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Oth
 er Solid Tumors\nNCT06006169 | PHASE2 | RECRUITING | sponsor: Sichuan Bail
 i Pharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-lin
 e results usually follow later.\nDate precision: month (shown on the first
  day)\nSource: https://clinicaltrials.gov/study/NCT06006169\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06006169
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f610c79fb1824d9b1454@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P2 readout (est.): A Study 
 of SI-B003\, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Pat
 ients With Locally Advanced or Metastatic Esophageal Cancer\, Gastric Canc
 er\, Colorectal Cancer and Other Gastrointestinal Tumors
DESCRIPTION:A Study of SI-B003\, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclo
 nal Antibody in Patients With Locally Advanced or Metastatic Esophageal Ca
 ncer\, Gastric Cancer\, Colorectal Cancer and Other Gastrointestinal Tumor
 s\nNCT06008054 | PHASE2 | RECRUITING | sponsor: Sichuan Baili Pharmaceutic
 al Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usua
 lly follow later.\nDate precision: month (shown on the first day)\nSource:
  https://clinicaltrials.gov/study/NCT06008054\nScheduling/reference data f
 rom public records\; dates can move. Not investment\, legal or medical adv
 ice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06008054
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d6ab4a0f42d01aa072a1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P1/P2 readout (est.): A Stu
 dy of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locall
 y Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastroin
 testinal Tumors
DESCRIPTION:A Study of BL-M07D1 in Patients With a Variety of Solid Tumors 
 Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urin
 ary and Gastrointestinal Tumors\nNCT06031584 | PHASE1/PHASE2 | RECRUITING 
 | sponsor: Sichuan Baili Pharmaceutical Co.\, Ltd.\nPrimary completion dat
 e (ESTIMATED)\; top-line results usually follow later.\nDate precision: mo
 nth (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT
 06031584\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06031584
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cf1125ed2dc062f76bec@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P2 readout (est.): A Study 
 of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advan
 ced or Recurrent Metastatic HER2 Negative Breast Cancer
DESCRIPTION:A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresec
 table Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
 \nNCT06042894 | PHASE2 | RECRUITING | sponsor: Sichuan Baili Pharmaceutica
 l Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nDate precision: month (shown on the first day)\nSource: 
 https://clinicaltrials.gov/study/NCT06042894\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06042894
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:58b269a5a0c8b1e98764@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:NS Pharma\, Inc. P2 readout (est.): Trial of Efficacy and Safety of
  NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With P
 olyangiitis
DESCRIPTION:Trial of Efficacy and Safety of NS-229 Versus Placebo in Patien
 ts With Eosinophilic Granulomatosis With Polyangiitis\nNCT06046222 | PHASE
 2 | ACTIVE_NOT_RECRUITING | sponsor: NS Pharma\, Inc.\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nDate precision:
  month (shown on the first day)\nSource: https://clinicaltrials.gov/study/
 NCT06046222\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06046222
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b77b5b23c10e39403086@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Institut de Recherches Internationales Servier (I.R.I.S.) P1/P2 rea
 dout (est.): A Study of BN104 in the Treatment of Acute Leukemia
DESCRIPTION:A Study of BN104 in the Treatment of Acute Leukemia\nNCT0605281
 3 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Institut de Recherche
 s Internationales Servier (I.R.I.S.)\nPrimary completion date (ESTIMATED)\
 ; top-line results usually follow later.\nDate precision: month (shown on 
 the first day)\nSource: https://clinicaltrials.gov/study/NCT06052813\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06052813
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7c7223fcb4e7f30b60e9@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P1/P2 readout (est.): A Stu
 dy of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other 
 Hematological Malignancies
DESCRIPTION:A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lym
 phoma and Other Hematological Malignancies\nNCT06066203 | PHASE1/PHASE2 | 
 RECRUITING | sponsor: Sichuan Baili Pharmaceutical Co.\, Ltd.\nPrimary com
 pletion date (ESTIMATED)\; top-line results usually follow later.\nDate pr
 ecision: month (shown on the first day)\nSource: https://clinicaltrials.go
 v/study/NCT06066203\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06066203
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dcb4207430cdcb31c088@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Frantz Viral Therapeutics\, LLC P2 readout (est.): ART-VIN IIB
DESCRIPTION:Phase II Study of Artesunate Ointment for the Treatment of Vulv
 ar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL\, VIN2/3)\nNCT
 06075264 | PHASE2 | RECRUITING | sponsor: Frantz Viral Therapeutics\, LLC\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nDate precision: month (shown on the first day)\nSource: https://clini
 caltrials.gov/study/NCT06075264\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06075264
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:27cb181a99cd5034036d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Panafina\, Inc. P2 readout (est.): A Study to Evaluate the Safety a
 nd Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancre
 atitis
DESCRIPTION:A Study to Evaluate the Safety and Efficacy of a Single Dose of
  RABI-767 in Participants With Acute Pancreatitis\nNCT06080789 | PHASE2 | 
 RECRUITING | sponsor: Panafina\, Inc.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nSource: https://clinicaltrials.gov/study/NCT06080789\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06080789
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7580f6e5c3c3cceb3f4b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Nexcella Inc. P1/P2 readout (est.): NEXICART-2
DESCRIPTION:Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloi
 dosis\nNCT06097832 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Nexc
 ella Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nDate precision: month (shown on the first day)\nSource: htt
 ps://clinicaltrials.gov/study/NCT06097832\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06097832
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1817f81049549aaae5ca@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ABBV P2 readout (est.): Study to Assess Adverse Events and Change i
 n Disease Activity in Previously Treated Adult Participants Receiving Intr
 avenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Co
 mbination With IV Fluorouracil\, Folinic Acid\, and Bevacizumab
DESCRIPTION:Study to Assess Adverse Events and Change in Disease Activity i
 n Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-40
 0 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fl
 uorouracil\, Folinic Acid\, and Bevacizumab\nNCT06107413 | PHASE2 | ACTIVE
 _NOT_RECRUITING | sponsor: AbbVie\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nDate precision: month (shown on the
  first day)\nTicker ABBV (confidence 0.9)\nSource: https://clinicaltrials.
 gov/study/NCT06107413\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06107413
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:72d7e56910a4c5806237@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:LXEO P1/P2 readout (est.): Gene Therapy for ACM Due to a PKP2 Patho
 genic Variant
DESCRIPTION:Gene Therapy for ACM Due to a PKP2 Pathogenic Variant\nNCT06109
 181 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Lexeo Therapeutics\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nDate precision: month (shown on the first day)\nTicker LXEO (confiden
 ce 0.9)\nSource: https://clinicaltrials.gov/study/NCT06109181\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06109181
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:97bb4a1b028afe998a49@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P1/P2 readout (est.): A Stu
 dy of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally
  Advanced or Metastatic Non-Small Cell Lung Cancer
DESCRIPTION:A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER
 2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer\nNCT061
 14511 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sichuan Baili Pha
 rmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nDate precision: month (shown on the first day)
 \nSource: https://clinicaltrials.gov/study/NCT06114511\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06114511
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fa22a78c053b2bc4ed63@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. P1/P2 readout (es
 t.): A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in
  the Treatment of Myelofibrosis (MF)
DESCRIPTION:A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsu
 les in the Treatment of Myelofibrosis (MF)\nNCT06122831 | PHASE1/PHASE2 | 
 RECRUITING | sponsor: Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd.\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nDate precision: month (shown on the first day)\nSource: https://clinica
 ltrials.gov/study/NCT06122831\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06122831
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:814df84ba8fa9cdf8c03@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:BHVN P2/P3 readout (est.): RISE 2
DESCRIPTION:A Study to Determine if BHV-7000 is Effective and Safe in Adult
 s With Refractory Focal Onset Epilepsy\nNCT06132893 | PHASE2/PHASE3 | ACTI
 VE_NOT_RECRUITING | sponsor: Biohaven Therapeutics Ltd.\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nDate precisio
 n: month (shown on the first day)\nTicker BHVN (confidence 0.9)\nSource: h
 ttps://clinicaltrials.gov/study/NCT06132893\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06132893
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:26c3cb73c3e30efcfda4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Bivision Pharmaceuticals\, Inc. P1/P2 readout (est.): Phase 1/2 Cli
 nical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advance
 d Prostate Cancer
DESCRIPTION:Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection 
 in Patients With Advanced Prostate Cancer\nNCT06139575 | PHASE1/PHASE2 | R
 ECRUITING | sponsor: Bivision Pharmaceuticals\, Inc.\nPrimary completion d
 ate (ESTIMATED)\; top-line results usually follow later.\nDate precision: 
 month (shown on the first day)\nSource: https://clinicaltrials.gov/study/N
 CT06139575\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06139575
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7b6f90aa234aedc774e8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Xenothera SAS P1/P2 readout (est.): FIPO23
DESCRIPTION:FIH XON7 in Advanced/Metastatic Solid Tumors\nNCT06154291 | PHA
 SE1/PHASE2 | RECRUITING | sponsor: Xenothera SAS\nPrimary completion date 
 (ESTIMATED)\; top-line results usually follow later.\nDate precision: mont
 h (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT06
 154291\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06154291
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fa6f69b25bb808b7e316@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. P1/P2 readout (es
 t.): A Study of TQB2930 for Injection Monotherapy or Combination Therapy i
 n Patients With Recurrent/Metastatic Breast Cancer
DESCRIPTION:A Study of TQB2930 for Injection Monotherapy or Combination The
 rapy in Patients With Recurrent/Metastatic Breast Cancer\nNCT06202261 | PH
 ASE1/PHASE2 | RECRUITING | sponsor: Chia Tai Tianqing Pharmaceutical Group
  Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nDate precision: month (shown on the first day)\nSource: h
 ttps://clinicaltrials.gov/study/NCT06202261\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06202261
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:04e1dc7b5c2a00f0c9b6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Boryung Pharmaceutical Co.\, Ltd P3 readout (est.): A Study to Eval
 uate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of BR1019A and BR10
 19B Combination Therapy\nNCT06220773 | PHASE3 | RECRUITING | sponsor: Bory
 ung Pharmaceutical Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nDate precision: month (shown on the firs
 t day)\nSource: https://clinicaltrials.gov/study/NCT06220773\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06220773
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9aac43bc5b146e3e04f2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:RemeGen Co.\, Ltd. P2/P3 readout (est.): DV Combined With Cadonilim
 ab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Ju
 nction Adenocarcinoma After Progression on First-line Therapy
DESCRIPTION:DV Combined With Cadonilimab in Subjects With HER2-expressing G
 astric Cancer and Gastroesophageal Junction Adenocarcinoma After Progressi
 on on First-line Therapy\nNCT06221748 | PHASE2/PHASE3 | RECRUITING | spons
 or: RemeGen Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nDate precision: month (shown on the first day)
 \nSource: https://clinicaltrials.gov/study/NCT06221748\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06221748
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:177c3bbc615bd263a588@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Alyssum Therapeutics P1/P2 readout (est.): Study to Investigate the
  Safety\, Tolerability\, Pharmacokinetics\, Pharmocodynamics and Prelimina
 ry Antitumor Activity of AT-1965 in Patients With Advanced\, Refractory or
  Recurrent Solid Tumors
DESCRIPTION:Study to Investigate the Safety\, Tolerability\, Pharmacokineti
 cs\, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Pat
 ients With Advanced\, Refractory or Recurrent Solid Tumors\nNCT06234098 | 
 PHASE1/PHASE2 | RECRUITING | sponsor: Alyssum Therapeutics\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nDate preci
 sion: month (shown on the first day)\nSource: https://clinicaltrials.gov/s
 tudy/NCT06234098\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06234098
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d76a58bba829a67d6326@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Huiyu Pharmaceutical Co.\, Ltd P1/P2 readout (est.): Phase 
 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring
  KRAS Mutation
DESCRIPTION:Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid
  Tumors Harboring KRAS Mutation\nNCT06243354 | PHASE1/PHASE2 | RECRUITING 
 | sponsor: Sichuan Huiyu Pharmaceutical Co.\, Ltd\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nDate precision: mon
 th (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT0
 6243354\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06243354
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:200fa4babaf10dbe4ab1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:EIKN P2 readout (est.): A Phase 2 Study of EIK1001 in Combo With Pe
 mbrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
DESCRIPTION:A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chem
 otherapy in Patients With Stage 4 NSCLC\nNCT06246110 | PHASE2 | ACTIVE_NOT
 _RECRUITING | sponsor: Eikon Therapeutics\nPrimary completion date (ESTIMA
 TED)\; top-line results usually follow later.\nDate precision: month (show
 n on the first day)\nTicker EIKN (confidence 0.9)\nSource: https://clinica
 ltrials.gov/study/NCT06246110\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06246110
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:889391b26ead8494a046@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Songqi Gao P1/P2 readout (est.): Evaluation of a Targeted Magnetic 
 Resonance Imaging Contrast Agent in Prostate Cancer Patients
DESCRIPTION:Evaluation of a Targeted Magnetic Resonance Imaging Contrast Ag
 ent in Prostate Cancer Patients\nNCT06262139 | PHASE1/PHASE2 | RECRUITING 
 | sponsor: Songqi Gao\nPrimary completion date (ESTIMATED)\; top-line resu
 lts usually follow later.\nDate precision: month (shown on the first day)\
 nSource: https://clinicaltrials.gov/study/NCT06262139\nScheduling/referenc
 e data from public records\; dates can move. Not investment\, legal or med
 ical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06262139
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5c9008448cdccfe800dd@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:PCRX P3 readout (est.): ZILRETTA in Subjects With Shoulder Osteoart
 hritis
DESCRIPTION:ZILRETTA in Subjects With Shoulder Osteoarthritis\nNCT06269705 
 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Pacira Pharmaceuticals\, Inc\n
 Primary completion date (ESTIMATED)\; top-line results usually follow late
 r.\nDate precision: month (shown on the first day)\nTicker PCRX (confidenc
 e 0.9)\nSource: https://clinicaltrials.gov/study/NCT06269705\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06269705
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:195cceccd83da22a1ae8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:GOSS P3 readout (est.): Open-label Extension Study of Seralutinib i
 n Adult Subjects With PAH (PROSERA-EXT)
DESCRIPTION:Open-label Extension Study of Seralutinib in Adult Subjects Wit
 h PAH (PROSERA-EXT)\nNCT06274801 | PHASE3 | RECRUITING | sponsor: Gossamer
  Bio USA\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results us
 ually follow later.\nDate precision: month (shown on the first day)\nTicke
 r GOSS (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT06274
 801\nScheduling/reference data from public records\; dates can move. Not i
 nvestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06274801
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c3ce27b481eaf0182fd5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Latticon Antibody Therapeutics\, Inc P1/P2 readout (est.): LIGHTSPE
 ED-1
DESCRIPTION:A First-in-Human\, Phase 1/2 Study of LAT010 in Patients With A
 dvanced Solid Tumors (LIGHTSPEED-1)\nNCT06277219 | PHASE1/PHASE2 | RECRUIT
 ING | sponsor: Latticon Antibody Therapeutics\, Inc\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nDate precision: m
 onth (shown on the first day)\nSource: https://clinicaltrials.gov/study/NC
 T06277219\nScheduling/reference data from public records\; dates can move.
  Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06277219
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4ec1ac26d3f1ec3c96f1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:OMER P2 readout (est.): Long-Term Safety\, Tolerability and Efficac
 y of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
DESCRIPTION:Long-Term Safety\, Tolerability and Efficacy of OMS906 in Parox
 ysmal Nocturnal Hemoglobinuria\nNCT06298955 | PHASE2 | ACTIVE_NOT_RECRUITI
 NG | sponsor: Omeros Corporation\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nDate precision: month (shown on the 
 first day)\nTicker OMER (confidence 0.9)\nSource: https://clinicaltrials.g
 ov/study/NCT06298955\nScheduling/reference data from public records\; date
 s can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06298955
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:35b8718ebe5c5e8a701d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Kind Pharmaceuticals LLC P2 readout (est.): A Study of Safety and E
 fficiency of AND017 in Patients With β-thalassemia
DESCRIPTION:A Study of Safety and Efficiency of AND017 in Patients With β-
 thalassemia\nNCT06302491 | PHASE2 | RECRUITING | sponsor: Kind Pharmaceuti
 cals LLC\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nDate precision: month (shown on the first day)\nSource: http
 s://clinicaltrials.gov/study/NCT06302491\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06302491
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8be618e5664399af27cc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Kind Pharmaceuticals LLC P2 readout (est.): A Study of Efficacy and
  Safety of AND017 in Patients With Myelodysplastic Syndrome
DESCRIPTION:A Study of Efficacy and Safety of AND017 in Patients With Myelo
 dysplastic Syndrome\nNCT06304103 | PHASE2 | RECRUITING | sponsor: Kind Pha
 rmaceuticals LLC\nPrimary completion date (ESTIMATED)\; top-line results u
 sually follow later.\nDate precision: month (shown on the first day)\nSour
 ce: https://clinicaltrials.gov/study/NCT06304103\nScheduling/reference dat
 a from public records\; dates can move. Not investment\, legal or medical 
 advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06304103
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:404d9a10dfb7428f907a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Zhejiang Haichang Biotech Co.\, Ltd. P2 readout (est.): Phase 2 Stu
 dy of WGI-0301 for Advanced HCC
DESCRIPTION:Phase 2 Study of WGI-0301 for Advanced HCC\nNCT06309485 | PHASE
 2 | RECRUITING | sponsor: Zhejiang Haichang Biotech Co.\, Ltd.\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nDate p
 recision: month (shown on the first day)\nSource: https://clinicaltrials.g
 ov/study/NCT06309485\nScheduling/reference data from public records\; date
 s can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06309485
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fb0af0b6b7f2be56410e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Theravectys S.A. P1/P2 readout (est.): A Study to Evaluate Lenti-HP
 V-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
DESCRIPTION:A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cer
 vical or Oropharyngeal Cancer\nNCT06319963 | PHASE1/PHASE2 | RECRUITING | 
 sponsor: Theravectys S.A.\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nDate precision: month (shown on the first d
 ay)\nSource: https://clinicaltrials.gov/study/NCT06319963\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06319963
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:09a6c01f71bae9c289fb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SOGP P2 readout (est.): SPI-1005 in Adults Receiving Cochlear Impla
 nt
DESCRIPTION:SPI-1005 in Adults Receiving Cochlear Implant\nNCT06340633 | PH
 ASE2 | RECRUITING | sponsor: Sound Pharmaceuticals\, Incorporated\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nDat
 e precision: month (shown on the first day)\nTicker SOGP (confidence 0.9)\
 nSource: https://clinicaltrials.gov/study/NCT06340633\nScheduling/referenc
 e data from public records\; dates can move. Not investment\, legal or med
 ical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06340633
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c18855a114d5a5bf9cd4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ReAlta Life Sciences\, Inc. P2 readout (est.): AURORA
DESCRIPTION:Safety\, PK\, PD\, Dosing\, and Efficacy of RLS-0071for the Tre
 atment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus
 -Host Disease\nNCT06343792 | PHASE2 | RECRUITING | sponsor: ReAlta Life Sc
 iences\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usua
 lly follow later.\nDate precision: month (shown on the first day)\nSource:
  https://clinicaltrials.gov/study/NCT06343792\nScheduling/reference data f
 rom public records\; dates can move. Not investment\, legal or medical adv
 ice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06343792
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:79bde9b0992c54783222@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Beijing Scitech-Mq Pharmaceuticals Limited P1/P2 readout (est.): A 
 Study of ST-1898 for Unresectable or Metastatic Melanoma
DESCRIPTION:A Study of ST-1898 for Unresectable or Metastatic Melanoma\nNCT
 06359860 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Beijing Scitec
 h-Mq Pharmaceuticals Limited\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nDate precision: month (shown on the firs
 t day)\nSource: https://clinicaltrials.gov/study/NCT06359860\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06359860
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:25b265ccf0583d078f25@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Octapharma P3 readout (est.): Study of IV Human Plasma-derived C1 E
 sterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficienc
 y for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedem
 a Attacks
DESCRIPTION:Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentr
 ate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-pr
 ocedure Preventing of Acute Hereditary Angioedema Attacks\nNCT06361537 | P
 HASE3 | RECRUITING | sponsor: Octapharma\nPrimary completion date (ESTIMAT
 ED)\; top-line results usually follow later.\nDate precision: month (shown
  on the first day)\nSource: https://clinicaltrials.gov/study/NCT06361537\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06361537
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9bf78626ec7181147875@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P3 readout (est.): A Study 
 Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Ad
 vanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung0
 2)
DESCRIPTION:A Study Comparing BL-B01D1 With Docetaxel in Patients With Unre
 sectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung
  Cancer(PANKU-Lung02)\nNCT06382129 | PHASE3 | ACTIVE_NOT_RECRUITING | spon
 sor: Sichuan Baili Pharmaceutical Co.\, Ltd.\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nDate precision: month (s
 hown on the first day)\nSource: https://clinicaltrials.gov/study/NCT063821
 29\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06382129
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2a6eb1f846c164087703@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:GeneCradle Inc P1/P2 readout (est.): Evaluation of the Safety and E
 fficacy of Late-onset Pompe Disease Gene Therapy Drug
DESCRIPTION:Evaluation of the Safety and Efficacy of Late-onset Pompe Disea
 se Gene Therapy Drug\nNCT06391736 | PHASE1/PHASE2 | RECRUITING | sponsor: 
 GeneCradle Inc\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nDate precision: month (shown on the first day)\nSource
 : https://clinicaltrials.gov/study/NCT06391736\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06391736
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fa28b0fd8f87221ceae2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:858 Therapeutics\, Inc. P1/P2 readout (est.): ERADIC8
DESCRIPTION:A Study of PARG Inhibitor ETX-19477 in Patients With Advanced S
 olid Malignancies\nNCT06395519 | PHASE1/PHASE2 | RECRUITING | sponsor: 858
  Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nDate precision: month (shown on the first day)\n
 Source: https://clinicaltrials.gov/study/NCT06395519\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06395519
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d08a18a3d8fa6d2f7d25@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:NoNO Inc. P2 readout (est.): NoNO-42 Trial in Acute Ischemic Stroke
  Patients Selected for Thrombolysis With or Without Endovascular Thrombect
 omy
DESCRIPTION:NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Th
 rombolysis With or Without Endovascular Thrombectomy\nNCT06403267 | PHASE2
  | RECRUITING | sponsor: NoNO Inc.\nPrimary completion date (ESTIMATED)\; 
 top-line results usually follow later.\nDate precision: month (shown on th
 e first day)\nSource: https://clinicaltrials.gov/study/NCT06403267\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06403267
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7368e78341fadfd20011@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P2 readout (est.): A Study 
 of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothel
 ial Carcinoma
DESCRIPTION:A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or
  Metastatic Urothelial Carcinoma\nNCT06405425 | PHASE2 | RECRUITING | spon
 sor: Sichuan Baili Pharmaceutical Co.\, Ltd.\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nDate precision: month (s
 hown on the first day)\nSource: https://clinicaltrials.gov/study/NCT064054
 25\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06405425
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fde43515a10285da20b6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:AXSM P3 readout (est.): ENGAGE
DESCRIPTION:Elucidating TAAR-1\, Dopamine\, and Norepinephrine in Binge Eat
 ing Disorder Using Solriamfetol\nNCT06413433 | PHASE3 | RECRUITING | spons
 or: Axsome Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nDate precision: month (shown on the fi
 rst day)\nTicker AXSM (confidence 0.9)\nSource: https://clinicaltrials.gov
 /study/NCT06413433\nScheduling/reference data from public records\; dates 
 can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06413433
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e4896daa7332121ddc2b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:NMD Pharma A/S P2 readout (est.): SYNAPSE-MG
DESCRIPTION:Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patient
 s With Myasthenia Gravis\nNCT06414954 | PHASE2 | RECRUITING | sponsor: NMD
  Pharma A/S\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nDate precision: month (shown on the first day)\nSource: h
 ttps://clinicaltrials.gov/study/NCT06414954\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06414954
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:35598c99f517a1e7e398@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Highlight Therapeutics P2 readout (est.): SPOTLIGHT204
DESCRIPTION:Clinical Trial to Evaluate BO-112 in Patients With Basal Cell C
 arcinoma (BCC)\nNCT06422936 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Hi
 ghlight Therapeutics\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nDate precision: month (shown on the first day)\n
 Source: https://clinicaltrials.gov/study/NCT06422936\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06422936
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:51136055193ddd33efa5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Georgiamune Inc P1/P2 readout (est.): Safety and Tolerability Study
  of GIM-531 in Advanced Solid Tumors
DESCRIPTION:Safety and Tolerability Study of GIM-531 in Advanced Solid Tumo
 rs\nNCT06425926 | PHASE1/PHASE2 | RECRUITING | sponsor: Georgiamune Inc\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nDate precision: month (shown on the first day)\nSource: https://clinica
 ltrials.gov/study/NCT06425926\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06425926
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b435cbd66e25e6f90f3c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P2 readout (est.): A Study 
 of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Smal
 l Cell Lung Cancer
DESCRIPTION:A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With E
 xtensive-stage Small Cell Lung Cancer\nNCT06437509 | PHASE2 | RECRUITING |
  sponsor: Sichuan Baili Pharmaceutical Co.\, Ltd.\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nDate precision: mon
 th (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT0
 6437509\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06437509
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fa958720115f9ed5c629@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:BHVN P2 readout (est.): Long-term Safety and Tolerability of BHV-70
 00
DESCRIPTION:Long-term Safety and Tolerability of BHV-7000\nNCT06443463 | PH
 ASE2 | ENROLLING_BY_INVITATION | sponsor: Biohaven Therapeutics Ltd.\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Date precision: month (shown on the first day)\nTicker BHVN (confidence 0.
 9)\nSource: https://clinicaltrials.gov/study/NCT06443463\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06443463
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1dd175f57094160f35fa@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Prove pharm P3 readout (est.): Indigotindisulfonate Sodium Injectio
 n\, USP as an Aid in the Determination of Ureteral Patency in Pediatric Pa
 tients
DESCRIPTION:Indigotindisulfonate Sodium Injection\, USP as an Aid in the De
 termination of Ureteral Patency in Pediatric Patients\nNCT06448143 | PHASE
 3 | NOT_YET_RECRUITING | sponsor: Prove pharm\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nDate precision: month (
 shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT06448
 143\nScheduling/reference data from public records\; dates can move. Not i
 nvestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06448143
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:674c25ba707051a27af6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ABVX P2 readout (est.): ENHANCE-CD
DESCRIPTION:Efficacy and Safety of Obefazimod in Subjects With Moderately t
 o Severely Active Crohn's Disease\nNCT06456593 | PHASE2 | RECRUITING | spo
 nsor: Abivax S.A.\nPrimary completion date (ESTIMATED)\; top-line results 
 usually follow later.\nDate precision: month (shown on the first day)\nTic
 ker ABVX (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT064
 56593\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06456593
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:36ec4c88770f8ba5b331@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ABBV P3 readout (est.): Intrepid
DESCRIPTION:A Study to Assess Disease Activity and Safety of Lutikizumab in
  Adult and Adolescent Participants With Moderate to Severe Hidradenitis Su
 ppurativa\nNCT06468228 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: AbbVie\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nDate precision: month (shown on the first day)\nTicker ABBV (confiden
 ce 0.9)\nSource: https://clinicaltrials.gov/study/NCT06468228\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06468228
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0e8c7bf096d588e7e457@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P2 readout (est.): A Study 
 of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally
  Advanced or Recurrent Metastatic Triple-negative Breast Cancer
DESCRIPTION:A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With U
 nresectable Locally Advanced or Recurrent Metastatic Triple-negative Breas
 t Cancer\nNCT06471205 | PHASE2 | RECRUITING | sponsor: Sichuan Baili Pharm
 aceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nDate precision: month (shown on the first day)\n
 Source: https://clinicaltrials.gov/study/NCT06471205\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06471205
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5877f6f2b778736b755a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Shanghai BDgene Co.\, Ltd. P2 readout (est.): A Phase Ⅱa Study of
  the Safety\, Tolerability and Efficacy of BD111 in Herpes Simplex Virus T
 ype I Stromal Keratitis
DESCRIPTION:A Phase Ⅱa Study of the Safety\, Tolerability and Efficacy of
  BD111 in Herpes Simplex Virus Type I Stromal Keratitis\nNCT06474442 | PHA
 SE2 | RECRUITING | sponsor: Shanghai BDgene Co.\, Ltd.\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nDate precision
 : month (shown on the first day)\nSource: https://clinicaltrials.gov/study
 /NCT06474442\nScheduling/reference data from public records\; dates can mo
 ve. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06474442
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:81fba62de99ae748ed89@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:VIS\, Inc. P3 readout (est.): Opti-K™
DESCRIPTION:Phase III Presbyopia Correction Using the VIS Opti-K™ System\
 nNCT06487897 | PHASE3 | RECRUITING | sponsor: VIS\, Inc.\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nDate precisi
 on: month (shown on the first day)\nSource: https://clinicaltrials.gov/stu
 dy/NCT06487897\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06487897
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7a8787606fb47bb7ae9a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P3 readout (est.): A Study 
 Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lu
 ng Cancer(PANKU-Lung03)
DESCRIPTION:A Study Comparing BL-B01D1 With Topotecan in Patients With Recu
 rrent Small Cell Lung Cancer(PANKU-Lung03)\nNCT06500026 | PHASE3 | ACTIVE_
 NOT_RECRUITING | sponsor: Sichuan Baili Pharmaceutical Co.\, Ltd.\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nDat
 e precision: month (shown on the first day)\nSource: https://clinicaltrial
 s.gov/study/NCT06500026\nScheduling/reference data from public records\; d
 ates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06500026
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2a3ec2531c4acd6c110e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Meribank Biotech Co.\, Ltd. P1/P2 readout (est.): Mesenchymal Stem 
 Cells for Frailty Syndrome
DESCRIPTION:Mesenchymal Stem Cells for Frailty Syndrome\nNCT06501066 | PHAS
 E1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Meribank Biotech Co.\, Ltd.\n
 Primary completion date (ESTIMATED)\; top-line results usually follow late
 r.\nDate precision: month (shown on the first day)\nSource: https://clinic
 altrials.gov/study/NCT06501066\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06501066
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1cf6eac874e416e90b3c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SCG Cell Therapy Pte. Ltd. P1/P2 readout (est.): Phase 1/2 Study of
  Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinom
 a
DESCRIPTION:Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients Wi
 th HPV16/52-positive Carcinoma\nNCT06505551 | PHASE1/PHASE2 | NOT_YET_RECR
 UITING | sponsor: SCG Cell Therapy Pte. Ltd.\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nDate precision: month (s
 hown on the first day)\nSource: https://clinicaltrials.gov/study/NCT065055
 51\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06505551
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4ba1e0b3412ca083b116@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Nanjing Chia-tai Tianqing Pharmaceutical P3 readout (est.): A Study
  of Ramelteon in Chinese Patients With Chronic Insomnia
DESCRIPTION:A Study of Ramelteon in Chinese Patients With Chronic Insomnia\
 nNCT06512363 | PHASE3 | NOT_YET_RECRUITING | sponsor: Nanjing Chia-tai Tia
 nqing Pharmaceutical\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nDate precision: month (shown on the first day)\n
 Source: https://clinicaltrials.gov/study/NCT06512363\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06512363
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4bc39f4e08e5f67203f3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Ryvu Therapeutics SA P2 readout (est.): JASPIS-01
DESCRIPTION:MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-ce
 ll Non-Hodgkin Lymphoma (JASPIS-01)\nNCT06534437 | PHASE2 | RECRUITING | s
 ponsor: Ryvu Therapeutics SA\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nDate precision: month (shown on the firs
 t day)\nSource: https://clinicaltrials.gov/study/NCT06534437\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06534437
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1585a7c7ec9f9fb7763d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:DNTH P2 readout (est.): MOMENTUM
DESCRIPTION:A Clinical Study to Evaluate DNTH103 in Adults With Multifocal 
 Motor Neuropathy\nNCT06537999 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: 
 Dianthus Therapeutics\nPrimary completion date (ESTIMATED)\; top-line resu
 lts usually follow later.\nDate precision: month (shown on the first day)\
 nTicker DNTH (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NC
 T06537999\nScheduling/reference data from public records\; dates can move.
  Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06537999
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8d0d037ac7ff3b41fc8f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. P1/P2 readout (est.): A Study o
 f HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanc
 ed Prostate Cancer
DESCRIPTION:A Study of HRS-5041 Tablets Combined With Antitumor Therapy in 
 Subjects With Advanced Prostate Cancer\nNCT06568094 | PHASE1/PHASE2 | RECR
 UITING | sponsor: Jiangsu HengRui Medicine Co.\, Ltd.\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nDate precision:
  month (shown on the first day)\nSource: https://clinicaltrials.gov/study/
 NCT06568094\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06568094
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:07e8339bbd07be8fb9a2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:AXSM P3 readout (est.): Studying Solriamfetol Modulation of TAAR-1\
 , Dopamine\, and Norepinephrine in Shift Work Disorder (SUSTAIN)
DESCRIPTION:Studying Solriamfetol Modulation of TAAR-1\, Dopamine\, and Nor
 epinephrine in Shift Work Disorder (SUSTAIN)\nNCT06568367 | PHASE3 | RECRU
 ITING | sponsor: Axsome Therapeutics\, Inc.\nPrimary completion date (ESTI
 MATED)\; top-line results usually follow later.\nDate precision: month (sh
 own on the first day)\nTicker AXSM (confidence 0.9)\nSource: https://clini
 caltrials.gov/study/NCT06568367\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06568367
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:52cce0ef1a2085043b22@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:MDWD P3 readout (est.): VALUE
DESCRIPTION:A Double Blind Study Performed to Evaluate the Efficacy and the
  Safety of EscharEx in Debridement of VLU (VALUE)\nNCT06568627 | PHASE3 | 
 RECRUITING | sponsor: MediWound Ltd\nPrimary completion date (ESTIMATED)\;
  top-line results usually follow later.\nDate precision: month (shown on t
 he first day)\nTicker MDWD (confidence 0.9)\nSource: https://clinicaltrial
 s.gov/study/NCT06568627\nScheduling/reference data from public records\; d
 ates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06568627
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0fa07856ae2650649285@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutic
 al Co.\, Ltd. P2 readout (est.): Efficacy and Safety of Recombinant Human 
 FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects Wi
 th Non-alcoholic Steatohepatitis (NASH)
DESCRIPTION:Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protei
 n for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steat
 ohepatitis (NASH)\nNCT06569524 | PHASE2 | RECRUITING | sponsor: Chia Tai T
 ianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.\, Ltd.\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nDate precision: month (shown on the first day)\nSource: https://clinical
 trials.gov/study/NCT06569524\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06569524
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:71f7d6d4ac22ff3d3b4c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Wuxi Cellular Biopharmaceutical Group Ltd. P3 readout (est.): Allog
 enic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Oste
 oarthritis
DESCRIPTION:Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatm
 ent of Knee Osteoarthritis\nNCT06570291 | PHASE3 | RECRUITING | sponsor: W
 uxi Cellular Biopharmaceutical Group Ltd.\nPrimary completion date (ESTIMA
 TED)\; top-line results usually follow later.\nDate precision: month (show
 n on the first day)\nSource: https://clinicaltrials.gov/study/NCT06570291\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06570291
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3917b1a192065705f4e1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Angitia Biopharmaceuticals P2 readout (est.): ARTEMIS
DESCRIPTION:A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women 
 wIth Low Bone MasS (ARTEMIS)\nNCT06577935 | PHASE2 | ACTIVE_NOT_RECRUITING
  | sponsor: Angitia Biopharmaceuticals\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nDate precision: month (shown o
 n the first day)\nSource: https://clinicaltrials.gov/study/NCT06577935\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06577935
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5fc9f34d87a747bb35d4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sunhawk Vision Biotech\, Inc. P2 readout (est.): A Study of SHJ002 
 Sterile Ophthalmic Solution for Myopia Control
DESCRIPTION:A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Contro
 l\nNCT06579287 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sunhawk Vision 
 Biotech\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nDate precision: month (shown on the first day)\nSource
 : https://clinicaltrials.gov/study/NCT06579287\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06579287
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5f812e1078b3496377c5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:iCoat Medical AB P2/P3 readout (est.): A Trial to Assess Efficacy a
 nd Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve
  Its Function in Recipients of DCD Kidneys
DESCRIPTION:A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admi
 n of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD 
 Kidneys\nNCT06582485 | PHASE2/PHASE3 | NOT_YET_RECRUITING | sponsor: iCoat
  Medical AB\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nDate precision: month (shown on the first day)\nSource: h
 ttps://clinicaltrials.gov/study/NCT06582485\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06582485
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8a829e9c7e031eb6d4cf@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dr. Falk Pharma GmbH P3 readout (est.): EOS-4
DESCRIPTION:Once Daily Versus Twice Daily Budesonide Orodispersible Tablets
  for Induction of Remission in EoE\nNCT06596252 | PHASE3 | ACTIVE_NOT_RECR
 UITING | sponsor: Dr. Falk Pharma GmbH\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nDate precision: month (shown o
 n the first day)\nSource: https://clinicaltrials.gov/study/NCT06596252\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06596252
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:101e15af18b633a056aa@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Shanghai Hengrui Pharmaceutical Co.\, Ltd. P1/P2 readout (est.): A 
 Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
DESCRIPTION:A Trial of SHR-7787 Injection in Patients With Advanced Solid T
 umors\nNCT06605222 | PHASE1/PHASE2 | RECRUITING | sponsor: Shanghai Hengru
 i Pharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-lin
 e results usually follow later.\nDate precision: month (shown on the first
  day)\nSource: https://clinicaltrials.gov/study/NCT06605222\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06605222
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:189f4fe0b3097c17cd7b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:DCTH P2 readout (est.): DEL-LIVER
DESCRIPTION:Evaluation of the Safety and Efficacy of Treatment w/High Dose 
 Melphalan Given Directly Into the Liver Followed by Treatment w/Approved C
 ancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastat
 ic Colorectal Cancer w/Liver Dominant Disease\nNCT06607458 | PHASE2 | RECR
 UITING | sponsor: Delcath Systems Inc.\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nDate precision: month (shown o
 n the first day)\nTicker DCTH (confidence 0.9)\nSource: https://clinicaltr
 ials.gov/study/NCT06607458\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06607458
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7dd9d38cccdb5e5cd702@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Filament Health Corp. P2 readout (est.): PEX010-Assisted Therapy fo
 r Opioid Use Disorder (OUD): a Feasibility Study
DESCRIPTION:PEX010-Assisted Therapy for Opioid Use Disorder (OUD): a Feasib
 ility Study\nNCT06608459 | PHASE2 | NOT_YET_RECRUITING | sponsor: Filament
  Health Corp.\nPrimary completion date (ESTIMATED)\; top-line results usua
 lly follow later.\nDate precision: month (shown on the first day)\nSource:
  https://clinicaltrials.gov/study/NCT06608459\nScheduling/reference data f
 rom public records\; dates can move. Not investment\, legal or medical adv
 ice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06608459
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b8805a1c51748d4d1b1b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:LaNova Medicines Limited P1/P2 readout (est.): Study of LM-299 in S
 ubjects Advanced Malignant Tumors
DESCRIPTION:Study of LM-299 in Subjects Advanced Malignant Tumors\nNCT06650
 566 | PHASE1/PHASE2 | RECRUITING | sponsor: LaNova Medicines Limited\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Date precision: month (shown on the first day)\nSource: https://clinicaltr
 ials.gov/study/NCT06650566\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06650566
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:da1cde6c67396cca56c9@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Ranok Therapeutics (Hangzhou) Co.\, Ltd. P1/P2 readout (est.): TRIA
 D1
DESCRIPTION:A Study of RNK08954 in Subjects With Advanced Solid Tumors With
  KRAS ((Kirsten Rat Sarcoma) G12D Mutation\nNCT06667544 | PHASE1/PHASE2 | 
 RECRUITING | sponsor: Ranok Therapeutics (Hangzhou) Co.\, Ltd.\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nDate p
 recision: month (shown on the first day)\nSource: https://clinicaltrials.g
 ov/study/NCT06667544\nScheduling/reference data from public records\; date
 s can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06667544
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:58c2026f21af945ec6b7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. P3 readout (est.): A 
 Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated\, Ad
 vanced or Metastatic NSCLC
DESCRIPTION:A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR
 -mutated\, Advanced or Metastatic NSCLC\nNCT06671379 | PHASE3 | ACTIVE_NOT
 _RECRUITING | sponsor: Suzhou Suncadia Biopharmaceuticals Co.\, Ltd.\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Date precision: month (shown on the first day)\nSource: https://clinicaltr
 ials.gov/study/NCT06671379\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06671379
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4b3a72210860da179730@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Technophage\, SA P1/P2 readout (est.): eSpine
DESCRIPTION:Phase 1b/2a Clinical Trial to Determine the Safety\, Tolerabili
 ty and Efficacy of TZ-161 in Spinal Cord Injury\nNCT06677229 | PHASE1/PHAS
 E2 | RECRUITING | sponsor: Technophage\, SA\nPrimary completion date (ESTI
 MATED)\; top-line results usually follow later.\nDate precision: month (sh
 own on the first day)\nSource: https://clinicaltrials.gov/study/NCT0667722
 9\nScheduling/reference data from public records\; dates can move. Not inv
 estment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06677229
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b3aef5170d61a0ab82e8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Wuhan Optics Valley Vcanbiopharma Co.\, Ltd. P1/P2 readout (est.): 
 ESTEVS-I/II
DESCRIPTION:A Phase I/II Trial of VUM02 Injection for Steroid-refractory Ac
 ute Graft-versus-host Disease (SR-aGvHD) Treatment\nNCT06677255 | PHASE1/P
 HASE2 | NOT_YET_RECRUITING | sponsor: Wuhan Optics Valley Vcanbiopharma Co
 .\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nDate precision: month (shown on the first day)\nSource: http
 s://clinicaltrials.gov/study/NCT06677255\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06677255
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b5bb72a6099330e53ea1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:TR Therapeutics P3 readout (est.): TRIVIA
DESCRIPTION:Tissue Repair Gel in Venous Leg Ulcers in AU/US\nNCT06707103 | 
 PHASE3 | RECRUITING | sponsor: TR Therapeutics\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nDate precision: month 
 (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT0670
 7103\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06707103
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8394a9b69a6d69900467@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co
 .\, Ltd. P2 readout (est.): A Clinical Study of TQC2731 Injection in Patie
 nts With Moderate to Severe Chronic Obstructive Pulmonary Disease
DESCRIPTION:A Clinical Study of TQC2731 Injection in Patients With Moderate
  to Severe Chronic Obstructive Pulmonary Disease\nNCT06707883 | PHASE2 | A
 CTIVE_NOT_RECRUITING | sponsor: Shanghai Chia Tai Tianqing Pharmaceutical 
 Technology Development Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nDate precision: month (shown on the
  first day)\nSource: https://clinicaltrials.gov/study/NCT06707883\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06707883
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c16df92ac8e247c21e44@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SKBBY P3 readout (est.): A Study of SKB264 in Combination With Pemb
 rolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-L
 ine Treatment for PD-L1 Negative Patients With Locally Advanced or Metasta
 tic Non-Squamous Non-Small Cell Lung Cancer
DESCRIPTION:A Study of SKB264 in Combination With Pembrolizumab Versus Chem
 otherapy in Combination With Pembrolizumab as First-Line Treatment for PD-
 L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-
 Small Cell Lung Cancer\nNCT06711900 | PHASE3 | ACTIVE_NOT_RECRUITING | spo
 nsor: Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd.\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nDate precisi
 on: month (shown on the first day)\nTicker SKBBY (confidence 0.6)\nSource:
  https://clinicaltrials.gov/study/NCT06711900\nScheduling/reference data f
 rom public records\; dates can move. Not investment\, legal or medical adv
 ice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06711900
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2dbe8581bdfdf82addab@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Napo Pharmaceuticals\, Inc. P2/P3 readout (est.): Ascending Doses o
 f Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion D
 isease (MVID)
DESCRIPTION:Ascending Doses of Crofelemer Powder for Oral Solution in Pedia
 tric Microvillus Inclusion Disease (MVID)\nNCT06721871 | PHASE2/PHASE3 | A
 CTIVE_NOT_RECRUITING | sponsor: Napo Pharmaceuticals\, Inc.\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nDate prec
 ision: month (shown on the first day)\nSource: https://clinicaltrials.gov/
 study/NCT06721871\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06721871
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:afbddb860f948d2926e2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Shandong New Time Pharmaceutical Co.\, LTD P2 readout (est.): Phase
  II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral N
 europathy
DESCRIPTION:Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Indu
 ced Peripheral Neuropathy\nNCT06722950 | PHASE2 | NOT_YET_RECRUITING | spo
 nsor: Shandong New Time Pharmaceutical Co.\, LTD\nPrimary completion date 
 (ESTIMATED)\; top-line results usually follow later.\nDate precision: mont
 h (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT06
 722950\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06722950
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e4b82f0ed8fb1702ea25@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Centessa Pharmaceuticals (UK) Limited P2 readout (est.): CRYSTAL-1
DESCRIPTION:A Study of ORX750 in Participants With Narcolepsy and Idiopathi
 c Hypersomnia\nNCT06752668 | PHASE2 | RECRUITING | sponsor: Centessa Pharm
 aceuticals (UK) Limited\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nDate precision: month (shown on the first day
 )\nSource: https://clinicaltrials.gov/study/NCT06752668\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06752668
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:36f9aedafd200a1402e5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Qilu Pharmaceutical Co.\, Ltd. P3 readout (est.): A Study to Evalua
 te Efficacy\, and Safety of QL2107 Plus Chemo and Compare With Keytruda in
  Participants With IV nqNSCLC
DESCRIPTION:A Study to Evaluate Efficacy\, and Safety of QL2107 Plus Chemo 
 and Compare With Keytruda in Participants With IV nqNSCLC\nNCT06754644 | P
 HASE3 | RECRUITING | sponsor: Qilu Pharmaceutical Co.\, Ltd.\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nDate pre
 cision: month (shown on the first day)\nSource: https://clinicaltrials.gov
 /study/NCT06754644\nScheduling/reference data from public records\; dates 
 can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06754644
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ee0d2e7281bf8f500179@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Akeso P3 readout (est.): AK112 or Placebo Plus Nab-Paclitaxel as Fi
 rst-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negat
 ive Breast Cancer
DESCRIPTION:AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in
  Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer\nNC
 T06767527 | PHASE3 | RECRUITING | sponsor: Akeso\nPrimary completion date 
 (ESTIMATED)\; top-line results usually follow later.\nDate precision: mont
 h (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT06
 767527\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06767527
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2385be1f70435a1907b2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Azidus Brasil P3 readout (est.): Efficacy and Safety of Nitazoxanid
 e 600 Mg in the Outpatient Treatment of COVID-19 and Influenza
DESCRIPTION:Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Tr
 eatment of COVID-19 and Influenza\nNCT06817096 | PHASE3 | NOT_YET_RECRUITI
 NG | sponsor: Azidus Brasil\nPrimary completion date (ESTIMATED)\; top-lin
 e results usually follow later.\nDate precision: month (shown on the first
  day)\nSource: https://clinicaltrials.gov/study/NCT06817096\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06817096
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:977cc861cb629b952a30@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Shandong Suncadia Medicine Co.\, Ltd. P2 readout (est.): Study on t
 he Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Eject
 ion Fraction/Preserved Ejection Fraction Heart Failure and Obesity
DESCRIPTION:Study on the Efficacy and Safety of HRS-7535 in Patients With M
 ild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failur
 e and Obesity\nNCT06820099 | PHASE2 | RECRUITING | sponsor: Shandong Sunca
 dia Medicine Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nDate precision: month (shown on the first day
 )\nSource: https://clinicaltrials.gov/study/NCT06820099\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06820099
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6510421c007dd6d3df12@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. P1/P2 readout (est.):
  A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sen
 sitive Recurrent Ovarian Cancer
DESCRIPTION:A Clinical Study of SHR-A1811 Combined With Chemotherapy for Pl
 atinum Sensitive Recurrent Ovarian Cancer\nNCT06840002 | PHASE1/PHASE2 | R
 ECRUITING | sponsor: Suzhou Suncadia Biopharmaceuticals Co.\, Ltd.\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nDa
 te precision: month (shown on the first day)\nSource: https://clinicaltria
 ls.gov/study/NCT06840002\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06840002
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6d7f14d0f64f4bb20462@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Astria Therapeutics\, Inc. P3 readout (est.): ALPHA-ORBIT
DESCRIPTION:A Study of Navenibart in Participants With Hereditary Angioedem
 a\nNCT06842823 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Astria Therapeu
 tics\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nDate precision: month (shown on the first day)\nSource: h
 ttps://clinicaltrials.gov/study/NCT06842823\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06842823
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:beb26521abd8e53a0bcc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. P2 readout (est.): A 
 Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC
DESCRIPTION:A Phase II Clinical Study of SHR-1826 for Injection in Patients
  With NSCLC\nNCT06844474 | PHASE2 | RECRUITING | sponsor: Suzhou Suncadia 
 Biopharmaceuticals Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nSource: https://clinicaltrials.gov/study/NCT06844474\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06844474
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a57fcca780138195afd6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:DWTX P2 readout (est.): Efficacy and Safety Study of Halneuron in t
 he Treatment of Chemotherapy-Induced Neuropathic Pain
DESCRIPTION:Efficacy and Safety Study of Halneuron in the Treatment of Chem
 otherapy-Induced Neuropathic Pain\nNCT06848348 | PHASE2 | ACTIVE_NOT_RECRU
 ITING | sponsor: Dogwood Therapeutics Inc.\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nDate precision: month (sho
 wn on the first day)\nTicker DWTX (confidence 0.9)\nSource: https://clinic
 altrials.gov/study/NCT06848348\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06848348
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:15136308cbf9fe9a8f0f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Cardiac Success P2 readout (est.): Vsling™ I: Clinical Evaluation
  of the Vsling™ Device for Ventricular Repair in Patients With Heart Fai
 lure
DESCRIPTION:Vsling™ I: Clinical Evaluation of the Vsling™ Device for Ve
 ntricular Repair in Patients With Heart Failure\nNCT06851949 | PHASE2 | RE
 CRUITING | sponsor: Cardiac Success\nPrimary completion date (ESTIMATED)\;
  top-line results usually follow later.\nDate precision: month (shown on t
 he first day)\nSource: https://clinicaltrials.gov/study/NCT06851949\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06851949
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:af7c5d9ca17d7d90cc6f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Regenerative Ocular Immunobiologics LLC P1/P2 readout (est.): oGVHD
DESCRIPTION:Study of d-MAPPS™ Ophthalmic Solution\, Safety\, Tolerability
 \, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disea
 se (oGVHD)\nNCT06852768 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor:
  Regenerative Ocular Immunobiologics LLC\nPrimary completion date (ESTIMAT
 ED)\; top-line results usually follow later.\nDate precision: month (shown
  on the first day)\nSource: https://clinicaltrials.gov/study/NCT06852768\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06852768
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cc4fb88f346966999be6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SOGP P3 readout (est.): SPI-1005 for the Treatment of Meniere's Dis
 ease (Open Label)
DESCRIPTION:SPI-1005 for the Treatment of Meniere's Disease (Open Label)\nN
 CT06859788 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Sound Pharmaceutica
 ls\, Incorporated\nPrimary completion date (ESTIMATED)\; top-line results 
 usually follow later.\nDate precision: month (shown on the first day)\nTic
 ker SOGP (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT068
 59788\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06859788
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dc7055e5d81a8fccec14@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. P2 readout (est.)
 : Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythe
 matosus (SLE)
DESCRIPTION:Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lup
 us Erythematosus (SLE)\nNCT06859931 | PHASE2 | NOT_YET_RECRUITING | sponso
 r: Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd.\nPrimary completion d
 ate (ESTIMATED)\; top-line results usually follow later.\nDate precision: 
 month (shown on the first day)\nSource: https://clinicaltrials.gov/study/N
 CT06859931\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06859931
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4d56a5c888c6e323ed67@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:DSGN P1/P2 readout (est.): A Multiple Ascending Dose Study of DT-21
 6P2 in Patients With Friedreich's Ataxia
DESCRIPTION:A Multiple Ascending Dose Study of DT-216P2 in Patients With Fr
 iedreich's Ataxia\nNCT06874010 | PHASE1/PHASE2 | RECRUITING | sponsor: Des
 ign Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nDate precision: month (shown on the first day
 )\nTicker DSGN (confidence 0.9)\nSource: https://clinicaltrials.gov/study/
 NCT06874010\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06874010
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:20cb7c779583daa69c3f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Jina Pharmaceuticals Inc. P2 readout (est.): A Study to Investigate
  Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet 
 in Adult Participants with Prostate Cancer
DESCRIPTION:A Study to Investigate Efficacy and Safety of Different Dose Re
 gimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cance
 r\nNCT06890832 | PHASE2 | NOT_YET_RECRUITING | sponsor: Jina Pharmaceutica
 ls Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually fo
 llow later.\nDate precision: month (shown on the first day)\nSource: https
 ://clinicaltrials.gov/study/NCT06890832\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06890832
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c750003323765e332627@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:jCyte\, Inc P2 readout (est.): Safety of a Single\, Intravitreal In
 jection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
DESCRIPTION:Safety of a Single\, Intravitreal Injection of 6.0M jCell (Famz
 eretcel) in Retinitis Pigmentosa (RP)\nNCT06912633 | PHASE2 | ACTIVE_NOT_R
 ECRUITING | sponsor: jCyte\, Inc\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nDate precision: month (shown on the 
 first day)\nSource: https://clinicaltrials.gov/study/NCT06912633\nScheduli
 ng/reference data from public records\; dates can move. Not investment\, l
 egal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06912633
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e47c6db9636adbb9b0f8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Shandong Suncadia Medicine Co.\, Ltd. P2 readout (est.): A Phase II
  Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patient
 s With Advanced Malignant Tumour
DESCRIPTION:A Phase II Clinical Study of HRS-7058 in Combination With Antit
 umor Drugs in Patients With Advanced Malignant Tumour\nNCT06915142 | PHASE
 2 | RECRUITING | sponsor: Shandong Suncadia Medicine Co.\, Ltd.\nPrimary c
 ompletion date (ESTIMATED)\; top-line results usually follow later.\nDate 
 precision: month (shown on the first day)\nSource: https://clinicaltrials.
 gov/study/NCT06915142\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06915142
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:87ad6046961d2bc81704@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Qilu Pharmaceutical Co.\, Ltd. P2 readout (est.): Combination of QL
 S31905\, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positiv
 e Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal 
 Junction (GEJ) Adenocarcinoma
DESCRIPTION:Combination of QLS31905\, QL2107 and Chemotherapy as First-line
  Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic 
 Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma\nNCT06942767 | P
 HASE2 | NOT_YET_RECRUITING | sponsor: Qilu Pharmaceutical Co.\, Ltd.\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Date precision: month (shown on the first day)\nSource: https://clinicaltr
 ials.gov/study/NCT06942767\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06942767
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:56d582cbf53d03035e89@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Akeso P1/P2 readout (est.): AK129 Combination Therapy for Advanced 
 Solid Tumors
DESCRIPTION:AK129 Combination Therapy for Advanced Solid Tumors\nNCT0694382
 0 | PHASE1/PHASE2 | RECRUITING | sponsor: Akeso\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nDate precision: month
  (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT069
 43820\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06943820
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6e4c98f311b796212273@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:MANE P3 readout (est.): Safety and Efficacy of VDPHL01 in Males Wit
 h AGA
DESCRIPTION:Safety and Efficacy of VDPHL01 in Males With AGA\nNCT06972264 |
  PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Veradermics\, Inc.\nPrimary com
 pletion date (ESTIMATED)\; top-line results usually follow later.\nDate pr
 ecision: month (shown on the first day)\nTicker MANE (confidence 0.9)\nSou
 rce: https://clinicaltrials.gov/study/NCT06972264\nScheduling/reference da
 ta from public records\; dates can move. Not investment\, legal or medical
  advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06972264
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:986841b44ec540850c48@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Fujian Shengdi Pharmaceutical Co.\, Ltd. P3 readout (est.): A Phase
  III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subj
 ects With Obstructive Sleep Apnea (OSA) and Obesity
DESCRIPTION:A Phase III Study Evaluating the Efficacy and Safety of HRS9531
  Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity\nNCT
 06974851 | PHASE3 | RECRUITING | sponsor: Fujian Shengdi Pharmaceutical Co
 .\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nDate precision: month (shown on the first day)\nSource: http
 s://clinicaltrials.gov/study/NCT06974851\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06974851
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:38241f876c49f4a300ec@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. P1/P2 readout (est.): A Clinica
 l Study of HRS-6209 Combined With Other Treatment Regimens in Patients Wit
 h Breast Cancer
DESCRIPTION:A Clinical Study of HRS-6209 Combined With Other Treatment Regi
 mens in Patients With Breast Cancer\nNCT06974929 | PHASE1/PHASE2 | RECRUIT
 ING | sponsor: Jiangsu HengRui Medicine Co.\, Ltd.\nPrimary completion dat
 e (ESTIMATED)\; top-line results usually follow later.\nDate precision: mo
 nth (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT
 06974929\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06974929
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4076c4ed4536eec88a84@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Ryvu Therapeutics SA P2 readout (est.): ROVER-01
DESCRIPTION:RVU120 Rollover Study\nNCT06987058 | PHASE2 | ENROLLING_BY_INVI
 TATION | sponsor: Ryvu Therapeutics SA\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nDate precision: month (shown o
 n the first day)\nSource: https://clinicaltrials.gov/study/NCT06987058\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06987058
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:436fbcf6149e195c64dc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Minghui Pharmaceutical (Hangzhou) Ltd P3 readout (est.): MHB018A Tr
 eatment in Patients With Active Thyroid Eye Disease
DESCRIPTION:MHB018A Treatment in Patients With Active Thyroid Eye Disease\n
 NCT06989918 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Minghui Pharmaceut
 ical (Hangzhou) Ltd\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nS
 ource: https://clinicaltrials.gov/study/NCT06989918\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06989918
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9327a9b41141201ee092@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Fujian Shengdi Pharmaceutical Co.\, Ltd. P3 readout (est.): A Multi
 center\, Randomized\, Double-blind\, Placebo-controlled Phase III Clinical
  Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subject
 s With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airwa
 y Pressure Ventilation (PAP) Therapy
DESCRIPTION:A Multicenter\, Randomized\, Double-blind\, Placebo-controlled 
 Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 In
 jection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are
  on Positive Airway Pressure Ventilation (PAP) Therapy\nNCT06994650 | PHAS
 E3 | ACTIVE_NOT_RECRUITING | sponsor: Fujian Shengdi Pharmaceutical Co.\, 
 Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually follo
 w later.\nDate precision: month (shown on the first day)\nSource: https://
 clinicaltrials.gov/study/NCT06994650\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06994650
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c82b8cd4c50a3be6a155@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:KRYS P1/P2 readout (est.): EMERALD-1
DESCRIPTION:A Study Comparing KB801 Verse Placebo in Patients With Stage 2 
 or 3 Neurotrophic Keratitis\nNCT06999733 | PHASE1/PHASE2 | RECRUITING | sp
 onsor: Krystal Biotech\, Inc.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nTicker KRYS (confidence 0.9)\nSource: https://clinicaltrials.gov/
 study/NCT06999733\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06999733
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9c399b854a9f9d0a9ae1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:PRAX P3 readout (est.): EMERALD
DESCRIPTION:A Clinical Trial for Participants With DEE to Assess Efficacy\,
  Safety\, Tolerability\, and PK of Relutrigine\nNCT07010471 | PHASE3 | ACT
 IVE_NOT_RECRUITING | sponsor: Praxis Precision Medicines\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nDate precisi
 on: month (shown on the first day)\nTicker PRAX (confidence 0.9)\nSource: 
 https://clinicaltrials.gov/study/NCT07010471\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07010471
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f05e339bbf3731124ed6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:KRYS P3 readout (est.): IOLITE
DESCRIPTION:A Study Comparing KB803 and Matched Placebo in Patients With Dy
 strophic Epidermolysis Bullosa\nNCT07016750 | PHASE3 | RECRUITING | sponso
 r: Krystal Biotech\, Inc.\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nDate precision: month (shown on the first d
 ay)\nTicker KRYS (confidence 0.9)\nSource: https://clinicaltrials.gov/stud
 y/NCT07016750\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07016750
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:227fec5e580455965f52@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:PRAX P3 readout (est.): A Clinical Trial of Elsunersen in Pediatric
  SCN2A-DEE to Assess Efficacy and Safety
DESCRIPTION:A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess
  Efficacy and Safety\nNCT07019922 | PHASE3 | RECRUITING | sponsor: Praxis 
 Precision Medicines\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nT
 icker PRAX (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0
 7019922\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07019922
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b0b64fdc1f8e65c4d16a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Imbria Pharmaceuticals\, Inc. P2 readout (est.): FORTITUDE-HCM
DESCRIPTION:A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in
  Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy\nNC
 T07023614 | PHASE2 | RECRUITING | sponsor: Imbria Pharmaceuticals\, Inc.\n
 Primary completion date (ESTIMATED)\; top-line results usually follow late
 r.\nDate precision: month (shown on the first day)\nSource: https://clinic
 altrials.gov/study/NCT07023614\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07023614
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4ded32362e845affba64@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:iRegene Therapeutics Co.\, Ltd. P2 readout (est.): The Safety\, Fea
 sibility and Efficacy of NouvNeu001 for Parkinson's Disease
DESCRIPTION:The Safety\, Feasibility and Efficacy of NouvNeu001 for Parkins
 on's Disease\nNCT07028632 | PHASE2 | NOT_YET_RECRUITING | sponsor: iRegene
  Therapeutics Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nDate precision: month (shown on the first da
 y)\nSource: https://clinicaltrials.gov/study/NCT07028632\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07028632
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a1e485b39e12a00ac2ec@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:AVIR P3 readout (est.): C-Forward: Efficacy and Safety of BEM/RZR v
 s SOF/VEL in Subjects With Chronic HCV
DESCRIPTION:C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subject
 s With Chronic HCV\nNCT07037277 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor
 : Atea Pharmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nTicker AVIR (confidence 0.9)\nSource: https://clinicaltrials.gov/
 study/NCT07037277\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07037277
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5fd763c186afc169eff9@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Kedrion S.p.A. P3 readout (est.): ITP
DESCRIPTION:A Study Investigating Intravenous Human Normal Immunoglobulin 1
 0% in Adults With Chronic Immune Thrombocytopenia (ITP)\nNCT07059000 | PHA
 SE3 | RECRUITING | sponsor: Kedrion S.p.A.\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nDate precision: month (sho
 wn on the first day)\nSource: https://clinicaltrials.gov/study/NCT07059000
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07059000
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:786cd3e65e3d13dffe08@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Galderma R&D P2 readout (est.): CPUO
DESCRIPTION:Proof of Concept Study to Assess the Pharmacokinetics/Pharmacod
 ynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (
 CPUO)\nNCT07074977 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Galderma R&
 D\nPrimary completion date (ESTIMATED)\; top-line results usually follow l
 ater.\nDate precision: month (shown on the first day)\nSource: https://cli
 nicaltrials.gov/study/NCT07074977\nScheduling/reference data from public r
 ecords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07074977
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e44f322cbc4773c7c8af@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Qilu Pharmaceutical Co.\, Ltd. P3 readout (est.): Study to Assess t
 he Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resista
 nt Enterobacteriaceae Infections
DESCRIPTION:Study to Assess the Efficacy and Safety of Meropenem and Pralur
 bactam in Carbapenem-Resistant Enterobacteriaceae Infections\nNCT07089186 
 | PHASE3 | RECRUITING | sponsor: Qilu Pharmaceutical Co.\, Ltd.\nPrimary c
 ompletion date (ESTIMATED)\; top-line results usually follow later.\nDate 
 precision: month (shown on the first day)\nSource: https://clinicaltrials.
 gov/study/NCT07089186\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07089186
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3dd026675caa0e0e7208@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Celltrion P3 readout (est.): Efficacy and Safety of Add-On Therapy 
 With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alo
 gliptin and Metformin
DESCRIPTION:Efficacy and Safety of Add-On Therapy With Empagliflozin in Pat
 ients With Type 2 Diabetes on a Background of Alogliptin and Metformin\nNC
 T07093476 | PHASE3 | RECRUITING | sponsor: Celltrion\nPrimary completion d
 ate (ESTIMATED)\; top-line results usually follow later.\nDate precision: 
 month (shown on the first day)\nSource: https://clinicaltrials.gov/study/N
 CT07093476\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07093476
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5debe2a6711c82c9ce26@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:VIR P3 readout (est.): A Study to Evaluate Tobevibart+Elebsiran in 
 Participants With Chronic HDV Infection Not Virologically Suppressed With 
 Bulevirtide
DESCRIPTION:A Study to Evaluate Tobevibart+Elebsiran in Participants With C
 hronic HDV Infection Not Virologically Suppressed With Bulevirtide\nNCT071
 28550 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Vir Biotechnology\, Inc.
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nDate precision: month (shown on the first day)\nTicker VIR (confiden
 ce 0.9)\nSource: https://clinicaltrials.gov/study/NCT07128550\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07128550
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6160cc417fb6e7313bd3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Newsoara HYK Biopharmaceutical (Shanghai) Co.\, Ltd. P1/P2 readout 
 (est.): Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients
  With Late Phase SCLC
DESCRIPTION:Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patie
 nts With Late Phase SCLC\nNCT07136285 | PHASE1/PHASE2 | RECRUITING | spons
 or: Newsoara HYK Biopharmaceutical (Shanghai) Co.\, Ltd.\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nDate precisi
 on: month (shown on the first day)\nSource: https://clinicaltrials.gov/stu
 dy/NCT07136285\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07136285
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ce30aaae3222710ff5bd@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:EicOsis Human Health Inc. P1/P2 readout (est.): STEP
DESCRIPTION:Safety\, Tolerability and Exploratory Efficacy of EC5026 in Par
 kinson's Disease (STEP Study)\nNCT07142044 | PHASE1/PHASE2 | RECRUITING | 
 sponsor: EicOsis Human Health Inc.\nPrimary completion date (ESTIMATED)\; 
 top-line results usually follow later.\nDate precision: month (shown on th
 e first day)\nSource: https://clinicaltrials.gov/study/NCT07142044\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07142044
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e749f63274a6d0487c9d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:One-carbon Therapeutics AB P1/P2 readout (est.): ODIN
DESCRIPTION:Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced
  Solid Tumors\nNCT07151040 | PHASE1/PHASE2 | RECRUITING | sponsor: One-car
 bon Therapeutics AB\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nS
 ource: https://clinicaltrials.gov/study/NCT07151040\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07151040
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8f760bdc5e5c6bd7c516@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:LLY P2 readout (est.): A Study to Evaluate LY3537021 for the Treatm
 ent of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
DESCRIPTION:A Study to Evaluate LY3537021 for the Treatment of Nausea and V
 omiting Caused by Chemotherapy in Adults With Cancer\nNCT07169851 | PHASE2
  | RECRUITING | sponsor: Eli Lilly and Company\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nDate precision: month 
 (shown on the first day)\nTicker LLY (confidence 0.95)\nSource: https://cl
 inicaltrials.gov/study/NCT07169851\nScheduling/reference data from public 
 records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07169851
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2263451ef949c462b049@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Otsuka Pharmaceutical Co.\, Ltd. P3 readout (est.): A Phase 3 Trial
  to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adu
 lt Patients With Atopic Dermatitis
DESCRIPTION:A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 
 Foam to the Vehicle in Adult Patients With Atopic Dermatitis\nNCT07173478 
 | PHASE3 | NOT_YET_RECRUITING | sponsor: Otsuka Pharmaceutical Co.\, Ltd.\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nDate precision: month (shown on the first day)\nSource: https://clini
 caltrials.gov/study/NCT07173478\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07173478
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b98a22ec10975f05ce3e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:AVLN P2 readout (est.): AURA-IPF
DESCRIPTION:AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and
  Efficacy of AP02 (Nintedanib Solution) in IPF\nNCT07194382 | PHASE2 | REC
 RUITING | sponsor: Avalyn Pharma Inc.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nTicker AVLN (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT07194382\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07194382
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:018ee37dc1ee392f603a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Qilu Pharmaceutical Co.\, Ltd. P1/P2 readout (est.): A Clinical Stu
 dy of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapi
 es in Subjects With Advanced Prostate Cancer
DESCRIPTION:A Clinical Study of QLC5508 and/or QLH12016 in Combination With
  Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer\nNCT
 07198633 | PHASE1/PHASE2 | RECRUITING | sponsor: Qilu Pharmaceutical Co.\,
  Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nDate precision: month (shown on the first day)\nSource: https:/
 /clinicaltrials.gov/study/NCT07198633\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07198633
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9d7badc0ede5bff2a03f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Elion Therapeutics\, Inc. P2 readout (est.): Phase 2 EL219 Versus L
 iposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
DESCRIPTION:Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole f
 or Early Antifungal Therapy\nNCT07215273 | PHASE2 | RECRUITING | sponsor: 
 Elion Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nDate precision: month (shown on the first d
 ay)\nSource: https://clinicaltrials.gov/study/NCT07215273\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07215273
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:22a34d40e4d301c9983c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:VNDA P3 readout (est.): Study to Evaluate the Efficacy and Safety o
 f VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
DESCRIPTION:Study to Evaluate the Efficacy and Safety of VQW-765 for the On
 -Demand Treatment of Social Anxiety Disorder\nNCT07221578 | PHASE3 | ACTIV
 E_NOT_RECRUITING | sponsor: Vanda Pharmaceuticals\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nDate precision: mon
 th (shown on the first day)\nTicker VNDA (confidence 0.9)\nSource: https:/
 /clinicaltrials.gov/study/NCT07221578\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07221578
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0839ceaf68216f8f43ee@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Shandong Suncadia Medicine Co.\, Ltd. P2 readout (est.): A Phase 2 
 Clinical Study to Evaluate the Efficacy\, Safety\, and Pharmacokinetics of
  HRS-7085 Tablets in Patients With Inflammatory Bowel Disease
DESCRIPTION:A Phase 2 Clinical Study to Evaluate the Efficacy\, Safety\, an
 d Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel
  Disease\nNCT07229950 | PHASE2 | RECRUITING | sponsor: Shandong Suncadia M
 edicine Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results
  usually follow later.\nDate precision: month (shown on the first day)\nSo
 urce: https://clinicaltrials.gov/study/NCT07229950\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07229950
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ef4ea54773cbb9df1824@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Ingenia Therapeutics INC P1/P2 readout (est.): A Study to Investiga
 te IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Dise
 ase
DESCRIPTION:A Study to Investigate IGT-303 in Healthy Volunteers and Partic
 ipants With Chronic Kidney Disease\nNCT07231679 | PHASE1/PHASE2 | RECRUITI
 NG | sponsor: Ingenia Therapeutics INC\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nDate precision: month (shown o
 n the first day)\nSource: https://clinicaltrials.gov/study/NCT07231679\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07231679
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cdeed5a4e2a768c28eaf@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Grand Shuyang Life Sciences (Chengdu) Co.\, Ltd. P3 readout (est.):
  An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment 
 of Primary Immune Thrombocytopenia
DESCRIPTION:An Open-label Study of Intravenous Immunoglobulin (5%) for the 
 Treatment of Primary Immune Thrombocytopenia\nNCT07233213 | PHASE3 | RECRU
 ITING | sponsor: Grand Shuyang Life Sciences (Chengdu) Co.\, Ltd.\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nDat
 e precision: month (shown on the first day)\nSource: https://clinicaltrial
 s.gov/study/NCT07233213\nScheduling/reference data from public records\; d
 ates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07233213
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:71af13950f6ca2f59e58@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Shenyang Sunshine Pharmaceutical Co.\, LTD. P2 readout (est.): A Ph
 ase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advan
 ced Gastrointestinal Cancers
DESCRIPTION:A Phase II Clinical Study Evaluating SSGJ-706 in Combination Th
 erapy for Advanced Gastrointestinal Cancers\nNCT07233850 | PHASE2 | NOT_YE
 T_RECRUITING | sponsor: Shenyang Sunshine Pharmaceutical Co.\, LTD.\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nD
 ate precision: month (shown on the first day)\nSource: https://clinicaltri
 als.gov/study/NCT07233850\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07233850
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3bba400e1dbdf5c7264c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dong-A ST Co.\, Ltd. P2 readout (est.): Clinical Trial to Evaluate 
 the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Com
 bination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glyc
 emic Control
DESCRIPTION:Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 W
 hen Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Ty
 pe 2 Diabetes Who Have Inadequate Glycemic Control\nNCT07239440 | PHASE2 |
  NOT_YET_RECRUITING | sponsor: Dong-A ST Co.\, Ltd.\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nDate precision: m
 onth (shown on the first day)\nSource: https://clinicaltrials.gov/study/NC
 T07239440\nScheduling/reference data from public records\; dates can move.
  Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07239440
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ab7e1a5ecd5cf0a6e019@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Ventus Therapeutics U.S.\, Inc. P2 readout (est.): AERIS
DESCRIPTION:A Multicenter\, Randomized\, Double-Blind\, Placebo-Controlled\
 , Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and 
 Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythe
 matosus With or Without Systemic Lupus Erythematosus\nNCT07260877 | PHASE2
  | ACTIVE_NOT_RECRUITING | sponsor: Ventus Therapeutics U.S.\, Inc.\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nD
 ate precision: month (shown on the first day)\nSource: https://clinicaltri
 als.gov/study/NCT07260877\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07260877
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5c8fda41d5b934f081c3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Novaliq GmbH P2 readout (est.): EYETAC
DESCRIPTION:Tacrolimus Ophthalmic Solution for the Treatment of Non-infecti
 ous Anterior Uveitis\nNCT07285070 | PHASE2 | ACTIVE_NOT_RECRUITING | spons
 or: Novaliq GmbH\nPrimary completion date (ESTIMATED)\; top-line results u
 sually follow later.\nDate precision: month (shown on the first day)\nSour
 ce: https://clinicaltrials.gov/study/NCT07285070\nScheduling/reference dat
 a from public records\; dates can move. Not investment\, legal or medical 
 advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07285070
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:200badcd4db2472a7308@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Intra-IMMUSG Pte Ltd P2/P3 readout (est.): PRL3-zumab
DESCRIPTION:Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patien
 ts\nNCT07290088 | PHASE2/PHASE3 | RECRUITING | sponsor: Intra-IMMUSG Pte L
 td\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nDate precision: month (shown on the first day)\nSource: https://cl
 inicaltrials.gov/study/NCT07290088\nScheduling/reference data from public 
 records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07290088
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1f4f61baf155c34cd68d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Fujian Shengdi Pharmaceutical Co.\, Ltd. P2 readout (est.): Phase I
 I Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertensio
 n
DESCRIPTION:Phase II Clinical Study of HRS-9563 in Patients With Mild to Mo
 derate Hypertension\nNCT07297797 | PHASE2 | ACTIVE_NOT_RECRUITING | sponso
 r: Fujian Shengdi Pharmaceutical Co.\, Ltd.\nPrimary completion date (ESTI
 MATED)\; top-line results usually follow later.\nDate precision: month (sh
 own on the first day)\nSource: https://clinicaltrials.gov/study/NCT0729779
 7\nScheduling/reference data from public records\; dates can move. Not inv
 estment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07297797
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e3d390e061b1731a4f16@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Enveda Therapeutics P2 readout (est.): Study of ENV-294 in Adults W
 ith Moderate-to-Severe Atopic Dermatitis
DESCRIPTION:Study of ENV-294 in Adults With Moderate-to-Severe Atopic Derma
 titis\nNCT07298395 | PHASE2 | RECRUITING | sponsor: Enveda Therapeutics\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nDate precision: month (shown on the first day)\nSource: https://clinica
 ltrials.gov/study/NCT07298395\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07298395
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1741f2dc2746e2da7eda@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Enveda Therapeutics P2 readout (est.): ENV-294 for Moderate-to-Seve
 re Asthma: A 12-Week Study in Adults
DESCRIPTION:ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adult
 s\nNCT07301255 | PHASE2 | RECRUITING | sponsor: Enveda Therapeutics\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nD
 ate precision: month (shown on the first day)\nSource: https://clinicaltri
 als.gov/study/NCT07301255\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07301255
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fdd38c49bbc384bb7de5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Henan Genuine Biotech Co.\, Ltd. P2 readout (est.): A Phase Ⅱa Cl
 inical Study of CL-197 Capsules
DESCRIPTION:A Phase Ⅱa Clinical Study of CL-197 Capsules\nNCT07308782 | P
 HASE2 | RECRUITING | sponsor: Henan Genuine Biotech Co.\, Ltd.\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nDate p
 recision: month (shown on the first day)\nSource: https://clinicaltrials.g
 ov/study/NCT07308782\nScheduling/reference data from public records\; date
 s can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07308782
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:70faefe80cc8909c75ad@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:VapeAway P2 readout (est.): CONQUER
DESCRIPTION:The CONQUER Trial - Cessation Of Nicotine\, QUitting With E-cig
 arette Reduction\nNCT07322432 | PHASE2 | RECRUITING | sponsor: VapeAway\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nDate precision: month (shown on the first day)\nSource: https://clinica
 ltrials.gov/study/NCT07322432\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07322432
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:afb4f87ae229e836688f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pulmovant\, Inc. P2 readout (est.): A Study of Mosliciguat in Combi
 nation With Inhaled Treprostinil in PH-ILD
DESCRIPTION:A Study of Mosliciguat in Combination With Inhaled Treprostinil
  in PH-ILD\nNCT07333183 | PHASE2 | RECRUITING | sponsor: Pulmovant\, Inc.\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nDate precision: month (shown on the first day)\nSource: https://clini
 caltrials.gov/study/NCT07333183\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07333183
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5d4cc4b79f435de07bdf@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Next Life Sciences P2 readout (est.): Plan A Occlusion and Reversal
  System Feasibility Study
DESCRIPTION:Plan A Occlusion and Reversal System Feasibility Study\nNCT0736
 1120 | PHASE2 | RECRUITING | sponsor: Next Life Sciences\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nDate precisi
 on: month (shown on the first day)\nSource: https://clinicaltrials.gov/stu
 dy/NCT07361120\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07361120
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:63f4eabf0952cfdc2a92@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:TRAW P2 readout (est.): This is an Early-stage Clinical Trial to De
 termine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With 
 Mild to Moderate Influenza
DESCRIPTION:This is an Early-stage Clinical Trial to Determine a Safe and E
 ffective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Inf
 luenza\nNCT07371650 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Traws Phar
 ma\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nDate precision: month (shown on the first day)\nTicker TRAW
  (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07371650\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07371650
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9ccf73ca7f4f8c2a4847@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Toll Biotech Co. Ltd. (Beijing) P2 readout (est.): Safety and Effic
 acy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
DESCRIPTION:Safety and Efficacy of TollB-001 Tablets in Moderate to Severe 
 Rheumatoid Arthritis\nNCT07408024 | PHASE2 | RECRUITING | sponsor: Toll Bi
 otech Co. Ltd. (Beijing)\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nDate precision: month (shown on the first da
 y)\nSource: https://clinicaltrials.gov/study/NCT07408024\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07408024
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9e611a8c8763c9ea6e96@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Shanghai Yidian Pharmaceutical Technology Development Co.\, Ltd. P2
  readout (est.): Efficacy and Safety of YD0743 Treatment for Sepsis-Associ
 ated ARDS
DESCRIPTION:Efficacy and Safety of YD0743 Treatment for Sepsis-Associated A
 RDS\nNCT07413094 | PHASE2 | RECRUITING | sponsor: Shanghai Yidian Pharmace
 utical Technology Development Co.\, Ltd.\nPrimary completion date (ESTIMAT
 ED)\; top-line results usually follow later.\nDate precision: month (shown
  on the first day)\nSource: https://clinicaltrials.gov/study/NCT07413094\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07413094
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:29e8f217418277995f87@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:PT. Prodia Stem Cell Indonesia P1/P2 readout (est.): Mesenchymal St
 em Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant 
 Therapy for Sepsis
DESCRIPTION:Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchyma
 l Stem Cells as Adjuvant Therapy for Sepsis\nNCT07439848 | PHASE1/PHASE2 |
  RECRUITING | sponsor: PT. Prodia Stem Cell Indonesia\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nDate precision:
  month (shown on the first day)\nSource: https://clinicaltrials.gov/study/
 NCT07439848\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07439848
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:df3bfa7b7819f236f94b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. P2 readout (est.): A Study Comp
 aring Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individuali
 zed-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled 
 With Oral Antihyperglycemic Agents
DESCRIPTION:A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Ti
 tration and Individualized-Dose Titration in Adults With Type 2 Diabetes I
 nadequately Controlled With Oral Antihyperglycemic Agents\nNCT07472725 | P
 HASE2 | ACTIVE_NOT_RECRUITING | sponsor: Jiangsu HengRui Medicine Co.\, Lt
 d.\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nDate precision: month (shown on the first day)\nSource: https://cl
 inicaltrials.gov/study/NCT07472725\nScheduling/reference data from public 
 records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07472725
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e546e2762fdc02a89c1f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ENTA P2 readout (est.): A Phase 2 Study to Investigate the Efficacy
  and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months
  of Age Infected With Respiratory Syncytial Virus
DESCRIPTION:A Phase 2 Study to Investigate the Efficacy and Safety of Zelic
 apavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected Wit
 h Respiratory Syncytial Virus\nNCT07482657 | PHASE2 | RECRUITING | sponsor
 : Enanta Pharmaceuticals\, Inc\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nDate precision: month (shown on the fi
 rst day)\nTicker ENTA (confidence 0.9)\nSource: https://clinicaltrials.gov
 /study/NCT07482657\nScheduling/reference data from public records\; dates 
 can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07482657
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d4ef510d098b3fa3abac@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Qilu Pharmaceutical Co.\, Ltd. P3 readout (est.): Efficacy and Safe
 ty of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 D
 iabetes
DESCRIPTION:Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metform
 in in Subjects With Type 2 Diabetes\nNCT07487103 | PHASE3 | NOT_YET_RECRUI
 TING | sponsor: Qilu Pharmaceutical Co.\, Ltd.\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nDate precision: month 
 (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT0748
 7103\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07487103
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c6dd1994a5586ba01787@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Qilu Pharmaceutical Co.\, Ltd. P3 readout (est.): A Clinical Study 
 of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macula
 r Degeneration
DESCRIPTION:A Clinical Study of QL1207H Injection Versus Aflibercept for Ne
 ovascular Age-related Macular Degeneration\nNCT07489586 | PHASE3 | NOT_YET
 _RECRUITING | sponsor: Qilu Pharmaceutical Co.\, Ltd.\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nDate precision:
  month (shown on the first day)\nSource: https://clinicaltrials.gov/study/
 NCT07489586\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07489586
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4724d9ce776499982fcb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Qilu Pharmaceutical Co.\, Ltd. P2 readout (est.): QLS1410 in Partic
 ipants With Uncontrolled Hypertension
DESCRIPTION:QLS1410 in Participants With Uncontrolled Hypertension\nNCT0748
 9612 | PHASE2 | ENROLLING_BY_INVITATION | sponsor: Qilu Pharmaceutical Co.
 \, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually fo
 llow later.\nDate precision: month (shown on the first day)\nSource: https
 ://clinicaltrials.gov/study/NCT07489612\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07489612
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:202e6de6c6feba271dfe@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Vergent Bioscience\, Inc. P3 readout (est.): VISUALIZE-2
DESCRIPTION:Evaluation of the Safety and Efficacy of Abenacianine (VGT-309)
  to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung\
 nNCT07499674 | PHASE3 | RECRUITING | sponsor: Vergent Bioscience\, Inc.\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nDate precision: month (shown on the first day)\nSource: https://clinica
 ltrials.gov/study/NCT07499674\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07499674
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:594fa0352070df7be782@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:KARD P2 readout (est.): KARDINAL-ASH
DESCRIPTION:Study of Efficacy and Safety of Tonlamarsen in Participants Wit
 h a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypert
 ension\nNCT07511361 | PHASE2 | RECRUITING | sponsor: Kardigan\, Inc.\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Date precision: month (shown on the first day)\nTicker KARD (confidence 0.
 9)\nSource: https://clinicaltrials.gov/study/NCT07511361\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07511361
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b7851e0c87e16c7f15df@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. P2
  readout (est.): A Phase 2 Study of HW211026
DESCRIPTION:A Phase 2 Study of HW211026\nNCT07513454 | PHASE2 | NOT_YET_REC
 RUITING | sponsor: Hubei Bio-Pharmaceutical Industrial Technological Insti
 tute Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nDate precision: month (shown on the first day)\nSource: htt
 ps://clinicaltrials.gov/study/NCT07513454\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07513454
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fce4db1dff6998d5f0da@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:OCS P2/P3 readout (est.): PREDICT-1
DESCRIPTION:A Clinical Study Evaluating Licaminlimab for Dry Eye Disease\nN
 CT07548632 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Oculis\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Date precision: month (shown on the first day)\nTicker OCS (confidence 0.6
 )\nSource: https://clinicaltrials.gov/study/NCT07548632\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07548632
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ac842de07f370142fe88@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Mabwell (Shanghai) Bioscience Co.\, Ltd. P2 readout (est.): A Phase
  II Study of 9MW3811 in Patients With Pathological Scar
DESCRIPTION:A Phase II Study of 9MW3811 in Patients With Pathological Scar\
 nNCT07576608 | PHASE2 | RECRUITING | sponsor: Mabwell (Shanghai) Bioscienc
 e Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nDate precision: month (shown on the first day)\nSource: 
 https://clinicaltrials.gov/study/NCT07576608\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07576608
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2b2df921a52691047e4f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Chengdu Suncadia Medicine Co.\, Ltd. P2 readout (est.): A Clinical 
 Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria
DESCRIPTION:A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneo
 us Urticaria\nNCT07613866 | PHASE2 | NOT_YET_RECRUITING | sponsor: Chengdu
  Suncadia Medicine Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nSource: https://clinicaltrials.gov/study/NCT07613866\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07613866
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e20c8ef2b3190d08f913@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Chengdu Kangnuoxing Biopharma\,Inc. P3 readout (est.): Study on the
  Treatment of Adolescent Patients With Seasonal Allergic Rhinitis
DESCRIPTION:Study on the Treatment of Adolescent Patients With Seasonal All
 ergic Rhinitis\nNCT07678931 | PHASE3 | RECRUITING | sponsor: Chengdu Kangn
 uoxing Biopharma\,Inc.\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nDate precision: month (shown on the first day)
 \nSource: https://clinicaltrials.gov/study/NCT07678931\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07678931
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1c0adf53046769db3b8f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Guangdong Hengrui Pharmaceutical Co.\, Ltd P3 readout (est.): A Cli
 nical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Pa
 tients With Seasonal Allergic Rhinitis
DESCRIPTION:A Clinical Study Evaluating the Efficacy and Safety of SHR-1819
  Injection in Patients With Seasonal Allergic Rhinitis\nNCT07688772 | PHAS
 E3 | ACTIVE_NOT_RECRUITING | sponsor: Guangdong Hengrui Pharmaceutical Co.
 \, Ltd\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nDate precision: month (shown on the first day)\nSource: https:
 //clinicaltrials.gov/study/NCT07688772\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07688772
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a2efe1c0dd0a55c453ae@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Heron Neutron Medical Corp. P1/P2 readout (est.): A Study to Evalua
 te the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Sol
 id Tumors
DESCRIPTION:A Study to Evaluate the Safety and Diagnostic Performance of F1
 8 FBPA PET/CT Imaging in Solid Tumors\nNCT07691775 | PHASE1/PHASE2 | RECRU
 ITING | sponsor: Heron Neutron Medical Corp.\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nDate precision: month (s
 hown on the first day)\nSource: https://clinicaltrials.gov/study/NCT076917
 75\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07691775
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5abc0ae15bd9a54357e4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:CNTB P2 readout (est.): Rademikibart IV for Acute Asthma and COPD E
 xacerbation
DESCRIPTION:Rademikibart IV for Acute Asthma and COPD Exacerbation\nNCT0770
 5737 | PHASE2 | RECRUITING | sponsor: Connect Biopharm LLC\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nDate preci
 sion: month (shown on the first day)\nTicker CNTB (confidence 0.6)\nSource
 : https://clinicaltrials.gov/study/NCT07705737\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07705737
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ba14b48f38ec2664628e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Fujian Shengdi Pharmaceutical Co.\, Ltd. P2 readout (est.): A Clini
 cal Trial of HRS5580 for Injection Combined With Palonosetron Hydrochlorid
 e for the Prevention of Postoperative Nausea and Vomiting
DESCRIPTION:A Clinical Trial of HRS5580 for Injection Combined With Palonos
 etron Hydrochloride for the Prevention of Postoperative Nausea and Vomitin
 g\nNCT07709897 | PHASE2 | RECRUITING | sponsor: Fujian Shengdi Pharmaceuti
 cal Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nDate precision: month (shown on the first day)\nSource
 : https://clinicaltrials.gov/study/NCT07709897\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07709897
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b3821927e6ad62a57077@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:HROW P3 readout (est.): A Phase 3 Study Evaluating the Safety and E
 fficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular
  Inflammation and Pain After Ophthalmic Surgery
DESCRIPTION:A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE
 ® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pa
 in After Ophthalmic Surgery\nNCT07832552 | PHASE3 | ENROLLING_BY_INVITATIO
 N | sponsor: Harrow Inc\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nDate precision: month (shown on the first day
 )\nTicker HROW (confidence 0.9)\nSource: https://clinicaltrials.gov/study/
 NCT07832552\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07832552
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:79bb204d8662e7e91f09@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:TTIPF P2 readout (est.): Pilot Study of TTI-0102 in Cystinosis
DESCRIPTION:Pilot Study of TTI-0102 in Cystinosis\nNCT07837726 | PHASE2 | N
 OT_YET_RECRUITING | sponsor: Thiogenesis Therapeutics\, Inc.\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nDate pre
 cision: month (shown on the first day)\nTicker TTIPF (confidence 0.9)\nSou
 rce: https://clinicaltrials.gov/study/NCT07837726\nScheduling/reference da
 ta from public records\; dates can move. Not investment\, legal or medical
  advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07837726
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:802aff4cac6904078b30@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Danisco P1/P2 readout (est.): A Study of Single and Combination Lip
 ase Dietary Supplements to Increase Fatty Acid Absorption in Generally Hea
 lth Adults
DESCRIPTION:A Study of Single and Combination Lipase Dietary Supplements to
  Increase Fatty Acid Absorption in Generally Health Adults\nNCT07893288 | 
 PHASE1/PHASE2 | NOT_YET_RECRUITING | sponsor: Danisco\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nDate precision:
  month (shown on the first day)\nSource: https://clinicaltrials.gov/study/
 NCT07893288\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07893288
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b7da0c058b3189ce647b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dexa Medica Group P2/P3 readout (est.): The Efficacy and Safety of 
 DLBS1442 in Patients With Primary Dysmenorrhea
DESCRIPTION:The Efficacy and Safety of DLBS1442 in Patients With Primary Dy
 smenorrhea\nNCT07937462 | PHASE2/PHASE3 | RECRUITING | sponsor: Dexa Medic
 a Group\nPrimary completion date (ESTIMATED)\; top-line results usually fo
 llow later.\nDate precision: month (shown on the first day)\nSource: https
 ://clinicaltrials.gov/study/NCT07937462\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07937462
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:bc29c8a70c1be583a208@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Janssen Research & Development\, LLC P3 readout (est.): PROTEUS
DESCRIPTION:A Study of Apalutamide in Participants With High-Risk\, Localiz
 ed or Locally Advanced Prostate Cancer Who Are Candidates for Radical Pros
 tatectomy\nNCT03767244 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Janssen
  Research & Development\, LLC\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nSource: https://clinicaltrials.gov/stud
 y/NCT03767244\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03767244
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:65c7fe9810c41a4042c1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Intra-IMMUSG Pte Ltd P2 readout (est.): A Study to Assess Safety an
 d Efficacy of PRL3-Zumab in Patients With Solid Tumors
DESCRIPTION:A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients
  With Solid Tumors\nNCT04452955 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor
 : Intra-IMMUSG Pte Ltd\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT04
 452955\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04452955
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4c1034cc38b20d08d712@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:EpicentRx\, Inc. P2 readout (est.): BETA-PRIME
DESCRIPTION:A Study of AdAPT-001 in Subjects With Sarcoma and Refractory So
 lid Tumors\nNCT04673942 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Epicen
 tRx\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nSource: https://clinicaltrials.gov/study/NCT04673942\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04673942
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1f061add0456ec9cd260@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Octapharma P3 readout (est.): Efficacy of Atenativ in Patients With
  Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
DESCRIPTION:Efficacy of Atenativ in Patients With Congenital Antithrombin D
 eficiency Undergoing Surgery or Delivery\nNCT04918173 | PHASE3 | RECRUITIN
 G | sponsor: Octapharma\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0
 4918173\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04918173
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:925204daf367ee6e7df1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:K-Group\, Beta\, Inc.\, a wholly owned subsidiary of Zentalis Pharm
 aceuticals\, Inc P2 readout (est.): DENALI
DESCRIPTION:A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resist
 ant High-Grade Serous Ovarian\, Fallopian Tube or Primary Peritoneal Cance
 r\nNCT05128825 | PHASE2 | RECRUITING | sponsor: K-Group\, Beta\, Inc.\, a 
 wholly owned subsidiary of Zentalis Pharmaceuticals\, Inc\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nSource: htt
 ps://clinicaltrials.gov/study/NCT05128825\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05128825
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d70ca6e2f2ea26270853@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Shanghai Pharmaceuticals Holding Co.\, Ltd P2/P3 readout (est.): Sa
 fety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the 
 Treatment of Locally Advanced or Metastatic Breast Cancer
DESCRIPTION:Safety and Efficacy of SPH4336 in Combination With Endocrine Th
 erapy in the Treatment of Locally Advanced or Metastatic Breast Cancer\nNC
 T05860465 | PHASE2/PHASE3 | RECRUITING | sponsor: Shanghai Pharmaceuticals
  Holding Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-line results
  usually follow later.\nSource: https://clinicaltrials.gov/study/NCT058604
 65\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05860465
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:41d66a07157623bb3149@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Tasly Pharmaceutical Group Co.\, Ltd P3 readout (est.): A Study of 
 Comparing Overall Improvement of Patients With Spondyloarthritis Treated W
 ith Jitongning Tablets and Placebo
DESCRIPTION:A Study of Comparing Overall Improvement of Patients With Spond
 yloarthritis Treated With Jitongning Tablets and Placebo\nNCT06000956 | PH
 ASE3 | RECRUITING | sponsor: Tasly Pharmaceutical Group Co.\, Ltd\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nSou
 rce: https://clinicaltrials.gov/study/NCT06000956\nScheduling/reference da
 ta from public records\; dates can move. Not investment\, legal or medical
  advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06000956
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7d6b065757fadb90925d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:RNAC P2 readout (est.): SLE-001
DESCRIPTION:Descartes-08 for Patients With Systemic Lupus Erythematosus\nNC
 T06038474 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Cartesian Therapeuti
 cs\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nTicker RNAC (confidence 0.9)\nSource: https://clinicaltrials.gov/s
 tudy/NCT06038474\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06038474
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7aa597c0e3fd4523b273@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:FindCure Biosciences (ZhongShan) Co.\, Ltd. P1/P2 readout (est.): A
  Study of FC084CSA in Combination of Tislelizumab in Patients With Advance
 d Malignant Solid Tumors
DESCRIPTION:A Study of FC084CSA in Combination of Tislelizumab in Patients 
 With Advanced Malignant Solid Tumors\nNCT06499350 | PHASE1/PHASE2 | RECRUI
 TING | sponsor: FindCure Biosciences (ZhongShan) Co.\, Ltd.\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nSource: h
 ttps://clinicaltrials.gov/study/NCT06499350\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06499350
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e7479892ac235551f4c7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:AP Biosciences Inc. P1/P2 readout (est.): A Study of AP402 in HER2-
 Positive Patients With Locally or Advanced Solid Tumors
DESCRIPTION:A Study of AP402 in HER2-Positive Patients With Locally or Adva
 nced Solid Tumors\nNCT06669975 | PHASE1/PHASE2 | RECRUITING | sponsor: AP 
 Biosciences Inc.\nPrimary completion date (ESTIMATED)\; top-line results u
 sually follow later.\nSource: https://clinicaltrials.gov/study/NCT06669975
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06669975
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:986f8fa6d1c242a29f2a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Beijing Biostar Pharmaceuticals Co.\, Ltd. P2 readout (est.): Utide
 lone Injection Combined with Bevacizumab Injection for Non-small Cell Lung
  Cancer Patients with Brain Metastases
DESCRIPTION:Utidelone Injection Combined with Bevacizumab Injection for Non
 -small Cell Lung Cancer Patients with Brain Metastases\nNCT06683703 | PHAS
 E2 | NOT_YET_RECRUITING | sponsor: Beijing Biostar Pharmaceuticals Co.\, L
 td.\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nSource: https://clinicaltrials.gov/study/NCT06683703\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06683703
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d0b37b51623bd83c5df6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:BIIB P3 readout (est.): TRANSCEND
DESCRIPTION:A Study to Learn More About the Effects and Safety of Felzartam
 ab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated 
 Rejection (AMR)\nNCT06685757 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: B
 iogen\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nTicker BIIB (confidence 0.9)\nSource: https://clinicaltrials.go
 v/study/NCT06685757\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06685757
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3b4221e02a389799cd38@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Shanghai Vitalgen BioPharma Co.\, Ltd. P3 readout (est.): Study to 
 Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With 
 Bietti Crystalline Dystrophy
DESCRIPTION:Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Thera
 py in Patients With Bietti Crystalline Dystrophy\nNCT06699108 | PHASE3 | A
 CTIVE_NOT_RECRUITING | sponsor: Shanghai Vitalgen BioPharma Co.\, Ltd.\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nSource: https://clinicaltrials.gov/study/NCT06699108\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06699108
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cb1838763378c489d340@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SNY P3 readout (est.): Study of the Safety and Immunogenicity of Ca
 tch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21)
  in Healthy Infants\, Toddlers\, Children\, and Adolescents
DESCRIPTION:Study of the Safety and Immunogenicity of Catch-up Vaccination 
 With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants
 \, Toddlers\, Children\, and Adolescents\nNCT06838000 | PHASE3 | ACTIVE_NO
 T_RECRUITING | sponsor: Sanofi Pasteur\, a Sanofi Company\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nTicker SNY 
 (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT06838000\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06838000
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5644d10c9c0c18870621@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:CellARTs Inc. P1/P2 readout (est.): SDTO
DESCRIPTION:Spermatogonial Differentiation Via Testicular Organoid\nNCT0684
 1861 | PHASE1/PHASE2 | RECRUITING | sponsor: CellARTs Inc.\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nSource: ht
 tps://clinicaltrials.gov/study/NCT06841861\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06841861
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:28da8ab92dacece77037@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. P2 re
 adout (est.): FCN-338 in Combination With Azacitidine or Chemotherapy in M
 yeloid Neoplasms
DESCRIPTION:FCN-338 in Combination With Azacitidine or Chemotherapy in Myel
 oid Neoplasms\nNCT06858618 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sha
 nghai Fosun Pharmaceutical Industrial Development Co. Ltd.\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nSource: ht
 tps://clinicaltrials.gov/study/NCT06858618\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06858618
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2148e4c16fa472142ead@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SNY P1/P2 readout (est.): Study to Evaluate the Safety and the Immu
 nogenicity of a Second Generation Structurally Designed mRNA Vaccine Candi
 date Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants
  Aged 18 Years and Older
DESCRIPTION:Study to Evaluate the Safety and the Immunogenicity of a Second
  Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic 
 Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Old
 er\nNCT06907511 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sanofi\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nTicker SNY (confidence 0.9)\nSource: https://clinicaltrials.gov/study
 /NCT06907511\nScheduling/reference data from public records\; dates can mo
 ve. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06907511
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c0c542a2392ddd5e0f83@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:HealthBio\, Inc. P2/P3 readout (est.): IMPACT-LC
DESCRIPTION:A Multi-Center\, Individually-Randomized\, Double-Blind\, Place
 bo-Controlled\, Parallel-Group\, Superiority Trial to Evaluate the Efficac
 y of the Combination of Maraviroc and Atorvastatin for the Treatment of Su
 bjects With Long COVID\nNCT06974084 | PHASE2/PHASE3 | NOT_YET_RECRUITING |
  sponsor: HealthBio\, Inc.\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nSource: https://clinicaltrials.gov/study/N
 CT06974084\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06974084
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f870c9ed4266cfe64002@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Virchow Group P3 readout (est.): VBPL-IVIGP3
DESCRIPTION:Efficacy\, Safety and Pharmacokinetic of Virchow IVIG in PID Pa
 tients\nNCT07017036 | PHASE3 | NOT_YET_RECRUITING | sponsor: Virchow Group
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nSource: https://clinicaltrials.gov/study/NCT07017036\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07017036
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6993c376bde1175ef77b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Fujian Akeylink Biotechnology Co.\, Ltd. P3 readout (est.): To Eval
 uate the Efficacy\, Safety and Population Pharmacokinetics of GST-HG141 in
  Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response t
 o Antiviral Drug Treatment
DESCRIPTION:To Evaluate the Efficacy\, Safety and Population Pharmacokineti
 cs of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Ina
 dequate Response to Antiviral Drug Treatment\nNCT07090759 | PHASE3 | RECRU
 ITING | sponsor: Fujian Akeylink Biotechnology Co.\, Ltd.\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nSource: htt
 ps://clinicaltrials.gov/study/NCT07090759\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07090759
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a57b88a49a628cd313de@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Guangdong Raynovent Biotech Co.\, Ltd P3 readout (est.): A Study of
  RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and
  Exercise Alone
DESCRIPTION:A Study of RAY1225 in Participants With Type 2 Diabetes Not Con
 trolled With Diet and Exercise Alone\nNCT07139535 | PHASE3 | NOT_YET_RECRU
 ITING | sponsor: Guangdong Raynovent Biotech Co.\, Ltd\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nSource: https:
 //clinicaltrials.gov/study/NCT07139535\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07139535
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f7e762098736909d1cce@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Guangdong Raynovent Biotech Co.\, Ltd P3 readout (est.): A Study of
  RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs i
 n Participants With Type 2 Diabetes
DESCRIPTION:A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral
  Antidiabetic Drugs in Participants With Type 2 Diabetes\nNCT07139548 | PH
 ASE3 | NOT_YET_RECRUITING | sponsor: Guangdong Raynovent Biotech Co.\, Ltd
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nSource: https://clinicaltrials.gov/study/NCT07139548\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07139548
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f72aba6e18f2592d64ad@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ASTEROGENE Biomedical Co. Ltd. P1/P2 readout (est.): EvaluatIon of 
 Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease
DESCRIPTION:EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degen
 erative Disc Disease\nNCT07168603 | PHASE1/PHASE2 | RECRUITING | sponsor: 
 ASTEROGENE Biomedical Co. Ltd.\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nSource: https://clinicaltrials.gov/stu
 dy/NCT07168603\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07168603
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4d5e7a14c64c0dbe83da@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:JYAMS PET Research & Development Limited P3 readout (est.): Evaluat
 e the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impa
 irment and Subjects With Normal Cognitive Function
DESCRIPTION:Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-rela
 ted Cognitive Impairment and Subjects With Normal Cognitive Function\nNCT0
 7422857 | PHASE3 | RECRUITING | sponsor: JYAMS PET Research & Development 
 Limited\nPrimary completion date (ESTIMATED)\; top-line results usually fo
 llow later.\nSource: https://clinicaltrials.gov/study/NCT07422857\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07422857
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5fbf684e2aa8144defc3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:VNDA P3 readout (est.): A Study to Evaluate Tradipitant on Treating
  Nausea and Vomiting Induced by GLP-1R Agonist Use
DESCRIPTION:A Study to Evaluate Tradipitant on Treating Nausea and Vomiting
  Induced by GLP-1R Agonist Use\nNCT07446439 | PHASE3 | RECRUITING | sponso
 r: Vanda Pharmaceuticals\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nTicker VNDA (confidence 0.9)\nSource: https:
 //clinicaltrials.gov/study/NCT07446439\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07446439
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b2d83be16ddf27164c32@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261202
DTEND;VALUE=DATE:20261203
SUMMARY:PFE P3 readout (est.): B7981027
DESCRIPTION:A Study to Learn About Medicine Called Ritlecitinib in Children
  Aged Between 6 to 12 Years With Severe Alopecia Areata\nNCT07029711 | PHA
 SE3 | ACTIVE_NOT_RECRUITING | sponsor: Pfizer\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nTicker PFE (confidence 
 0.9)\nSource: https://clinicaltrials.gov/study/NCT07029711\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07029711
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:57a7d42226e19971843b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:REGN P2 readout (est.): FERVENT-1
DESCRIPTION:A Study to Test the Safety\, Tolerability\, and Efficacy of an 
 Antibody\, REGN7999\, Injected Under the Skin for the Treatment of Iron Ov
 erload in Adult Participants With Non-Transfusion Dependent β-thalassemia
 \, Using MRI Scans to Measure Iron Levels in the Body\nNCT06421636 | PHASE
 2 | ACTIVE_NOT_RECRUITING | sponsor: Regeneron Pharmaceuticals\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nTicker
  REGN (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT064216
 36\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06421636
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1ef54f975c361739ae7a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Eisai Inc. P2 readout (est.): A Study of E2814 With Concurrent Leca
 nemab Treatment in Participants With Early Alzheimer's Disease
DESCRIPTION:A Study of E2814 With Concurrent Lecanemab Treatment in Partici
 pants With Early Alzheimer's Disease\nNCT06602258 | PHASE2 | ACTIVE_NOT_RE
 CRUITING | sponsor: Eisai Inc.\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nSource: https://clinicaltrials.gov/stu
 dy/NCT06602258\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06602258
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:be3c6f1e8801496601f9@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:NVS P2 readout (est.): An Open-label Study of JSB462 (Luxdegalutami
 de) in Combination With Abiraterone in Adult Male Patients With Metastatic
  Hormone-sensitive Prostate Cancer (mHSPC)
DESCRIPTION:An Open-label Study of JSB462 (Luxdegalutamide) in Combination 
 With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive 
 Prostate Cancer (mHSPC)\nNCT06991556 | PHASE2 | ACTIVE_NOT_RECRUITING | sp
 onsor: Novartis Pharmaceuticals\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nTicker NVS (confidence 0.9)\nSource: 
 https://clinicaltrials.gov/study/NCT06991556\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06991556
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9899bab22cbfcc19087a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261204
DTEND;VALUE=DATE:20261205
SUMMARY:PFE P3 readout (est.): A Study to Learn About the Safety\, Tolerabi
 lity\, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Dise
 ase Vaccine
DESCRIPTION:A Study to Learn About the Safety\, Tolerability\, and Immunoge
 nicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine\nNCT075
 00506 | PHASE3 | RECRUITING | sponsor: Pfizer\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nTicker PFE (confidence 
 0.9)\nSource: https://clinicaltrials.gov/study/NCT07500506\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07500506
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8e850f7e21482ce36867@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261205
DTEND;VALUE=DATE:20261206
SUMMARY:Suzhou Forlong Biotechnology Co.\, Ltd P1/P2 readout (est.): A Stud
 y of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
DESCRIPTION:A Study of FL115 in Combination With a PD-1 Antibody in Advance
 d Solid Tumors\nNCT07131202 | PHASE1/PHASE2 | RECRUITING | sponsor: Suzhou
  Forlong Biotechnology Co.\, Ltd\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nSource: https://clinicaltrials.gov/s
 tudy/NCT07131202\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07131202
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:af9a4d099fd9cd5eb428@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261205
DTEND;VALUE=DATE:20261206
SUMMARY:Haisco Pharmaceutical Group Co.\, Ltd. P2 readout (est.): A Study t
 o Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primar
 y IgA Nephropathy
DESCRIPTION:A Study to Evaluate the Long-Term Safety and Efficacy of HSK392
 97 Tablets in Primary IgA Nephropathy\nNCT07616700 | PHASE2 | RECRUITING |
  sponsor: Haisco Pharmaceutical Group Co.\, Ltd.\nPrimary completion date 
 (ESTIMATED)\; top-line results usually follow later.\nSource: https://clin
 icaltrials.gov/study/NCT07616700\nScheduling/reference data from public re
 cords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07616700
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:24c82079f0d902b4415b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261207
DTEND;VALUE=DATE:20261208
SUMMARY:Alexion Pharmaceuticals\, Inc. P3 readout (est.): ECU-NMO-304
DESCRIPTION:Efficacy\, Safety\, PK\, PD\, and ADA of Eculizumab in Chinese 
 Adults With NMOSD\nNCT06724809 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor:
  Alexion Pharmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nSource: https://clinicaltrials.gov/st
 udy/NCT06724809\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06724809
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:70d72c6cedc57e711a67@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261209
SUMMARY:Janssen Research & Development\, LLC P3 readout (est.): LIBREXIA-AF
DESCRIPTION:A Study of Milvexian Versus Apixaban in Participants With Atria
 l Fibrillation\nNCT05757869 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Ja
 nssen Research & Development\, LLC\nPrimary completion date (ESTIMATED)\; 
 top-line results usually follow later.\nSource: https://clinicaltrials.gov
 /study/NCT05757869\nScheduling/reference data from public records\; dates 
 can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05757869
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fd3fda57bf19e0a9d02e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261209
SUMMARY:PFE P2 readout (est.): A 16-Week Study to Learn About the Study Med
 icine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lum
 ps\, Known by the Medical Term\, Hidradenitis Suppurativa\, or HS.
DESCRIPTION:A 16-Week Study to Learn About the Study Medicine Called Ritlec
 itinib in Adults With Long Lasting Painful Red Skin Lumps\, Known by the M
 edical Term\, Hidradenitis Suppurativa\, or HS.\nNCT07228390 | PHASE2 | AC
 TIVE_NOT_RECRUITING | sponsor: Pfizer\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nTicker PFE (confidence 0.9)\nSo
 urce: https://clinicaltrials.gov/study/NCT07228390\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07228390
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7b41a167fc6b53a05205@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261210
SUMMARY:Karuna Therapeutics\, Inc.\, a Bristol Myers Squibb company P3 read
 out (est.): A Study to Assess Efficacy and Safety of KarXT for the Treatme
 nt of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
DESCRIPTION:A Study to Assess Efficacy and Safety of KarXT for the Treatmen
 t of Psychosis Associated With Alzheimer's Disease (ADEPT-2)\nNCT06126224 
 | PHASE3 | RECRUITING | sponsor: Karuna Therapeutics\, Inc.\, a Bristol My
 ers Squibb company\nPrimary completion date (ESTIMATED)\; top-line results
  usually follow later.\nSource: https://clinicaltrials.gov/study/NCT061262
 24\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06126224
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:68eef1a7cc0bd9bcc421@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261210
SUMMARY:SK Bioscience Co.\, Ltd. P1/P2 readout (est.): A Phase I/II\, Dose-
 finding Study to Assess the Safety\, Reactogenicity\, and Immunogenicity o
 f a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.
DESCRIPTION:A Phase I/II\, Dose-finding Study to Assess the Safety\, Reacto
 genicity\, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine
  (GBP511) in Healthy Adults.\nNCT07280858 | PHASE1/PHASE2 | ACTIVE_NOT_REC
 RUITING | sponsor: SK Bioscience Co.\, Ltd.\nPrimary completion date (ESTI
 MATED)\; top-line results usually follow later.\nSource: https://clinicalt
 rials.gov/study/NCT07280858\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07280858
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ff479c8fe0551fd861eb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Shanghai Pharmaceuticals Holding Co.\, Ltd P2 readout (est.): Effic
 acy and Safety of LT3001 on Treating the Acute Ischemic Stroke
DESCRIPTION:Efficacy and Safety of LT3001 on Treating the Acute Ischemic St
 roke\nNCT05686642 | PHASE2 | RECRUITING | sponsor: Shanghai Pharmaceutical
 s Holding Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nSource: https://clinicaltrials.gov/study/NCT05686
 642\nScheduling/reference data from public records\; dates can move. Not i
 nvestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05686642
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e4ff432836339299d959@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Boehringer Ingelheim P3 readout (est.): Beamion LUNG-2: A Study to 
 Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small
  Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
DESCRIPTION:Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631
 ) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutation
 s Compared With Standard Treatment\nNCT06151574 | PHASE3 | ACTIVE_NOT_RECR
 UITING | sponsor: Boehringer Ingelheim\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nSource: https://clinicaltrials
 .gov/study/NCT06151574\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06151574
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b4f76c4976a1c9a3c6ec@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:AZN P2 readout (est.): BaxDuo-Baltic
DESCRIPTION:A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Co
 mbination With Baxdrostat Compared With Baxdrostat on Albuminuria in Parti
 cipants With Chronic Kidney Disease and High Blood Pressure.\nNCT07222917 
 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: AstraZeneca\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nTicker AZN (c
 onfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07222917\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07222917
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5e89f496817544b4f407@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:GlaxoSmithKline P2 readout (est.): Extended Access of Momelotinib i
 n Adults With Myelofibrosis
DESCRIPTION:Extended Access of Momelotinib in Adults With Myelofibrosis\nNC
 T03441113 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: GlaxoSmithKline\nPri
 mary completion date (ESTIMATED)\; top-line results usually follow later.\
 nSource: https://clinicaltrials.gov/study/NCT03441113\nScheduling/referenc
 e data from public records\; dates can move. Not investment\, legal or med
 ical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03441113
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c0fe3f800822cad08a91@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:Seagen\, a wholly owned subsidiary of Pfizer P2 readout (est.): A S
 tudy of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer
  That Expresses HER2
DESCRIPTION:A Study of Disitamab Vedotin Alone or With Pembrolizumab in Uro
 thelial Cancer That Expresses HER2\nNCT04879329 | PHASE2 | RECRUITING | sp
 onsor: Seagen\, a wholly owned subsidiary of Pfizer\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nSource: https://c
 linicaltrials.gov/study/NCT04879329\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04879329
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f3f4482e96d0cf7e79e7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:Ausper Biopharma Co.\, Ltd. P2 readout (est.): A Study to Evaluate 
 the Efficacy and Safety of AHB-137 Injection in Participants With Chronic 
 Hepatitis B (CHB)
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of AHB-137 Injectio
 n in Participants With Chronic Hepatitis B (CHB)\nNCT07137910 | PHASE2 | R
 ECRUITING | sponsor: Ausper Biopharma Co.\, Ltd.\nPrimary completion date 
 (ESTIMATED)\; top-line results usually follow later.\nSource: https://clin
 icaltrials.gov/study/NCT07137910\nScheduling/reference data from public re
 cords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07137910
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4f777d576c5705fb6517@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:Beijing QL Biopharmaceutical Co.\,Ltd P2 readout (est.): Efficacy a
 nd Safety of ZT006 in Overweight and Obese Participants
DESCRIPTION:Efficacy and Safety of ZT006 in Overweight and Obese Participan
 ts\nNCT07230132 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Beijing QL Bio
 pharmaceutical Co.\,Ltd\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0
 7230132\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07230132
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fbc6073edecd24f513f3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:CSPC Megalith Biopharmaceutical Co.\,Ltd. P3 readout (est.): SYNSTA
 R-02
DESCRIPTION:A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osime
 rtinib in Patients With Locally Advanced or Metastatic NSCLC\nNCT07376382 
 | PHASE3 | NOT_YET_RECRUITING | sponsor: CSPC Megalith Biopharmaceutical C
 o.\,Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nSource: https://clinicaltrials.gov/study/NCT07376382\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07376382
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e7ba9565dbc2e0bf682b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:Shenzhen Salubris Pharmaceuticals Co.\, Ltd. P2 readout (est.): A P
 hase II\, Randomized\, Double-Blind\, Placebo-Controlled Study of Oral SAL
 0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Ev
 ents
DESCRIPTION:A Phase II\, Randomized\, Double-Blind\, Placebo-Controlled Stu
 dy of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Car
 diovascular Events\nNCT07729475 | PHASE2 | NOT_YET_RECRUITING | sponsor: S
 henzhen Salubris Pharmaceuticals Co.\, Ltd.\nPrimary completion date (ESTI
 MATED)\; top-line results usually follow later.\nSource: https://clinicalt
 rials.gov/study/NCT07729475\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07729475
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8f9e2f77ad8131e46015@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261213
DTEND;VALUE=DATE:20261214
SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. P3 readout (est.): To Evaluate 
 the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic 
 Arthritis
DESCRIPTION:To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjec
 ts of Active Psoriatic Arthritis\nNCT04957550 | PHASE3 | ACTIVE_NOT_RECRUI
 TING | sponsor: Jiangsu HengRui Medicine Co.\, Ltd.\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nSource: https://c
 linicaltrials.gov/study/NCT04957550\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04957550
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:57d40ed0c51e2131b826@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:BMY P2 readout (est.): AURORA-HFpEF
DESCRIPTION:Study to Evaluate Safety\, Tolerability and Drug Levels of BMS-
 986435/MYK-224 in Participants With Heart Failure With Preserved Ejection 
 Fraction (HFpEF)\nNCT06122779 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: 
 Bristol-Myers Squibb\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nTicker BMY (confidence 0.9)\nSource: https://cli
 nicaltrials.gov/study/NCT06122779\nScheduling/reference data from public r
 ecords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06122779
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5f64ddad39685ffb7aa8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:GlaxoSmithKline P2 readout (est.): RUBY-J
DESCRIPTION:A Study of Dostarlimab in Combination With Carboplatin-paclitax
 el in Japanese Participants With Primary Advanced or Recurrent Endometrial
  Cancer\nNCT06317311 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: GlaxoSmit
 hKline\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nSource: https://clinicaltrials.gov/study/NCT06317311\nScheduli
 ng/reference data from public records\; dates can move. Not investment\, l
 egal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06317311
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ed4c88f60437e23a2078@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:AMGN P3 readout (est.): Eucalyptus
DESCRIPTION:Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pemb
 rolizumab)\nNCT06430866 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Amgen\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nTicker AMGN (confidence 0.9)\nSource: https://clinicaltrials.gov/stud
 y/NCT06430866\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06430866
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8493f6df19f268d873d2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:GlaxoSmithKline P3 readout (est.): A Study on the Immune Response a
 nd Safety of the Second Dose of an Investigational Chickenpox Vaccine When
  Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months 
 of Age
DESCRIPTION:A Study on the Immune Response and Safety of the Second Dose of
  an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Mo
 nths After a First Dose at 12 to 15 Months of Age\nNCT06806137 | PHASE3 | 
 RECRUITING | sponsor: GlaxoSmithKline\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nSource: https://clinicaltrials.
 gov/study/NCT06806137\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06806137
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4efa60f6e64c2d5af55a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:NVO P2 readout (est.): A Research Study on How Well Different Doses
  of the Medicine NNC0662-0419 Help People Living With Overweight or Obesit
 y
DESCRIPTION:A Research Study on How Well Different Doses of the Medicine NN
 C0662-0419 Help People Living With Overweight or Obesity\nNCT07184632 | PH
 ASE2 | ACTIVE_NOT_RECRUITING | sponsor: Novo Nordisk A/S\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nTicker NVO (
 confidence 0.95)\nSource: https://clinicaltrials.gov/study/NCT07184632\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07184632
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4a7648e921b9b73edec7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Beijing Tide Pharmaceutical Co.\, Ltd P2 readout (est.): TRD205
DESCRIPTION:Efficacy and Safety of TRD205 Tablets for Postoperative Analges
 ia in Unilateral Total Hip Arthroplasty (Phase IIb)\nNCT07543796 | PHASE2 
 | RECRUITING | sponsor: Beijing Tide Pharmaceutical Co.\, Ltd\nPrimary com
 pletion date (ESTIMATED)\; top-line results usually follow later.\nSource:
  https://clinicaltrials.gov/study/NCT07543796\nScheduling/reference data f
 rom public records\; dates can move. Not investment\, legal or medical adv
 ice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07543796
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0223eb84341b6582ecc7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Gedeon Richter Plc. P3 readout (est.): Efficacy and Safety of Carip
 razine in the Treatment of Adolescent Participants (13 to 17 Years of Age)
  With Schizophrenia
DESCRIPTION:Efficacy and Safety of Cariprazine in the Treatment of Adolesce
 nt Participants (13 to 17 Years of Age) With Schizophrenia\nNCT03817502 | 
 PHASE3 | RECRUITING | sponsor: Gedeon Richter Plc.\nPrimary completion dat
 e (ESTIMATED)\; top-line results usually follow later.\nSource: https://cl
 inicaltrials.gov/study/NCT03817502\nScheduling/reference data from public 
 records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03817502
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:29e54c126b9cc54d6d13@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:PMVP P1/P2 readout (est.): The Evaluation of PC14586 in Patients Wi
 th Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
DESCRIPTION:The Evaluation of PC14586 in Patients With Advanced Solid Tumor
 s Harboring a TP53 Y220C Mutation (PYNNACLE)\nNCT04585750 | PHASE1/PHASE2 
 | RECRUITING | sponsor: PMV Pharmaceuticals\, Inc\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nTicker PMVP (confid
 ence 0.9)\nSource: https://clinicaltrials.gov/study/NCT04585750\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04585750
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:70375d1b28a9d7718675@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Janssen Research & Development\, LLC P2/P3 readout (est.): Efficacy
  and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demy
 elinating Polyneuropathy (CIDP)
DESCRIPTION:Efficacy and Safety Study of Nipocalimab for Adults With Chroni
 c Inflammatory Demyelinating Polyneuropathy (CIDP)\nNCT05327114 | PHASE2/P
 HASE3 | RECRUITING | sponsor: Janssen Research & Development\, LLC\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nSo
 urce: https://clinicaltrials.gov/study/NCT05327114\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05327114
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6b9cdbd41f5b9755f8ee@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:GV20 Therapeutics P1/P2 readout (est.): A Study of GV20-0251 Monoth
 erapy and GV20-0251 in Combination With Pembrolizumab in Participants With
  Solid Tumor Malignancies
DESCRIPTION:A Study of GV20-0251 Monotherapy and GV20-0251 in Combination W
 ith Pembrolizumab in Participants With Solid Tumor Malignancies\nNCT056694
 30 | PHASE1/PHASE2 | RECRUITING | sponsor: GV20 Therapeutics\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nSource: 
 https://clinicaltrials.gov/study/NCT05669430\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05669430
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8169a31d9faa6ec911d7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:EXEL P3 readout (est.): STELLAR-304
DESCRIPTION:Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanc
 ed or Metastatic Non-Clear Cell Renal Cell Carcinoma\nNCT05678673 | PHASE3
  | ACTIVE_NOT_RECRUITING | sponsor: Exelixis\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker EXEL (confidence 
 0.9)\nSource: https://clinicaltrials.gov/study/NCT05678673\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05678673
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e6ce634b7825202e68e2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:PLL TX AUSTRALIA PTY LTD P1/P2 readout (est.): A Study to Evaluate 
 the Safety\, Efficacy\, and Pharmacodynamics of PLL001 in ALS Patients
DESCRIPTION:A Study to Evaluate the Safety\, Efficacy\, and Pharmacodynamic
 s of PLL001 in ALS Patients\nNCT06513546 | PHASE1/PHASE2 | NOT_YET_RECRUIT
 ING | sponsor: PLL TX AUSTRALIA PTY LTD\nPrimary completion date (ESTIMATE
 D)\; top-line results usually follow later.\nSource: https://clinicaltrial
 s.gov/study/NCT06513546\nScheduling/reference data from public records\; d
 ates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06513546
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0a5cc055f8b840b4aaf3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Alexion Pharmaceuticals\, Inc. P3 readout (est.): PK\, PD\, Safety\
 , and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Gener
 alized Myasthenia Gravis
DESCRIPTION:PK\, PD\, Safety\, and Efficacy Study of Gefurulimab in Pediatr
 ic Patients With AChR+ Generalized Myasthenia Gravis\nNCT06607627 | PHASE3
  | RECRUITING | sponsor: Alexion Pharmaceuticals\, Inc.\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nSource: https
 ://clinicaltrials.gov/study/NCT06607627\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06607627
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:95e2745deb8b36ea2f04@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:EXACT Therapeutics AS P2 readout (est.): ENACT
DESCRIPTION:Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatm
 ent of Locally Advanced Pancreatic Cancer\nNCT06850623 | PHASE2 | RECRUITI
 NG | sponsor: EXACT Therapeutics AS\nPrimary completion date (ESTIMATED)\;
  top-line results usually follow later.\nSource: https://clinicaltrials.go
 v/study/NCT06850623\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06850623
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5d5bc46c06a1075462f8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:CERS P2 readout (est.): A Recovery and Lifespan Study Using INTERCE
 PT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With
  AS-1
DESCRIPTION:A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells P
 repared Using the INTERCEPT Blood System for RBCs With AS-1\nNCT07015437 |
  PHASE2 | RECRUITING | sponsor: Cerus Corporation\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nTicker CERS (confid
 ence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07015437\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07015437
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7bfdedbd41d444aa3a9d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Ipsen P3 readout (est.): LAURITE 1
DESCRIPTION:A Study to Assess the Effectiveness and Safety of IPN10200 in A
 dults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows\nNCT
 07427797 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Ipsen\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nSource: ht
 tps://clinicaltrials.gov/study/NCT07427797\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07427797
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:aaa0f7ab42a1b739de03@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Ipsen P3 readout (est.): LAURITE 2
DESCRIPTION:A Study to Assess the Effectiveness and Safety of IPN10200 Over
  Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eye
 brows\nNCT07435428 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Ipsen\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Source: https://clinicaltrials.gov/study/NCT07435428\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07435428
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:11f12591fef97cf7e93a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261216
DTEND;VALUE=DATE:20261217
SUMMARY:Hoffmann-La Roche P3 readout (est.): Cielo
DESCRIPTION:A Study to Evaluate the Efficacy\, Safety\, Pharmacokinetics (P
 K)\, and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N
 -methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inact
 ivated 1 (LGI1) Encephalitis\nNCT05503264 | PHASE3 | ACTIVE_NOT_RECRUITING
  | sponsor: Hoffmann-La Roche\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nSource: https://clinicaltrials.gov/stud
 y/NCT05503264\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05503264
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:770b5424ce44b6505da1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261216
DTEND;VALUE=DATE:20261217
SUMMARY:Shanghai JMT-Bio Inc. P3 readout (est.): Neo-Healer
DESCRIPTION:A Phase III Study of KN026 in Combination With HB1801 ± Carbop
 latin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive
  Breast Cancer\nNCT06747338 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Sh
 anghai JMT-Bio Inc.\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nSource: https://clinicaltrials.gov/study/NCT06747
 338\nScheduling/reference data from public records\; dates can move. Not i
 nvestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06747338
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ba09db051ad8f667387c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:BMY P2 readout (est.): TargetTau-1
DESCRIPTION:Study to Evaluate the Efficacy\, Safety\, and Tolerability of a
 n Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Earl
 y Alzheimer's Disease\nNCT06268886 | PHASE2 | ACTIVE_NOT_RECRUITING | spon
 sor: Bristol-Myers Squibb\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nTicker BMY (confidence 0.9)\nSource: https:
 //clinicaltrials.gov/study/NCT06268886\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06268886
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3a98f67d8f955489c32c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Ipsen P3 readout (est.): ELONSEN
DESCRIPTION:A Study of Elafibranor in Adult Japanese Participants With Prim
 ary Biliary Cholangitis (PBC)\nNCT06730061 | PHASE3 | ACTIVE_NOT_RECRUITIN
 G | sponsor: Ipsen\nPrimary completion date (ESTIMATED)\; top-line results
  usually follow later.\nSource: https://clinicaltrials.gov/study/NCT067300
 61\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06730061
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e92f658ad985b591ee00@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:SNY P2 readout (est.): CHROMA CD
DESCRIPTION:A Study to Investigate Efficacy and Safety of Brivekimig in Par
 ticipants With Crohn's Disease\nNCT06958536 | PHASE2 | RECRUITING | sponso
 r: Sanofi\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nTicker SNY (confidence 0.9)\nSource: https://clinicaltrials
 .gov/study/NCT06958536\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06958536
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c5d8b40d2db2836e7ab2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:SNY P2 readout (est.): COLOR UC
DESCRIPTION:A Study to Investigate the Efficacy and Safety of Brivekimig in
  Adult Participants With Ulcerative Colitis\nNCT06975722 | PHASE2 | ACTIVE
 _NOT_RECRUITING | sponsor: Sanofi\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nTicker SNY (confidence 0.9)\nSource
 : https://clinicaltrials.gov/study/NCT06975722\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06975722
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5706de3fb54b2e0f8981@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:TAK P3 readout (est.): A Trial of TAK-861 for the Treatment of Narc
 olepsy With Cataplexy
DESCRIPTION:A Trial of TAK-861 for the Treatment of Narcolepsy With Cataple
 xy\nNCT07363720 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Takeda\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nTi
 cker TAK (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT073
 63720\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07363720
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:86e8371b8392a329996b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261218
DTEND;VALUE=DATE:20261219
SUMMARY:Han Xu\, M.D.\, Ph.D.\, FAPCR\, Sponsor-Investigator\, IRB Chair P2
 /P3 readout (est.): Drugs-SNPs
DESCRIPTION:Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single 
 Nucleotide Polymorphisms\nNCT06062810 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUIT
 ING | sponsor: Han Xu\, M.D.\, Ph.D.\, FAPCR\, Sponsor-Investigator\, IRB 
 Chair\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nSource: https://clinicaltrials.gov/study/NCT06062810\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06062810
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c195a088012480cafadf@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261218
DTEND;VALUE=DATE:20261219
SUMMARY:Han Xu\, M.D.\, Ph.D.\, FAPCR\, Medical Director\, IRB Chair P2/P3 
 readout (est.): Drug-SNP
DESCRIPTION:Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single
  Nucleotide Polymorphisms\nNCT07145333 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUI
 TING | sponsor: Han Xu\, M.D.\, Ph.D.\, FAPCR\, Medical Director\, IRB Cha
 ir\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nSource: https://clinicaltrials.gov/study/NCT07145333\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07145333
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:53683cfefc8248622ba0@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261218
DTEND;VALUE=DATE:20261219
SUMMARY:Ausper Biopharma Co.\, Ltd. P3 readout (est.): Study of AHB-137 in 
 Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Ana
 logues (NAs)(AUSHINE)
DESCRIPTION:Study of AHB-137 in Participants With Chronic Hepatitis B (CHB)
  Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)\nNCT07246889 | PHASE3
  | ACTIVE_NOT_RECRUITING | sponsor: Ausper Biopharma Co.\, Ltd.\nPrimary c
 ompletion date (ESTIMATED)\; top-line results usually follow later.\nSourc
 e: https://clinicaltrials.gov/study/NCT07246889\nScheduling/reference data
  from public records\; dates can move. Not investment\, legal or medical a
 dvice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07246889
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3c2bad008d9b64bc6659@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Haisco Pharmaceutical Group Co.\, Ltd. P2 readout (est.): A Phase 2
  Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients
  With Moderate-to-Severe Plaque Psoriasis
DESCRIPTION:A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy an
 d Safety in Patients With Moderate-to-Severe Plaque Psoriasis\nNCT07158268
  | PHASE2 | NOT_YET_RECRUITING | sponsor: Haisco Pharmaceutical Group Co.\
 , Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nSource: https://clinicaltrials.gov/study/NCT07158268\nScheduli
 ng/reference data from public records\; dates can move. Not investment\, l
 egal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07158268
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1ea1464e164d19037b41@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:TJ Biopharma Co.\, Ltd. P3 readout (est.): A Phase III Clinical Stu
 dy to Evaluate the Efficacy\, Safety\, and Tolerability of Plonmarlimab in
  Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-assoc
 iated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activa
 tion Syndrome [MAS])
DESCRIPTION:A Phase III Clinical Study to Evaluate the Efficacy\, Safety\, 
 and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheu
 matic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytos
 is (Also Known as Macrophage Activation Syndrome [MAS])\nNCT07208058 | PHA
 SE3 | RECRUITING | sponsor: TJ Biopharma Co.\, Ltd.\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nSource: https://c
 linicaltrials.gov/study/NCT07208058\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07208058
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d087800038ad007045fb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261221
DTEND;VALUE=DATE:20261222
SUMMARY:UCB Biopharma SRL P3 readout (est.): A Study to Assess the Pharmaco
 kinetics and Safety of Bimekizumab in Children and Adolescents With Modera
 te to Severe Hidradenitis Suppurativa
DESCRIPTION:A Study to Assess the Pharmacokinetics and Safety of Bimekizuma
 b in Children and Adolescents With Moderate to Severe Hidradenitis Suppura
 tiva\nNCT06921850 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: UCB Biopharm
 a SRL\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nSource: https://clinicaltrials.gov/study/NCT06921850\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06921850
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0e24b2c05fc383b9165e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:MRK P1/P2 readout (est.): A Study of Belzutifan (MK-6482) in Combin
 ation With Palbociclib Versus Belzutifan Monotherapy in Participants With 
 Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
DESCRIPTION:A Study of Belzutifan (MK-6482) in Combination With Palbociclib
  Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Ca
 rcinoma (MK-6482-024/LITESPARK-024)\nNCT05468697 | PHASE1/PHASE2 | ACTIVE_
 NOT_RECRUITING | sponsor: Merck Sharp & Dohme LLC\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nTicker MRK (confide
 nce 0.6)\nSource: https://clinicaltrials.gov/study/NCT05468697\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05468697
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3a2153c0fa1b2ae72b86@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Janssen Pharmaceutica N.V.\, Belgium P2 readout (est.): Reτain
DESCRIPTION:A Study of JNJ-64042056 in Participants With Preclinical Alzhei
 mer's Disease\nNCT06544616 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Jan
 ssen Pharmaceutica N.V.\, Belgium\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nSource: https://clinicaltrials.gov/
 study/NCT06544616\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06544616
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cd96aac9a892726f78db@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Boehringer Ingelheim P2 readout (est.): A Study to Test Different D
 oses of BI 1584862 in People With a Distinct Form of Age-related Macular D
 egeneration (AMD) Called Geographic Atrophy
DESCRIPTION:A Study to Test Different Doses of BI 1584862 in People With a 
 Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic 
 Atrophy\nNCT06769048 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Boehringe
 r Ingelheim\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nSource: https://clinicaltrials.gov/study/NCT06769048\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06769048
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3ffc9b5d7875fe0d4632@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Adverum Biotechnologies\, Inc. P3 readout (est.): ARTEMIS
DESCRIPTION:Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec)
  in Participants With Neovascular Age-Related Macular Degeneration\nNCT068
 56577 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Adverum Biotechnologies\
 , Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nSource: https://clinicaltrials.gov/study/NCT06856577\nScheduli
 ng/reference data from public records\; dates can move. Not investment\, l
 egal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06856577
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d7bd297694832fa3081c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Taisho Pharmaceutical Co.\, Ltd. P3 readout (est.): A Phase 3 Study
  of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Bi
 nders
DESCRIPTION:A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemo
 dialysis With Phosphate Binders\nNCT07285291 | PHASE3 | RECRUITING | spons
 or: Taisho Pharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\
 ; top-line results usually follow later.\nSource: https://clinicaltrials.g
 ov/study/NCT07285291\nScheduling/reference data from public records\; date
 s can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07285291
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1b94b10f27433c3a0014@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Healthgen Biotechnology Corp. P2 readout (est.): Efficacy and Safet
 y of OsrhCT Before Upper Endoscopy on Improving Visualization of the Gastr
 ic Mucosa.
DESCRIPTION:Efficacy and Safety of OsrhCT Before Upper Endoscopy on Improvi
 ng Visualization of the Gastric Mucosa.\nNCT07893600 | PHASE2 | NOT_YET_RE
 CRUITING | sponsor: Healthgen Biotechnology Corp.\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nSource: https://cli
 nicaltrials.gov/study/NCT07893600\nScheduling/reference data from public r
 ecords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07893600
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9996a9bb8c93dd09bd32@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:R-Bio P3 readout (est.): Follow-up Study for Participants of Joints
 tem Phase 3 Clinical Trial
DESCRIPTION:Follow-up Study for Participants of Jointstem Phase 3 Clinical 
 Trial\nNCT04427930 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: R-Bio\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Source: https://clinicaltrials.gov/study/NCT04427930\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04427930
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:52be3d9371de80389977@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:AZN P3 readout (est.): DOMINICA
DESCRIPTION:A Multicentre\, Randomised\, Double-blind\, Parallel Group\, Pl
 acebo-controlled\, Time-to-first Asthma Exacerbation Phase III Efficacy an
 d Safety Study of Benralizumab in Paediatric Patients With Severe Eosinoph
 ilic Asthma\nNCT05692180 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Astra
 Zeneca\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nTicker AZN (confidence 0.9)\nSource: https://clinicaltrials.go
 v/study/NCT05692180\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05692180
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e83e71bc9fa3edef1880@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:NVS P2 readout (est.): PSMACare
DESCRIPTION:A Phase II Study of AAA617 Alone and AAA617 in Combination With
  ARPI in Patients With PSMA PET Scan Positive CRPC\nNCT05849298 | PHASE2 |
  ACTIVE_NOT_RECRUITING | sponsor: Novartis Pharmaceuticals\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nTicker NVS
  (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05849298\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05849298
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ffc7ff59778471c1a0dd@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Cho Pharma Inc. P1/P2 readout (est.): A Study to Assess Safety and 
 Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjec
 ts With Refractory or Relapsed Non-Hodgkin's Lymphoma
DESCRIPTION:A Study to Assess Safety and Efficacy of CHO-H01 as a Single Ag
 ent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non
 -Hodgkin's Lymphoma\nNCT05950165 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
  sponsor: Cho Pharma Inc.\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nSource: https://clinicaltrials.gov/study/NC
 T05950165\nScheduling/reference data from public records\; dates can move.
  Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05950165
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7f95ece9fdb52f298764@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:HTOO P2 readout (est.): AlphaBreak
DESCRIPTION:FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metas
 tatic Castration-Resistant Prostate Cancer (mCRPC)\nNCT06402331 | PHASE2 |
  ACTIVE_NOT_RECRUITING | sponsor: Fusion Pharmaceuticals Inc.\nPrimary com
 pletion date (ESTIMATED)\; top-line results usually follow later.\nTicker 
 HTOO (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT0640233
 1\nScheduling/reference data from public records\; dates can move. Not inv
 estment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06402331
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0837292088d2a5268f7a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:SNY P2 readout (est.): RESULT
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Frexalimab\, Bri
 vekimig\, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primar
 y Focal Segmental Glomerulosclerosis or Minimal Change Disease\nNCT0650070
 2 | PHASE2 | RECRUITING | sponsor: Sanofi\nPrimary completion date (ESTIMA
 TED)\; top-line results usually follow later.\nTicker SNY (confidence 0.9)
 \nSource: https://clinicaltrials.gov/study/NCT06500702\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06500702
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9200171ce2c00d3c8b96@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Changchun GeneScience Pharmaceutical Co.\, Ltd. P2 readout (est.): 
 A Phase II Study of PEG-rhGH Injection for Short Children Born Small for G
 estational Age: Efficacy\, Safety\, and Pharmacokinetics
DESCRIPTION:A Phase II Study of PEG-rhGH Injection for Short Children Born 
 Small for Gestational Age: Efficacy\, Safety\, and Pharmacokinetics\nNCT07
 260500 | PHASE2 | RECRUITING | sponsor: Changchun GeneScience Pharmaceutic
 al Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usua
 lly follow later.\nSource: https://clinicaltrials.gov/study/NCT07260500\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07260500
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e50f5ea2ebc641903d4c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:OncoZenge AB P3 readout (est.): BEAM-Pain
DESCRIPTION:A Clinical Study to Compare BupiZenge With Lidocaine for Pain D
 ue to Oral Mucositis in Patients With Head and Neck Cancer.\nNCT07672236 |
  PHASE3 | RECRUITING | sponsor: OncoZenge AB\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nSource: https://clinical
 trials.gov/study/NCT07672236\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07672236
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:624e110a8c396b9e268b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Shanghai Kechow Pharma\, Inc. P3 readout (est.): Efficacy and Safet
 y of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Meta
 static Colorectal Cancer
DESCRIPTION:Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patient
 s With BRAF V600E-mutant Metastatic Colorectal Cancer\nNCT06008119 | PHASE
 3 | RECRUITING | sponsor: Shanghai Kechow Pharma\, Inc.\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nSource: https
 ://clinicaltrials.gov/study/NCT06008119\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06008119
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fdcea45a674391966690@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Nanjing Leads Biolabs Co.\,Ltd P2 readout (est.): A Clinical Trial 
 of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substu
 dy 01(NSCLC)]
DESCRIPTION:A Clinical Trial of LBL-024 Combination Drug in Patients With A
 dvanced Solid Tumours[Substudy 01(NSCLC)]\nNCT06783647 | PHASE2 | RECRUITI
 NG | sponsor: Nanjing Leads Biolabs Co.\,Ltd\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nSource: https://clinical
 trials.gov/study/NCT06783647\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06783647
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:00e343e34bd637146a41@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Jiangsu Healthy Life Innovation Medical Technology Co.\, Ltd P3 rea
 dout (est.): Clinical Study of Tumor Treating Fields Combined with Gemcita
 bine and Albumin-bound Paclitaxel in the First-line Treatment of Locally A
 dvanced Pancreatic Cancer
DESCRIPTION:Clinical Study of Tumor Treating Fields Combined with Gemcitabi
 ne and Albumin-bound Paclitaxel in the First-line Treatment of Locally Adv
 anced Pancreatic Cancer\nNCT05653453 | PHASE3 | RECRUITING | sponsor: Jian
 gsu Healthy Life Innovation Medical Technology Co.\, Ltd\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nSource: http
 s://clinicaltrials.gov/study/NCT05653453\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05653453
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0bcff9e6ff0882516f64@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:CSPC ZhongQi Pharmaceutical Technology Co.\, Ltd. P2 readout (est.)
 : A Study to Evaluate the Efficacy and Safety of the Combination of Glumet
 inib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of 
 MET-overexpressed Non-small Cell Lung Cancer
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of the Combination 
 of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Trea
 tment of MET-overexpressed Non-small Cell Lung Cancer\nNCT06525350 | PHASE
 2 | NOT_YET_RECRUITING | sponsor: CSPC ZhongQi Pharmaceutical Technology C
 o.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nSource: https://clinicaltrials.gov/study/NCT06525350\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06525350
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ff3754b80b3a1fa61737@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:GlaxoSmithKline P3 readout (est.): A Study on the Immune Response a
 nd Safety of an Investigational Chickenpox Vaccine When Given to Healthy C
 hildren 12 to 15 Months of Age
DESCRIPTION:A Study on the Immune Response and Safety of an Investigational
  Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age\
 nNCT06740630 | PHASE3 | RECRUITING | sponsor: GlaxoSmithKline\nPrimary com
 pletion date (ESTIMATED)\; top-line results usually follow later.\nSource:
  https://clinicaltrials.gov/study/NCT06740630\nScheduling/reference data f
 rom public records\; dates can move. Not investment\, legal or medical adv
 ice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06740630
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:22ad286ed7fcc89f8577@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:PFE P2 readout (est.): A Study to Learn About Ritlecitinib for the 
 Potential Treatment of Chronic Spontaneous Urticaria in Adults.
DESCRIPTION:A Study to Learn About Ritlecitinib for the Potential Treatment
  of Chronic Spontaneous Urticaria in Adults.\nNCT07219615 | PHASE2 | RECRU
 ITING | sponsor: Pfizer\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nTicker PFE (confidence 0.9)\nSource: https://
 clinicaltrials.gov/study/NCT07219615\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07219615
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:bf82e51a76abb88ccd45@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261226
DTEND;VALUE=DATE:20261227
SUMMARY:CanariaBio Inc. P3 readout (est.): FLORA-5
DESCRIPTION:Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced
  Epithelial Ovarian Cancer Following Optimal Debulking Surgery\nNCT0449811
 7 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: CanariaBio Inc.\nPrimary com
 pletion date (ESTIMATED)\; top-line results usually follow later.\nSource:
  https://clinicaltrials.gov/study/NCT04498117\nScheduling/reference data f
 rom public records\; dates can move. Not investment\, legal or medical adv
 ice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04498117
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:90437b35da8f89cd6b48@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261226
DTEND;VALUE=DATE:20261227
SUMMARY:INCY P3 readout (est.): STOP-HS LTE
DESCRIPTION:A Study to Evaluate the Long-Term Safety and Efficacy of Povorc
 itinib in Participants With Moderate to Severe Hidradenitis Suppurativa\nN
 CT06212999 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Incyte Corporation\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nTicker INCY (confidence 0.9)\nSource: https://clinicaltrials.gov/stud
 y/NCT06212999\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06212999
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6da73f45bbb75ef219f7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Stemline Therapeutics\, Inc. P1/P2 readout (est.): ELEVATE
DESCRIPTION:Open-Label Umbrella Study To Evaluate Safety And Efficacy Of El
 acestrant In Various Combination In Participants With Metastatic Breast Ca
 ncer\nNCT05563220 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Steml
 ine Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0
 5563220\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05563220
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2dfa755279b0bd76eb14@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Akeso P2 readout (est.): A Study to Evaluate the Efficacy and Safet
 y of AK139 in Participants With Asthma
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of AK139 in Partici
 pants With Asthma\nNCT07436221 | PHASE2 | NOT_YET_RECRUITING | sponsor: Ak
 eso\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nSource: https://clinicaltrials.gov/study/NCT07436221\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07436221
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fe5357f448222834b6bf@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Dompé Farmaceutici S.p.A P2 readout (est.): An Exploratory Efficac
 y and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With V
 ehicle in Participants With Dry Eye Disease
DESCRIPTION:An Exploratory Efficacy and Safety Study of DFL24498 Topical Op
 hthalmic Solution Compared With Vehicle in Participants With Dry Eye Disea
 se\nNCT07503886 | PHASE2 | RECRUITING | sponsor: Dompé Farmaceutici S.p.A
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nSource: https://clinicaltrials.gov/study/NCT07503886\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07503886
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:035097f84d841f664d86@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Amplexd Therapeutics\, Inc. P2 readout (est.): Phase II Study of Dy
 splasix™ Intravaginal Suppositories in Patients Patients With High-Risk 
 HPV and Mild Cervical Cytologic Abnormalities
DESCRIPTION:Phase II Study of Dysplasix™ Intravaginal Suppositories in Pa
 tients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormaliti
 es\nNCT07572396 | PHASE2 | RECRUITING | sponsor: Amplexd Therapeutics\, In
 c.\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nSource: https://clinicaltrials.gov/study/NCT07572396\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07572396
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:26ae1cd32277ec685d96@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Hoffmann-La Roche P1/P2 readout (est.): A Study to Evaluate the Saf
 ety\, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp 
 Alfa in Combination With Obinutuzumab and in Combination With Glofitamab F
 ollowing a Pre-Treatment Dose of Obinutuzumab in Participants With Relapse
 d/Refractory B-Cell Non-Hodgkin's Lymphoma
DESCRIPTION:A Study to Evaluate the Safety\, Pharmacokinetics and Prelimina
 ry Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzuma
 b and in Combination With Glofitamab Following a Pre-Treatment Dose of Obi
 nutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Ly
 mphoma\nNCT04077723 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Hof
 fmann-La Roche\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nSource: https://clinicaltrials.gov/study/NCT04077723\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04077723
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c1750137799b29d760a8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:GlaxoSmithKline P2 readout (est.): A Long-term Treatment Extension 
 Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/T
 ESARO-sponsored Niraparib Study
DESCRIPTION:A Long-term Treatment Extension Study of Niraparib in Participa
 nts Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
 \nNCT04641247 | PHASE2 | RECRUITING | sponsor: GlaxoSmithKline\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nSource
 : https://clinicaltrials.gov/study/NCT04641247\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04641247
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9f289b70855ffa417c71@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Beijing InnoCare Pharma Tech Co.\, Ltd. P1/P2 readout (est.): A Pha
 se I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-
 Hodgkin's Lymphoma (B-NHL)
DESCRIPTION:A Phase I/II Study of CM355 in Patients With Relapsed or Refrac
 tory B-Cell Non-Hodgkin's Lymphoma (B-NHL)\nNCT05210868 | PHASE1/PHASE2 | 
 ACTIVE_NOT_RECRUITING | sponsor: Beijing InnoCare Pharma Tech Co.\, Ltd.\n
 Primary completion date (ESTIMATED)\; top-line results usually follow late
 r.\nSource: https://clinicaltrials.gov/study/NCT05210868\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05210868
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8ad2b9e252655d08ab24@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Frantz Viral Therapeutics\, LLC P2 readout (est.): anal HSIL HIV-
DESCRIPTION:Artesunate Suppositories for the Treatment of HIV-negative Pati
 ents With Intra-anal HSIL\nNCT05555862 | PHASE2 | ACTIVE_NOT_RECRUITING | 
 sponsor: Frantz Viral Therapeutics\, LLC\nPrimary completion date (ESTIMAT
 ED)\; top-line results usually follow later.\nSource: https://clinicaltria
 ls.gov/study/NCT05555862\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05555862
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1fe5bd4867257671ddce@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Chengdu Origen Biotechnology Co.\, Ltd. P1/P2 readout (est.): Safet
 y and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-
 related Macular Degeneration (nAMD)
DESCRIPTION:Safety and Tolerability of KH631 Gene Therapy in Subjects With 
 Neovascular Age-related Macular Degeneration (nAMD)\nNCT05672121 | PHASE1/
 PHASE2 | RECRUITING | sponsor: Chengdu Origen Biotechnology Co.\, Ltd.\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nSource: https://clinicaltrials.gov/study/NCT05672121\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05672121
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:86a2901bc31710d55d06@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Nanjing Leads Biolabs Co.\,Ltd P1/P2 readout (est.): A Clinical Tri
 al of LBL-024 Combined With Etoposide and Platinum in Patients With Advanc
 ed Neuroendocrine Carcinoma
DESCRIPTION:A Clinical Trial of LBL-024 Combined With Etoposide and Platinu
 m in Patients With Advanced Neuroendocrine Carcinoma\nNCT06157827 | PHASE1
 /PHASE2 | RECRUITING | sponsor: Nanjing Leads Biolabs Co.\,Ltd\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nSource
 : https://clinicaltrials.gov/study/NCT06157827\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06157827
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b153c3e6b8f6115c4bb3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Jiangsu Topcel-KH Pharmaceutical Co.\, Ltd. P3 readout (est.): Phas
 e 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas i
 n Patients With Crohn's Disease
DESCRIPTION:Phase 3 Study of Human TH-SC01 Cell Injection for Treating Peri
 anal Fistulas in Patients With Crohn's Disease\nNCT06925594 | PHASE3 | REC
 RUITING | sponsor: Jiangsu Topcel-KH Pharmaceutical Co.\, Ltd.\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nSource
 : https://clinicaltrials.gov/study/NCT06925594\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06925594
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f51b7f477de2ef8bd561@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:GlaxoSmithKline P3 readout (est.): A Study to Compare Safety of 4 W
 eeks Exposure to Propellants Hydrofluoroalkane 1\,1-difluoroethane (HFA-15
 2a) and HFA-1\,1\,1\,2-tetrafluoroethane (134a)
DESCRIPTION:A Study to Compare Safety of 4 Weeks Exposure to Propellants Hy
 drofluoroalkane 1\,1-difluoroethane (HFA-152a) and HFA-1\,1\,1\,2-tetraflu
 oroethane (134a)\nNCT07645248 | PHASE3 | RECRUITING | sponsor: GlaxoSmithK
 line\nPrimary completion date (ESTIMATED)\; top-line results usually follo
 w later.\nSource: https://clinicaltrials.gov/study/NCT07645248\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07645248
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8090c55c7c7540202236@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261229
DTEND;VALUE=DATE:20261230
SUMMARY:Suzhou Sanegene Bio Inc. P2 readout (est.): A Study of SGB-9768 in 
 Patients With Complement-mediated Kidney Diseases
DESCRIPTION:A Study of SGB-9768 in Patients With Complement-mediated Kidney
  Diseases\nNCT06786338 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Suzhou 
 Sanegene Bio Inc.\nPrimary completion date (ESTIMATED)\; top-line results 
 usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0678633
 8\nScheduling/reference data from public records\; dates can move. Not inv
 estment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06786338
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a552f9d2e10ea592f95d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261229
DTEND;VALUE=DATE:20261230
SUMMARY:REGN P2 readout (est.): ASCEND-QW
DESCRIPTION:A Study to See How Safe and Effective Alirocumab is When Given 
 Weekly to Adult Participants Who Have Hypercholesterolemia\nNCT07477704 | 
 PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Regeneron Pharmaceuticals\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nT
 icker REGN (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0
 7477704\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07477704
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b9ce7c1e7d150bd5e3cd@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261229
DTEND;VALUE=DATE:20261230
SUMMARY:Arctic Therapeutics P2 readout (est.): HCCAA
DESCRIPTION:Safety\, Tolerability and Efficacy of NPI-001 in Patients With 
 Hereditary Cystatin C Amyloid Angiopathy (HCCAA)\nNCT07716865 | PHASE2 | A
 CTIVE_NOT_RECRUITING | sponsor: Arctic Therapeutics\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nSource: https://c
 linicaltrials.gov/study/NCT07716865\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07716865
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4c5c439a16ec9ed20872@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Teclison Ltd. P2 readout (est.): TATE-PD1
DESCRIPTION:Combination of TATE and PD-1 Inhibitor in Liver Cancer\nNCT0325
 9867 | PHASE2 | RECRUITING | sponsor: Teclison Ltd.\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nSource: https://c
 linicaltrials.gov/study/NCT03259867\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03259867
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fb53bcf1084afcf1336c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:SUPN P1/P2 readout (est.): FIAS
DESCRIPTION:BIS-001-ER for the Treatment of Adult Focal Impaired Awareness 
 Seizures\nNCT03474770 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: S
 upernus Pharmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nTicker SUPN (confidence 0.9)\nSource: 
 https://clinicaltrials.gov/study/NCT03474770\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03474770
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:169c14f54a1f4b612a1f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Xynomic Pharmaceuticals\, Inc. P3 readout (est.): A Study of Pazopa
 nib With or Without Abexinostat in Patients With Locally Advanced or Metas
 tatic Renal Cell Carcinoma (RENAVIV)
DESCRIPTION:A Study of Pazopanib With or Without Abexinostat in Patients Wi
 th Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)\nNCT03592
 472 | PHASE3 | RECRUITING | sponsor: Xynomic Pharmaceuticals\, Inc.\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nS
 ource: https://clinicaltrials.gov/study/NCT03592472\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03592472
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:466be4d6b7817bcf516d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:3D Medicines (Sichuan) Co.\, Ltd. P2 readout (est.): KN035 for dMMR
 /MSI-H Advanced Solid Tumors
DESCRIPTION:KN035 for dMMR/MSI-H Advanced Solid Tumors\nNCT03667170 | PHASE
 2 | ACTIVE_NOT_RECRUITING | sponsor: 3D Medicines (Sichuan) Co.\, Ltd.\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nSource: https://clinicaltrials.gov/study/NCT03667170\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03667170
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7d0eb60411a27e5eeaee@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bionic Sight LLC P1/P2 readout (est.): BS01 in Patients With Retini
 tis Pigmentosa
DESCRIPTION:BS01 in Patients With Retinitis Pigmentosa\nNCT04278131 | PHASE
 1/PHASE2 | RECRUITING | sponsor: Bionic Sight LLC\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nSource: https://cli
 nicaltrials.gov/study/NCT04278131\nScheduling/reference data from public r
 ecords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04278131
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7401fcd8013c72c9f742@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:SLS P1/P2 readout (est.): Study of SLS009 (Formerly GFH009) a Poten
 t Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancie
 s and High-Risk Newly Diagnosed AML
DESCRIPTION:Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK
 9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly 
 Diagnosed AML\nNCT04588922 | PHASE1/PHASE2 | RECRUITING | sponsor: Sellas 
 Life Sciences Group\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nTicker SLS (confidence 0.9)\nSource: https://clin
 icaltrials.gov/study/NCT04588922\nScheduling/reference data from public re
 cords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04588922
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:43c780bf8f5bda5bda87@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Janssen Research & Development\, LLC P3 readout (est.): SunRISe-2
DESCRIPTION:A Study of TAR-200 in Combination With Cetrelimab Versus Concur
 rent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer
  (MIBC) of the Bladder\nNCT04658862 | PHASE3 | ACTIVE_NOT_RECRUITING | spo
 nsor: Janssen Research & Development\, LLC\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nSource: https://clinicaltr
 ials.gov/study/NCT04658862\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04658862
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0ac1a280ed5fe4425e95@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:NTHI P2 readout (est.): NEO100 and High-Grade Meningioma
DESCRIPTION:NEO100 and High-Grade Meningioma\nNCT05023018 | PHASE2 | RECRUI
 TING | sponsor: Neonc Technologies\, Inc.\nPrimary completion date (ESTIMA
 TED)\; top-line results usually follow later.\nTicker NTHI (confidence 0.9
 )\nSource: https://clinicaltrials.gov/study/NCT05023018\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05023018
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:154d13a175d3bb9cd8e1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Akeso P2 readout (est.): A Study of AK117/AK112 in Metastatic Tripl
 e-Negative Breast Cancer
DESCRIPTION:A Study of AK117/AK112 in Metastatic Triple-Negative Breast Can
 cer\nNCT05227664 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Akeso\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nSo
 urce: https://clinicaltrials.gov/study/NCT05227664\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05227664
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1a0e41f28635c497d376@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:NATCO Pharma Ltd. P2 readout (est.): Study to Evaluate the Safety a
 nd Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients 
 With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma\, W
 ho Progressed on or After Immune Checkpoint Inhibitor Therapy
DESCRIPTION:Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in
  Combination With Paclitaxel in Patients With Recurrent and/or Metastatic 
 Head and Neck Squamous Cell Carcinoma\, Who Progressed on or After Immune 
 Checkpoint Inhibitor Therapy\nNCT05283226 | PHASE2 | RECRUITING | sponsor:
  NATCO Pharma Ltd.\nPrimary completion date (ESTIMATED)\; top-line results
  usually follow later.\nSource: https://clinicaltrials.gov/study/NCT052832
 26\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05283226
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8b837e4ff3d4af38bb03@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:CanariaBio Inc. P2 readout (est.): A Clinical Study Evaluating a Co
 mbination of Oregovomab and Niraparib in Adult Women With Platinum Sensiti
 ve Recurrent Ovarian Cancer.
DESCRIPTION:A Clinical Study Evaluating a Combination of Oregovomab and Nir
 aparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.\nN
 CT05335993 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: CanariaBio Inc.\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nSource: https://clinicaltrials.gov/study/NCT05335993\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05335993
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b0982abdb83ccef4d6c2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ganzhou Hemay Pharmaceutical Co.\, Ltd P2 readout (est.): Phase II 
 Study of Hemay005 in Patients With Active Ulcerative Colitis
DESCRIPTION:Phase II Study of Hemay005 in Patients With Active Ulcerative C
 olitis\nNCT05486104 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Ganzhou He
 may Pharmaceutical Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nSource: https://clinicaltrials.gov/study
 /NCT05486104\nScheduling/reference data from public records\; dates can mo
 ve. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05486104
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:847889be32ee9455e17c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Chengdu Zenitar Biomedical Technology Co.\, Ltd P2 readout (est.): 
 Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or
  Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
DESCRIPTION:Study of Purinostat Mesylate for Injection in the Treatment of 
 Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)\nNCT05563
 844 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Chengdu Zenitar Biomedical
  Technology Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-line resu
 lts usually follow later.\nSource: https://clinicaltrials.gov/study/NCT055
 63844\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05563844
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:22ee89318718b167ffd8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:SKBBY P2 readout (est.): SKB264 Monotherapy in Selected Subjects Wi
 th Advanced Solid Tumors
DESCRIPTION:SKB264 Monotherapy in Selected Subjects With Advanced Solid Tum
 ors\nNCT05631262 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sichuan Kelun
 -Biotech Biopharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nTicker SKBBY (confidence 0.6)\n
 Source: https://clinicaltrials.gov/study/NCT05631262\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05631262
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e60954abfbb724172f7b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:QNRX P2/P3 readout (est.): Open Label\, Safety and Efficacy Study o
 f QRX003 Lotion in Subjects With Netherton Syndrome
DESCRIPTION:Open Label\, Safety and Efficacy Study of QRX003 Lotion in Subj
 ects With Netherton Syndrome\nNCT05789056 | PHASE2/PHASE3 | RECRUITING | s
 ponsor: Quoin Pharmaceuticals\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nTicker QNRX (confidence 0.9)\nSource: h
 ttps://clinicaltrials.gov/study/NCT05789056\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05789056
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d5598d1bd574ac0df1e3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:PFE P3 readout (est.): VERITAC-3
DESCRIPTION:Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole 
 + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer\nNCT05909397 | PHASE
 3 | ACTIVE_NOT_RECRUITING | sponsor: Pfizer\nPrimary completion date (ESTI
 MATED)\; top-line results usually follow later.\nTicker PFE (confidence 0.
 9)\nSource: https://clinicaltrials.gov/study/NCT05909397\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05909397
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f647436d28d0f410a013@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Suzhou Abogen Biosciences Co.\, Ltd. P1/P2 readout (est.): Phase 
 Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
DESCRIPTION:Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced So
 lid Tumors\nNCT06088004 | PHASE1/PHASE2 | RECRUITING | sponsor: Suzhou Abo
 gen Biosciences Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nSource: https://clinicaltrials.gov/study/N
 CT06088004\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06088004
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5c9e402826b0dd216ba7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Beijing Konruns Pharmaceutical Co.\, Ltd. P3 readout (est.): A Stud
 y of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With 
 Advanced Esophageal Cancer
DESCRIPTION:A Study of KC1036 Versus Investigator's Choice of Chemotherapy 
 in Patients With Advanced Esophageal Cancer\nNCT06194734 | PHASE3 | RECRUI
 TING | sponsor: Beijing Konruns Pharmaceutical Co.\, Ltd.\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nSource: htt
 ps://clinicaltrials.gov/study/NCT06194734\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06194734
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:05f4b9c4e515cc413537@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:AskGene Pharma\, Inc. P3 readout (est.): ASKB589 in Combination Wit
 h CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ 
 Adenocarcinoma
DESCRIPTION:ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patient
 s With Advanced or Metastatic GC/GEJ Adenocarcinoma\nNCT06206733 | PHASE3 
 | ACTIVE_NOT_RECRUITING | sponsor: AskGene Pharma\, Inc.\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nSource: http
 s://clinicaltrials.gov/study/NCT06206733\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06206733
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9b86013d346faf9f25c4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. P3 readout (est.): G-HOPE-001
DESCRIPTION:A Multicenter\, Phase 3 Study of IBI343 Monotherapy Versus Trea
 tment of Investigator's Choice in Subjects With Previously Treated\, Claud
 in (CLDN) 18.2-positive\, HER2-negative\, Gastric or Gastroesophageal Junc
 tion Adenocarcinoma (G-HOPE-001)\nNCT06238843 | PHASE3 | ACTIVE_NOT_RECRUI
 TING | sponsor: Innovent Biologics (Suzhou) Co. Ltd.\nPrimary completion d
 ate (ESTIMATED)\; top-line results usually follow later.\nSource: https://
 clinicaltrials.gov/study/NCT06238843\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06238843
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3e04c77b7d0e58aee62c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:NVS P2 readout (est.): Iptacopan in Patients With ANCA Associated V
 asculitis
DESCRIPTION:Iptacopan in Patients With ANCA Associated Vasculitis\nNCT06388
 941 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Novartis Pharmaceuticals\n
 Primary completion date (ESTIMATED)\; top-line results usually follow late
 r.\nTicker NVS (confidence 0.9)\nSource: https://clinicaltrials.gov/study/
 NCT06388941\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06388941
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:47be9a8a29a6ef0c2a9e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Shanghai Jiaolian Drug Research and Development Co.\, Ltd P2/P3 rea
 dout (est.): A Clinical Study of B007 in the Treatment of Generalized Myas
 thenia Gravis.
DESCRIPTION:A Clinical Study of B007 in the Treatment of Generalized Myasth
 enia Gravis.\nNCT06447597 | PHASE2/PHASE3 | RECRUITING | sponsor: Shanghai
  Jiaolian Drug Research and Development Co.\, Ltd\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nSource: https://cli
 nicaltrials.gov/study/NCT06447597\nScheduling/reference data from public r
 ecords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06447597
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6ed210b17a62f93e6923@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. P2 readout (est.): SH
 R-8068 in Combination With Adebrelimab\, Bevacizumab\, and Platinum-Based 
 Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tra
 ct Cancer
DESCRIPTION:SHR-8068 in Combination With Adebrelimab\, Bevacizumab\, and Pl
 atinum-Based Chemotherapy as First-line Treatment in Patients With Advance
 d Biliary Tract Cancer\nNCT06465563 | PHASE2 | ACTIVE_NOT_RECRUITING | spo
 nsor: Suzhou Suncadia Biopharmaceuticals Co.\, Ltd.\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nSource: https://c
 linicaltrials.gov/study/NCT06465563\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06465563
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:202748e6f7f8815cb7ac@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:L & L Bio Co.\, Ltd.\, Ningbo\, China P1/P2 readout (est.): TRIGGER
 CD8
DESCRIPTION:A Study to Evaluate LB1410 in Combination With LB4330 in Patien
 ts With Advanced or Metastatic Solid Tumors\nNCT06468358 | PHASE1/PHASE2 |
  RECRUITING | sponsor: L & L Bio Co.\, Ltd.\, Ningbo\, China\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nSource: 
 https://clinicaltrials.gov/study/NCT06468358\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06468358
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:27c7e16373a03c55f082@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Meribank Biotech Co.\, Ltd. P2 readout (est.): Treatment of Chronic
  Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem C
 ells
DESCRIPTION:Treatment of Chronic Obstructive Pulmonary Disease by Infusion 
 of Allogenic Mesenchymal Stem Cells\nNCT06491043 | PHASE2 | RECRUITING | s
 ponsor: Meribank Biotech Co.\, Ltd.\nPrimary completion date (ESTIMATED)\;
  top-line results usually follow later.\nSource: https://clinicaltrials.go
 v/study/NCT06491043\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06491043
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f3d9cd7ea358dd1353c6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Allotera Therapeutics P2 readout (est.): A Phase 2 Study of WU-CART
 -007\, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphobla
 stic Leukemia and Lymphoblastic Lymphoma (T-RRex)
DESCRIPTION:A Phase 2 Study of WU-CART-007\, an Anti-CD7 Allogeneic CAR-T C
 ell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymph
 oma (T-RRex)\nNCT06514794 | PHASE2 | RECRUITING | sponsor: Allotera Therap
 eutics\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nSource: https://clinicaltrials.gov/study/NCT06514794\nScheduli
 ng/reference data from public records\; dates can move. Not investment\, l
 egal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06514794
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:be791f233d86c5b9d68d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:S1 Biopharma\, Inc. P2 readout (est.): Study of S1B-408 in Women Wi
 th Orgasmic Dysfunction
DESCRIPTION:Study of S1B-408 in Women With Orgasmic Dysfunction\nNCT0651605
 5 | PHASE2 | NOT_YET_RECRUITING | sponsor: S1 Biopharma\, Inc.\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nSource
 : https://clinicaltrials.gov/study/NCT06516055\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06516055
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c05a16c17389345083b1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Amorphical Ltd. P2 readout (est.): Evaluating the Safety and Effica
 cy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyro
 idism in Adults
DESCRIPTION:Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for
  Hypocalcemia Associated With Hypoparathyroidism in Adults\nNCT06547151 | 
 PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Amorphical Ltd.\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nSource: htt
 ps://clinicaltrials.gov/study/NCT06547151\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06547151
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:53533f6c60d7206608f4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Janssen Research & Development\, LLC P3 readout (est.): Phase 3 Stu
 dy of Adjunctive Treatment With Seltorexant in Adult and Elderly Participa
 nts With Major Depressive Disorder and Insomnia Symptoms
DESCRIPTION:Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult
  and Elderly Participants With Major Depressive Disorder and Insomnia Symp
 toms\nNCT06559306 | PHASE3 | RECRUITING | sponsor: Janssen Research & Deve
 lopment\, LLC\nPrimary completion date (ESTIMATED)\; top-line results usua
 lly follow later.\nSource: https://clinicaltrials.gov/study/NCT06559306\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06559306
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4469b99bdc87792d1a0e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Jiangsu vcare pharmaceutical technology co.\, LTD P3 readout (est.)
 : Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Sy
 ndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
DESCRIPTION:Efficacy and Safety Study of Vicagrel in Patients With Acute Co
 ronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)\
 nNCT06577519 | PHASE3 | RECRUITING | sponsor: Jiangsu vcare pharmaceutical
  technology co.\, LTD\nPrimary completion date (ESTIMATED)\; top-line resu
 lts usually follow later.\nSource: https://clinicaltrials.gov/study/NCT065
 77519\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06577519
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:edc982593c2004877ce3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Akeso P1/P2 readout (est.): AK112 and Cadonilimab Combined With Che
 motherapy for 1L Treatment of Metastatic Pancreatic Cancer
DESCRIPTION:AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatme
 nt of Metastatic Pancreatic Cancer\nNCT06646055 | PHASE1/PHASE2 | ACTIVE_N
 OT_RECRUITING | sponsor: Akeso\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nSource: https://clinicaltrials.gov/stu
 dy/NCT06646055\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06646055
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e9e35b57f93243cbb777@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Jiangsu vcare pharmaceutical technology co.\, LTD P3 readout (est.)
 : Phase III Clinical Study of VC004 in Patients With Localized Advanced/ M
 etastatic Solid Tumors
DESCRIPTION:Phase III Clinical Study of VC004 in Patients With Localized Ad
 vanced/ Metastatic Solid Tumors\nNCT06658353 | PHASE3 | RECRUITING | spons
 or: Jiangsu vcare pharmaceutical technology co.\, LTD\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nSource: https:/
 /clinicaltrials.gov/study/NCT06658353\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06658353
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d59c6d03d0121e0cdd86@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Jiangsu Alphamab Biopharmaceuticals Co.\, Ltd P3 readout (est.): JS
 KN003 in Platinum-Resistant\, Relapsed Epithelial Ovarian Cancer
DESCRIPTION:JSKN003 in Platinum-Resistant\, Relapsed Epithelial Ovarian Can
 cer\nNCT06751485 | PHASE3 | NOT_YET_RECRUITING | sponsor: Jiangsu Alphamab
  Biopharmaceuticals Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nSource: https://clinicaltrials.gov/stud
 y/NCT06751485\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06751485
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6f165a22ee8eba9b45f0@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Swedish Orphan Biovitrum P2 readout (est.): A Study to Assess the E
 ffectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAX
 IS)
DESCRIPTION:A Study to Assess the Effectiveness and Safety of Pacritinib in
  Patients With VEXAS Syndrome (PAXIS)\nNCT06782373 | PHASE2 | RECRUITING |
  sponsor: Swedish Orphan Biovitrum\nPrimary completion date (ESTIMATED)\; 
 top-line results usually follow later.\nSource: https://clinicaltrials.gov
 /study/NCT06782373\nScheduling/reference data from public records\; dates 
 can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06782373
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f8318899c982b5b2946f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Astellas Pharma Global Development\, Inc. P1/P2 readout (est.): XNW
 27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies
 .
DESCRIPTION:XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Stan
 dard Therapies.\nNCT06792435 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | spo
 nsor: Astellas Pharma Global Development\, Inc.\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nSource: https://clini
 caltrials.gov/study/NCT06792435\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06792435
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7d43f95d77d293a7b4b8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:RNAC P3 readout (est.): Investigating an mRNA CAR T-cell Therapy\, 
 Known as Descartes-08\, as a Potential Approach to Treat Myasthenia Gravis
DESCRIPTION:Investigating an mRNA CAR T-cell Therapy\, Known as Descartes-0
 8\, as a Potential Approach to Treat Myasthenia Gravis\nNCT06799247 | PHAS
 E3 | ACTIVE_NOT_RECRUITING | sponsor: Cartesian Therapeutics\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nTicker R
 NAC (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06799247
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06799247
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:00bf7a883938f95b503f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:ThromBio Pty. Ltd. P2 readout (est.): Co-STARS
DESCRIPTION:Safety\, Tolerability and Efficacy of Adjunctive TBO-309 in Rep
 erfusion for Stroke With Tandem Occlusion\nNCT06813651 | PHASE2 | RECRUITI
 NG | sponsor: ThromBio Pty. Ltd.\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nSource: https://clinicaltrials.gov/s
 tudy/NCT06813651\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06813651
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5ac92960a6719d143870@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:4TEEN4 Pharmaceuticals GmbH P1/P2 readout (est.): PROCARD 2a
DESCRIPTION:A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Proci
 zumab (PCZ\; AK1967) in Critical Cardiovascular Care.\nNCT06832722 | PHASE
 1/PHASE2 | RECRUITING | sponsor: 4TEEN4 Pharmaceuticals GmbH\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nSource: 
 https://clinicaltrials.gov/study/NCT06832722\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06832722
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:bb298de61a2701c194e6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Wuhan Createrna Science and Technology Co.\, Ltd P2/P3 readout (est
 .): Long-term Safety and Tolerability of MY008211A Tablets in Patients Wit
 h Paroxysmal Nocturnal Hemoglobinuria
DESCRIPTION:Long-term Safety and Tolerability of MY008211A Tablets in Patie
 nts With Paroxysmal Nocturnal Hemoglobinuria\nNCT06933914 | PHASE2/PHASE3 
 | RECRUITING | sponsor: Wuhan Createrna Science and Technology Co.\, Ltd\n
 Primary completion date (ESTIMATED)\; top-line results usually follow late
 r.\nSource: https://clinicaltrials.gov/study/NCT06933914\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06933914
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ee17d9746811a2deec89@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:QNRX P2/P3 readout (est.): Clinical Study of QRX003 Lotion in Subje
 cts With Netherton Syndrome
DESCRIPTION:Clinical Study of QRX003 Lotion in Subjects With Netherton Synd
 rome\nNCT06953466 | PHASE2/PHASE3 | RECRUITING | sponsor: Quoin Pharmaceut
 icals\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nTicker QNRX (confidence 0.9)\nSource: https://clinicaltrials.go
 v/study/NCT06953466\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06953466
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e43cc5e8c1aacd6c5114@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:SVA P3 readout (est.): Immunogenicity and Safety of Rabies Vaccine 
 (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen
DESCRIPTION:Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Ce
 ll) in a Pre-exposure Prophylaxis Regimen\nNCT07055295 | PHASE3 | NOT_YET_
 RECRUITING | sponsor: Sinovac Biotech Co.\, Ltd\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nTicker SVA (confidenc
 e 0.9)\nSource: https://clinicaltrials.gov/study/NCT07055295\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07055295
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:90a454d5f0c3a55e82c6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Shanghai Henlius Biotech P2 readout (est.): Phase II\, Open-label\,
  Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-P
 D-L1 ADC) in Subjects With Advanced Colorectal Cancer
DESCRIPTION:Phase II\, Open-label\, Multicenter Study to Evaluate the Effic
 acy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colo
 rectal Cancer\nNCT07106892 | PHASE2 | RECRUITING | sponsor: Shanghai Henli
 us Biotech\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nSource: https://clinicaltrials.gov/study/NCT07106892\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07106892
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:315001b2b20d8086d4c0@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Lubris Bio Pty Ltd P2 readout (est.): A PHASE II PROSPECTIVE RANDOM
 IZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHP
 RG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR 
 THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
DESCRIPTION:A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUD
 Y ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN 
 PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATE
 D DRY EYE DISEASE\nNCT07118241 | PHASE2 | RECRUITING | sponsor: Lubris Bio
  Pty Ltd\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nSource: https://clinicaltrials.gov/study/NCT07118241\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07118241
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:bcba6ebd83fb89a88a38@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:XyloCor Therapeutics\, Inc. P2 readout (est.): EXACT-CABG
DESCRIPTION:Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenes
 is in CAD Patients Undergoing Treatment With CABG\nNCT07118449 | PHASE2 | 
 NOT_YET_RECRUITING | sponsor: XyloCor Therapeutics\, Inc.\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nSource: htt
 ps://clinicaltrials.gov/study/NCT07118449\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07118449
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b6e2bda923a4c4eca458@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ebima Clifford Okundaye P2/P3 readout (est.): QRX3 in ARF
DESCRIPTION:Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in
  Hospitalized Patients ( QRX-3 in ARF)\nNCT07161843 | PHASE2/PHASE3 | NOT_
 YET_RECRUITING | sponsor: Ebima Clifford Okundaye\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nSource: https://cli
 nicaltrials.gov/study/NCT07161843\nScheduling/reference data from public r
 ecords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07161843
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ee070a6a9a525e577ee8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HC Biopharma Inc. P2 readout (est.): HC010 in First-line PD-L1 Posi
 tive Advanced NSCLC Patients
DESCRIPTION:HC010 in First-line PD-L1 Positive Advanced NSCLC Patients\nNCT
 07169552 | PHASE2 | RECRUITING | sponsor: HC Biopharma Inc.\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nSource: h
 ttps://clinicaltrials.gov/study/NCT07169552\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07169552
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c1bdcd881d4db3fe8e82@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Getz Pharma P3 readout (est.): Acotiamide vs Itopride in Postprandi
 al Distress Syndrome
DESCRIPTION:Acotiamide vs Itopride in Postprandial Distress Syndrome\nNCT07
 174297 | PHASE3 | NOT_YET_RECRUITING | sponsor: Getz Pharma\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nSource: h
 ttps://clinicaltrials.gov/study/NCT07174297\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07174297
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fbc5855dd58359319fdd@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Shionogi P2 readout (est.): A Study of S-337395 in Symptomatic Nonh
 ospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High 
 Risk of Progression to Severe Disease
DESCRIPTION:A Study of S-337395 in Symptomatic Nonhospitalized Adults With 
 Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to S
 evere Disease\nNCT07214571 | PHASE2 | RECRUITING | sponsor: Shionogi\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Source: https://clinicaltrials.gov/study/NCT07214571\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07214571
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4f9abfb39737d1075af1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Beijing Continent Pharmaceutical Co\, Ltd. P2/P3 readout (est.): Pi
 rfenidone Capsules in the Treatment of Radiation-induced Lung Injury With 
 or Without Immune Pneumonia
DESCRIPTION:Pirfenidone Capsules in the Treatment of Radiation-induced Lung
  Injury With or Without Immune Pneumonia\nNCT07388680 | PHASE2/PHASE3 | RE
 CRUITING | sponsor: Beijing Continent Pharmaceutical Co\, Ltd.\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nSource
 : https://clinicaltrials.gov/study/NCT07388680\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07388680
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:11165360f63664b26a75@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Shanghai Henlius Biotech P2 readout (est.): A Phase II Study to Eva
 luate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor P
 ositive\, HER2 Negative Locally Advanced or Metastatic Breast Cancer
DESCRIPTION:A Phase II Study to Evaluate the Efficacy and Safety of HLX43 i
 n Patients With Hormone Receptor Positive\, HER2 Negative Locally Advanced
  or Metastatic Breast Cancer\nNCT07459738 | PHASE2 | NOT_YET_RECRUITING | 
 sponsor: Shanghai Henlius Biotech\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nSource: https://clinicaltrials.gov/
 study/NCT07459738\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07459738
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:790226037cb43c24122c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Skingenix\, Inc. P2 readout (est.): Phase 2 Pilot Study of the Safe
 ty and Efficacy of Topical MW-III in Thermal Burns
DESCRIPTION:Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-II
 I in Thermal Burns\nNCT01297400 | PHASE2 | RECRUITING | sponsor: Skingenix
 \, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually fo
 llow later.\nSource: https://clinicaltrials.gov/study/NCT01297400\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT01297400
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:18ed70bf52ac6e471f57@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Janssen Research & Development\, LLC P3 readout (est.): CAN3001
DESCRIPTION:A Long-term Extension Study of PCI-32765 (Ibrutinib)\nNCT018046
 86 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Janssen Research & Developm
 ent\, LLC\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nSource: https://clinicaltrials.gov/study/NCT01804686\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT01804686
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6c547d7a6712d46e4891@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Partner Therapeutics\, Inc. P2 readout (est.): A Study of Zenocutuz
 umab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eN
 RGy)
DESCRIPTION:A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumo
 rs Harboring an NRG1 Fusion (eNRGy)\nNCT02912949 | PHASE2 | ACTIVE_NOT_REC
 RUITING | sponsor: Partner Therapeutics\, Inc.\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nSource: https://clinic
 altrials.gov/study/NCT02912949\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT02912949
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:84a02a0464c41150e2ae@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sclnow Biotechnology Co.\, Ltd. P2 readout (est.): The Safety/Effic
 acy of hUC Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patient
 s With Osteoarthritis
DESCRIPTION:The Safety/Efficacy of hUC Mesenchymal Stem Cells（19#iSCLife
 ®-OA） Therapy for Patients With Osteoarthritis\nNCT03383081 | PHASE2 | 
 RECRUITING | sponsor: Sclnow Biotechnology Co.\, Ltd.\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nSource: https:/
 /clinicaltrials.gov/study/NCT03383081\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03383081
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d6b2f9b6b7774b21a937@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:JCR Pharmaceuticals Co.\, Ltd. P2 readout (est.): An Extension Stud
 y of JR-141-BR21 in Patients With Mucopolysaccharidosis II
DESCRIPTION:An Extension Study of JR-141-BR21 in Patients With Mucopolysacc
 haridosis II\nNCT03708965 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: JCR 
 Pharmaceuticals Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nSource: https://clinicaltrials.gov/study/N
 CT03708965\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03708965
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9045e2319376c205e40c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Eisai Inc. P3 readout (est.): Clarity AD
DESCRIPTION:A Study to Confirm Safety and Efficacy of Lecanemab in Particip
 ants With Early Alzheimer's Disease\nNCT03887455 | PHASE3 | ACTIVE_NOT_REC
 RUITING | sponsor: Eisai Inc.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nSource: https://clinicaltrials.gov/stud
 y/NCT03887455\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03887455
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5db12fe351cd3bbae94a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Iperboreal Pharma Srl P3 readout (est.): ELIXIR
DESCRIPTION:Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.\n
 NCT03994471 | PHASE3 | RECRUITING | sponsor: Iperboreal Pharma Srl\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nSo
 urce: https://clinicaltrials.gov/study/NCT03994471\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03994471
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a11c6d459224be0087d4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Amicus Therapeutics P3 readout (est.): A Study to Evaluate Migalast
 at in Fabry Subjects With Amenable GLA Variant and Renal Disease
DESCRIPTION:A Study to Evaluate Migalastat in Fabry Subjects With Amenable 
 GLA Variant and Renal Disease\nNCT04020055 | PHASE3 | ACTIVE_NOT_RECRUITIN
 G | sponsor: Amicus Therapeutics\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nSource: https://clinicaltrials.gov/s
 tudy/NCT04020055\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04020055
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:85d831973f738539cf7f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:OncoC4\, Inc. P1/P2 readout (est.): PRESERVE-001
DESCRIPTION:Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combi
 nation of Anti-PD-1 in Advanced Solid Tumors and NSCLC\nNCT04140526 | PHAS
 E1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: OncoC4\, Inc.\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nSource: ht
 tps://clinicaltrials.gov/study/NCT04140526\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04140526
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2da32381153fb21da13c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ONC P3 readout (est.): A Study to Evaluate Long-term Safety of Zanu
 brutinib Regimens in Participants With B-Cell Malignancies Who Participate
 d in BeiGene Parent Studies of Zanubrutinib
DESCRIPTION:A Study to Evaluate Long-term Safety of Zanubrutinib Regimens i
 n Participants With B-Cell Malignancies Who Participated in BeiGene Parent
  Studies of Zanubrutinib\nNCT04170283 | PHASE3 | ACTIVE_NOT_RECRUITING | s
 ponsor: BeOne Medicines\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nTicker ONC (confidence 0.9)\nSource: https://
 clinicaltrials.gov/study/NCT04170283\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04170283
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:30e17c7d959c030c6c0b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:BicycleTx Limited P1/P2 readout (est.): Study BT5528-100 in Patient
 s With Advanced Solid Tumors Associated With EphA2 Expression
DESCRIPTION:Study BT5528-100 in Patients With Advanced Solid Tumors Associa
 ted With EphA2 Expression\nNCT04180371 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUI
 TING | sponsor: BicycleTx Limited\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nSource: https://clinicaltrials.gov/
 study/NCT04180371\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04180371
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:99963362dc1a5b3c77e5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chongqing Precision Biotech Co.\, Ltd P1/P2 readout (est.): BCMA-Ta
 rgeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Pla
 sma Cell Disease
DESCRIPTION:BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multip
 le Myeloma and Plasma Cell Disease\nNCT04271644 | PHASE1/PHASE2 | RECRUITI
 NG | sponsor: Chongqing Precision Biotech Co.\, Ltd\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nSource: https://c
 linicaltrials.gov/study/NCT04271644\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04271644
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f0e0375751973ab83f8f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TRB Chemedica P3 readout (est.): Evaluation of the Structural Modif
 ication Effect of Diacerein (Artrodar®) in Knee Osteoarthritic Patients
DESCRIPTION:Evaluation of the Structural Modification Effect of Diacerein (
 Artrodar®) in Knee Osteoarthritic Patients\nNCT04318041 | PHASE3 | ACTIVE
 _NOT_RECRUITING | sponsor: TRB Chemedica\nPrimary completion date (ESTIMAT
 ED)\; top-line results usually follow later.\nSource: https://clinicaltria
 ls.gov/study/NCT04318041\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04318041
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0331a4bf8e69c4f3eb5d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:PFE P2 readout (est.): PF-07104091 as a Single Agent and in Combina
 tion Therapy
DESCRIPTION:PF-07104091 as a Single Agent and in Combination Therapy\nNCT04
 553133 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Pfizer\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nTicker PFE 
 (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT04553133\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04553133
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:397baea82d3f60f3cd38@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. P3 readout (est.): A Multicente
 r\, Randomized\, Double-Blind\, Placebo-Controlled Phase III Study of Fuzu
 loparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Pla
 cebo Combined With AA-P as First-Line Treatment in Patients With Metastati
 c Castration-Resistant Prostate Cancer
DESCRIPTION:A Multicenter\, Randomized\, Double-Blind\, Placebo-Controlled 
 Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Predn
 isone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in 
 Patients With Metastatic Castration-Resistant Prostate Cancer\nNCT04691804
  | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Jiangsu HengRui Medicine Co.\
 , Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nSource: https://clinicaltrials.gov/study/NCT04691804\nScheduli
 ng/reference data from public records\; dates can move. Not investment\, l
 egal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04691804
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1975d05546d1866ff4b8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chongqing Precision Biotech Co.\, Ltd P1/P2 readout (est.): a Clini
 cal Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refract
 ory Multiple Myeloma and Plasma Cell Disease
DESCRIPTION:a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy i
 n Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease\nNCT0477633
 0 | PHASE1/PHASE2 | RECRUITING | sponsor: Chongqing Precision Biotech Co.\
 , Ltd\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nSource: https://clinicaltrials.gov/study/NCT04776330\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04776330
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b634dd6116f26a121c1d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chongqing Precision Biotech Co.\, Ltd P1/P2 readout (est.): a Clini
 cal Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refrac
 tory B-ALL
DESCRIPTION:a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell 
 in Relapsed/Refractory B-ALL\nNCT04781634 | PHASE1/PHASE2 | RECRUITING | s
 ponsor: Chongqing Precision Biotech Co.\, Ltd\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nSource: https://clinica
 ltrials.gov/study/NCT04781634\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04781634
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2004006d5c08112f9a83@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Miltenyi Biomedicine GmbH P2 readout (est.): DALY II USA/ MB-CART20
 19.1 for DLBCL
DESCRIPTION:DALY II USA/ MB-CART2019.1 for DLBCL\nNCT04792489 | PHASE2 | RE
 CRUITING | sponsor: Miltenyi Biomedicine GmbH\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nSource: https://clinica
 ltrials.gov/study/NCT04792489\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04792489
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:41f834ac250db8ba72ca@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Kamau Therapeutics P1/P2 readout (est.): Restore
DESCRIPTION:Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (H
 bS to HbA) to Treat Severe Sickle Cell Disease\nNCT04819841 | PHASE1/PHASE
 2 | RECRUITING | sponsor: Kamau Therapeutics\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nSource: https://clinical
 trials.gov/study/NCT04819841\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04819841
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7a955accc2a896ad75ea@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Mercator MedSystems\, Inc. P2 readout (est.): DEXTERITY-AFP
DESCRIPTION:Perivenous Dexamethasone Therapy: Examining Reduction of Inflam
 mation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DV
 T\nNCT04862468 | PHASE2 | RECRUITING | sponsor: Mercator MedSystems\, Inc.
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nSource: https://clinicaltrials.gov/study/NCT04862468\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04862468
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2620e66cb4c2fda35df5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:GOVX P2 readout (est.): SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA
  SARS-COV-2 Vaccine in Patients With Blood Cancer
DESCRIPTION:SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine 
 in Patients With Blood Cancer\nNCT04977024 | PHASE2 | ACTIVE_NOT_RECRUITIN
 G | sponsor: GeoVax\, Inc.\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nTicker GOVX (confidence 0.6)\nSource: http
 s://clinicaltrials.gov/study/NCT04977024\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04977024
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c97f61507db76393a084@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AMO Pharma Limited P2/P3 readout (est.): REACH CDM X
DESCRIPTION:Safety and Efficacy of Tideglusib in Congenital or Childhood On
 set Myotonic Dystrophy\nNCT05004129 | PHASE2/PHASE3 | RECRUITING | sponsor
 : AMO Pharma Limited\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0500
 4129\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05004129
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f0a4a8fc095e2ca1f302@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:PFE P3 readout (est.): Continued Access Study for Participants Deri
 ving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
DESCRIPTION:Continued Access Study for Participants Deriving Benefit in Pfi
 zer-Sponsored Avelumab Parent Studies That Are Closing\nNCT05059522 | PHAS
 E3 | ACTIVE_NOT_RECRUITING | sponsor: Pfizer\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker PFE (confidence 0
 .9)\nSource: https://clinicaltrials.gov/study/NCT05059522\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05059522
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:314d790d2705a7dfbfbf@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lumosa Therapeutics Co.\, Ltd. P2 readout (est.): A Study to Evalua
 te the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoi
 ng EVT
DESCRIPTION:A Study to Evaluate the Safety and Efficacy of LT3001 Drug Prod
 uct in Subjects AIS Undergoing EVT\nNCT05198323 | PHASE2 | ACTIVE_NOT_RECR
 UITING | sponsor: Lumosa Therapeutics Co.\, Ltd.\nPrimary completion date 
 (ESTIMATED)\; top-line results usually follow later.\nSource: https://clin
 icaltrials.gov/study/NCT05198323\nScheduling/reference data from public re
 cords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05198323
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fe91dda633e12caf758c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Akeso P1/P2 readout (est.): A Phase Ib/II Study of AK112 in Combina
 tion With AK117 in Advanced Malignant Tumors
DESCRIPTION:A Phase Ib/II Study of AK112 in Combination With AK117 in Advan
 ced Malignant Tumors\nNCT05229497 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING 
 | sponsor: Akeso\nPrimary completion date (ESTIMATED)\; top-line results u
 sually follow later.\nSource: https://clinicaltrials.gov/study/NCT05229497
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05229497
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7e2b21c7829106553d9a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TaiRx\, Inc. P2 readout (est.): CVM-1118 in Combination With Nivolu
 mab for Unresectable Advanced Hepatocellular Carcinoma
DESCRIPTION:CVM-1118 in Combination With Nivolumab for Unresectable Advance
 d Hepatocellular Carcinoma\nNCT05257590 | PHASE2 | RECRUITING | sponsor: T
 aiRx\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nSource: https://clinicaltrials.gov/study/NCT05257590\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05257590
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:851e2d368efc4ca6fc04@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SKBBY P1/P2 readout (est.): A Study of KL590586 in Patients With Ad
 vanced Solid Tumors
DESCRIPTION:A Study of KL590586 in Patients With Advanced Solid Tumors\nNCT
 05265091 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sichuan Kelun-
 Biotech Biopharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\
 ; top-line results usually follow later.\nTicker SKBBY (confidence 0.6)\nS
 ource: https://clinicaltrials.gov/study/NCT05265091\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05265091
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:166a783561b6ef6d35b3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBO P1/P2 readout (est.): Study to Evaluate IMP9064 as a Monotherap
 y or in Combination in Patients With Advanced Solid Tumors
DESCRIPTION:Study to Evaluate IMP9064 as a Monotherapy or in Combination in
  Patients With Advanced Solid Tumors\nNCT05269316 | PHASE1/PHASE2 | RECRUI
 TING | sponsor: Impact Therapeutics\, Inc.\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nTicker IBO (confidence 0.6
 )\nSource: https://clinicaltrials.gov/study/NCT05269316\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05269316
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f711ff55a8741ba84386@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:RemeGen Co.\, Ltd. P3 readout (est.): A Study of RC48-ADC Combined 
 With Toripalimab For First-line Treatment of Urothelial Carcinoma
DESCRIPTION:A Study of RC48-ADC Combined With Toripalimab For First-line Tr
 eatment of Urothelial Carcinoma\nNCT05302284 | PHASE3 | RECRUITING | spons
 or: RemeGen Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT05
 302284\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05302284
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f65016d30b8660c65cc3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AZN P3 readout (est.): ROSY-D
DESCRIPTION:Roll Over StudY for Patients Who Have Completed a Previous Onco
 logy Study With Durvalumab\nNCT05303532 | PHASE3 | ENROLLING_BY_INVITATION
  | sponsor: AstraZeneca\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nTicker AZN (confidence 0.9)\nSource: https://
 clinicaltrials.gov/study/NCT05303532\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05303532
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d0d239181a64b5b34188@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pell Bio-Med Technology Co.\, Ltd. P1/P2 readout (est.): Phase 1/2 
 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T\; PL001) for Re
 lapsed or Refractory B-cell Lymphoma
DESCRIPTION:Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 
 CAR-T\; PL001) for Relapsed or Refractory B-cell Lymphoma\nNCT05326243 | P
 HASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Pell Bio-Med Technology Co
 .\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nSource: https://clinicaltrials.gov/study/NCT05326243\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05326243
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d4dad2e7da9168156681@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Excelsior P2 readout (est.): A Study of Oral EX039 in Subjects with
  Mild Alzheimer's Disease
DESCRIPTION:A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease
 \nNCT05413655 | PHASE2 | RECRUITING | sponsor: Excelsior\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nSource: http
 s://clinicaltrials.gov/study/NCT05413655\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05413655
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dfb31806b8ef8e34cc81@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. P3 readout (est.): A Trial of S
 HR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive
 \, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treate
 d With Trastuzumab and Taxane
DESCRIPTION:A Trial of SHR-A1811versus Pyrotinib in Combination With Capeci
 tabine in HER2-Positive\, Unresectable and/or Metastatic Breast Cancer Sub
 jects Previously Treated With Trastuzumab and Taxane\nNCT05424835 | PHASE3
  | ACTIVE_NOT_RECRUITING | sponsor: Jiangsu HengRui Medicine Co.\, Ltd.\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nSource: https://clinicaltrials.gov/study/NCT05424835\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05424835
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:24b429e52550ef66e2e1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cloudbreak Therapeutics\, LLC P3 readout (est.): A Clinical Trial o
 n Safety and Efficacy of CBT-001 in Patients With Pterygium
DESCRIPTION:A Clinical Trial on Safety and Efficacy of CBT-001 in Patients 
 With Pterygium\nNCT05456425 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Cl
 oudbreak Therapeutics\, LLC\nPrimary completion date (ESTIMATED)\; top-lin
 e results usually follow later.\nSource: https://clinicaltrials.gov/study/
 NCT05456425\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05456425
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ecd633acc2fcbfba691b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:MNOV P2 readout (est.): MN-001 in Non-alcoholic Fatty Liver Disease
 \, Type 2 Diabetes Mellitus\, and Hypertriglyceridemia
DESCRIPTION:MN-001 in Non-alcoholic Fatty Liver Disease\, Type 2 Diabetes M
 ellitus\, and Hypertriglyceridemia\nNCT05464784 | PHASE2 | ACTIVE_NOT_RECR
 UITING | sponsor: MediciNova\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nTicker MNOV (confidence 0.9)\nSource: ht
 tps://clinicaltrials.gov/study/NCT05464784\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05464784
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dd7f0926b6ee6d229eab@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zhejiang ACEA Pharmaceutical Co. Ltd. P1/P2 readout (est.): Safety 
 and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or 
 Refractory Multiple Myeloma
DESCRIPTION:Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjuga
 te in Relapsed or Refractory Multiple Myeloma\nNCT05565807 | PHASE1/PHASE2
  | RECRUITING | sponsor: Zhejiang ACEA Pharmaceutical Co. Ltd.\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nSource
 : https://clinicaltrials.gov/study/NCT05565807\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05565807
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fd4c1814a16c52e8d1d1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Hoffmann-La Roche P2 readout (est.): A Study Evaluating Different I
 mmunotherapies (LAG-3 and PD-1 With or Without TIGIT\, Compared to PD-L1 A
 lone) in Participants With Untreated Locally Advanced Metastatic Urothelia
 l Cancer
DESCRIPTION:A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 Wi
 th or Without TIGIT\, Compared to PD-L1 Alone) in Participants With Untrea
 ted Locally Advanced Metastatic Urothelial Cancer\nNCT05645692 | PHASE2 | 
 ACTIVE_NOT_RECRUITING | sponsor: Hoffmann-La Roche\nPrimary completion dat
 e (ESTIMATED)\; top-line results usually follow later.\nSource: https://cl
 inicaltrials.gov/study/NCT05645692\nScheduling/reference data from public 
 records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05645692
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:95bb6933ba3bc45ef03b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:INSM P2/P3 readout (est.): An Extension Study of Treprostinil Palmi
 til Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
DESCRIPTION:An Extension Study of Treprostinil Palmitil Inhalation Powder (
 TPIP) for Pulmonary Arterial Hypertension (PAH)\nNCT05649748 | PHASE2/PHAS
 E3 | ACTIVE_NOT_RECRUITING | sponsor: Insmed Incorporated\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nTicker INSM
  (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05649748\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05649748
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3b5da2f60f07101d2f0a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olatec Therapeutics\, Inc. P2/P3 readout (est.): Study of Dapansutr
 ile Tablets in Subjects With an Acute Gout Flare
DESCRIPTION:Study of Dapansutrile Tablets in Subjects With an Acute Gout Fl
 are\nNCT05658575 | PHASE2/PHASE3 | RECRUITING | sponsor: Olatec Therapeuti
 cs\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nSource: https://clinicaltrials.gov/study/NCT05658575\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05658575
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6a90fda403a7b2c6b67e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:VTRS P3 readout (est.): OPUS-2
DESCRIPTION:A Research Study to Evaluate the Efficacy and Safety of Cenerim
 od in Subjects Suffering From Systemic Lupus Erythematosus\nNCT05672576 | 
 PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Viatris Innovation GmbH\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nTic
 ker VTRS (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT056
 72576\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05672576
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1cf0f4f4d589987a5cbc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AUG Therapeutics P3 readout (est.): An Extension Study Assessing th
 e Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Defi
 ciency Type II
DESCRIPTION:An Extension Study Assessing the Safety and Efficacy of AVTX-80
 3 in Subjects With Leukocyte Adhesion Deficiency Type II\nNCT05754450 | PH
 ASE3 | RECRUITING | sponsor: AUG Therapeutics\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nSource: https://clinica
 ltrials.gov/study/NCT05754450\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05754450
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9d58c47aaad4a176b196@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lin BioScience\, Inc P1/P2 readout (est.): The Safety and Tolerabil
 ity of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
DESCRIPTION:The Safety and Tolerability of LBS-007 in Patients With Relapse
 d or Resistant Acute Leukaemias\nNCT05756322 | PHASE1/PHASE2 | RECRUITING 
 | sponsor: Lin BioScience\, Inc\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nSource: https://clinicaltrials.gov/st
 udy/NCT05756322\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05756322
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9981f667b22628a2964e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AskGene Pharma\, Inc. P1/P2 readout (est.): A Study of ASKG915 in P
 atients With Selected Advanced Solid Tumors.
DESCRIPTION:A Study of ASKG915 in Patients With Selected Advanced Solid Tum
 ors.\nNCT05867420 | PHASE1/PHASE2 | RECRUITING | sponsor: AskGene Pharma\,
  Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nSource: https://clinicaltrials.gov/study/NCT05867420\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05867420
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cacdbadfdb2a48166023@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shanghai Pharmaceuticals Holding Co.\, Ltd P2 readout (est.): Effic
 acy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast 
 Cancer Patients With Brain Metastases.
DESCRIPTION:Efficacy and Safety of SPH4336 in Combination With Endocrine Th
 erapy in Breast Cancer Patients With Brain Metastases.\nNCT05872347 | PHAS
 E2 | RECRUITING | sponsor: Shanghai Pharmaceuticals Holding Co.\, Ltd\nPri
 mary completion date (ESTIMATED)\; top-line results usually follow later.\
 nSource: https://clinicaltrials.gov/study/NCT05872347\nScheduling/referenc
 e data from public records\; dates can move. Not investment\, legal or med
 ical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05872347
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:63dc3c7955504c102678@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Hoffmann-La Roche P2 readout (est.): TAHOE
DESCRIPTION:Afimkibart (RO7790121) for the Treatment of Moderate to Severe 
 Active Crohn's Disease\nNCT05910528 | PHASE2 | ACTIVE_NOT_RECRUITING | spo
 nsor: Hoffmann-La Roche\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0
 5910528\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05910528
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:70f6613f60fbf4562285@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:CMND P1/P2 readout (est.): A First in Human Study of CMND-100 in He
 althy and Alcohol Use Disorder (AUD) Subjects
DESCRIPTION:A First in Human Study of CMND-100 in Healthy and Alcohol Use D
 isorder (AUD) Subjects\nNCT05913752 | PHASE1/PHASE2 | RECRUITING | sponsor
 : Clearmind Medicine Inc.\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nTicker CMND (confidence 0.9)\nSource: https
 ://clinicaltrials.gov/study/NCT05913752\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05913752
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:07329a37d8020a653677@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shanghai Pharmaceuticals Holding Co.\, Ltd P1/P2 readout (est.): A 
 Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With
  Cadonilimab in Patients With Advanced Solid Tumors.
DESCRIPTION:A Study to Efficacy and Safety of SPH4336 Monotherapy or in Com
 bination With Cadonilimab in Patients With Advanced Solid Tumors.\nNCT0594
 4224 | PHASE1/PHASE2 | RECRUITING | sponsor: Shanghai Pharmaceuticals Hold
 ing Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-line results usua
 lly follow later.\nSource: https://clinicaltrials.gov/study/NCT05944224\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05944224
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f3b5fae82a244262cdc4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Asia Cell Therapeutics (Shanghai) Co.\, Ltd. P1/P2 readout (est.): 
 Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With 
 Decompensated Hepatitis B Cirrhosis
DESCRIPTION:Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Pat
 ients With Decompensated Hepatitis B Cirrhosis\nNCT05948982 | PHASE1/PHASE
 2 | NOT_YET_RECRUITING | sponsor: Asia Cell Therapeutics (Shanghai) Co.\, 
 Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually follo
 w later.\nSource: https://clinicaltrials.gov/study/NCT05948982\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05948982
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:99eda1ea658c4ac82380@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Allist Pharmaceuticals\, Inc. P2 readout (est.): A Phase II Study E
 valuating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer a
 nd Other Solid Tumors Harboring the KRAS p.G12C Mutation.
DESCRIPTION:A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Pati
 ents With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G1
 2C Mutation.\nNCT06008288 | PHASE2 | RECRUITING | sponsor: Allist Pharmace
 uticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nSource: https://clinicaltrials.gov/study/NCT06008288\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06008288
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f2f7e3cf0546a5eaaccc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Aveta Biomics\, Inc. P1/P2 readout (est.): Treatment of Patients Wi
 th Recurrent High-Grade Glioma With APG-157 and Bevacizumab
DESCRIPTION:Treatment of Patients With Recurrent High-Grade Glioma With APG
 -157 and Bevacizumab\nNCT06011109 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING 
 | sponsor: Aveta Biomics\, Inc.\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nSource: https://clinicaltrials.gov/st
 udy/NCT06011109\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06011109
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3db069a4717353ad93be@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Teva Branded Pharmaceutical Products R&D LLC P3 readout (est.): A S
 tudy to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuter
 ol Sulfate is Effective in Preventing Asthma Exacerbations
DESCRIPTION:A Study to Test if a Fixed-Dose Combination of Fluticasone Prop
 ionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations\n
 NCT06052267 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Teva Branded Pharm
 aceutical Products R&D LLC\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nSource: https://clinicaltrials.gov/study/N
 CT06052267\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06052267
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:834ca59a589e68a3bca0@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chimeric Therapeutics P1/P2 readout (est.): A Phase 1/2 Study to Ev
 aluate CHM-2101\, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR
 ) T Cell Therapy
DESCRIPTION:A Phase 1/2 Study to Evaluate CHM-2101\, an Autologous Cadherin
  17 Chimeric Antigen Receptor (CAR) T Cell Therapy\nNCT06055439 | PHASE1/P
 HASE2 | ACTIVE_NOT_RECRUITING | sponsor: Chimeric Therapeutics\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nSource
 : https://clinicaltrials.gov/study/NCT06055439\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06055439
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:374ce0e467cad4f85a67@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Mabwell (Shanghai) Bioscience Co.\, Ltd. P1/P2 readout (est.): 9MW2
 821 Combined With Toripalimab Injection in Subjects With Local Advanced or
  Metastatic Urothelial Cancer
DESCRIPTION:9MW2821 Combined With Toripalimab Injection in Subjects With Lo
 cal Advanced or Metastatic Urothelial Cancer\nNCT06079112 | PHASE1/PHASE2 
 | RECRUITING | sponsor: Mabwell (Shanghai) Bioscience Co.\, Ltd.\nPrimary 
 completion date (ESTIMATED)\; top-line results usually follow later.\nSour
 ce: https://clinicaltrials.gov/study/NCT06079112\nScheduling/reference dat
 a from public records\; dates can move. Not investment\, legal or medical 
 advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06079112
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6458fcf9bae4318253ee@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SKBBY P3 readout (est.): Study of SKB264 for Locally Advanced\, Rec
 urrent or Metastatic HR+/HER2- Breast Cancer
DESCRIPTION:Study of SKB264 for Locally Advanced\, Recurrent or Metastatic 
 HR+/HER2- Breast Cancer\nNCT06081959 | PHASE3 | RECRUITING | sponsor: Sich
 uan Kelun-Biotech Biopharmaceutical Co.\, Ltd.\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nTicker SKBBY (confiden
 ce 0.6)\nSource: https://clinicaltrials.gov/study/NCT06081959\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06081959
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d18f3c7f48ab308b3e2c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bio-Thera Solutions P1/P2 readout (est.): Evaluate the Safety\, Tol
 erability of BAT6026
DESCRIPTION:Evaluate the Safety\, Tolerability of BAT6026\nNCT06094179 | PH
 ASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Bio-Thera Solutions\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nSo
 urce: https://clinicaltrials.gov/study/NCT06094179\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06094179
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1fc6fc360453f2c5f92c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AAPG P3 readout (est.): Global Trial in APG2575 for Patients With C
 LL/SLL
DESCRIPTION:Global Trial in APG2575 for Patients With CLL/SLL\nNCT06104566 
 | PHASE3 | RECRUITING | sponsor: Ascentage Pharma Group Inc.\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nTicker A
 APG (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06104566
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06104566
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6d373e190b5ca15de00f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Guangzhou JOYO Pharma Co.\, Ltd P2/P3 readout (est.): SC1011 Twice 
 Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis 
 (IPF)
DESCRIPTION:SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopa
 thic Pulmonary Fibrosis (IPF)\nNCT06125327 | PHASE2/PHASE3 | RECRUITING | 
 sponsor: Guangzhou JOYO Pharma Co.\, Ltd\nPrimary completion date (ESTIMAT
 ED)\; top-line results usually follow later.\nSource: https://clinicaltria
 ls.gov/study/NCT06125327\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06125327
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dfab5f96df29f1f04e0a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Hangzhou Gensciences Biopharmaceutical Co.\, Ltd. P3 readout (est.)
 : Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Sever
 e Hemophilia A
DESCRIPTION:Study of Efficacy and Safety of FRSW107 in Pediatric Patients W
 ith Severe Hemophilia A\nNCT06136507 | PHASE3 | NOT_YET_RECRUITING | spons
 or: Hangzhou Gensciences Biopharmaceutical Co.\, Ltd.\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nSource: https:/
 /clinicaltrials.gov/study/NCT06136507\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06136507
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ba434b8f72d711c21151@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SRPT P1/P2 readout (est.): Study of SRP-1003 in Participants With T
 ype 1 Myotonic Dystrophy
DESCRIPTION:Study of SRP-1003 in Participants With Type 1 Myotonic Dystroph
 y\nNCT06138743 | PHASE1/PHASE2 | ENROLLING_BY_INVITATION | sponsor: Sarept
 a Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-line resu
 lts usually follow later.\nTicker SRPT (confidence 0.9)\nSource: https://c
 linicaltrials.gov/study/NCT06138743\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06138743
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:09f332eaf0f5eab9bb98@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rhizen Pharmaceuticals SA P2 readout (est.): Efficacy and Safety of
  Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC
 )
DESCRIPTION:Efficacy and Safety of Tenalisib in Patients With Metastatic Tr
 iple Negative Breast Cancer (TNBC)\nNCT06189209 | PHASE2 | RECRUITING | sp
 onsor: Rhizen Pharmaceuticals SA\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nSource: https://clinicaltrials.gov/s
 tudy/NCT06189209\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06189209
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c9bc7285f429c4877d88@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azure Biotech Inc. P2 readout (est.): Proof of Concept Study of Vag
 inal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
DESCRIPTION:Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrop
 hy in Postmenopausal Women\nNCT06197568 | PHASE2 | RECRUITING | sponsor: A
 zure Biotech Inc.\nPrimary completion date (ESTIMATED)\; top-line results 
 usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0619756
 8\nScheduling/reference data from public records\; dates can move. Not inv
 estment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06197568
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:76241a231f9647eb354d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Frantz Viral Therapeutics\, LLC P2 readout (est.): ART-AIN IIB-2
DESCRIPTION:Artesunate Ointment for the Treatment of Anal HSIL in HIV-negat
 ive Participants\nNCT06206564 | PHASE2 | RECRUITING | sponsor: Frantz Vira
 l Therapeutics\, LLC\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0620
 6564\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06206564
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7f9419e76a82551f1fee@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shanghai Pharmaceuticals Holding Co.\, Ltd P1/P2 readout (est.): A 
 Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subje
 cts With Advanced Solid Tumors
DESCRIPTION:A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibi
 tors in Subjects With Advanced Solid Tumors\nNCT06214143 | PHASE1/PHASE2 |
  RECRUITING | sponsor: Shanghai Pharmaceuticals Holding Co.\, Ltd\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nSou
 rce: https://clinicaltrials.gov/study/NCT06214143\nScheduling/reference da
 ta from public records\; dates can move. Not investment\, legal or medical
  advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06214143
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2e6c9f01342043d583af@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Arsenal Biosciences\, Inc. P1/P2 readout (est.): AB-2100\, an Integ
 rated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal C
 ell Carcinoma (ccRCC)
DESCRIPTION:AB-2100\, an Integrated Circuit T Cell Therapy in Patients With
  Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)\nNCT06245915 | PHASE1/P
 HASE2 | ACTIVE_NOT_RECRUITING | sponsor: Arsenal Biosciences\, Inc.\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nS
 ource: https://clinicaltrials.gov/study/NCT06245915\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06245915
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:435d203fb7eed7687182@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serum Institute of India Pvt. Ltd. P3 readout (est.): Clinical Stud
 y to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Age
 d 15-25 Years
DESCRIPTION:Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in W
 omen Living With HIV Aged 15-25 Years\nNCT06281119 | PHASE3 | ACTIVE_NOT_R
 ECRUITING | sponsor: Serum Institute of India Pvt. Ltd.\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nSource: https
 ://clinicaltrials.gov/study/NCT06281119\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06281119
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cad80192a5f3f17f4f2d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Materia Medica Holding P3 readout (est.): Clinical Trial of the Eff
 icacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacte
 rial Cystitis
DESCRIPTION:Clinical Trial of the Efficacy and Safety of Raphamin in Preven
 tion of Recurrences of Chronic Bacterial Cystitis\nNCT06284265 | PHASE3 | 
 ACTIVE_NOT_RECRUITING | sponsor: Materia Medica Holding\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nSource: https
 ://clinicaltrials.gov/study/NCT06284265\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06284265
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f25d561c0fdf79d387b2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ENCell P1/P2 readout (est.): Evaluate the Safety and Efficacy of EN
 001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b:
  Open-label\, Dose-escalation\, Single-center\; Phase 2a: Randomized\, Dou
 ble-blind\, Placebo-controlled\, Multicenter)
DESCRIPTION:Evaluate the Safety and Efficacy of EN001 in Patients With Char
 cot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label\, Dose-escala
 tion\, Single-center\; Phase 2a: Randomized\, Double-blind\, Placebo-contr
 olled\, Multicenter)\nNCT06328712 | PHASE1/PHASE2 | RECRUITING | sponsor: 
 ENCell\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nSource: https://clinicaltrials.gov/study/NCT06328712\nScheduli
 ng/reference data from public records\; dates can move. Not investment\, l
 egal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06328712
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0aada0bd6ea9764ab4fb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Avistone Biotechnology Co.\, Ltd. P1/P2 readout (est.): KYLIN-1
DESCRIPTION:Vebreltinib Plus PLB1004 in EGFR-mutated\, Advanced NSCLC With 
 MET Amplification or MET Overexpression Following EGFR-TKI\nNCT06343064 | 
 PHASE1/PHASE2 | RECRUITING | sponsor: Avistone Biotechnology Co.\, Ltd.\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nSource: https://clinicaltrials.gov/study/NCT06343064\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06343064
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b5cc3bd053dad2903206@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Abscint NV/SA P2 readout (est.): HERMIA
DESCRIPTION:HER2 Targeted Molecular Imaging in mBC and Other Metastatic Sol
 id Carcinomas Using 68Ga-ABS011\nNCT06369831 | PHASE2 | RECRUITING | spons
 or: Abscint NV/SA\nPrimary completion date (ESTIMATED)\; top-line results 
 usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0636983
 1\nScheduling/reference data from public records\; dates can move. Not inv
 estment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06369831
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d6bf4b03bc2b66065809@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Genfleet Therapeutics (Shanghai) Inc. P1/P2 readout (est.): A Study
  of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or R
 efractory DLBCL
DESCRIPTION:A Study of GFH009 in Combination With Zanubrutinib in Subjects 
 With Relapsed or Refractory DLBCL\nNCT06375733 | PHASE1/PHASE2 | RECRUITIN
 G | sponsor: Genfleet Therapeutics (Shanghai) Inc.\nPrimary completion dat
 e (ESTIMATED)\; top-line results usually follow later.\nSource: https://cl
 inicaltrials.gov/study/NCT06375733\nScheduling/reference data from public 
 records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06375733
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b3ca86be7f6359c5e77a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. P2 readout (est.): Phase II Cli
 nical Study of SHR-A1811 in Patients With HER2 Expression / Amplification 
 of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Can
 cer
DESCRIPTION:Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expr
 ession / Amplification of Locally Advanced Unresectable or Recurrent Metas
 tatic Biliary Tract Cancer\nNCT06413745 | PHASE2 | ACTIVE_NOT_RECRUITING |
  sponsor: Jiangsu HengRui Medicine Co.\, Ltd.\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nSource: https://clinica
 ltrials.gov/study/NCT06413745\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06413745
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8174925408a87c8890ce@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shanghai Pharmaceuticals Holding Co.\, Ltd P2 readout (est.): A Cli
 nical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated B
 iliary Tract OR Colorectal Cancer Patients.
DESCRIPTION:A Clinical Study of SPH5030 Tablets in the Treatment of Her2-po
 sitive/Mutated Biliary Tract OR Colorectal Cancer Patients.\nNCT06434597 |
  PHASE2 | RECRUITING | sponsor: Shanghai Pharmaceuticals Holding Co.\, Ltd
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nSource: https://clinicaltrials.gov/study/NCT06434597\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06434597
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1e6503a97cfc6b8fb540@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shanghai Jiaolian Drug Research and Development Co.\, Ltd P2 readou
 t (est.): A Study of B013 in Combination With Paclitaxel in Patients With 
 Platinum-resistant Recurrent Ovarian Cancer.
DESCRIPTION:A Study of B013 in Combination With Paclitaxel in Patients With
  Platinum-resistant Recurrent Ovarian Cancer.\nNCT06434610 | PHASE2 | RECR
 UITING | sponsor: Shanghai Jiaolian Drug Research and Development Co.\, Lt
 d\nPrimary completion date (ESTIMATED)\; top-line results usually follow l
 ater.\nSource: https://clinicaltrials.gov/study/NCT06434610\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06434610
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ec0feed6697505e54e84@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shanghai Jiaolian Drug Research and Development Co.\, Ltd P2/P3 rea
 dout (est.): A Clinical Study of B007 in the Treatment of Pemphigus.
DESCRIPTION:A Clinical Study of B007 in the Treatment of Pemphigus.\nNCT064
 54357 | PHASE2/PHASE3 | RECRUITING | sponsor: Shanghai Jiaolian Drug Resea
 rch and Development Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nSource: https://clinicaltrials.gov/stud
 y/NCT06454357\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06454357
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2836527543556426bc69@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shanghai Jiaolian Drug Research and Development Co.\, Ltd P2/P3 rea
 dout (est.): A Clinical Study of B007 in the Treatment of Primary Membrano
 us Nephropathy.
DESCRIPTION:A Clinical Study of B007 in the Treatment of Primary Membranous
  Nephropathy.\nNCT06470191 | PHASE2/PHASE3 | RECRUITING | sponsor: Shangha
 i Jiaolian Drug Research and Development Co.\, Ltd\nPrimary completion dat
 e (ESTIMATED)\; top-line results usually follow later.\nSource: https://cl
 inicaltrials.gov/study/NCT06470191\nScheduling/reference data from public 
 records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06470191
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:00354d910a00044cde2c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Kartos Therapeutics\, Inc. P3 readout (est.): POIESIS
DESCRIPTION:Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Na
 ïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolit
 inib\nNCT06479135 | PHASE3 | RECRUITING | sponsor: Kartos Therapeutics\, I
 nc.\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nSource: https://clinicaltrials.gov/study/NCT06479135\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06479135
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f9b16c77d9ea897901f3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Xenothera SAS P1/P2 readout (est.): PALT1
DESCRIPTION:Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
 \nNCT06495723 | PHASE1/PHASE2 | RECRUITING | sponsor: Xenothera SAS\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nS
 ource: https://clinicaltrials.gov/study/NCT06495723\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06495723
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:efe6aa3e10e2e9ef628b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:NaviFUS Corporation P3 readout (est.): A Prospective Pivotal Study 
 to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or
  Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS Sy
 stem in Recurrent Glioblastoma Multiforme Patients
DESCRIPTION:A Prospective Pivotal Study to Evaluate the Efficacy and Safety
  of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focus
 ed Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Mult
 iforme Patients\nNCT06496971 | PHASE3 | RECRUITING | sponsor: NaviFUS Corp
 oration\nPrimary completion date (ESTIMATED)\; top-line results usually fo
 llow later.\nSource: https://clinicaltrials.gov/study/NCT06496971\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06496971
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f9c6d6cda495a3796bbe@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Spirovant Sciences\, Inc. P1/P2 readout (est.): SAAVe
DESCRIPTION:A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosi
 s (CF)\nNCT06526923 | PHASE1/PHASE2 | RECRUITING | sponsor: Spirovant Scie
 nces\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nSource: https://clinicaltrials.gov/study/NCT06526923\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06526923
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d594375136c9147168df@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Boehringer Ingelheim P3 readout (est.): EASi-KIDNEY™ (The Studies
  of Heart & Kidney Protection With BI 690517 in Combination With Empaglifl
 ozin)
DESCRIPTION:EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With B
 I 690517 in Combination With Empagliflozin)\nNCT06531824 | PHASE3 | ACTIVE
 _NOT_RECRUITING | sponsor: Boehringer Ingelheim\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nSource: https://clini
 caltrials.gov/study/NCT06531824\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06531824
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e656303f4832a6fab374@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Excyte Biopharma Ltd P1/P2 readout (est.): Study of YK012 in B-cell
  Acute Lymphoblastic Leukemia
DESCRIPTION:Study of YK012 in B-cell Acute Lymphoblastic Leukemia\nNCT06580
 301 | PHASE1/PHASE2 | RECRUITING | sponsor: Excyte Biopharma Ltd\nPrimary 
 completion date (ESTIMATED)\; top-line results usually follow later.\nSour
 ce: https://clinicaltrials.gov/study/NCT06580301\nScheduling/reference dat
 a from public records\; dates can move. Not investment\, legal or medical 
 advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06580301
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fa33d6cfed184d957cdd@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Longboard Pharmaceuticals P3 readout (est.): A Phase 3\, Placebo-Co
 ntrolled Study to Investigate LP352 in Children and Adults With Dravet Syn
 drome (DS)
DESCRIPTION:A Phase 3\, Placebo-Controlled Study to Investigate LP352 in Ch
 ildren and Adults With Dravet Syndrome (DS)\nNCT06660394 | PHASE3 | ACTIVE
 _NOT_RECRUITING | sponsor: Longboard Pharmaceuticals\nPrimary completion d
 ate (ESTIMATED)\; top-line results usually follow later.\nSource: https://
 clinicaltrials.gov/study/NCT06660394\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06660394
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:945e50f518092788f03c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Corza Medical GmbH P3 readout (est.): A Study to Compare the Effica
 cy and Safety of TachoSil and Surgicel Original as an Adjunct to Control M
 ild to Moderate Soft Tissue Bleeding During Surgery
DESCRIPTION:A Study to Compare the Efficacy and Safety of TachoSil and Surg
 icel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleedi
 ng During Surgery\nNCT06664775 | PHASE3 | RECRUITING | sponsor: Corza Medi
 cal GmbH\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nSource: https://clinicaltrials.gov/study/NCT06664775\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06664775
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c19b1e75b33dec67afee@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tasly Pharmaceutical Group Co.\, Ltd P2 readout (est.): Efficacy an
 d Safety of Jia Shen Tablets in Chronic Heart Failure
DESCRIPTION:Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failur
 e\nNCT06669169 | PHASE2 | NOT_YET_RECRUITING | sponsor: Tasly Pharmaceutic
 al Group Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-line results
  usually follow later.\nSource: https://clinicaltrials.gov/study/NCT066691
 69\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06669169
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cbc4858552fcf750f3be@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:JAZZ P2 readout (est.): A Phase 2 Study of Zanidatamab in Patients 
 With HER2-expressing Tumors
DESCRIPTION:A Phase 2 Study of Zanidatamab in Patients With HER2-expressing
  Tumors\nNCT06695845 | PHASE2 | RECRUITING | sponsor: Jazz Pharmaceuticals
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nTicker JAZZ (confidence 0.9)\nSource: https://clinicaltrials.gov/stu
 dy/NCT06695845\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06695845
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5cef84260e002ebc62d7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tasly Pharmaceutical Group Co.\, Ltd P3 readout (est.): A Study of 
 Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
DESCRIPTION:A Study of Lianxiaxiaopi Granules in the Treatment of Postprand
 ial Distress Syndrome\nNCT06696261 | PHASE3 | RECRUITING | sponsor: Tasly 
 Pharmaceutical Group Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nSource: https://clinicaltrials.gov/stu
 dy/NCT06696261\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06696261
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:10b8bf2d5c84e0def13d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Hangzhou Hanx Biopharmaceuticals\, Ltd. P1/P2 readout (est.): A Pha
 se 2 Study of HX301 in Patients with High-grade Giloma
DESCRIPTION:A Phase 2 Study of HX301 in Patients with High-grade Giloma\nNC
 T06703255 | PHASE1/PHASE2 | RECRUITING | sponsor: Hangzhou Hanx Biopharmac
 euticals\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results us
 ually follow later.\nSource: https://clinicaltrials.gov/study/NCT06703255\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06703255
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8f5a8292ce4b0b646014@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Beijing Biostar Pharmaceuticals Co.\, Ltd. P2 readout (est.): Utide
 lone Capsule Monotherapy for Patients with Advanced Solid Tumors
DESCRIPTION:Utidelone Capsule Monotherapy for Patients with Advanced Solid 
 Tumors\nNCT06730581 | PHASE2 | NOT_YET_RECRUITING | sponsor: Beijing Biost
 ar Pharmaceuticals Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nSource: https://clinicaltrials.gov/stud
 y/NCT06730581\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06730581
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:30306b3c1dc99c7cd9b1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shanghai Henlius Biotech P2 readout (est.): A Phase II Clinical Stu
 dy to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patien
 ts With Advanced Gynecological Malignant Tumors
DESCRIPTION:A Phase II Clinical Study to Evaluate the Efficacy and Safety o
 f HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant
  Tumors\nNCT06769152 | PHASE2 | RECRUITING | sponsor: Shanghai Henlius Bio
 tech\nPrimary completion date (ESTIMATED)\; top-line results usually follo
 w later.\nSource: https://clinicaltrials.gov/study/NCT06769152\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06769152
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:177c66f23a3de7006857@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jiangsu Alphamab Biopharmaceuticals Co.\, Ltd P1/P2 readout (est.):
  JSKN033 in Chinese Subjects with Advanced Malignant Tumors
DESCRIPTION:JSKN033 in Chinese Subjects with Advanced Malignant Tumors\nNCT
 06770881 | PHASE1/PHASE2 | NOT_YET_RECRUITING | sponsor: Jiangsu Alphamab 
 Biopharmaceuticals Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nSource: https://clinicaltrials.gov/study
 /NCT06770881\nScheduling/reference data from public records\; dates can mo
 ve. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06770881
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fa51f77fbcd154f20c32@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shionogi P2 readout (est.): Safety and Efficacy Study of Sivopixant
 \, Acetazolamide and SASS-001 in Sleep Apnea
DESCRIPTION:Safety and Efficacy Study of Sivopixant\, Acetazolamide and SAS
 S-001 in Sleep Apnea\nNCT06776432 | PHASE2 | ACTIVE_NOT_RECRUITING | spons
 or: Shionogi\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nSource: https://clinicaltrials.gov/study/NCT06776432\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06776432
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:23c486d6cad9b84d61ff@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. P2 readout (est.): A Study to 
 Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrol
 izumab in Patients With Unresectable Locally Advanced or Metastatic Mucosa
 l or Acral Melanoma Who Had Not Previously Received Systemic Therapy
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of IBI363 Monothera
 py Compared to Pembrolizumab in Patients With Unresectable Locally Advance
 d or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received 
 Systemic Therapy\nNCT06797297 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: 
 Innovent Biologics (Suzhou) Co. Ltd.\nPrimary completion date (ESTIMATED)\
 ; top-line results usually follow later.\nSource: https://clinicaltrials.g
 ov/study/NCT06797297\nScheduling/reference data from public records\; date
 s can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06797297
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:656c7d1a87637b67f6b6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Evopoint Biosciences Inc. P1/P2 readout (est.): Study of XNW28012 i
 n Subjects With Advanced Solid Tumors Who Failed Standard Treatments
DESCRIPTION:Study of XNW28012 in Subjects With Advanced Solid Tumors Who Fa
 iled Standard Treatments\nNCT06799637 | PHASE1/PHASE2 | RECRUITING | spons
 or: Evopoint Biosciences Inc.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nSource: https://clinicaltrials.gov/stud
 y/NCT06799637\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06799637
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:eecf028296baee5e2529@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ono Pharmaceutical Co.\, Ltd. P2 readout (est.): A Study of ONO-202
 0 in Patients With Agitation Associated With Alzheimer's Disease Dementia
DESCRIPTION:A Study of ONO-2020 in Patients With Agitation Associated With 
 Alzheimer's Disease Dementia\nNCT06803823 | PHASE2 | RECRUITING | sponsor:
  Ono Pharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nSource: https://clinicaltrials.gov/stu
 dy/NCT06803823\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06803823
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8b3421874d39878dfa28@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Biocity Biopharmaceutics Co.\, Ltd. P3 readout (est.): A Study of S
 C0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
DESCRIPTION:A Study of SC0062 Capsule for the Treatment of IgA Nephropathy 
 with Proteinuria\nNCT06819826 | PHASE3 | RECRUITING | sponsor: Biocity Bio
 pharmaceutics Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT
 06819826\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06819826
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:70b1f091f25f2372d165@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Valenta Pharm JSC P2 readout (est.): Efficacy\, Safety\, and Tolera
 bility of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia
DESCRIPTION:Efficacy\, Safety\, and Tolerability of 4-MUST Tablets in Chron
 ic Cholecystitis and Biliary Dyskinesia\nNCT06842966 | PHASE2 | RECRUITING
  | sponsor: Valenta Pharm JSC\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nSource: https://clinicaltrials.gov/stud
 y/NCT06842966\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06842966
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6d7e8cc8532be265d16d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Valenta Pharm JSC P2 readout (est.): Study to Evaluate the Efficacy
  and Safety of Different Doses of Graminidin With Anesthetic\, a Metered D
 ose Topical Spray\, in the Treatment of Acute Infectious and Inflammatory 
 Pharyngeal Diseases Compared With Drug Septolete Total\, Lozenges
DESCRIPTION:Study to Evaluate the Efficacy and Safety of Different Doses of
  Graminidin With Anesthetic\, a Metered Dose Topical Spray\, in the Treatm
 ent of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With
  Drug Septolete Total\, Lozenges\nNCT06843018 | PHASE2 | RECRUITING | spon
 sor: Valenta Pharm JSC\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT06
 843018\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06843018
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f4005b2e30b60ca1d439@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Laboratorios Silanes S.A. de C.V. P3 readout (est.): Efficacy Anda 
 Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Ar
 thritis
DESCRIPTION:Efficacy Anda Safety of Etoricoxib With Betamethasone for the T
 reatment of Acute Gout Arthritis\nNCT06863701 | PHASE3 | RECRUITING | spon
 sor: Laboratorios Silanes S.A. de C.V.\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nSource: https://clinicaltrials
 .gov/study/NCT06863701\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06863701
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d0d31ef89bd29a714a6d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. P3 readout (est.): A Study Com
 paring IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Me
 tabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
DESCRIPTION:A Study Comparing IBI362 vs Semaglutide in Chinese Overweight o
 r Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease 
 （MAFLD）\nNCT06884293 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Innov
 ent Biologics (Suzhou) Co. Ltd.\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nSource: https://clinicaltrials.gov/st
 udy/NCT06884293\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06884293
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9160ec0cda674e078cb6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Hangzhou Highlightll Pharmaceutical Co.\, Ltd P3 readout (est.): A 
 Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid 
 Arthritis
DESCRIPTION:A Long-term Extension Clinical Study of TLL-018 in Patients Wit
 h Rheumatoid Arthritis\nNCT06887127 | PHASE3 | ACTIVE_NOT_RECRUITING | spo
 nsor: Hangzhou Highlightll Pharmaceutical Co.\, Ltd\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nSource: https://c
 linicaltrials.gov/study/NCT06887127\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06887127
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3b94293ade66d203ea95@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Innovent Biologics Technology Limited (Shanghai R&D Center) P2 read
 out (est.): A Study to Evaluate the Efficacy and Safety of IBI302 inSubjec
 ts With Diabetic Macular Edema（DME）
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of IBI302 inSubject
 s With Diabetic Macular Edema（DME）\nNCT06908876 | PHASE2 | ACTIVE_NOT_
 RECRUITING | sponsor: Innovent Biologics Technology Limited (Shanghai R&D 
 Center)\nPrimary completion date (ESTIMATED)\; top-line results usually fo
 llow later.\nSource: https://clinicaltrials.gov/study/NCT06908876\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06908876
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7b99b95fd9a58267929e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Blueprint Medicines Corporation P2 readout (est.): Study of BLU-808
  in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria 
 (CSU)
DESCRIPTION:Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chr
 onic Spontaneous Urticaria (CSU)\nNCT06931405 | PHASE2 | ACTIVE_NOT_RECRUI
 TING | sponsor: Blueprint Medicines Corporation\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nSource: https://clini
 caltrials.gov/study/NCT06931405\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06931405
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:826fe8e5b50567796243@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jacobio Pharmaceuticals Co.\, Ltd. P1/P2 readout (est.): A Phase I/
 IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KR
 AS Gene Alteration
DESCRIPTION:A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Soli
 d Tumors Harboring KRAS Gene Alteration\nNCT06959615 | PHASE1/PHASE2 | REC
 RUITING | sponsor: Jacobio Pharmaceuticals Co.\, Ltd.\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nSource: https:/
 /clinicaltrials.gov/study/NCT06959615\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06959615
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:00b1470992e4d78876df@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Changchun GeneScience Pharmaceutical Co.\, Ltd. P3 readout (est.): 
 Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus
  Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer 
 in the Cachexia Phase
DESCRIPTION:Nano-crystalline Megestrol Acetate Combined With Standard Treat
 ment Versus Standard Treatment for First-line Extensive-stage Small Cell L
 ung Cancer in the Cachexia Phase\nNCT06961201 | PHASE3 | NOT_YET_RECRUITIN
 G | sponsor: Changchun GeneScience Pharmaceutical Co.\, Ltd.\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nSource: 
 https://clinicaltrials.gov/study/NCT06961201\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06961201
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:15c01072f22c3db09f81@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Clarity Pharmaceuticals Ltd P3 readout (est.): AMPLIFY
DESCRIPTION:64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study 
 of Participants With Biochemical Recurrence of Prostate Cancer\nNCT0697084
 7 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Clarity Pharmaceuticals Ltd\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nSource: https://clinicaltrials.gov/study/NCT06970847\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06970847
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:36adb9850078536fe17e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:GeneCradle Inc P3 readout (est.): Safety and Efficacy Evaluation of
  GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Pati
 ents With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
DESCRIPTION:Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrat
 hecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscul
 ar Atrophy (SMA) - Phase III\nNCT06971094 | PHASE3 | ACTIVE_NOT_RECRUITING
  | sponsor: GeneCradle Inc\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nSource: https://clinicaltrials.gov/study/N
 CT06971094\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06971094
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d438393b28c82f2f2cb1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Hillhurst Biopharmaceuticals\, Inc. P2 readout (est.): LoCaMoTE-PD
DESCRIPTION:Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety\, T
 olerability\, PK\, and Biomarkers in Parkinson's Disease\nNCT07005180 | PH
 ASE2 | RECRUITING | sponsor: Hillhurst Biopharmaceuticals\, Inc.\nPrimary 
 completion date (ESTIMATED)\; top-line results usually follow later.\nSour
 ce: https://clinicaltrials.gov/study/NCT07005180\nScheduling/reference dat
 a from public records\; dates can move. Not investment\, legal or medical 
 advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07005180
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:854df351352a66ee5a32@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:EL3 Bio\, LLC. P2 readout (est.): A Double-Blind\, Randomized\, Pla
 cebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Efficac
 y of L2-01 in Subjects With Crohn's Disease
DESCRIPTION:A Double-Blind\, Randomized\, Placebo-Controlled Phase II Clini
 cal Trial to Evaluate the Safety and Efficacy of L2-01 in Subjects With Cr
 ohn's Disease\nNCT07010926 | PHASE2 | NOT_YET_RECRUITING | sponsor: EL3 Bi
 o\, LLC.\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nSource: https://clinicaltrials.gov/study/NCT07010926\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07010926
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8291dfd5f04986fb2e3b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shenyang Sunshine Pharmaceutical Co.\, LTD. P2 readout (est.): SSGJ
 -705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid
  Tumors
DESCRIPTION:SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-E
 xpressing Solid Tumors\nNCT07022002 | PHASE2 | RECRUITING | sponsor: Sheny
 ang Sunshine Pharmaceutical Co.\, LTD.\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nSource: https://clinicaltrials
 .gov/study/NCT07022002\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07022002
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:409d4af725c71f2e310a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Imbioray (Hangzhou) Biomedicine Co.\, Ltd. P2 readout (est.): A Stu
 dy of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Ce
 ll Carcinoma
DESCRIPTION:A Study of IBR854 Combined With Pazopanib Versus Pazopanib in A
 dvanced Renal Cell Carcinoma\nNCT07087158 | PHASE2 | RECRUITING | sponsor:
  Imbioray (Hangzhou) Biomedicine Co.\, Ltd.\nPrimary completion date (ESTI
 MATED)\; top-line results usually follow later.\nSource: https://clinicalt
 rials.gov/study/NCT07087158\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07087158
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e88464a49773aa7d6743@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. P3 readout (est.): A Clinical 
 Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inact
 ive Thyroid Eye Disease
DESCRIPTION:A Clinical Study to Evaluate the Efficacy and Safety of IBI311 
 in Subjects With Inactive Thyroid Eye Disease\nNCT07113262 | PHASE3 | RECR
 UITING | sponsor: Innovent Biologics (Suzhou) Co. Ltd.\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nSource: https:
 //clinicaltrials.gov/study/NCT07113262\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07113262
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7fd98bae321c4edf90dd@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shanghai Synvida Biotechnology Co.\,Ltd. P2 readout (est.): A Clini
 cal Study to Evaluate the Safety\, Tolerability\, Pharmacokinetics and Imm
 unogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
DESCRIPTION:A Clinical Study to Evaluate the Safety\, Tolerability\, Pharma
 cokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmona
 ry Fibrosis\nNCT07121413 | PHASE2 | RECRUITING | sponsor: Shanghai Synvida
  Biotechnology Co.\,Ltd.\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT
 07121413\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07121413
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b2c6af4ddc7cf7229781@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ScinnoHub Pharmaceutical Co.\, Ltd. P2 readout (est.): TKA
DESCRIPTION:Study on BT-114143 Reducing Perioperative Bleeding in Total Kne
 e Arthroplasty（TKA）\nNCT07127042 | PHASE2 | RECRUITING | sponsor: Scin
 noHub Pharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nSource: https://clinicaltrials.gov/st
 udy/NCT07127042\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07127042
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5771a9bbe9e1cd82e746@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:VivaVision Biotech\, Inc P3 readout (est.): A Phase 3 Study of VVN4
 61 Ophthalmic Solution for Noninfectious Anterior Uveitis
DESCRIPTION:A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious
  Anterior Uveitis\nNCT07136805 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor:
  VivaVision Biotech\, Inc\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nSource: https://clinicaltrials.gov/study/NC
 T07136805\nScheduling/reference data from public records\; dates can move.
  Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07136805
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:80fa18f35cbf8966b50f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shanghai Cell Therapy Group Co.\,Ltd P1/P2 readout (est.): Explorat
 ory Study of Super DC Cell Injection in Preventing Recurrence After Radica
 l Surgery for Tumors
DESCRIPTION:Exploratory Study of Super DC Cell Injection in Preventing Recu
 rrence After Radical Surgery for Tumors\nNCT07146672 | PHASE1/PHASE2 | REC
 RUITING | sponsor: Shanghai Cell Therapy Group Co.\,Ltd\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nSource: https
 ://clinicaltrials.gov/study/NCT07146672\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07146672
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a3c8af129a87be558457@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Qilu Pharmaceutical Co.\, Ltd. P3 readout (est.): Pharmacokinetic S
 tudy of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lu
 ng Cancer (NSCLC)
DESCRIPTION:Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant 
 Therapy of Non-Small Cell Lung Cancer (NSCLC)\nNCT07162883 | PHASE3 | ACTI
 VE_NOT_RECRUITING | sponsor: Qilu Pharmaceutical Co.\, Ltd.\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nSource: h
 ttps://clinicaltrials.gov/study/NCT07162883\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07162883
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d95784c61e34bd70158c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Mapi Pharma Ltd. P1/P2 readout (est.): Pharmacokinetics\, Safety\, 
 Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Carip
 razine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Ca
 riprazine
DESCRIPTION:Pharmacokinetics\, Safety\, Tolerability and Efficacy of a Subc
 utaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subje
 cts Eligible for Treatment With Oral Cariprazine\nNCT07185815 | PHASE1/PHA
 SE2 | RECRUITING | sponsor: Mapi Pharma Ltd.\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nSource: https://clinical
 trials.gov/study/NCT07185815\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07185815
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a3d5b27fa444d5e534ae@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Galderma R&D P3 readout (est.): AKLIEF
DESCRIPTION:A Study to Compare the Efficacy\, Safety and Pharmacokinetics o
 f Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris\nNCT07
 186413 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Galderma R&D\nPrimary c
 ompletion date (ESTIMATED)\; top-line results usually follow later.\nSourc
 e: https://clinicaltrials.gov/study/NCT07186413\nScheduling/reference data
  from public records\; dates can move. Not investment\, legal or medical a
 dvice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07186413
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:207bda8bff4941f058f5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HK inno.N Corporation P3 readout (est.): Study to Evaluate the Effi
 cacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweigh
 t Without Diabetes Mellitus
DESCRIPTION:Study to Evaluate the Efficacy and Safety of IN-B00009 Injectio
 n in Adults With Obesity or Overweight Without Diabetes Mellitus\nNCT07192
 263 | PHASE3 | NOT_YET_RECRUITING | sponsor: HK inno.N Corporation\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nSo
 urce: https://clinicaltrials.gov/study/NCT07192263\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07192263
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1c60c029816706e523fe@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Elixiron Immunotherapeutics (Hong Kong) Ltd. P2 readout (est.): Pha
 se 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
DESCRIPTION:Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Pati
 ents\nNCT07223229 | PHASE2 | RECRUITING | sponsor: Elixiron Immunotherapeu
 tics (Hong Kong) Ltd.\nPrimary completion date (ESTIMATED)\; top-line resu
 lts usually follow later.\nSource: https://clinicaltrials.gov/study/NCT072
 23229\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07223229
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:279e2b5bfa3e39923e37@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SUPN P2 readout (est.): Double-blind\, Placebo-controlled Study in 
 Adults With Major Depressive Disorder
DESCRIPTION:Double-blind\, Placebo-controlled Study in Adults With Major De
 pressive Disorder\nNCT07226661 | PHASE2 | RECRUITING | sponsor: Supernus P
 harmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-line resu
 lts usually follow later.\nTicker SUPN (confidence 0.9)\nSource: https://c
 linicaltrials.gov/study/NCT07226661\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07226661
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:52ec5f6acf163f9edd38@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:RemeGen Co.\, Ltd. P3 readout (est.): A Study of Telitacicept in Pa
 tients With Ocular Myasthenia Gravis (OMG)
DESCRIPTION:A Study of Telitacicept in Patients With Ocular Myasthenia Grav
 is (OMG)\nNCT07249632 | PHASE3 | RECRUITING | sponsor: RemeGen Co.\, Ltd.\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nSource: https://clinicaltrials.gov/study/NCT07249632\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07249632
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2cedad3d7d4ae918d4d1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ostia Sciences P2 readout (est.): Efficacy of SALI-10 Oral Probioti
 cs in Experimental Gingivitis
DESCRIPTION:Efficacy of SALI-10 Oral Probiotics in Experimental Gingivitis\
 nNCT07256743 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Ostia Sciences\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nSource: https://clinicaltrials.gov/study/NCT07256743\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07256743
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4892249976cd90d646f8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tasly Pharmaceutical Group Co.\, Ltd P1/P2 readout (est.): A Phase 
 I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatm
 ent of Chronic Heart Failure
DESCRIPTION:A Phase I/II Clinical Trial of Intramyocardial Injection of Huc
 MSCs for the Treatment of Chronic Heart Failure\nNCT07265349 | PHASE1/PHAS
 E2 | RECRUITING | sponsor: Tasly Pharmaceutical Group Co.\, Ltd\nPrimary c
 ompletion date (ESTIMATED)\; top-line results usually follow later.\nSourc
 e: https://clinicaltrials.gov/study/NCT07265349\nScheduling/reference data
  from public records\; dates can move. Not investment\, legal or medical a
 dvice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07265349
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0d65739957744a134127@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TheiaNova Ltd. P1/P2 readout (est.): Study of TN-001 Topical Eyedro
 ps for Keratoconus
DESCRIPTION:Study of TN-001 Topical Eyedrops for Keratoconus\nNCT07388069 |
  PHASE1/PHASE2 | ENROLLING_BY_INVITATION | sponsor: TheiaNova Ltd.\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nSo
 urce: https://clinicaltrials.gov/study/NCT07388069\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07388069
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b6ee16afc9c1eaa90c13@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Initiator Pharma P2 readout (est.): A Phase 2 Study to Evaluate the
  Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia
 )
DESCRIPTION:A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafens
 ine in Vulvodynia (Provoked Vestibulodynia)\nNCT07391241 | PHASE2 | ACTIVE
 _NOT_RECRUITING | sponsor: Initiator Pharma\nPrimary completion date (ESTI
 MATED)\; top-line results usually follow later.\nSource: https://clinicalt
 rials.gov/study/NCT07391241\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07391241
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5650779aa6e49657ff3e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. P2 readout (est.): IBI363 as N
 eoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
DESCRIPTION:IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Sm
 all Cell Lung Cancer\nNCT07402070 | PHASE2 | NOT_YET_RECRUITING | sponsor:
  Innovent Biologics (Suzhou) Co. Ltd.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nSource: https://clinicaltrials.
 gov/study/NCT07402070\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07402070
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:12f4ae54bca9d1401f33@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Beijing Tuohua Weiye Biotechnology Co.\, Ltd. P1/P2 readout (est.):
  HBV-DC
DESCRIPTION:Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells I
 njection in Patients With Decompensated Hepatitis B Cirrhosis\nNCT07413549
  | PHASE1/PHASE2 | RECRUITING | sponsor: Beijing Tuohua Weiye Biotechnolog
 y Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nSource: https://clinicaltrials.gov/study/NCT07413549\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07413549
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9d327d10c55f22cffc2e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TARS P2 readout (est.): Study of Lotilaner Ophthalmic Gel in Patien
 ts With Ocular Rosacea (KORE)
DESCRIPTION:Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosac
 ea (KORE)\nNCT07443202 | PHASE2 | ENROLLING_BY_INVITATION | sponsor: Tarsu
 s Pharmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nTicker TARS (confidence 0.9)\nSource: https:
 //clinicaltrials.gov/study/NCT07443202\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07443202
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:974fee6a690a4e68c814@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sinotau Pharmaceutical Group P2 readout (est.): STB-XTR-003
DESCRIPTION:PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injecti
 on and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy\n
 NCT07443696 | PHASE2 | RECRUITING | sponsor: Sinotau Pharmaceutical Group\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nSource: https://clinicaltrials.gov/study/NCT07443696\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07443696
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5ddb6f07c9acca9c8466@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tasly Pharmaceutical Group Co.\, Ltd P2/P3 readout (est.): A Study 
 of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Modera
 te to Severe Depression
DESCRIPTION:A Study of the Effectiveness and Safety of JS1-1-01 Tablet in P
 atients With Moderate to Severe Depression\nNCT07485595 | PHASE2/PHASE3 | 
 NOT_YET_RECRUITING | sponsor: Tasly Pharmaceutical Group Co.\, Ltd\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nSo
 urce: https://clinicaltrials.gov/study/NCT07485595\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07485595
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6e0100664c1b1abeb9ee@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sano Chemicals Inc P2 readout (est.): BLOSSOM
DESCRIPTION:Biweekly Long-term Occidiofungin Study for Suppression of Mycot
 ic Recurrence\nNCT07521137 | PHASE2 | RECRUITING | sponsor: Sano Chemicals
  Inc\nPrimary completion date (ESTIMATED)\; top-line results usually follo
 w later.\nSource: https://clinicaltrials.gov/study/NCT07521137\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07521137
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:66147e497d8d5892923a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Shanghai RAAS Blood Products Co.\, Ltd. P1/P2 readout (est.): An Op
 en-label\, Multicenter Phase I/II Clinical Trial to Evaluate the Safety\, 
 Tolerability\, Efficacy\, and Pharmacokinetic/Pharmacodynamic (PK/PD) Char
 acteristics of SR604 Injection in Patients With Hemophilia A/B and Congeni
 tal Factor VII Deficiency
DESCRIPTION:An Open-label\, Multicenter Phase I/II Clinical Trial to Evalua
 te the Safety\, Tolerability\, Efficacy\, and Pharmacokinetic/Pharmacodyna
 mic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia
  A/B and Congenital Factor VII Deficiency\nNCT07644832 | PHASE1/PHASE2 | R
 ECRUITING | sponsor: Shanghai RAAS Blood Products Co.\, Ltd.\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nSource: 
 https://clinicaltrials.gov/study/NCT07644832\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07644832
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ec0a16048bedfe6eb09a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:E-nitiate Biopharmaceuticals (Hangzhou) Co.\, Ltd. P2 readout (est.
 ): A Multicenter\, Randomized\, Parallel-Group\, Double-Blind\, Placebo-Co
 ntrolled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY
 201 Tablets in Subjects With Non-Segmental Vitiligo
DESCRIPTION:A Multicenter\, Randomized\, Parallel-Group\, Double-Blind\, Pl
 acebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safe
 ty of QY201 Tablets in Subjects With Non-Segmental Vitiligo\nNCT07712523 |
  PHASE2 | RECRUITING | sponsor: E-nitiate Biopharmaceuticals (Hangzhou) Co
 .\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nSource: https://clinicaltrials.gov/study/NCT07712523\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07712523
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:af191d27cc63d3fb7ec2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Guangdong Hengrui Pharmaceutical Co.\, Ltd P2 readout (est.): Phase
  II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis
DESCRIPTION:Phase II Clinical Trial of SHR-1139 Injection in Patients With 
 Psoriasis\nNCT07719530 | PHASE2 | RECRUITING | sponsor: Guangdong Hengrui 
 Pharmaceutical Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT
 07719530\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07719530
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:09db909e4430fede624d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. P3 readout (est.): Safety and E
 fficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bol
 us Maintenance in Adults
DESCRIPTION:Safety and Efficacy of HRS-9190 Compared to Rocuronium for Trac
 heal Intubation and Bolus Maintenance in Adults\nNCT07746726 | PHASE3 | RE
 CRUITING | sponsor: Jiangsu HengRui Medicine Co.\, Ltd.\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nSource: https
 ://clinicaltrials.gov/study/NCT07746726\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07746726
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e25d6c0f6a016fba1efa@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. P2 readout (est.): A Open-Labe
 l Phase in Participants With Multiple Myeloma
DESCRIPTION:A Open-Label Phase in Participants With Multiple Myeloma\nNCT07
 764861 | PHASE2 | NOT_YET_RECRUITING | sponsor: Innovent Biologics (Suzhou
 ) Co. Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nSource: https://clinicaltrials.gov/study/NCT07764861\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07764861
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:80058917a5116a2ee0b4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:PT Bio Farma P3 readout (est.): Immunogenicity and Safety of HPV-4 
 Vaccine With or Without Td Vaccine in Children
DESCRIPTION:Immunogenicity and Safety of HPV-4 Vaccine With or Without Td V
 accine in Children\nNCT07824310 | PHASE3 | NOT_YET_RECRUITING | sponsor: P
 T Bio Farma\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nSource: https://clinicaltrials.gov/study/NCT07824310\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07824310
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7d0e4532f0031cde6f34@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Hexin (Suzhou) Pharmaceutical Technology Co.\, Ltd P2 readout (est.
 ): A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection fo
 r PET/CT Imaging
DESCRIPTION:A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Inje
 ction for PET/CT Imaging\nNCT07920835 | PHASE2 | RECRUITING | sponsor: Hex
 in (Suzhou) Pharmaceutical Technology Co.\, Ltd\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nSource: https://clini
 caltrials.gov/study/NCT07920835\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07920835
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c179d8d827d67fc3c784@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Imvax P2 readout (est.): A Phase 2b Clinical Study With a Combinati
 on Immunotherapy in Newly Diagnosed Patients With Glioblastoma
DESCRIPTION:A Phase 2b Clinical Study With a Combination Immunotherapy in N
 ewly Diagnosed Patients With Glioblastoma\nNCT04485949 | PHASE2 | ACTIVE_N
 OT_RECRUITING | sponsor: Imvax\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nDate precision: month (shown on the fi
 rst day)\nSource: https://clinicaltrials.gov/study/NCT04485949\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04485949
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fab410b5daa60e957023@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:BicycleTx Limited P1/P2 readout (est.): Study BT8009-100 in Subject
 s With Nectin-4 Expressing Advanced Malignancies
DESCRIPTION:Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced 
 Malignancies\nNCT04561362 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponso
 r: BicycleTx Limited\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nDate precision: month (shown on the first day)\n
 Source: https://clinicaltrials.gov/study/NCT04561362\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04561362
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3636e18fe3107bd81b6a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:ELDN P1/P2 readout (est.): Safety\, Pharmacokinetics\, and Efficacy
  of AT 1501 in Patients Undergoing Kidney Transplant
DESCRIPTION:Safety\, Pharmacokinetics\, and Efficacy of AT 1501 in Patients
  Undergoing Kidney Transplant\nNCT05027906 | PHASE1/PHASE2 | RECRUITING | 
 sponsor: Eledon Pharmaceuticals\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nDate precision: month (shown on the f
 irst day)\nTicker ELDN (confidence 0.9)\nSource: https://clinicaltrials.go
 v/study/NCT05027906\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05027906
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:aa2c10d092ddd73bece8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:MIRM P2 readout (est.): VANTAGE
DESCRIPTION:A Study to Evaluate Efficacy and Safety of an Investigational D
 rug Named Volixibat in Patients With Itching Caused by Primary Biliary Cho
 langitis\nNCT05050136 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Mirum Ph
 armaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nDate precision: month (shown on the first day)\n
 Ticker MIRM (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT
 05050136\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05050136
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:371200b0a658cfc5cac5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.\, Ltd. P2 readout 
 (est.): A Study to Evaluate Efficacy and Safety of Light Dose in Subjects 
 With PWB Treated With Hemoporfin PDT
DESCRIPTION:A Study to Evaluate Efficacy and Safety of Light Dose in Subjec
 ts With PWB Treated With Hemoporfin PDT\nNCT05171894 | PHASE2 | RECRUITING
  | sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.\, Ltd.\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nD
 ate precision: month (shown on the first day)\nSource: https://clinicaltri
 als.gov/study/NCT05171894\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05171894
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ec2697aa2cf43072d575@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Vantive Health LLC P3 readout (est.): Safety Evaluation of Prismoci
 trate 18 in Patients Receiving CRRT
DESCRIPTION:Safety Evaluation of Prismocitrate 18 in Patients Receiving CRR
 T\nNCT05399537 | PHASE3 | RECRUITING | sponsor: Vantive Health LLC\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nDa
 te precision: month (shown on the first day)\nSource: https://clinicaltria
 ls.gov/study/NCT05399537\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05399537
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8c76b75c15867118acf7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Vaderis Therapeutics AG P1/P2 readout (est.): Assess Safety and Eff
 icacy of VAD044 in HHT Patients
DESCRIPTION:Assess Safety and Efficacy of VAD044 in HHT Patients\nNCT054063
 62 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Vaderis Therapeutics
  AG\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nDate precision: month (shown on the first day)\nSource: https://c
 linicaltrials.gov/study/NCT05406362\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05406362
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6ee31ec3b7174c3e2b3f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:EWTX P2 readout (est.): A Study of EDG-5506 in Children With Duchen
 ne Muscular Dystrophy (LYNX)
DESCRIPTION:A Study of EDG-5506 in Children With Duchenne Muscular Dystroph
 y (LYNX)\nNCT05540860 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Edgewise
  Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nDate precision: month (shown on the first day)\n
 Ticker EWTX (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT
 05540860\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05540860
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:808530e310d58da72d10@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Biocad P3 readout (est.): NEO-MIMAJOR
DESCRIPTION:A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgo
 limab) in Patients With Resectable Stage III Skin Melanoma\nNCT05751928 | 
 PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Biocad\nPrimary completion date 
 (ESTIMATED)\; top-line results usually follow later.\nDate precision: mont
 h (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT05
 751928\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05751928
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ca5ab77176e7d4f05cae@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:QBiotics Group Limited P2 readout (est.): A Clinical Study to Inves
 tigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarco
 ma
DESCRIPTION:A Clinical Study to Investigate the Efficacy of Intratumoral Ti
 gilanol Tiglate in Soft Tissue Sarcoma\nNCT05755113 | PHASE2 | RECRUITING 
 | sponsor: QBiotics Group Limited\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nDate precision: month (shown on the
  first day)\nSource: https://clinicaltrials.gov/study/NCT05755113\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05755113
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d92a01fdf4b831c87d03@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:EMS P3 readout (est.): GENERA
DESCRIPTION:Efficacy and Safety of OMA102 in the Treatment of Female Patter
 n Hair Loss\nNCT05824065 | PHASE3 | NOT_YET_RECRUITING | sponsor: EMS\nPri
 mary completion date (ESTIMATED)\; top-line results usually follow later.\
 nDate precision: month (shown on the first day)\nSource: https://clinicalt
 rials.gov/study/NCT05824065\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05824065
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:666ba758d261703cebb0@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:LigaChem Biosciences\, Inc. P1/P2 readout (est.): A Study to Evalua
 te TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in
  Advanced Solid Tumors
DESCRIPTION:A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combina
 tion With an Anti-PD-1 Ab in Advanced Solid Tumors\nNCT05941507 | PHASE1/P
 HASE2 | RECRUITING | sponsor: LigaChem Biosciences\, Inc.\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nDate precis
 ion: month (shown on the first day)\nSource: https://clinicaltrials.gov/st
 udy/NCT05941507\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05941507
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d56d5efec69d1501670f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Skyline Therapeutics (US) Inc. P1/P2 readout (est.): Phase I/II Stu
 dy of SKG0106 Intravitreal Injection in Patients With Neovascular Age-rela
 ted Macular Degeneration (nAMD)
DESCRIPTION:Phase I/II Study of SKG0106 Intravitreal Injection in Patients 
 With Neovascular Age-related Macular Degeneration (nAMD)\nNCT05986864 | PH
 ASE1/PHASE2 | RECRUITING | sponsor: Skyline Therapeutics (US) Inc.\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nDa
 te precision: month (shown on the first day)\nSource: https://clinicaltria
 ls.gov/study/NCT05986864\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05986864
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9ee860ce0c0025306744@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:GILD P2 readout (est.): PALEKONA
DESCRIPTION:Study of Tilpisertib Fosmecarbil in Participants With Moderatel
 y to Severely Active Ulcerative Colitis\nNCT06029972 | PHASE2 | ACTIVE_NOT
 _RECRUITING | sponsor: Gilead Sciences\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nDate precision: month (shown o
 n the first day)\nTicker GILD (confidence 0.9)\nSource: https://clinicaltr
 ials.gov/study/NCT06029972\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06029972
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1ef86db6cf623a96504f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Dr. F. Köhler Chemie GmbH P2 readout (est.): Study of Organ Perfus
 ion in Heart Transplantation in Children
DESCRIPTION:Study of Organ Perfusion in Heart Transplantation in Children\n
 NCT06032195 | PHASE2 | RECRUITING | sponsor: Dr. F. Köhler Chemie GmbH\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nDate precision: month (shown on the first day)\nSource: https://clinica
 ltrials.gov/study/NCT06032195\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06032195
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:70fc1810224f51ad694f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:ABBV P2/P3 readout (est.): LIVIGNO-2
DESCRIPTION:A Study to Assess the Dose\, Adverse Events\, and Change in Dis
 ease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combinat
 ion With Budigalimab as an IV Solution in Adult Participants With Hepatoce
 llular Carcinoma (HCC)\nNCT06109272 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITIN
 G | sponsor: AbbVie\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nT
 icker ABBV (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0
 6109272\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06109272
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f80d19dd38265dd62dac@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. P1/P2 readout (est.): A Stu
 dy of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic Malign
 ancies
DESCRIPTION:A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gy
 necologic Malignancies\nNCT06131450 | PHASE1/PHASE2 | RECRUITING | sponsor
 : Sichuan Baili Pharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMA
 TED)\; top-line results usually follow later.\nDate precision: month (show
 n on the first day)\nSource: https://clinicaltrials.gov/study/NCT06131450\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06131450
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6891d9c1ca96ec0e1705@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:OncoVerity\, Inc. P2 readout (est.): A Study Comparing Venetoclax a
 nd Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Dia
 gnosed AML Ineligible for Intensive Therapy
DESCRIPTION:A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab t
 o Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensi
 ve Therapy\nNCT06384261 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: OncoVe
 rity\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nDate precision: month (shown on the first day)\nSource: h
 ttps://clinicaltrials.gov/study/NCT06384261\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06384261
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8a4f38cb7c71d475c786@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Jacobio Pharmaceuticals Co.\, Ltd. P1/P2 readout (est.): JAB-30355 
 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
DESCRIPTION:JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53
  Y220C Mutation\nNCT06386146 | PHASE1/PHASE2 | RECRUITING | sponsor: Jacob
 io Pharmaceuticals Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nSource: https://clinicaltrials.gov/study/NCT06386146\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06386146
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f9eeb46d998eb7387f00@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:LRMR P2 readout (est.): An Open-Label Study of CTI-1601 in Subjects
  With Friedreich's Ataxia
DESCRIPTION:An Open-Label Study of CTI-1601 in Subjects With Friedreich's A
 taxia\nNCT06447025 | PHASE2 | RECRUITING | sponsor: Larimar Therapeutics\,
  Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nDate precision: month (shown on the first day)\nTicker LRMR (co
 nfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06447025\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06447025
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6ffddd515ad6a903714f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:LXRX P3 readout (est.): SONATA-HCM
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Sotagliflozin in
  Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy\n
 NCT06481891 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Lexicon Pharmaceut
 icals\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nDate precision: month (shown on the first day)\nTicker LXRX (co
 nfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06481891\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06481891
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f5ce918fb57d5df3975c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. P3 readout (est.)
 : A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-E
 xpressing Recurrent/Metastatic Breast Cancer
DESCRIPTION:A Clinical Trial of TQB2102 for Injection in the Treatment of H
 ER2 Low-Expressing Recurrent/Metastatic Breast Cancer\nNCT06561607 | PHASE
 3 | ACTIVE_NOT_RECRUITING | sponsor: Chia Tai Tianqing Pharmaceutical Grou
 p Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nDate precision: month (shown on the first day)\nSource: 
 https://clinicaltrials.gov/study/NCT06561607\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06561607
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e63a773306bfc28b8d1c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Akeso P3 readout (est.): A Phase 3 Study of AK112 Plus AK117 Versus
  Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carc
 inoma (R/M HNSCC)
DESCRIPTION:A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Rec
 urrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)\nNC
 T06601335 | PHASE3 | RECRUITING | sponsor: Akeso\nPrimary completion date 
 (ESTIMATED)\; top-line results usually follow later.\nDate precision: mont
 h (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT06
 601335\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06601335
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ea46d07dad0a7a2f389e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:RARE P3 readout (est.): Setrusumab in Pediatric Japanese Subjects W
 ith Osteogenesis Imperfecta
DESCRIPTION:Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imp
 erfecta\nNCT06636071 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Ultrageny
 x Pharmaceutical Inc\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nDate precision: month (shown on the first day)\n
 Ticker RARE (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT
 06636071\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06636071
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b9e4470593aa39eedf31@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Rempex (a wholly owned subsidiary of Melinta Therapeutics\, LLC) P2
  readout (est.): A Study to Evaluate the Safety\, Tolerability\, and Pharm
 acokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary 
 Tract Infection\, Including Acute Pyelonephritis
DESCRIPTION:A Study to Evaluate the Safety\, Tolerability\, and Pharmacokin
 etics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract 
 Infection\, Including Acute Pyelonephritis\nNCT06672978 | PHASE2 | ACTIVE_
 NOT_RECRUITING | sponsor: Rempex (a wholly owned subsidiary of Melinta The
 rapeutics\, LLC)\nPrimary completion date (ESTIMATED)\; top-line results u
 sually follow later.\nDate precision: month (shown on the first day)\nSour
 ce: https://clinicaltrials.gov/study/NCT06672978\nScheduling/reference dat
 a from public records\; dates can move. Not investment\, legal or medical 
 advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06672978
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ceffe596572998f04918@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:ABBV P3 readout (est.): Start Up Japan
DESCRIPTION:Safety and Efficacy of Upadacitinib in Combination With Topical
  Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan 
 With Moderate to Severe Atopic Dermatitis\nNCT06701331 | PHASE3 | ACTIVE_N
 OT_RECRUITING | sponsor: AbbVie\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nDate precision: month (shown on the f
 irst day)\nTicker ABBV (confidence 0.9)\nSource: https://clinicaltrials.go
 v/study/NCT06701331\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06701331
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ab5e0d0d1ec0e734af19@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Evopoint Biosciences Inc. P2 readout (est.): To Evaluate XNW5004 Ta
 blets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
DESCRIPTION:To Evaluate XNW5004 Tablets in Patients with Relapsed or Refrac
 tory Peripheral T Cell Lymphoma\nNCT06702605 | PHASE2 | NOT_YET_RECRUITING
  | sponsor: Evopoint Biosciences Inc.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nSource: https://clinicaltrials.gov/study/NCT06702605\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06702605
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b45fb066fa4c5ace1799@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:AION Healthspan\, Inc. P1/P2 readout (est.): UC-MSC-CKD
DESCRIPTION:A Study to Investigate the Safety\, Tolerability\, and Prelimin
 ary Efficacy With AION-301 Administered by Intravenous Infusion Compared W
 ith Placebo Administered by Intravenous Infusion Investigational Intervent
 ion in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease
  (CKD)\nNCT06721143 | PHASE1/PHASE2 | RECRUITING | sponsor: AION Healthspa
 n\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nDate precision: month (shown on the first day)\nSource: http
 s://clinicaltrials.gov/study/NCT06721143\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06721143
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e91c339e8415e9ac7d79@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:CStone Pharmaceuticals P1/P2 readout (est.): A Phase I/II Study of 
 CS2009 in Participants With Advanced Solid Tumors
DESCRIPTION:A Phase I/II Study of CS2009 in Participants With Advanced Soli
 d Tumors\nNCT06741644 | PHASE1/PHASE2 | RECRUITING | sponsor: CStone Pharm
 aceuticals\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nDate precision: month (shown on the first day)\nSource: ht
 tps://clinicaltrials.gov/study/NCT06741644\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06741644
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0bcb73c0a50fcadd0705@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Hope Biosciences Research Foundation P2 readout (est.): MS
DESCRIPTION:"HB-adMSCs for the Treatment of Patients With Multiple Sclerosi
 s"\nNCT06800404 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Hope Bioscienc
 es Research Foundation\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nDate precision: month (shown on the first day)
 \nSource: https://clinicaltrials.gov/study/NCT06800404\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06800404
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d0713ed101fb39f0a7e7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Marengo Therapeutics\, Inc. P1/P2 readout (est.): START-002
DESCRIPTION:A Study of Invikafusp Alfa (STAR0602)\, a Selective T Cell Rece
 ptor (TCR)-Targeting\, Bifunctional Antibody-fusion Molecule\, in Combinat
 ion With Sacituzumab Govitecan in Participants With Advanced Solid Tumors\
 nNCT06827613 | PHASE1/PHASE2 | RECRUITING | sponsor: Marengo Therapeutics\
 , Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nDate precision: month (shown on the first day)\nSource: https:
 //clinicaltrials.gov/study/NCT06827613\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06827613
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:43021e79e8496886b8bb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. P3 readout (est.)
 : A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Ra
 dioiodine-Refractory Differentiated Thyroid Carcinoma
DESCRIPTION:A Study of AL2846 Capsule Versus Placebo in the Treatment of Ad
 vanced Radioiodine-Refractory Differentiated Thyroid Carcinoma\nNCT0686097
 1 | PHASE3 | RECRUITING | sponsor: Chia Tai Tianqing Pharmaceutical Group 
 Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nDate precision: month (shown on the first day)\nSource: ht
 tps://clinicaltrials.gov/study/NCT06860971\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06860971
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:49be48a01be11a76a2a5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Resilience P3 readout (est.): RC-102
DESCRIPTION:Randomized Controlled Trial of Remote Symptoms Monitoring With 
 Resilience PRO Compared to Care As Usual Only\nNCT06867705 | PHASE3 | RECR
 UITING | sponsor: Resilience\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nDate precision: month (shown on the firs
 t day)\nSource: https://clinicaltrials.gov/study/NCT06867705\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06867705
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:64891cf2fc78429d02c3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:QED Therapeutics\, a BridgeBio company P2/P3 readout (est.): HCH
DESCRIPTION:An Interventional Study of Infigratinib in Children With Hypoch
 ondroplasia\nNCT06873035 | PHASE2/PHASE3 | ENROLLING_BY_INVITATION | spons
 or: QED Therapeutics\, a BridgeBio company\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nDate precision: month (sho
 wn on the first day)\nSource: https://clinicaltrials.gov/study/NCT06873035
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06873035
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5112d33d41d48d62b66e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:iOnctura P1/P2 readout (est.): PULMO-01
DESCRIPTION:A Study of Roginolisib (IOA-244) in Combination With Dostarlima
 b With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCL
 C) Patients\nNCT06879717 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor
 : iOnctura\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nDate precision: month (shown on the first day)\nSource: ht
 tps://clinicaltrials.gov/study/NCT06879717\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06879717
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ed8afa00862ccb2138b1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Zhejiang Teruisi Pharmaceutical Inc. P2 readout (est.): A Phase 2 S
 tudy of TRS005 in Patients With CD20-positive R/R DLBCL.
DESCRIPTION:A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DL
 BCL.\nNCT06886139 | PHASE2 | NOT_YET_RECRUITING | sponsor: Zhejiang Teruis
 i Pharmaceutical Inc.\nPrimary completion date (ESTIMATED)\; top-line resu
 lts usually follow later.\nDate precision: month (shown on the first day)\
 nSource: https://clinicaltrials.gov/study/NCT06886139\nScheduling/referenc
 e data from public records\; dates can move. Not investment\, legal or med
 ical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06886139
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:72cb2a16cfd99b057513@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:TenNor Therapeutics Inc. P1/P2 readout (est.): A Phase 1/2 Study to
  Evaluate the Safety\, PK and Efficacy of TNP-2092 Administered Via IA Inj
 ection in PJI Participants
DESCRIPTION:A Phase 1/2 Study to Evaluate the Safety\, PK and Efficacy of T
 NP-2092 Administered Via IA Injection in PJI Participants\nNCT06889701 | P
 HASE1/PHASE2 | RECRUITING | sponsor: TenNor Therapeutics Inc.\nPrimary com
 pletion date (ESTIMATED)\; top-line results usually follow later.\nDate pr
 ecision: month (shown on the first day)\nSource: https://clinicaltrials.go
 v/study/NCT06889701\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06889701
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6c895e63ec9d76f3f433@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:XENE P3 readout (est.): X-NOVA-OLE
DESCRIPTION:An Open-Label Study of Azetukalner in Major Depressive Disorder
 \nNCT06922110 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Xenon Pharmaceut
 icals Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nDate precision: month (shown on the first day)\nTicker XEN
 E (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06922110\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06922110
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6cfe533372df07086d75@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:BioMendics\, LLC P2 readout (est.): (TAMES)
DESCRIPTION:A Phase II\, Placebo Controlled\, Clinical Trial of Topical Tol
 aSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex
 \nNCT07027345 | PHASE2 | RECRUITING | sponsor: BioMendics\, LLC\nPrimary c
 ompletion date (ESTIMATED)\; top-line results usually follow later.\nDate 
 precision: month (shown on the first day)\nSource: https://clinicaltrials.
 gov/study/NCT07027345\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07027345
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:af56fdc1744a6b3c9c30@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Greg Bew P2 readout (est.): Evaluating Benzoyl Peroxide for Prevent
 ing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option
DESCRIPTION:Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 
 Outbreaks With Rescue Crossover Option\nNCT07032649 | PHASE2 | NOT_YET_REC
 RUITING | sponsor: Greg Bew\nPrimary completion date (ESTIMATED)\; top-lin
 e results usually follow later.\nDate precision: month (shown on the first
  day)\nSource: https://clinicaltrials.gov/study/NCT07032649\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07032649
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:864a043452015aff8d1b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:EyeD Pharma P1/P2 readout (est.): Safety and Efficacy of TimoD Sust
 ained-Release Implant in Participants With Glaucoma or Ocular Hypertension
  Undergoing Cataract Surgery
DESCRIPTION:Safety and Efficacy of TimoD Sustained-Release Implant in Parti
 cipants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery\n
 NCT07036510 | PHASE1/PHASE2 | RECRUITING | sponsor: EyeD Pharma\nPrimary c
 ompletion date (ESTIMATED)\; top-line results usually follow later.\nDate 
 precision: month (shown on the first day)\nSource: https://clinicaltrials.
 gov/study/NCT07036510\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07036510
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f5379ae1da81d12d3022@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Shanghai Henlius Biotech P2 readout (est.): A Study to Evaluate the
  Efficacy\, Safety\, and Tolerability of Human Sialidase Fusion Protein (H
 LX79) in Combination With Rituximab Injection Versus Placebo in Patients W
 ith Active Glomerulonephritis
DESCRIPTION:A Study to Evaluate the Efficacy\, Safety\, and Tolerability of
  Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Inje
 ction Versus Placebo in Patients With Active Glomerulonephritis\nNCT070383
 82 | PHASE2 | RECRUITING | sponsor: Shanghai Henlius Biotech\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nDate pre
 cision: month (shown on the first day)\nSource: https://clinicaltrials.gov
 /study/NCT07038382\nScheduling/reference data from public records\; dates 
 can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07038382
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:72e6f39ca4930dfe680b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:TLX P3 readout (est.): BiPASS
DESCRIPTION:PSMA PET Combined With MRI for the Detection of PCa\nNCT0705221
 4 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Telix Pharmaceuticals (Innov
 ations) Pty Limited\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nT
 icker TLX (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT07
 052214\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07052214
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:524cd9b837c4edc23939@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Qilu Pharmaceutical Co.\, Ltd. P3 readout (est.): A Comparative Stu
 dy to Valuating the Efficacy and Safety of QL1206 and Prolia®
DESCRIPTION:A Comparative Study to Valuating the Efficacy and Safety of QL1
 206 and Prolia®\nNCT07062978 | PHASE3 | RECRUITING | sponsor: Qilu Pharma
 ceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nS
 ource: https://clinicaltrials.gov/study/NCT07062978\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07062978
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b265c01f70c37a3dbd40@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Biocad P2 readout (est.): ULTRAMARINE
DESCRIPTION:Study of the Efficacy\, Safety\, Pharmacokinetics\, Pharmacodyn
 amics\, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe 
 Active Ulcerative Colitis\nNCT07080034 | PHASE2 | RECRUITING | sponsor: Bi
 ocad\nPrimary completion date (ESTIMATED)\; top-line results usually follo
 w later.\nDate precision: month (shown on the first day)\nSource: https://
 clinicaltrials.gov/study/NCT07080034\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07080034
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:26046149851e6b0c8a66@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Sun Pharmaceutical Industries\, Inc. P3 readout (est.): Study of Re
 formulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Sc
 alp
DESCRIPTION:Study of Reformulated Levulan Kerastick Plus PDT for Actinic Ke
 ratosis on Face and Scalp\nNCT07144345 | PHASE3 | RECRUITING | sponsor: Su
 n Pharmaceutical Industries\, Inc.\nPrimary completion date (ESTIMATED)\; 
 top-line results usually follow later.\nDate precision: month (shown on th
 e first day)\nSource: https://clinicaltrials.gov/study/NCT07144345\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07144345
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d7ee6508fcf4333975b0@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Sun Pharmaceutical Industries\, Inc. P3 readout (est.): Study of Re
 formulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extre
 mities
DESCRIPTION:Study of Reformulated Levulan Kerastick Plus PDT for Actinic Ke
 ratosis on Upper Extremities\nNCT07144852 | PHASE3 | RECRUITING | sponsor:
  Sun Pharmaceutical Industries\, Inc.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nSource: https://clinicaltrials.gov/study/NCT07144852\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07144852
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:43e0822237c846515340@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Shanghai Huilun Pharmaceutical Co.\, Ltd. P3 readout (est.): A Phas
 e III Clinical Study of H077 Sustained-Release Tablets Compared With Silod
 osin Capsules in the Treatment of Benign Prostatic Hyperplasia
DESCRIPTION:A Phase III Clinical Study of H077 Sustained-Release Tablets Co
 mpared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperp
 lasia\nNCT07146386 | PHASE3 | NOT_YET_RECRUITING | sponsor: Shanghai Huilu
 n Pharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-lin
 e results usually follow later.\nDate precision: month (shown on the first
  day)\nSource: https://clinicaltrials.gov/study/NCT07146386\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07146386
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:06896d6e758ba26b65c8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Alesta Therapeutics P1/P2 readout (est.): A Study to Assess Safety\
 , Tolerability\, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy 
 Adults and Adults With Hypophosphatasia in Order to Identify Suitable Dose
 s of ALE1
DESCRIPTION:A Study to Assess Safety\, Tolerability\, Pharmacokinetics and 
 Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasi
 a in Order to Identify Suitable Doses of ALE1\nNCT07179640 | PHASE1/PHASE2
  | RECRUITING | sponsor: Alesta Therapeutics\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nDate precision: month (s
 hown on the first day)\nSource: https://clinicaltrials.gov/study/NCT071796
 40\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07179640
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:77cd5fdb8bc9d0b10da0@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:HAFC P2 readout (est.): Study to Evaluate HM15275 in Obese or Overw
 eight Subjects Without Diabetes Mellitus
DESCRIPTION:Study to Evaluate HM15275 in Obese or Overweight Subjects Witho
 ut Diabetes Mellitus\nNCT07205900 | PHASE2 | ACTIVE_NOT_RECRUITING | spons
 or: Hanmi Pharmaceutical Company Limited\nPrimary completion date (ESTIMAT
 ED)\; top-line results usually follow later.\nDate precision: month (shown
  on the first day)\nTicker HAFC (confidence 0.6)\nSource: https://clinical
 trials.gov/study/NCT07205900\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07205900
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:942cc534647e9096195a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:MediLink Therapeutics (Suzhou) Co.\, Ltd. P1/P2 readout (est.): A S
 tudy of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
DESCRIPTION:A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumo
 rs\nNCT07208773 | PHASE1/PHASE2 | RECRUITING | sponsor: MediLink Therapeut
 ics (Suzhou) Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nDate precision: month (shown on the first day
 )\nSource: https://clinicaltrials.gov/study/NCT07208773\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07208773
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fa99b50fd2219d01657d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. P1/P2 readout (est.):
  A Study of SHR-4375 Injection in Combination With Other Antitumor Therapi
 es in Patients With Solid Tumors
DESCRIPTION:A Study of SHR-4375 Injection in Combination With Other Antitum
 or Therapies in Patients With Solid Tumors\nNCT07298772 | PHASE1/PHASE2 | 
 RECRUITING | sponsor: Suzhou Suncadia Biopharmaceuticals Co.\, Ltd.\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nD
 ate precision: month (shown on the first day)\nSource: https://clinicaltri
 als.gov/study/NCT07298772\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07298772
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2fc2749bece6c8e15c91@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Newleos Therapeutics\, Inc. P2 readout (est.): SOAR
DESCRIPTION:A Study of NTX-1472 in Social Anxiety Disorder\nNCT07323784 | P
 HASE2 | RECRUITING | sponsor: Newleos Therapeutics\, Inc.\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nDate precis
 ion: month (shown on the first day)\nSource: https://clinicaltrials.gov/st
 udy/NCT07323784\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07323784
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:deb795e7acbac4ee9ba9@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Inflammasome Therapeutics P1/P2 readout (est.): Kamlanoflast In Amy
 otrophic Lateral Sclerosis
DESCRIPTION:Kamlanoflast In Amyotrophic Lateral Sclerosis\nNCT07396818 | PH
 ASE1/PHASE2 | NOT_YET_RECRUITING | sponsor: Inflammasome Therapeutics\nPri
 mary completion date (ESTIMATED)\; top-line results usually follow later.\
 nDate precision: month (shown on the first day)\nSource: https://clinicalt
 rials.gov/study/NCT07396818\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07396818
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:955d0252838adf05e17e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Synendos Therapeutics AG P2 readout (est.): A Phase 2a Efficacy\, S
 afety\, Tolerability\, and PK Study of SYT-510 in Participants With Genera
 lized Anxiety Disorder
DESCRIPTION:A Phase 2a Efficacy\, Safety\, Tolerability\, and PK Study of S
 YT-510 in Participants With Generalized Anxiety Disorder\nNCT07478744 | PH
 ASE2 | RECRUITING | sponsor: Synendos Therapeutics AG\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nDate precision:
  month (shown on the first day)\nSource: https://clinicaltrials.gov/study/
 NCT07478744\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07478744
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4d0482516caf861deca4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Aribio Lab Co.\, Ltd. P2 readout (est.): Safety and Immunogenicity 
 of CVI-VZV-001 in Adults Aged 50 Years and Above
DESCRIPTION:Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Year
 s and Above\nNCT07481604 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Aribi
 o Lab Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results u
 sually follow later.\nDate precision: month (shown on the first day)\nSour
 ce: https://clinicaltrials.gov/study/NCT07481604\nScheduling/reference dat
 a from public records\; dates can move. Not investment\, legal or medical 
 advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07481604
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a6f9a15cda292542a1fb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:PRAX P3 readout (est.): POWER2
DESCRIPTION:Randomized Clinical Trial Evaluating the Efficacy and Safety of
  Vormatrigine in Adults With Focal Seizures\nNCT07505004 | PHASE3 | ACTIVE
 _NOT_RECRUITING | sponsor: Praxis Precision Medicines\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nDate precision:
  month (shown on the first day)\nTicker PRAX (confidence 0.9)\nSource: htt
 ps://clinicaltrials.gov/study/NCT07505004\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07505004
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d0001037b97106e3c6b6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:SVA P3 readout (est.): Phase Ⅲ Trial of Group ACYW135 Meningococc
 al Conjugate Vaccine in Children Aged 12-23 Months
DESCRIPTION:Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccin
 e in Children Aged 12-23 Months\nNCT07505836 | PHASE3 | RECRUITING | spons
 or: Sinovac Biotech Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nTicker SVA (confidence 0.9)\nSource: https://clinicaltrials.gov/s
 tudy/NCT07505836\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07505836
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:592b38699ccb77059cc2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Reistone Biopharma Company Limited P3 readout (est.): A Multicenter
 \, Randomized\, Double-Blind\, Placebo-Controlled Phase III Clinical Study
  to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients
  With Plaque Psoriasis.
DESCRIPTION:A Multicenter\, Randomized\, Double-Blind\, Placebo-Controlled 
 Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Oi
 ntment in Adult Patients With Plaque Psoriasis.\nNCT07543224 | PHASE3 | NO
 T_YET_RECRUITING | sponsor: Reistone Biopharma Company Limited\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nDate p
 recision: month (shown on the first day)\nSource: https://clinicaltrials.g
 ov/study/NCT07543224\nScheduling/reference data from public records\; date
 s can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07543224
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:af491f819b60fc765458@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:LABT P2 readout (est.): Phase 2a Dose Finding Study of Nu-3 Gel in 
 Subjects With Mild iDFU
DESCRIPTION:Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild i
 DFU\nNCT07565506 | PHASE2 | RECRUITING | sponsor: Lakewood-Amedex Inc\nPri
 mary completion date (ESTIMATED)\; top-line results usually follow later.\
 nDate precision: month (shown on the first day)\nTicker LABT (confidence 0
 .9)\nSource: https://clinicaltrials.gov/study/NCT07565506\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07565506
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e59a990dcbc97571760b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Hyundai Bioscience Co.\, Ltd. P2/P3 readout (est.): A Study of CP-C
 OV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue
 -like Illness (Part 2)
DESCRIPTION:A Study of CP-COV03 Compared With Placebo in Participants With 
 Dengue (Part 1) and Dengue-like Illness (Part 2)\nNCT07576868 | PHASE2/PHA
 SE3 | RECRUITING | sponsor: Hyundai Bioscience Co.\, Ltd.\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nDate precis
 ion: month (shown on the first day)\nSource: https://clinicaltrials.gov/st
 udy/NCT07576868\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07576868
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1e5da0da10038f866b84@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Actio Biosciences\, Inc. P2 readout (est.): KYRON
DESCRIPTION:A Study to Investigate the Safety\, Tolerability\, Pharmacokine
 tics\, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Part
 icipants With KCNT1-related Epilepsy\nNCT07600736 | PHASE2 | RECRUITING | 
 sponsor: Actio Biosciences\, Inc.\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nDate precision: month (shown on the
  first day)\nSource: https://clinicaltrials.gov/study/NCT07600736\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07600736
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:36252339da02543407ce@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:A. Menarini International Licensing S.A. P3 readout (est.): MEDICI
DESCRIPTION:Phase 3 Clinical Study Evaluating Efficacy\, Safety\, and Toler
 ability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults W
 ith Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at Hig
 h to Very High Cardiovascular Risk\, During a Treatment Period of Approxim
 ately 84 Days\nNCT07614958 | PHASE3 | RECRUITING | sponsor: A. Menarini In
 ternational Licensing S.A.\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nDate precision: month (shown on the first 
 day)\nSource: https://clinicaltrials.gov/study/NCT07614958\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07614958
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6ff1a3e6d2405b613894@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Prolium Bioscience\, Inc P1/P2 readout (est.): A Phase 1/2 Study of
  PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
DESCRIPTION:A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Particip
 ants With Systemic Sclerosis.\nNCT07641634 | PHASE1/PHASE2 | RECRUITING | 
 sponsor: Prolium Bioscience\, Inc\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nDate precision: month (shown on the
  first day)\nSource: https://clinicaltrials.gov/study/NCT07641634\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07641634
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5bd4b71a2de2b4b51f6c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Sensory Cloud\, Inc. P2 readout (est.): SensoryCloud
DESCRIPTION:A Study to Investigate the Efficacy and Safety of SC0032\, a Ma
 gnesium Salt Oral Spray\, in Adults With Refractory or Unexplained Chronic
  Cough\nNCT07690059 | PHASE2 | RECRUITING | sponsor: Sensory Cloud\, Inc.\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nDate precision: month (shown on the first day)\nSource: https://clini
 caltrials.gov/study/NCT07690059\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07690059
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e6d9dbe8b60cc5f2dc9f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Caravel Oculus Pty Ltd P2 readout (est.): A Study of CA201A Eye Dro
 ps to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Catarac
 t Surgery
DESCRIPTION:A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell
  Loss in Patients Undergoing Cataract Surgery\nNCT07694375 | PHASE2 | RECR
 UITING | sponsor: Caravel Oculus Pty Ltd\nPrimary completion date (ESTIMAT
 ED)\; top-line results usually follow later.\nDate precision: month (shown
  on the first day)\nSource: https://clinicaltrials.gov/study/NCT07694375\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07694375
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e88a5521aa7014500b08@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:CL P3 readout (est.): Clinical Evaluation of a Toothpaste for Denta
 l Plaque Reduction and Prevention of Gum Problems
DESCRIPTION:Clinical Evaluation of a Toothpaste for Dental Plaque Reduction
  and Prevention of Gum Problems\nNCT07842991 | PHASE3 | RECRUITING | spons
 or: Colgate Palmolive\nPrimary completion date (ESTIMATED)\; top-line resu
 lts usually follow later.\nDate precision: month (shown on the first day)\
 nTicker CL (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0
 7842991\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07842991
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ed5056b7721f09d2ace1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Adneuris Therapeutics\, Inc. P3 readout (est.): An Open-Label\, Saf
 ety and Efficacy Study of Cebranopadol in Participants With Acute Pain Wit
 h Surgical or Non-Surgical Origin
DESCRIPTION:An Open-Label\, Safety and Efficacy Study of Cebranopadol in Pa
 rticipants With Acute Pain With Surgical or Non-Surgical Origin\nNCT078450
 71 | PHASE3 | RECRUITING | sponsor: Adneuris Therapeutics\, Inc.\nPrimary 
 completion date (ESTIMATED)\; top-line results usually follow later.\nDate
  precision: month (shown on the first day)\nSource: https://clinicaltrials
 .gov/study/NCT07845071\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07845071
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:37ed49d0c4f7d3044076@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Aperta Biosciences\, LLC P2 readout (est.): VISTA-1X
DESCRIPTION:A Phase 2 Study to Compare Efficacy and Safety of a Novel Topic
 al Therapy (APT-001\, Spinosad 1.8%) in Patients With Blepharitis\nNCT0790
 4767 | PHASE2 | NOT_YET_RECRUITING | sponsor: Aperta Biosciences\, LLC\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nDate precision: month (shown on the first day)\nSource: https://clinical
 trials.gov/study/NCT07904767\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07904767
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fcaaee793335823cc263@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Cristcot LLC P2 readout (est.): A Three-Arm\, Randomized\, Placebo-
 Controlled\, Double-Blind Phase 2 Study to Evaluate the Safety and Efficac
 y of Two Dosage Regimens of a Novel Hydrocortisone Acetate Suppository For
 mulation Administered With a Proprietary Suppository Applicator in Subject
 s With Hemorrhoidal Disease
DESCRIPTION:A Three-Arm\, Randomized\, Placebo-Controlled\, Double-Blind Ph
 ase 2 Study to Evaluate the Safety and Efficacy of Two Dosage Regimens of 
 a Novel Hydrocortisone Acetate Suppository Formulation Administered With a
  Proprietary Suppository Applicator in Subjects With Hemorrhoidal Disease\
 nNCT07909291 | PHASE2 | NOT_YET_RECRUITING | sponsor: Cristcot LLC\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nDa
 te precision: month (shown on the first day)\nSource: https://clinicaltria
 ls.gov/study/NCT07909291\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07909291
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2de3025ae1a32980a56e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:SIGA P2 readout (est.): Study to Assess the Safety and Immunogenici
 ty of TPOXX® When Administered Orally for 28 Days With JYNNEOS
DESCRIPTION:Study to Assess the Safety and Immunogenicity of TPOXX® When A
 dministered Orally for 28 Days With JYNNEOS\nNCT04957485 | PHASE2 | ACTIVE
 _NOT_RECRUITING | sponsor: SIGA Technologies\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker SIGA (confidence 
 0.9)\nSource: https://clinicaltrials.gov/study/NCT04957485\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04957485
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:df92d97738ca91113e9a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Biotheus Inc. P2 readout (est.): A Study of PM8002 in Combination W
 ith Chemotherapy in Patients With NEN
DESCRIPTION:A Study of PM8002 in Combination With Chemotherapy in Patients 
 With NEN\nNCT05879055 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Biotheus
  Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nSource: https://clinicaltrials.gov/study/NCT05879055\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05879055
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:845d686aca673ec7af4e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Tasly Biopharmaceuticals Co.\, Ltd. P2 readout (est.): A Multicente
 r\, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B
 1962 Injection in the Treatment of Advanced Colorectal Cancer
DESCRIPTION:A Multicenter\, Open Phase IIb Clinical Study to Evaluate the E
 fficacy and Safety of B1962 Injection in the Treatment of Advanced Colorec
 tal Cancer\nNCT06838546 | PHASE2 | NOT_YET_RECRUITING | sponsor: Tasly Bio
 pharmaceuticals Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nSource: https://clinicaltrials.gov/study/N
 CT06838546\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06838546
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6b5bee528444193ff680@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Second Life Therapeutics P1/P2 readout (est.): SL-28 for Advanced S
 olid Tumours
DESCRIPTION:SL-28 for Advanced Solid Tumours\nNCT07341737 | PHASE1/PHASE2 |
  RECRUITING | sponsor: Second Life Therapeutics\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nSource: https://clini
 caltrials.gov/study/NCT07341737\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07341737
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c0cce79d9263f281e0f8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270103
DTEND;VALUE=DATE:20270104
SUMMARY:Shenzhen Kangzhe Biotechnology Co.\, Ltd. P2 readout (est.): Phase 
 II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia
DESCRIPTION:Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Me
 norrhagia\nNCT07402369 | PHASE2 | RECRUITING | sponsor: Shenzhen Kangzhe B
 iotechnology Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0
 7402369\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07402369
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:98a73efb0a1eb55126a7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:MLTX P3 readout (est.): IZAR-2
DESCRIPTION:Evaluation of Sonelokimab in Patients With Active Psoriatic Art
 hritis and Anti-TNFα Inadequate Response\nNCT06641089 | PHASE3 | ACTIVE_N
 OT_RECRUITING | sponsor: MoonLake Immunotherapeutics AG\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nTicker MLTX (
 confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06641089\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06641089
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:383c4d9be23a3c5382dc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:AZN P3 readout (est.): AZURE-HeFH
DESCRIPTION:A Phase III Study to Assess the Effect of AZD0780 on LDL-C in P
 atients With HeFH\nNCT07000136 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor:
  AstraZeneca\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nTicker AZN (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT07000136\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07000136
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a2f52201640337d93fa3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270105
DTEND;VALUE=DATE:20270106
SUMMARY:Hangzhou Sciwind Biosciences Co.\, Ltd. P1/P2 readout (est.): A Pha
 se Ib/IIa Study to Evaluate the Safety\, Tolerability\, Pharmacokinetics a
 nd Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants Wi
 th Overweight or Obesity
DESCRIPTION:A Phase Ib/IIa Study to Evaluate the Safety\, Tolerability\, Ph
 armacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese
  Participants With Overweight or Obesity\nNCT07243171 | PHASE1/PHASE2 | RE
 CRUITING | sponsor: Hangzhou Sciwind Biosciences Co.\, Ltd.\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nSource: h
 ttps://clinicaltrials.gov/study/NCT07243171\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07243171
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1d496042c54ecaa9fafa@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270105
DTEND;VALUE=DATE:20270106
SUMMARY:Shanghai Mabgeek Biotech.Co.Ltd P3 readout (est.): A Phase III Stud
 y of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
DESCRIPTION:A Phase III Study of MG-K10 in Adolescents With Moderate-to-Sev
 ere Atopic Dermatitis\nNCT07540442 | PHASE3 | NOT_YET_RECRUITING | sponsor
 : Shanghai Mabgeek Biotech.Co.Ltd\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nSource: https://clinicaltrials.gov/
 study/NCT07540442\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07540442
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:663aa53ce97540b103ba@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:AZN P3 readout (est.): DAISY
DESCRIPTION:Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (D
 AISY)\nNCT05925803 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: AstraZeneca
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nTicker AZN (confidence 0.9)\nSource: https://clinicaltrials.gov/stud
 y/NCT05925803\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05925803
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c37640b98878616f875b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:AMGN P1/P2 readout (est.): A Study of AMG 732 in Healthy Participan
 ts and Participants With Thyroid Eye Disease
DESCRIPTION:A Study of AMG 732 in Healthy Participants and Participants Wit
 h Thyroid Eye Disease\nNCT06401044 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING
  | sponsor: Amgen\nPrimary completion date (ESTIMATED)\; top-line results 
 usually follow later.\nTicker AMGN (confidence 0.9)\nSource: https://clini
 caltrials.gov/study/NCT06401044\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06401044
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e9e8c1d4c61bb37d1b62@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:BMY P1/P2 readout (est.): A Study to Evaluate BMS-986470 in Healthy
  Volunteers and Participants With Sickle Cell Disease
DESCRIPTION:A Study to Evaluate BMS-986470 in Healthy Volunteers and Partic
 ipants With Sickle Cell Disease\nNCT06481306 | PHASE1/PHASE2 | RECRUITING 
 | sponsor: Bristol-Myers Squibb\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nTicker BMY (confidence 0.9)\nSource: 
 https://clinicaltrials.gov/study/NCT06481306\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06481306
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ff46a0283d6da3f3f508@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:INCY P1/P2 readout (est.): A Ph1b/2 Study of Axatilimab Monotherapy
  in Chinese Participants With Recurrent or Refractory cGVHD
DESCRIPTION:A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participant
 s With Recurrent or Refractory cGVHD\nNCT06843408 | PHASE1/PHASE2 | ACTIVE
 _NOT_RECRUITING | sponsor: Incyte Corporation\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nTicker INCY (confidence
  0.9)\nSource: https://clinicaltrials.gov/study/NCT06843408\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06843408
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:54baccba1c55e2996cf9@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:Norgine P3 readout (est.): CLARITY
DESCRIPTION:A Study to Investigate Bowel Cleansing With PLENVU® Compared t
 o Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Prepar
 ation for Colonoscopy\nNCT07218523 | PHASE3 | RECRUITING | sponsor: Norgin
 e\nPrimary completion date (ESTIMATED)\; top-line results usually follow l
 ater.\nSource: https://clinicaltrials.gov/study/NCT07218523\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07218523
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6c28a105bc902b367217@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270107
DTEND;VALUE=DATE:20270108
SUMMARY:SNY P3 readout (est.): Study of a Single Dose of a 21-valent Pneumo
 coccal Conjugate Vaccine in Children and Adolescents With Sickle Cell Dise
 ase
DESCRIPTION:Study of a Single Dose of a 21-valent Pneumococcal Conjugate Va
 ccine in Children and Adolescents With Sickle Cell Disease\nNCT07247188 | 
 PHASE3 | RECRUITING | sponsor: Sanofi\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nTicker SNY (confidence 0.9)\nSo
 urce: https://clinicaltrials.gov/study/NCT07247188\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07247188
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9edb17adc53239b9a0d8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:AZN P3 readout (est.): PACIFIC-9
DESCRIPTION:A Global Study to Assess the Effects of Durvalumab With Oleclum
 ab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in P
 atients With Stage III Unresectable Non-Small Cell Lung Cancer\nNCT0522184
 0 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: AstraZeneca\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nTicker AZN 
 (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05221840\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05221840
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:af1468c7faa540f78bcb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:OCUL P3 readout (est.): Study to Evaluate the Efficacy and Safety o
 f Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age
 - Related Macular Degeneration
DESCRIPTION:Study to Evaluate the Efficacy and Safety of Intravitreal OTX-T
 KI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular De
 generation\nNCT06495918 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Ocular
  Therapeutix\, Inc.\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nTicker OCUL (confidence 0.9)\nSource: https://cli
 nicaltrials.gov/study/NCT06495918\nScheduling/reference data from public r
 ecords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06495918
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4d1aa7702320b6b1e977@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. P2 re
 adout (est.): A Multicenter\, Randomized\, Double-blind\, Placebo-controll
 ed Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safe
 ty of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
DESCRIPTION:A Multicenter\, Randomized\, Double-blind\, Placebo-controlled 
 Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety 
 of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis\nNC
 T06981091 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Shanghai Fosun Pharm
 aceutical Industrial Development Co. Ltd.\nPrimary completion date (ESTIMA
 TED)\; top-line results usually follow later.\nSource: https://clinicaltri
 als.gov/study/NCT06981091\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06981091
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0c47d32eb44ffd5778e1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270109
DTEND;VALUE=DATE:20270110
SUMMARY:GeneQuantum Healthcare (Suzhou) Co.\, Ltd. P3 readout (est.): A Tri
 al Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable 
 or Metastatic Breast Cancer
DESCRIPTION:A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positi
 ve Unresectable or Metastatic Breast Cancer\nNCT07673029 | PHASE3 | RECRUI
 TING | sponsor: GeneQuantum Healthcare (Suzhou) Co.\, Ltd.\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nSource: ht
 tps://clinicaltrials.gov/study/NCT07673029\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07673029
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:188604c780b9dc5cddcc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Celgene P3 readout (est.): SUCCESSOR-1
DESCRIPTION:A Study to Evaluate Mezigdomide\, Bortezomib and Dexamethasone 
 (MEZIVd) Versus Pomalidomide\, Bortezomib and Dexamethasone (PVd) in Parti
 cipants With Relapsed or Refractory Multiple Myeloma (RRMM)\nNCT05519085 |
  PHASE3 | RECRUITING | sponsor: Celgene\nPrimary completion date (ESTIMATE
 D)\; top-line results usually follow later.\nSource: https://clinicaltrial
 s.gov/study/NCT05519085\nScheduling/reference data from public records\; d
 ates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05519085
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dab1dd1ce885c1318c84@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:LaNova Medicines Limited P1/P2 readout (est.): A Phase I/II Study o
 f LM-101 Injection in Patients With Advanced Malignant Tumors
DESCRIPTION:A Phase I/II Study of LM-101 Injection in Patients With Advance
 d Malignant Tumors\nNCT05615974 | PHASE1/PHASE2 | RECRUITING | sponsor: La
 Nova Medicines Limited\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT05
 615974\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05615974
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4158d4e76215f259fa18@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:FutureGen Biopharmaceutical (Beijing) Co.\, Ltd P3 readout (est.): 
 M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Clau
 din (CLDN) 18.2-Positive\, HER2-Negative\, PD-L1 CPS<5\, Locally Advanced 
 Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Aden
 ocarcinoma.
DESCRIPTION:M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatme
 nt for Claudin (CLDN) 18.2-Positive\, HER2-Negative\, PD-L1 CPS<5\, Locall
 y Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction
  (GEJ) Adenocarcinoma.\nNCT06177041 | PHASE3 | RECRUITING | sponsor: Futur
 eGen Biopharmaceutical (Beijing) Co.\, Ltd\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nSource: https://clinicaltr
 ials.gov/study/NCT06177041\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06177041
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3c96d4e3ce020f1a20de@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:AZN P3 readout (est.): TROPION-Lung15
DESCRIPTION:A Study to Investigate the Efficacy and Safety of Dato-DXd With
  or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy 
 in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small
  Cell Lung Cancer\nNCT06417814 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor:
  AstraZeneca\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nTicker AZN (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT06417814\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06417814
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:21ffea3fc729667809d4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:EyeBiotech Ltd. P2/P3 readout (est.): BAROLO
DESCRIPTION:A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibiz
 umab (0.5 mg) in Participants With DME\nNCT06957080 | PHASE2/PHASE3 | ACTI
 VE_NOT_RECRUITING | sponsor: EyeBiotech Ltd.\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nSource: https://clinical
 trials.gov/study/NCT06957080\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06957080
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e45a0b4143be80897193@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:AZN P3 readout (est.): AZURE-LDL
DESCRIPTION:A Phase III Study to Assess the Effect of AZD0780 on LDL-C in P
 atients With Clinical ASCVD or at Risk for a First ASCVD Event\nNCT0700012
 3 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: AstraZeneca\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nTicker AZN 
 (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07000123\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07000123
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f6672bf68d76b66982bc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:MRK P3 readout (est.): Study of Pembrolizumab (MK-3475) Monotherapy
  Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Partic
 ipants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed 
 Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D
 46)
DESCRIPTION:Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab
  Govitecan in Combination With Pembrolizumab for Participants With Metasta
 tic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1
  (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)\nNCT05609968 | 
 PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Merck Sharp & Dohme LLC\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nTic
 ker MRK (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT0560
 9968\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05609968
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dadb3153549337895411@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:GlaxoSmithKline P2 readout (est.): A Study Evaluating Persistence o
 f the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) 
 Vaccine and the Safety and Immune Response Following Revaccination in Adul
 ts 18 Years of Age and Above Who Received Lung or Kidney Transplant
DESCRIPTION:A Study Evaluating Persistence of the Immune Response of the Ad
 juvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immu
 ne Response Following Revaccination in Adults 18 Years of Age and Above Wh
 o Received Lung or Kidney Transplant\nNCT07092865 | PHASE2 | ACTIVE_NOT_RE
 CRUITING | sponsor: GlaxoSmithKline\nPrimary completion date (ESTIMATED)\;
  top-line results usually follow later.\nSource: https://clinicaltrials.go
 v/study/NCT07092865\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07092865
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2424b2ad5195cba6904c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:iVascular S.L.U. P3 readout (est.): ANGIODAPT
DESCRIPTION:Ischemic and Bleeding Outcomes After Angiolite Stent Implantati
 on and an Abbreviated Dual Antiplatelet Therapy\nNCT05952206 | PHASE3 | AC
 TIVE_NOT_RECRUITING | sponsor: iVascular S.L.U.\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nSource: https://clini
 caltrials.gov/study/NCT05952206\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05952206
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:71d1096499d1310bf8eb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:Avirmax Biopharma Inc P1/P2 readout (est.): Clinical Study to Evalu
 ate the Safety\, Tolerability\, and Preliminary Efficacy of Intravitreal (
 IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascula
 r (Wet) Age-Related Macular Degeneration (wAMD)\, Including Symptomatic Ma
 cular Polypoidal Choroidal Vasculopathy (PCV)
DESCRIPTION:Clinical Study to Evaluate the Safety\, Tolerability\, and Prel
 iminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF
  Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration
  (wAMD)\, Including Symptomatic Macular Polypoidal Choroidal Vasculopathy 
 (PCV)\nNCT06550011 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Avir
 max Biopharma Inc\nPrimary completion date (ESTIMATED)\; top-line results 
 usually follow later.\nSource: https://clinicaltrials.gov/study/NCT0655001
 1\nScheduling/reference data from public records\; dates can move. Not inv
 estment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06550011
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:68007489a63a489ea8fa@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:AZN P3 readout (est.): ESSENCE
DESCRIPTION:A Study to Investigate Changes in Symptoms in Adult Participant
 s With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment Wi
 th Tezepelumab\nNCT06706817 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: As
 traZeneca\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nTicker AZN (confidence 0.9)\nSource: https://clinicaltrials
 .gov/study/NCT06706817\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06706817
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4de4bc23030bfba9983e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:Akeso P3 readout (est.): AK112 and Chemotherapy in First-line Metas
 tatic Colorectal Cancer
DESCRIPTION:AK112 and Chemotherapy in First-line Metastatic Colorectal Canc
 er\nNCT06951503 | PHASE3 | RECRUITING | sponsor: Akeso\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nSource: https:
 //clinicaltrials.gov/study/NCT06951503\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06951503
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a9ff61a683325cd1a461@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270114
DTEND;VALUE=DATE:20270115
SUMMARY:SBFM P3 readout (est.): A Study to Evaluate the Efficacy and Safety
  of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of 608 in Adult Sub
 jects With Active Ankylosing Spondylitis(AS)\nNCT07261644 | PHASE3 | RECRU
 ITING | sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co.\, Ltd.\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nTicker SBFM (confidence 0.6)\nSource: https://clinicaltrials.gov/study/N
 CT07261644\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07261644
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:36f917ed2eab1e1ca680@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270114
DTEND;VALUE=DATE:20270115
SUMMARY:NVO P2 readout (est.): A Research Study on How Well Different Doses
  of the Medicine UBT251 Help People Living With Overweight or Obesity
DESCRIPTION:A Research Study on How Well Different Doses of the Medicine UB
 T251 Help People Living With Overweight or Obesity\nNCT07395687 | PHASE2 |
  RECRUITING | sponsor: Novo Nordisk A/S\nPrimary completion date (ESTIMATE
 D)\; top-line results usually follow later.\nTicker NVO (confidence 0.95)\
 nSource: https://clinicaltrials.gov/study/NCT07395687\nScheduling/referenc
 e data from public records\; dates can move. Not investment\, legal or med
 ical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07395687
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:71d283bb82a17269e6aa@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:MRK P3 readout (est.): Efficacy Against Oral Persistent Infection\,
  Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9
 vHPV) in Men Aged 20-45 Years (V503-049)
DESCRIPTION:Efficacy Against Oral Persistent Infection\, Immunogenicity and
  Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 2
 0-45 Years (V503-049)\nNCT04199689 | PHASE3 | ACTIVE_NOT_RECRUITING | spon
 sor: Merck Sharp & Dohme LLC\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nTicker MRK (confidence 0.6)\nSource: htt
 ps://clinicaltrials.gov/study/NCT04199689\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04199689
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0254813ae5dfa594114d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Bioverativ\, a Sanofi company P3 readout (est.): XTEND-ed
DESCRIPTION:Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) i
 n Previously Treated Patients With Hemophilia A\nNCT04644575 | PHASE3 | AC
 TIVE_NOT_RECRUITING | sponsor: Bioverativ\, a Sanofi company\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nSource: 
 https://clinicaltrials.gov/study/NCT04644575\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04644575
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:57c5db36b700a8808351@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:REGN P3 readout (est.): A Trial to See if the Combination of Fianli
 mab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Dela
 ying Melanoma From Coming Back After it Has Been Removed With Surgery
DESCRIPTION:A Trial to See if the Combination of Fianlimab With Cemiplimab 
 Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From C
 oming Back After it Has Been Removed With Surgery\nNCT05608291 | PHASE3 | 
 ACTIVE_NOT_RECRUITING | sponsor: Regeneron Pharmaceuticals\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nTicker REG
 N (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05608291\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05608291
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a72f5ac84c185761d32d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:IDYA P2/P3 readout (est.): IDE196 (Darovasertib) in Combination Wit
 h Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
DESCRIPTION:IDE196 (Darovasertib) in Combination With Crizotinib as First-l
 ine Therapy in Metastatic Uveal Melanoma\nNCT05987332 | PHASE2/PHASE3 | AC
 TIVE_NOT_RECRUITING | sponsor: IDEAYA Biosciences\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nTicker IDYA (confid
 ence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05987332\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05987332
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:83d004e0bcbdc34b66ad@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:XBIT P2 readout (est.): Natrunix in Combination With Methotrexate f
 or Rheumatoid Arthritis Treatment
DESCRIPTION:Natrunix in Combination With Methotrexate for Rheumatoid Arthri
 tis Treatment\nNCT06590090 | PHASE2 | NOT_YET_RECRUITING | sponsor: XBiote
 ch\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nTicker XBIT (confidence 0.9)\nSource: https://clinicaltrial
 s.gov/study/NCT06590090\nScheduling/reference data from public records\; d
 ates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06590090
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:663d3ab5283160079f53@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Biostar Pharma\, Inc. P2 readout (est.): A Pivotal Phase II Clinica
 l Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast C
 ancer Patients With Brain Metastases
DESCRIPTION:A Pivotal Phase II Clinical Trial of Utidelone Injection Plus C
 apecitabine in HER2-negative Breast Cancer Patients With Brain Metastases\
 nNCT06764940 | PHASE2 | RECRUITING | sponsor: Biostar Pharma\, Inc.\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nS
 ource: https://clinicaltrials.gov/study/NCT06764940\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06764940
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:544429a43cb3291af79e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Huabo Biopharm Co.\, Ltd. P2 readout (est.): A Study of HB0025 Plus
  Nab-paclitaxel as First Line Therapy for TNBC
DESCRIPTION:A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for
  TNBC\nNCT07376629 | PHASE2 | ENROLLING_BY_INVITATION | sponsor: Huabo Bio
 pharm Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results u
 sually follow later.\nSource: https://clinicaltrials.gov/study/NCT07376629
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07376629
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:34d1a74e2620ab07d111@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:CRBP P1/P2 readout (est.): A Phase 1/2 Study to Investigate CRB-701
  in Solid Tumors
DESCRIPTION:A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors\nNCT06
 265727 | PHASE1/PHASE2 | RECRUITING | sponsor: Corbus Pharmaceuticals Inc.
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nTicker CRBP (confidence 0.9)\nSource: https://clinicaltrials.gov/stu
 dy/NCT06265727\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06265727
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c2e8e1b3ae4824e4cc1e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:NVS P3 readout (est.): ACS
DESCRIPTION:Evaluation of Efficacy and Safety of Early in Hospital Initiati
 on of Inclisiran Treatment in Patients With Acute Coronary Syndromes\nNCT0
 7102628 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Novartis Pharmaceutica
 ls\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nTicker NVS (confidence 0.9)\nSource: https://clinicaltrials.gov/st
 udy/NCT07102628\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07102628
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e743e178ded34787a2fc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:PFE P3 readout (est.): RENOIR
DESCRIPTION:Study to Evaluate the Efficacy\, Immunogenicity\, and Safety of
  RSVpreF in Adults.\nNCT05035212 | PHASE3 | ACTIVE_NOT_RECRUITING | sponso
 r: Pfizer\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nTicker PFE (confidence 0.9)\nSource: https://clinicaltrials
 .gov/study/NCT05035212\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05035212
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1b7e1d97f0940c50819c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:TAK P3 readout (est.): A Study to Evaluate the Safety and Tolerabil
 ity\, Pharmacokinetics\, and Antiviral Activity of Maribavir for the Treat
 ment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Ha
 ve Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ T
 ransplant (SOT)
DESCRIPTION:A Study to Evaluate the Safety and Tolerability\, Pharmacokinet
 ics\, and Antiviral Activity of Maribavir for the Treatment of Cytomegalov
 irus (CMV) Infection in Children and Adolescents Who Have Received a Hemat
 opoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)\nNC
 T05319353 | PHASE3 | RECRUITING | sponsor: Takeda\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nTicker TAK (confide
 nce 0.9)\nSource: https://clinicaltrials.gov/study/NCT05319353\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05319353
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:286ab689ac6188663d1f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:AZN P2 readout (est.): SOUND
DESCRIPTION:Savolitinib Combine With Durvalumab in EGFR Wild-type Locally A
 dvanced or Metastatic NSCLC\nNCT05374603 | PHASE2 | ACTIVE_NOT_RECRUITING 
 | sponsor: AstraZeneca\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nTicker AZN (confidence 0.9)\nSource: https://c
 linicaltrials.gov/study/NCT05374603\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05374603
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e66c795866686a937b82@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:Centre for Neuro Skills P1/P2 readout (est.): AER-TBI1
DESCRIPTION:Aerobic Exercise After Traumatic Brain Injury\nNCT05786729 | PH
 ASE1/PHASE2 | ENROLLING_BY_INVITATION | sponsor: Centre for Neuro Skills\n
 Primary completion date (ESTIMATED)\; top-line results usually follow late
 r.\nSource: https://clinicaltrials.gov/study/NCT05786729\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05786729
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:612a064f24bcf2e0bafa@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:SNY P1/P2 readout (est.): Study of a Human Metapneumovirus/Respirat
 ory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanopar
 ticle-based Formulation in Adults Aged 60 Years and Older
DESCRIPTION:Study of a Human Metapneumovirus/Respiratory Syncytial Virus mR
 NA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulatio
 n in Adults Aged 60 Years and Older\nNCT06686654 | PHASE1/PHASE2 | ACTIVE_
 NOT_RECRUITING | sponsor: Sanofi Pasteur\, a Sanofi Company\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nTicker SN
 Y (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT06686654\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06686654
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cf4594698e0cd693cf54@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Hoffmann-La Roche P3 readout (est.): HORIZON 1
DESCRIPTION:A Study Evaluating the Efficacy and Safety of Multiple Therapie
 s in Cohorts of Participants With Locally Advanced\, Unresectable\, Stage 
 III Non-Small Cell Lung Cancer (NSCLC)\nNCT05170204 | PHASE3 | ACTIVE_NOT_
 RECRUITING | sponsor: Hoffmann-La Roche\nPrimary completion date (ESTIMATE
 D)\; top-line results usually follow later.\nSource: https://clinicaltrial
 s.gov/study/NCT05170204\nScheduling/reference data from public records\; d
 ates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05170204
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:031dd87b97a6dad3298a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:SNY P1/P2 readout (est.): A First-in-human\, Dose Escalation and Do
 se Expansion Study of SAR445877 in Adult Participants With Advanced Solid 
 Tumors
DESCRIPTION:A First-in-human\, Dose Escalation and Dose Expansion Study of 
 SAR445877 in Adult Participants With Advanced Solid Tumors\nNCT05584670 | 
 PHASE1/PHASE2 | RECRUITING | sponsor: Sanofi\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker SNY (confidence 0
 .9)\nSource: https://clinicaltrials.gov/study/NCT05584670\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05584670
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4f7986aed187483f4525@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270120
DTEND;VALUE=DATE:20270121
SUMMARY:CELZ P1/P2 readout (est.): ADAPT
DESCRIPTION:Safety\, Tolerability\, and Effectiveness of Intramuscular Inje
 ction of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain\nNCT060
 53242 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Creative Medical 
 Technology Holdings Inc\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nTicker CELZ (confidence 0.9)\nSource: https:/
 /clinicaltrials.gov/study/NCT06053242\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06053242
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2ae80c7f32092a3e9aa6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270120
DTEND;VALUE=DATE:20270121
SUMMARY:TTRX P2/P3 readout (est.): GX-03 in AD
DESCRIPTION:A Double-Blind\, Randomized\, Vehicle-Controlled Phase 2 Study 
 to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate
  to Severe Atopic Dermatitis (Eczema)\nNCT07355075 | PHASE2/PHASE3 | RECRU
 ITING | sponsor: Turn Therapeutics\nPrimary completion date (ESTIMATED)\; 
 top-line results usually follow later.\nTicker TTRX (confidence 0.9)\nSour
 ce: https://clinicaltrials.gov/study/NCT07355075\nScheduling/reference dat
 a from public records\; dates can move. Not investment\, legal or medical 
 advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07355075
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d5f42d6fa4ccaeced35d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:TGTX P3 readout (est.): ENHANCE
DESCRIPTION:Study to Evaluate Safety\, Efficacy and Pharmacokinetics (PK) o
 f a Modified Regimen of Ublituximab\nNCT05877963 | PHASE3 | RECRUITING | s
 ponsor: TG Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nTicker TGTX (confidence 0.9)\nSource: 
 https://clinicaltrials.gov/study/NCT05877963\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05877963
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d189451e8ecce656ae9c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:AMGN P3 readout (est.): MARITIME-1
DESCRIPTION:Evaluation of Maridebart Cafraglutide in Adult Participants Wit
 hout Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nNCT06858
 839 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Amgen\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nTicker AMGN (co
 nfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06858839\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06858839
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:79d51bd783a3d0ef1739@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:AMGN P3 readout (est.): MARITIME-2
DESCRIPTION:Efficacy and Safety of Maridebart Cafraglutide in Adult Partici
 pants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nNC
 T06858878 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Amgen\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nTicker AM
 GN (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06858878\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06858878
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:23dc9d227d814b41dd70@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:Laboratoires Thea P2 readout (est.): A Study to Compare the Effecti
 veness and Safety of T1695 Versus Ciclosporin in Participants With Moderat
 e to Severe Vernal Keratoconjunctivitis
DESCRIPTION:A Study to Compare the Effectiveness and Safety of T1695 Versus
  Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunct
 ivitis\nNCT07169695 | PHASE2 | RECRUITING | sponsor: Laboratoires Thea\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nSource: https://clinicaltrials.gov/study/NCT07169695\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07169695
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c7e50b5d9aa494682d25@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270122
DTEND;VALUE=DATE:20270123
SUMMARY:Lupin Ltd. P3 readout (est.): An Open-Label\, Randomized\, Cross-Ov
 er Study to Investigate the Efficacy and Safety of Mexiletine PR Compared 
 to Mexiletine IR
DESCRIPTION:An Open-Label\, Randomized\, Cross-Over Study to Investigate th
 e Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR\nNCT07097
 701 | PHASE3 | RECRUITING | sponsor: Lupin Ltd.\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nSource: https://clini
 caltrials.gov/study/NCT07097701\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07097701
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a1048b69284a36675aa5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270123
DTEND;VALUE=DATE:20270124
SUMMARY:Egle Therapeutics P1/P2 readout (est.): First-in-human Trial of EGL
 -001 in Patients with Selected Advanced And/or Metastatic Solid Tumors
DESCRIPTION:First-in-human Trial of EGL-001 in Patients with Selected Advan
 ced And/or Metastatic Solid Tumors\nNCT06622486 | PHASE1/PHASE2 | RECRUITI
 NG | sponsor: Egle Therapeutics\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nSource: https://clinicaltrials.gov/st
 udy/NCT06622486\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06622486
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a8faea88cb2beb89b515@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270124
DTEND;VALUE=DATE:20270125
SUMMARY:Chengdu Syncor Pharmaceutical Co.\, Ltd. P2 readout (est.): Efficac
 y and Safety Study of BPR-101 Capsules in Combination With Metronidazole i
 n BV Patients
DESCRIPTION:Efficacy and Safety Study of BPR-101 Capsules in Combination Wi
 th Metronidazole in BV Patients\nNCT07483671 | PHASE2 | NOT_YET_RECRUITING
  | sponsor: Chengdu Syncor Pharmaceutical Co.\, Ltd.\nPrimary completion d
 ate (ESTIMATED)\; top-line results usually follow later.\nSource: https://
 clinicaltrials.gov/study/NCT07483671\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07483671
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:13d3b904d9cc35d67d05@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:NVS P1/P2 readout (est.): KontRASt-01
DESCRIPTION:Study of JDQ443 in Patients With Advanced Solid Tumors Harborin
 g the KRAS G12C Mutation\nNCT04699188 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUIT
 ING | sponsor: Novartis Pharmaceuticals\nPrimary completion date (ESTIMATE
 D)\; top-line results usually follow later.\nTicker NVS (confidence 0.9)\n
 Source: https://clinicaltrials.gov/study/NCT04699188\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04699188
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c7d88258871a682d44e0@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:VERX P3 readout (est.): Evaluation of the Long-term Safety and Effe
 ctiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Perip
 heral Neuropathy (DPN)
DESCRIPTION:Evaluation of the Long-term Safety and Effectiveness of Suzetri
 gine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DP
 N)\nNCT06696443 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Vertex Pharmac
 euticals Incorporated\nPrimary completion date (ESTIMATED)\; top-line resu
 lts usually follow later.\nTicker VERX (confidence 0.9)\nSource: https://c
 linicaltrials.gov/study/NCT06696443\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06696443
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6c041788a2636017be7e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:NVO P3 readout (est.): ONWARDS 11
DESCRIPTION:A Research Study to See How a Weekly Insulin\, Insulin Icodec\,
  Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine\, Bo
 th in Combination With Insulin Aspart\, in Adults With Type 1 Diabetes\nNC
 T07076199 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Novo Nordisk A/S\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nTicker NVO (confidence 0.95)\nSource: https://clinicaltrials.gov/study/N
 CT07076199\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07076199
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cbfb9f7e3f7dfe29c744@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:PFE P3 readout (est.): A Phase 3 Study in India to Describe the Saf
 ety and Immunogenicity of RSVpreF
DESCRIPTION:A Phase 3 Study in India to Describe the Safety and Immunogenic
 ity of RSVpreF\nNCT07653100 | PHASE3 | RECRUITING | sponsor: Pfizer\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nT
 icker PFE (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07
 653100\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07653100
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:86143d1a0f0c00ed84b1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270127
SUMMARY:GlaxoSmithKline P3 readout (est.): A Study to Compare the Efficacy\
 , Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With
  Asthma
DESCRIPTION:A Study to Compare the Efficacy\, Safety and Tolerability of FF
 /UMEC/VI With FF/VI in 12-17-year-olds With Asthma\nNCT05757102 | PHASE3 |
  ACTIVE_NOT_RECRUITING | sponsor: GlaxoSmithKline\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nSource: https://cli
 nicaltrials.gov/study/NCT05757102\nScheduling/reference data from public r
 ecords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05757102
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2a041b7fae76a9fed45b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:NVS P3 readout (est.): EPIK-B5
DESCRIPTION:Study to Assess the Efficacy and Safety of Alpelisib Plus Fulve
 strant in Participants With HR-positive (HR+)\, HER2-negative\, Advanced B
 reast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhi
 bitor.\nNCT05038735 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Novartis P
 harmaceuticals\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nTicker NVS (confidence 0.9)\nSource: https://clinicalt
 rials.gov/study/NCT05038735\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05038735
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1b4a6c157ad57d95634a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:ModernaTX\, Inc. P3 readout (est.): A Study of mRNA-1018-H5 Pandemi
 c Influenza Vaccine in Healthy Adults
DESCRIPTION:A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy A
 dults\nNCT07496450 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: ModernaTX\,
  Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nSource: https://clinicaltrials.gov/study/NCT07496450\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07496450
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fbeab5597db0279540de@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:IDYA P1/P2 readout (est.): Study of IDE196 in Patients With Solid T
 umors Harboring GNAQ/11 Mutations or PRKC Fusions
DESCRIPTION:Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11
  Mutations or PRKC Fusions\nNCT03947385 | PHASE1/PHASE2 | RECRUITING | spo
 nsor: IDEAYA Biosciences\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nTicker IDYA (confidence 0.9)\nSource: https:
 //clinicaltrials.gov/study/NCT03947385\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03947385
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:82cb970664b184f7a02c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:NVS P2 readout (est.): Study Assessing the Efficacy and Safety of T
 reatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant i
 n Chinese Men and Postmenopausal Women With Advanced Breast Cancer
DESCRIPTION:Study Assessing the Efficacy and Safety of Treatment With Alpel
 isib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and P
 ostmenopausal Women With Advanced Breast Cancer\nNCT04544189 | PHASE2 | AC
 TIVE_NOT_RECRUITING | sponsor: Novartis Pharmaceuticals\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nTicker NVS (c
 onfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT04544189\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04544189
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3c2ad869b7b783542030@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:NVS P3 readout (est.): APPEAR-C3G
DESCRIPTION:Study of Efficacy and Safety of Iptacopan in Patients With C3 G
 lomerulopathy.\nNCT04817618 | PHASE3 | RECRUITING | sponsor: Novartis Phar
 maceuticals\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nTicker NVS (confidence 0.9)\nSource: https://clinicaltria
 ls.gov/study/NCT04817618\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04817618
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1c57cdaffe2bd230f45f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Seagen\, a wholly owned subsidiary of Pfizer P3 readout (est.): Dis
 itamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated 
 Urothelial Cancer Expressing HER2
DESCRIPTION:Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previou
 sly Untreated Urothelial Cancer Expressing HER2\nNCT05911295 | PHASE3 | AC
 TIVE_NOT_RECRUITING | sponsor: Seagen\, a wholly owned subsidiary of Pfize
 r\nPrimary completion date (ESTIMATED)\; top-line results usually follow l
 ater.\nSource: https://clinicaltrials.gov/study/NCT05911295\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05911295
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:01816cc47c910dc989c5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:NVO P3 readout (est.): ARTEMIS
DESCRIPTION:ARTEMIS - A Research Study to Look at How Ziltivekimab Works Co
 mpared to Placebo in People With a Heart Attack\nNCT06118281 | PHASE3 | AC
 TIVE_NOT_RECRUITING | sponsor: Novo Nordisk A/S\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nTicker NVO (confidenc
 e 0.95)\nSource: https://clinicaltrials.gov/study/NCT06118281\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06118281
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dee46dcc9cb6fc3d86e8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:AZN P1/P2 readout (est.): CONTEMPO
DESCRIPTION:A Trial to Learn How Safe AZD9550 Monotherapy and Combined With
  AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With 
 Obesity and Overweight\nNCT06151964 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITIN
 G | sponsor: AstraZeneca\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nTicker AZN (confidence 0.9)\nSource: https:/
 /clinicaltrials.gov/study/NCT06151964\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06151964
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2eab180f726c0efa59ee@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Dynavax Technologies Corporation P2 readout (est.): Immunogenicity\
 , Safety\, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years 
 of Age
DESCRIPTION:Immunogenicity\, Safety\, and Tolerability of rF1V-1018 Vaccine
  in Adults 18 to 55 Years of Age\nNCT07207408 | PHASE2 | ACTIVE_NOT_RECRUI
 TING | sponsor: Dynavax Technologies Corporation\nPrimary completion date 
 (ESTIMATED)\; top-line results usually follow later.\nSource: https://clin
 icaltrials.gov/study/NCT07207408\nScheduling/reference data from public re
 cords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07207408
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0f94382fceb7c7b4282f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Tolmar Inc. P3 readout (est.): OVELIA
DESCRIPTION:Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate 
 in Breast Cancer\nNCT04906395 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: 
 Tolmar Inc.\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nSource: https://clinicaltrials.gov/study/NCT04906395\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04906395
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1690cf0bca217ea280d3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Shanghai Runshi Pharmaceutical Technology Co.\, Ltd P1/P2 readout (
 est.): A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
DESCRIPTION:A Study of Simmitinib Plus SG001 in Advanced Solid Tumors\nNCT0
 6132217 | PHASE1/PHASE2 | NOT_YET_RECRUITING | sponsor: Shanghai Runshi Ph
 armaceutical Technology Co.\, Ltd\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nSource: https://clinicaltrials.gov/
 study/NCT06132217\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06132217
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f9f7c567ccb9782f7d9e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Curasight P2 readout (est.): uTRACE-101
DESCRIPTION:Safety and Diagnostic Performance of uPAR PET Imaging in Locali
 sed\, Untreated Prostate Cancer\nNCT06474806 | PHASE2 | RECRUITING | spons
 or: Curasight\nPrimary completion date (ESTIMATED)\; top-line results usua
 lly follow later.\nSource: https://clinicaltrials.gov/study/NCT06474806\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06474806
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c96416687f19dd20b07f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Psivac Ltd P1/P2 readout (est.): IXACT
DESCRIPTION:Ixovex-1 Single Agent and Combination Therapy\nNCT06549946 | PH
 ASE1/PHASE2 | RECRUITING | sponsor: Psivac Ltd\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nSource: https://clinic
 altrials.gov/study/NCT06549946\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06549946
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c3b953dce9fc502a65de@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Hoffmann-La Roche P3 readout (est.): Ametrine-1
DESCRIPTION:A Study to Assess the Efficacy and Safety of Afimkibart (Also K
 nown as RO7790121) for Induction and Maintenance Therapy in Participants W
 ith Moderately to Severely Active Ulcerative Colitis\nNCT06589986 | PHASE3
  | ACTIVE_NOT_RECRUITING | sponsor: Hoffmann-La Roche\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nSource: https:/
 /clinicaltrials.gov/study/NCT06589986\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06589986
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2d61ba03e923df2bdaed@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Shanghai Runshi Pharmaceutical Technology Co.\, Ltd P3 readout (est
 .): A Study of Simmitinib Versus Chemotherapy for Participants With Advanc
 ed Oesophageal Squamous Cell Carcinoma
DESCRIPTION:A Study of Simmitinib Versus Chemotherapy for Participants With
  Advanced Oesophageal Squamous Cell Carcinoma\nNCT06656091 | PHASE3 | NOT_
 YET_RECRUITING | sponsor: Shanghai Runshi Pharmaceutical Technology Co.\, 
 Ltd\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nSource: https://clinicaltrials.gov/study/NCT06656091\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06656091
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e7182b929a6c7e5e33ed@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:SVA P3 readout (est.): Immunogenicity and Safety of Rabies Vaccine 
 (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen
DESCRIPTION:Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Ce
 ll) in a Simulated Post-exposure Prophylaxis Regimen\nNCT07055893 | PHASE3
  | NOT_YET_RECRUITING | sponsor: Sinovac Biotech Co.\, Ltd\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nTicker SVA
  (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07055893\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07055893
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:77f3455d62281442fc99@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:SCNLD P2 readout (est.): SCIB1 and iSCIB1+ in Melanoma Patients Rec
 eiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE St
 udy)
DESCRIPTION:SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With
  Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)\nNCT04079166 | P
 HASE2 | ACTIVE_NOT_RECRUITING | sponsor: Scancell Ltd\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nTicker SCNLD (c
 onfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT04079166\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04079166
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2a784a66cade349cd9c3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:MRK P3 readout (est.): Efficacy and Safety of Pembrolizumab (MK-347
 5) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-
 invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
DESCRIPTION:Efficacy and Safety of Pembrolizumab (MK-3475) in Combination W
 ith Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Ca
 ncer (MIBC) (MK-3475-992/KEYNOTE-992)\nNCT04241185 | PHASE3 | ACTIVE_NOT_R
 ECRUITING | sponsor: Merck Sharp & Dohme LLC\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker MRK (confidence 0
 .6)\nSource: https://clinicaltrials.gov/study/NCT04241185\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04241185
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:484ca8b4667c1750cc02@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Daiichi Sankyo Co.\, Ltd. P2 readout (est.): Long-term\, Extension 
 Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
DESCRIPTION:Long-term\, Extension Study of DS-5141b in Patients With Duchen
 ne Muscular Dystrophy\nNCT04433234 | PHASE2 | ACTIVE_NOT_RECRUITING | spon
 sor: Daiichi Sankyo Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nSource: https://clinicaltrials.gov/stu
 dy/NCT04433234\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04433234
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:acf275db8b8dafa1e1c9@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Actelion P3 readout (est.): PLATYPUS
DESCRIPTION:A Study Providing Treatment Access in Participants With Pulmona
 ry Hypertension Completing a Parent Study and Having no Other Option\nNCT0
 5179876 | PHASE3 | RECRUITING | sponsor: Actelion\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nSource: https://cli
 nicaltrials.gov/study/NCT05179876\nScheduling/reference data from public r
 ecords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05179876
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9a32485126a2f9a8e4e7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:CELZ P1/P2 readout (est.): CREATE-1
DESCRIPTION:Safety and Efficacy of CELZ-201 in Patients With Recent Onset T
 ype 1 Diabetes\nNCT05626712 | PHASE1/PHASE2 | RECRUITING | sponsor: Creati
 ve Medical Technology Holdings Inc\nPrimary completion date (ESTIMATED)\; 
 top-line results usually follow later.\nTicker CELZ (confidence 0.9)\nSour
 ce: https://clinicaltrials.gov/study/NCT05626712\nScheduling/reference dat
 a from public records\; dates can move. Not investment\, legal or medical 
 advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05626712
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:10bf83e5b640640a13ca@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:iRenix Medical\, Inc. P3 readout (est.): COMFORT
DESCRIPTION:Safety and Tolerability of IRX-101 in Patients Receiving Intrav
 itreal Injections\nNCT05750589 | PHASE3 | NOT_YET_RECRUITING | sponsor: iR
 enix Medical\, Inc.\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nSource: https://clinicaltrials.gov/study/NCT05750
 589\nScheduling/reference data from public records\; dates can move. Not i
 nvestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05750589
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:42422a271afe2e79d8a2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Janssen Research & Development\, LLC P1/P2 readout (est.): PolyDama
 s
DESCRIPTION:A Study of Combination Therapy With Amivantamab and Cetrelimab 
 in Participants With Metastatic Non-small Cell Lung Cancer\nNCT05908734 | 
 PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Janssen Research & Develo
 pment\, LLC\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nSource: https://clinicaltrials.gov/study/NCT05908734\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05908734
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c4e0d50f710c33f38eb1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Grit Biotechnology P2 readout (est.): Autologous Tumor Infiltrating
  Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or
  Metastatic Cervical Cancer
DESCRIPTION:Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Inje
 ction) for the Treatment of Recurrent or Metastatic Cervical Cancer\nNCT06
 241781 | PHASE2 | RECRUITING | sponsor: Grit Biotechnology\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nSource: ht
 tps://clinicaltrials.gov/study/NCT06241781\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06241781
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f3f145c8eb1a596f3b41@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:EXO Biologics S.A. P1/P2 readout (est.): EVENEW
DESCRIPTION:Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extr
 emely Preterm Infants\nNCT06279741 | PHASE1/PHASE2 | RECRUITING | sponsor:
  EXO Biologics S.A.\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nSource: https://clinicaltrials.gov/study/NCT06279
 741\nScheduling/reference data from public records\; dates can move. Not i
 nvestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06279741
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d1abc98e628f62bba487@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ono Pharmaceutical Co.\, Ltd. P3 readout (est.): ONO-2017 Study Jap
 anese Patients With Primary Generalized Tonic Clonic Seizures.
DESCRIPTION:ONO-2017 Study Japanese Patients With Primary Generalized Tonic
  Clonic Seizures.\nNCT06579573 | PHASE3 | RECRUITING | sponsor: Ono Pharma
 ceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nSource: https://clinicaltrials.gov/study/NCT06579
 573\nScheduling/reference data from public records\; dates can move. Not i
 nvestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06579573
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:27c98bba8f6941165acb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ono Pharmaceutical Co.\, Ltd. P2 readout (est.): Safety of Cenobama
 te in Japanese Subjects With Partial Onset Seizures
DESCRIPTION:Safety of Cenobamate in Japanese Subjects With Partial Onset Se
 izures\nNCT06590896 | PHASE2 | RECRUITING | sponsor: Ono Pharmaceutical Co
 .\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nSource: https://clinicaltrials.gov/study/NCT06590896\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06590896
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:92bce75c62c0bee61095@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Shanghai Runshi Pharmaceutical Technology Co.\, Ltd P2 readout (est
 .): A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade M
 eningioma
DESCRIPTION:A Phase II Study of SYHA1813 for Recurrent or Progressive High-
 Grade Meningioma\nNCT06739213 | PHASE2 | NOT_YET_RECRUITING | sponsor: Sha
 nghai Runshi Pharmaceutical Technology Co.\, Ltd\nPrimary completion date 
 (ESTIMATED)\; top-line results usually follow later.\nSource: https://clin
 icaltrials.gov/study/NCT06739213\nScheduling/reference data from public re
 cords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06739213
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:28892201fa86e5ed973a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:NeuroBiogen Co.\, Ltd P2 readout (est.): Study to Evaluate the Effi
 cacy and Safety of KDS2010 in Overweight or Obese Patients
DESCRIPTION:Study to Evaluate the Efficacy and Safety of KDS2010 in Overwei
 ght or Obese Patients\nNCT07009171 | PHASE2 | RECRUITING | sponsor: NeuroB
 iogen Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-line results us
 ually follow later.\nSource: https://clinicaltrials.gov/study/NCT07009171\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07009171
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1ddc4fcc9c6ee042f7b0@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:MediLink Therapeutics (Suzhou) Co.\, Ltd. P2 readout (est.): A Stud
 y of YL202 in Patients With Advanced Solid Tumors
DESCRIPTION:A Study of YL202 in Patients With Advanced Solid Tumors\nNCT072
 02364 | PHASE2 | RECRUITING | sponsor: MediLink Therapeutics (Suzhou) Co.\
 , Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nSource: https://clinicaltrials.gov/study/NCT07202364\nScheduli
 ng/reference data from public records\; dates can move. Not investment\, l
 egal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07202364
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:76242f0c074907366ed0@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Miltenyi Biomedicine GmbH P2 readout (est.): DALY II Japan
DESCRIPTION:DALY II Japan/MB-CART2019.1 for DLBCL\nNCT07288879 | PHASE2 | R
 ECRUITING | sponsor: Miltenyi Biomedicine GmbH\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nSource: https://clinic
 altrials.gov/study/NCT07288879\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07288879
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f760eea01fb4f4f9fcaa@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Dermavon Holdings Limited P2 readout (est.): A Multicenter\, Random
 ized\, Double-Blind\, Placebo-Controlled\, Phase Ⅱ Clinical Study to Eva
 luate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate 
 to Severe Atopic Dermatitis
DESCRIPTION:A Multicenter\, Randomized\, Double-Blind\, Placebo-Controlled\
 , Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001
  in Adult Patients With Moderate to Severe Atopic Dermatitis\nNCT07465120 
 | PHASE2 | NOT_YET_RECRUITING | sponsor: Dermavon Holdings Limited\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nSo
 urce: https://clinicaltrials.gov/study/NCT07465120\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07465120
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7cb8baf4d94811d73085@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:QNRX P2/P3 readout (est.): Phase 2/3 Clinical Study of QRX003 Lotio
 n in Subjects With Netherton Syndrome
DESCRIPTION:Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Neth
 erton Syndrome\nNCT07538583 | PHASE2/PHASE3 | RECRUITING | sponsor: Quoin 
 Pharmaceuticals\nPrimary completion date (ESTIMATED)\; top-line results us
 ually follow later.\nTicker QNRX (confidence 0.9)\nSource: https://clinica
 ltrials.gov/study/NCT07538583\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07538583
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f7b88df603367cc06edc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co.\, Ltd. P2 readout (
 est.): SYH2062 Injection in Participants With Mild to Moderate Essential H
 ypertension .
DESCRIPTION:SYH2062 Injection in Participants With Mild to Moderate Essenti
 al Hypertension .\nNCT07940075 | PHASE2 | RECRUITING | sponsor: CSPC Zhong
 nuo Pharmaceutical (Shijiazhuang) Co.\, Ltd.\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nSource: https://clinical
 trials.gov/study/NCT07940075\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07940075
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b70e72d79b53b92d1dc7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Lumicell\, Inc. P1/P2 readout (est.): Feasibility of the LUM Imagin
 g System for Detection of Gastrointestinal Cancers
DESCRIPTION:Feasibility of the LUM Imaging System for Detection of Gastroin
 testinal Cancers\nNCT02584244 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sp
 onsor: Lumicell\, Inc.\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nDate precision: month (shown on the first day)
 \nSource: https://clinicaltrials.gov/study/NCT02584244\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT02584244
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0ac13bf6c4c9def48651@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ABBV P1/P2 readout (est.): IMGN632 as Monotherapy or With Venetocla
 x and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Le
 ukemia
DESCRIPTION:IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine fo
 r Participants With CD123-Positive Acute Myeloid Leukemia\nNCT04086264 | P
 HASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: AbbVie\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nDate precision
 : month (shown on the first day)\nTicker ABBV (confidence 0.9)\nSource: ht
 tps://clinicaltrials.gov/study/NCT04086264\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04086264
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:baf4c55b0d6c253fb281@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Prevail Therapeutics P1/P2 readout (est.): Phase 1/2 Clinical Trial
  of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
DESCRIPTION:Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gauche
 r Disease (PROVIDE)\nNCT04411654 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
  sponsor: Prevail Therapeutics\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nDate precision: month (shown on the fi
 rst day)\nSource: https://clinicaltrials.gov/study/NCT04411654\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04411654
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:06f6d6b1adab13938685@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:SK Life Science\, Inc. P3 readout (est.): Investigate Efficacy and 
 Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With
  LGS in Children and Adults
DESCRIPTION:Investigate Efficacy and Safety of Carisbamate as Adjunctive Tr
 eatment for Seizures Associated With LGS in Children and Adults\nNCT052196
 17 | PHASE3 | RECRUITING | sponsor: SK Life Science\, Inc.\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nDate preci
 sion: month (shown on the first day)\nSource: https://clinicaltrials.gov/s
 tudy/NCT05219617\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05219617
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c14e25a787ce056e29e7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Day One Biopharmaceuticals\, Inc. P1/P2 readout (est.): A Study of 
 Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
DESCRIPTION:A Study of Emiltatug Ledadotin (Emi-Le) in Participants With So
 lid Tumors\nNCT05377996 | PHASE1/PHASE2 | RECRUITING | sponsor: Day One Bi
 opharmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nDate precision: month (shown on the first day
 )\nSource: https://clinicaltrials.gov/study/NCT05377996\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05377996
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:51d330b198526f63033c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:GILD P3 readout (est.): ASCENT-04
DESCRIPTION:Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Tr
 eatment of Physician's Choice and Pembrolizumab in Patients With Previousl
 y Untreated\, Locally Advanced Inoperable or Metastatic Triple-Negative Br
 east Cancer\nNCT05382286 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Gilea
 d Sciences\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nDate precision: month (shown on the first day)\nTicker GIL
 D (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05382286\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05382286
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5c865b6a2451913ac92b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:SparingVision P1/P2 readout (est.): PRODYGY
DESCRIPTION:Promising ROd-cone DYstrophy Gene therapY\nNCT05748873 | PHASE1
 /PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: SparingVision\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nDate precisi
 on: month (shown on the first day)\nSource: https://clinicaltrials.gov/stu
 dy/NCT05748873\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05748873
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7647c238363f2ad018a8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Celltrion P3 readout (est.): A Study to Compare Efficacy\, Pharmaco
 kinetics\, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients W
 ith Relapsing-remitting Multiple Sclerosis
DESCRIPTION:A Study to Compare Efficacy\, Pharmacokinetics\, Pharmacodynami
 cs and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting M
 ultiple Sclerosis\nNCT05906992 | PHASE3 | RECRUITING | sponsor: Celltrion\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nDate precision: month (shown on the first day)\nSource: https://clini
 caltrials.gov/study/NCT05906992\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05906992
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3ca261611ec77eac490f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Beijing Scitech-Mq Pharmaceuticals Limited P1/P2 readout (est.): St
 udy of ST-1898 in Advanced Renal Cell Carcinoma
DESCRIPTION:Study of ST-1898 in Advanced Renal Cell Carcinoma\nNCT06127238 
 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Beijing Scitech-Mq Phar
 maceuticals Limited\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nS
 ource: https://clinicaltrials.gov/study/NCT06127238\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06127238
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a7ab09b1a487c6b1c4fb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:KRYS P1/P2 readout (est.): KYANITE-1
DESCRIPTION:A Study Assessing KB707 for the Treatment of Advanced Solid Tum
 or Malignancies Affecting the Lungs\nNCT06228326 | PHASE1/PHASE2 | RECRUIT
 ING | sponsor: Krystal Biotech\, Inc.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nTicker KRYS (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT06228326\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06228326
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c48a674a9fb8e89a719f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:MediLink Therapeutics (Suzhou) Co.\, Ltd. P2 readout (est.): A Phas
 e II Study to Evaluate the Safety\, Efficacy\, and Pharmacokinetics of YL2
 01 in Patients With mCRPC
DESCRIPTION:A Phase II Study to Evaluate the Safety\, Efficacy\, and Pharma
 cokinetics of YL201 in Patients With mCRPC\nNCT06241846 | PHASE2 | RECRUIT
 ING | sponsor: MediLink Therapeutics (Suzhou) Co.\, Ltd.\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nDate precisi
 on: month (shown on the first day)\nSource: https://clinicaltrials.gov/stu
 dy/NCT06241846\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06241846
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6fd6b43bc4807748236e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:EMS P3 readout (est.): LIBERTÀ
DESCRIPTION:Efficacy and Safety of DEH113 in the Treatment of Menstrual Cra
 mp Pain Associated With Primary Dysmenorrhea\nNCT06268054 | PHASE3 | NOT_Y
 ET_RECRUITING | sponsor: EMS\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nDate precision: month (shown on the firs
 t day)\nSource: https://clinicaltrials.gov/study/NCT06268054\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06268054
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:199f0be1f1344fb09b7c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:SBFM P3 readout (est.): Efficacy and Safety Study of 610 in Patient
 s With Severe Asthma
DESCRIPTION:Efficacy and Safety Study of 610 in Patients With Severe Asthma
 \nNCT06323213 | PHASE3 | RECRUITING | sponsor: Sunshine Guojian Pharmaceut
 ical (Shanghai) Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nDate precision: month (shown on the first 
 day)\nTicker SBFM (confidence 0.6)\nSource: https://clinicaltrials.gov/stu
 dy/NCT06323213\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06323213
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:551825c4dd9982bcf29a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ABBV P2 readout (est.): A Study of Ocular Toxicity Evaluation and M
 itigation During Treatment With Mirvetuximab Soravtansine in Participants 
 With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
DESCRIPTION:A Study of Ocular Toxicity Evaluation and Mitigation During Tre
 atment With Mirvetuximab Soravtansine in Participants With Recurrent Ovari
 an Cancer With High Folate Receptor-Alpha Expression\nNCT06365853 | PHASE2
  | ACTIVE_NOT_RECRUITING | sponsor: AbbVie\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nDate precision: month (sho
 wn on the first day)\nTicker ABBV (confidence 0.9)\nSource: https://clinic
 altrials.gov/study/NCT06365853\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06365853
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:95cb84f41bbc7ad69459@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:LLY P2 readout (est.): A Study Comparing Abemaciclib Plus Temozolom
 ide to Temozolomide Monotherapy in Children and Young Adults With High-gra
 de Glioma Following Radiotherapy
DESCRIPTION:A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide
  Monotherapy in Children and Young Adults With High-grade Glioma Following
  Radiotherapy\nNCT06413706 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Eli
  Lilly and Company\nPrimary completion date (ESTIMATED)\; top-line results
  usually follow later.\nDate precision: month (shown on the first day)\nTi
 cker LLY (confidence 0.95)\nSource: https://clinicaltrials.gov/study/NCT06
 413706\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06413706
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6f4e0c6a29a8257106a5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:GNLX P2 readout (est.): VIRO-25
DESCRIPTION:Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-dou
 blet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docet
 axel in NSCL Cancer\nNCT06463665 | PHASE2 | RECRUITING | sponsor: Genelux 
 Corporation\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nDate precision: month (shown on the first day)\nTicker GN
 LX (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06463665\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06463665
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:74646cc7e9eb523707be@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ABBV P2 readout (est.): A Study to Assess Molecular Changes in Adul
 t Participants With Moderate to Severe Hidradenitis Suppurativa or With Mo
 derate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lu
 tikizumab
DESCRIPTION:A Study to Assess Molecular Changes in Adult Participants With 
 Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Ato
 pic Dermatitis Receiving Subcutaneous Injections of Lutikizumab\nNCT065246
 35 | PHASE2 | RECRUITING | sponsor: AbbVie\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nDate precision: month (sho
 wn on the first day)\nTicker ABBV (confidence 0.9)\nSource: https://clinic
 altrials.gov/study/NCT06524635\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06524635
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3f883a4a8005db127e41@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:DualityBio Inc. P1/P2 readout (est.): First-in-human Study of DB-14
 19 for Advanced/Metastatic Solid Tumors
DESCRIPTION:First-in-human Study of DB-1419 for Advanced/Metastatic Solid T
 umors\nNCT06554795 | PHASE1/PHASE2 | RECRUITING | sponsor: DualityBio Inc.
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nDate precision: month (shown on the first day)\nSource: https://clin
 icaltrials.gov/study/NCT06554795\nScheduling/reference data from public re
 cords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06554795
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f26e5d68487d43e703f2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ABBV P2 readout (est.): AURORA
DESCRIPTION:A Study to Investigate the Safety and Efficacy of MEDI0618 Comp
 ared to Placebo in Adult Participants With Episodic Migraine\nNCT06602479 
 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: AbbVie\nPrimary completion dat
 e (ESTIMATED)\; top-line results usually follow later.\nDate precision: mo
 nth (shown on the first day)\nTicker ABBV (confidence 0.9)\nSource: https:
 //clinicaltrials.gov/study/NCT06602479\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06602479
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fc48530af6a77ed8102c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:SXTP P2 readout (est.): TQ-BA-2024-3
DESCRIPTION:B-FREE Chronic Babesiosis Study\nNCT06656351 | PHASE2 | RECRUIT
 ING | sponsor: 60 Degrees Pharmaceuticals LLC\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nDate precision: month (
 shown on the first day)\nTicker SXTP (confidence 0.9)\nSource: https://cli
 nicaltrials.gov/study/NCT06656351\nScheduling/reference data from public r
 ecords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06656351
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:722c7e791d64f34151bb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:LLY P3 readout (est.): ADVANCE
DESCRIPTION:A Platform Trial for Pediatric Participants With Obesity or Ove
 rweight (LY900040)\nNCT06672549 | PHASE3 | RECRUITING | sponsor: Eli Lilly
  and Company\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nDate precision: month (shown on the first day)\nTicker L
 LY (confidence 0.95)\nSource: https://clinicaltrials.gov/study/NCT06672549
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06672549
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4e9e8bce9a4fb2f6855c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:SBFM P2 readout (est.): A Phase IIb Study of 610 in Participants Wi
 th Severe Eosinophilic Asthma
DESCRIPTION:A Phase IIb Study of 610 in Participants With Severe Eosinophil
 ic Asthma\nNCT06680947 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sunshin
 e Guojian Pharmaceutical (Shanghai) Co.\, Ltd.\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nDate precision: month 
 (shown on the first day)\nTicker SBFM (confidence 0.6)\nSource: https://cl
 inicaltrials.gov/study/NCT06680947\nScheduling/reference data from public 
 records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06680947
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4ce71dff6c22f2ac7f70@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Shandong New Time Pharmaceutical Co.\, LTD P2 readout (est.): Phase
  II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Pep
 tic Ulcer Bleeding
DESCRIPTION:Phase II Clinical Study of Vonorasan Fumarate Injection in the 
 Treatment of Peptic Ulcer Bleeding\nNCT06783257 | PHASE2 | NOT_YET_RECRUIT
 ING | sponsor: Shandong New Time Pharmaceutical Co.\, LTD\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nDate precis
 ion: month (shown on the first day)\nSource: https://clinicaltrials.gov/st
 udy/NCT06783257\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06783257
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:25af0c8f55a532043627@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Trust Bio-sonics\, Inc. P3 readout (est.): Safety and Efficacy Eval
 uation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocar
 diography
DESCRIPTION:Safety and Efficacy Evaluation of NH002 as a Contrast Agent in 
 Subjects Undergoing Cardiac Echocardiography\nNCT06815627 | PHASE3 | ACTIV
 E_NOT_RECRUITING | sponsor: Trust Bio-sonics\, Inc.\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nDate precision: m
 onth (shown on the first day)\nSource: https://clinicaltrials.gov/study/NC
 T06815627\nScheduling/reference data from public records\; dates can move.
  Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06815627
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:94863870790f5c4aeb92@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Bavarian Nordic P2 readout (est.): A Phase 2 Trial in Healthy Adult
  Participants of the Recombinant MVA-BN-WEV Vaccine
DESCRIPTION:A Phase 2 Trial in Healthy Adult Participants of the Recombinan
 t MVA-BN-WEV Vaccine\nNCT06899802 | PHASE2 | ACTIVE_NOT_RECRUITING | spons
 or: Bavarian Nordic\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nS
 ource: https://clinicaltrials.gov/study/NCT06899802\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06899802
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f84d10176c1c12764773@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Eurofarma Laboratorios S.A. P3 readout (est.): PANDORA
DESCRIPTION:Study of New Antiandrogenic Progestogen + Low-dose Estrogen for
  Moderate Acne Vulgaris\nNCT06905210 | PHASE3 | RECRUITING | sponsor: Euro
 farma Laboratorios S.A.\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nDate precision: month (shown on the first day
 )\nSource: https://clinicaltrials.gov/study/NCT06905210\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06905210
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0ce3dc1bbe6fbbe6f019@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ARWR P1/P2 readout (est.): A First-In-Human Study of ARO-ALK7 in Ad
 ults With Obesity With and Without Type 2 Diabetes Mellitus
DESCRIPTION:A First-In-Human Study of ARO-ALK7 in Adults With Obesity With 
 and Without Type 2 Diabetes Mellitus\nNCT06937203 | PHASE1/PHASE2 | RECRUI
 TING | sponsor: Arrowhead Pharmaceuticals\nPrimary completion date (ESTIMA
 TED)\; top-line results usually follow later.\nDate precision: month (show
 n on the first day)\nTicker ARWR (confidence 0.9)\nSource: https://clinica
 ltrials.gov/study/NCT06937203\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06937203
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1cc6de1a63c08df5498c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Celltrion P3 readout (est.): A Study to Compare Effects and Safety 
 of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lu
 ng Cancer
DESCRIPTION:A Study to Compare Effects and Safety of CT-P51 and Keytruda in
  Patients With Previously Untreated Metastatic Lung Cancer\nNCT06939595 | 
 PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Celltrion\nPrimary completion da
 te (ESTIMATED)\; top-line results usually follow later.\nDate precision: m
 onth (shown on the first day)\nSource: https://clinicaltrials.gov/study/NC
 T06939595\nScheduling/reference data from public records\; dates can move.
  Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06939595
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3c89fa51f5bd090122b1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ABBV P2 readout (est.): A Study to Evaluate Different Targeted Ther
 apies for Patients With Rheumatoid Arthritis
DESCRIPTION:A Study to Evaluate Different Targeted Therapies for Patients W
 ith Rheumatoid Arthritis\nNCT06972446 | PHASE2 | RECRUITING | sponsor: Abb
 Vie\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nDate precision: month (shown on the first day)\nTicker ABBV (conf
 idence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06972446\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06972446
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d6909d6c2880959e3ba5@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:KOD P3 readout (est.): PINNACLE
DESCRIPTION:A Phase 3 Study to Evaluate the Efficacy and Safety of Intravit
 real KSI-101 in Participants With Macular Edema Secondary to Inflammation 
 (MESI) - PINNACLE\nNCT06996080 | PHASE3 | RECRUITING | sponsor: Kodiak Sci
 ences Inc\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nDate precision: month (shown on the first day)\nTicker KOD 
 (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06996080\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06996080
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ce0f30b28f6fdfd3a16f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Fujian Shengdi Pharmaceutical Co.\, Ltd. P3 readout (est.): Efficac
 y and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With 
 Basal Insulin
DESCRIPTION:Efficacy and Safety of HRS9531 in Participants With Type 2 Diab
 etes Treated With Basal Insulin\nNCT07060456 | PHASE3 | RECRUITING | spons
 or: Fujian Shengdi Pharmaceutical Co.\, Ltd.\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nDate precision: month (s
 hown on the first day)\nSource: https://clinicaltrials.gov/study/NCT070604
 56\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07060456
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:be7a93e24656234b01a4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Keymed Biosciences Co.Ltd P3 readout (est.): A Study of Stapokibatr
 t in Children Subjects With Atopic Dermatitis
DESCRIPTION:A Study of Stapokibatrt in Children Subjects With Atopic Dermat
 itis\nNCT07106372 | PHASE3 | NOT_YET_RECRUITING | sponsor: Keymed Bioscien
 ces Co.Ltd\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nDate precision: month (shown on the first day)\nSource: ht
 tps://clinicaltrials.gov/study/NCT07106372\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07106372
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:600b3334aa01186f5ca7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ABCL P1/P2 readout (est.): Study Evaluating ABCL635 for Vasomotor S
 ymptoms of Menopause
DESCRIPTION:Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause\nN
 CT07118891 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: AbCellera Bi
 ologics Inc.\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nDate precision: month (shown on the first day)\nTicker A
 BCL (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07118891
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07118891
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:63a2092458ffbda11e20@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. P1/P2 readout (est.): A Phase I
 /II Clinical Study of FH-006 for Injection in Patients With Malignant Soli
 d Tumors
DESCRIPTION:A Phase I/II Clinical Study of FH-006 for Injection in Patients
  With Malignant Solid Tumors\nNCT07136142 | PHASE1/PHASE2 | RECRUITING | s
 ponsor: Jiangsu HengRui Medicine Co.\, Ltd.\nPrimary completion date (ESTI
 MATED)\; top-line results usually follow later.\nDate precision: month (sh
 own on the first day)\nSource: https://clinicaltrials.gov/study/NCT0713614
 2\nScheduling/reference data from public records\; dates can move. Not inv
 estment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07136142
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:40be0ae6180f22ea73d2@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:GI Innovation\, Inc. P1/P2 readout (est.): A Study of GI-108\, an A
 nti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein\, as Monotherapy in Patie
 nts With Advanced or Metastatic Solid Tumors
DESCRIPTION:A Study of GI-108\, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusio
 n Protein\, as Monotherapy in Patients With Advanced or Metastatic Solid T
 umors\nNCT07172802 | PHASE1/PHASE2 | RECRUITING | sponsor: GI Innovation\,
  Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nDate precision: month (shown on the first day)\nSource: https:/
 /clinicaltrials.gov/study/NCT07172802\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07172802
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d7c81268719052eef726@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Qilu Pharmaceutical Co.\, Ltd. P1/P2 readout (est.): A Phase Ib/II 
 Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Adva
 nced Breast Cancer
DESCRIPTION:A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inh
 ibitors in ER+/HER2- Advanced Breast Cancer\nNCT07173556 | PHASE1/PHASE2 |
  NOT_YET_RECRUITING | sponsor: Qilu Pharmaceutical Co.\, Ltd.\nPrimary com
 pletion date (ESTIMATED)\; top-line results usually follow later.\nDate pr
 ecision: month (shown on the first day)\nSource: https://clinicaltrials.go
 v/study/NCT07173556\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07173556
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0017c44618ef8ea6d7e7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Otsuka Pharmaceutical Co.\, Ltd. P3 readout (est.): A Phase 3 Trial
  of OPA-15406 Foam in Children and Infants With Atopic Dermatitis
DESCRIPTION:A Phase 3 Trial of OPA-15406 Foam in Children and Infants With 
 Atopic Dermatitis\nNCT07184645 | PHASE3 | NOT_YET_RECRUITING | sponsor: Ot
 suka Pharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nDate precision: month (shown on the fi
 rst day)\nSource: https://clinicaltrials.gov/study/NCT07184645\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07184645
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:96b38b8779941611c5a3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:LLY P2 readout (est.): RENEW-Smk-1
DESCRIPTION:A Study of Brenipatide in Adults Who Quit Smoking Cigarettes an
 d Want to Avoid Relapse\nNCT07223840 | PHASE2 | RECRUITING | sponsor: Eli 
 Lilly and Company\nPrimary completion date (ESTIMATED)\; top-line results 
 usually follow later.\nDate precision: month (shown on the first day)\nTic
 ker LLY (confidence 0.95)\nSource: https://clinicaltrials.gov/study/NCT072
 23840\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07223840
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:621f6c49ca2c616b403e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Suzhou HepaThera Biotech Co.\, Ltd. P2 readout (est.): A Clinical S
 tudy of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infec
 tion
DESCRIPTION:A Clinical Study of HT-101 and HT-102 in Patients With Chronic 
 Hepatitis B Virus Infection\nNCT07245953 | PHASE2 | ACTIVE_NOT_RECRUITING 
 | sponsor: Suzhou HepaThera Biotech Co.\, Ltd.\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nDate precision: month 
 (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT0724
 5953\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07245953
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d3b325047404d33691c7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Sovargen P1/P2 readout (est.): Safety\, Tolerability\, and Pharmaco
 kinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II
 )\, Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
DESCRIPTION:Safety\, Tolerability\, and Pharmacokinetics of SVG103 (Paxalis
 ib) in Focal Cortical Dysplasia Type II (FCD-II)\, Tuberous Sclerosis Comp
 lex (TSC) or Hemimegalencephaly (HME)\nNCT07287202 | PHASE1/PHASE2 | RECRU
 ITING | sponsor: Sovargen\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nDate precision: month (shown on the first d
 ay)\nSource: https://clinicaltrials.gov/study/NCT07287202\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07287202
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e277da79a4789939726d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:RDC Clinical Pty Ltd P2 readout (est.): Sleep and Stress Study
DESCRIPTION:Sleep and Stress Study\nNCT07315516 | PHASE2 | RECRUITING | spo
 nsor: RDC Clinical Pty Ltd\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nDate precision: month (shown on the first 
 day)\nSource: https://clinicaltrials.gov/study/NCT07315516\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07315516
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:49ea5ede419357330b6e@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:CADL P2 readout (est.): A Biomarker Study in Men With Localized Pro
 state Cancer Treated With Aglatimagene Besadenovec
DESCRIPTION:A Biomarker Study in Men With Localized Prostate Cancer Treated
  With Aglatimagene Besadenovec\nNCT07332000 | PHASE2 | RECRUITING | sponso
 r: Candel Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nTicker CADL (confidence 0.9)\nSource: https://clinicaltrials.gov/
 study/NCT07332000\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07332000
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:95ea3cbf1aac02b73dfe@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:NBIX P2 readout (est.): Efficacy\, Safety\, and Tolerability of NBI
 -1065890 Versus Placebo in Adults With Tardive Dyskinesia
DESCRIPTION:Efficacy\, Safety\, and Tolerability of NBI-1065890 Versus Plac
 ebo in Adults With Tardive Dyskinesia\nNCT07365462 | PHASE2 | RECRUITING |
  sponsor: Neurocrine Biosciences\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nDate precision: month (shown on the 
 first day)\nTicker NBIX (confidence 0.9)\nSource: https://clinicaltrials.g
 ov/study/NCT07365462\nScheduling/reference data from public records\; date
 s can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07365462
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3342d43e4e4f6ac8d8c3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. P1/P2 readout (es
 t.): Clinical Trial Evaluating TQB6411 Injection in Participant s With Eso
 phageal Cancer
DESCRIPTION:Clinical Trial Evaluating TQB6411 Injection in Participant s Wi
 th Esophageal Cancer\nNCT07367516 | PHASE1/PHASE2 | RECRUITING | sponsor: 
 Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd.\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nDate precision: mon
 th (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT0
 7367516\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07367516
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:31d7b4e56a9134dc019a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Bond Biosciences P1/P2 readout (est.): A Study to Evaluate BBI-001 
 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis
DESCRIPTION:A Study to Evaluate BBI-001 in Healthy Volunteers and in Patien
 ts With Hereditary Hemochromatosis\nNCT07371793 | PHASE1/PHASE2 | RECRUITI
 NG | sponsor: Bond Biosciences\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nDate precision: month (shown on the fi
 rst day)\nSource: https://clinicaltrials.gov/study/NCT07371793\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07371793
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b9fe6aa8eb5b9d2799a1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Sanaria Inc. P2 readout (est.): BFSPZL2
DESCRIPTION:Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults\nNCT0738
 5287 | PHASE2 | RECRUITING | sponsor: Sanaria Inc.\nPrimary completion dat
 e (ESTIMATED)\; top-line results usually follow later.\nDate precision: mo
 nth (shown on the first day)\nSource: https://clinicaltrials.gov/study/NCT
 07385287\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07385287
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a89dce1d1f42b0f70c56@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co.\, Ltd. P2 readout 
 (est.): A Multicenter\, Randomized\, Double-Masked\, Placebo-Controlled Pi
 lot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects Wi
 th Age-Related Cataract
DESCRIPTION:A Multicenter\, Randomized\, Double-Masked\, Placebo-Controlled
  Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects
  With Age-Related Cataract\nNCT07395986 | PHASE2 | ACTIVE_NOT_RECRUITING |
  sponsor: Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co.\, Ltd.\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nDat
 e precision: month (shown on the first day)\nSource: https://clinicaltrial
 s.gov/study/NCT07395986\nScheduling/reference data from public records\; d
 ates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07395986
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9bf922bee263fe8b63bf@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. P3 readout (est.)
 : Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-t
 o-Severe Chronic Obstructive Pulmonary Disease
DESCRIPTION:Evaluation of the Inhaled TQC3721 Suspension in Patients With M
 oderate-to-Severe Chronic Obstructive Pulmonary Disease\nNCT07464587 | PHA
 SE3 | RECRUITING | sponsor: Chia Tai Tianqing Pharmaceutical Group Co.\, L
 td.\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nDate precision: month (shown on the first day)\nSource: https://c
 linicaltrials.gov/study/NCT07464587\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07464587
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:94b5350d4048a5040e90@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:RIGImmune Inc. P1/P2 readout (est.): RIG 101 Trial in Healthy Adult
 s and Adults With Asthma
DESCRIPTION:RIG 101 Trial in Healthy Adults and Adults With Asthma\nNCT0748
 8897 | PHASE1/PHASE2 | RECRUITING | sponsor: RIGImmune Inc.\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nDate prec
 ision: month (shown on the first day)\nSource: https://clinicaltrials.gov/
 study/NCT07488897\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07488897
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4254ea5e4c34436c200f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Rivus Pharmaceuticals\, Inc. P2 readout (est.): AMPLIFY
DESCRIPTION:A Trial to Investigate Safety\, Exposure\, and Efficacy of HU6 
 Compared With Placebo in Adult Participants With Metabolic Dysfunction-ass
 ociated Steatohepatitis (MASH)\nNCT07491458 | PHASE2 | RECRUITING | sponso
 r: Rivus Pharmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nDate precision: month (shown on the f
 irst day)\nSource: https://clinicaltrials.gov/study/NCT07491458\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07491458
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:951af352bd24e0cb6d18@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ALC P3 readout (est.): Efficacy and Safety of FID 123472 Ophthalmic
  Solution for Ocular Redness in Adults
DESCRIPTION:Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocula
 r Redness in Adults\nNCT07531043 | PHASE3 | RECRUITING | sponsor: Alcon Re
 search\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nDate precision: month (shown on the first day)\nTicker ALC (co
 nfidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT07531043\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07531043
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5e83737a54e4c0b28d66@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Almirall\, S.A. P2 readout (est.): A Proof-of-Concept Study of LAD3
 28 in Adults With Hidradenitis Suppurativa
DESCRIPTION:A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis 
 Suppurativa\nNCT07547813 | PHASE2 | RECRUITING | sponsor: Almirall\, S.A.\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nDate precision: month (shown on the first day)\nSource: https://clini
 caltrials.gov/study/NCT07547813\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07547813
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a580b96ab5ce80fec4e9@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:TearSolutions\, Inc. P2 readout (est.): A Multicenter\, Randomized\
 , Vehicle-Controlled\, Double-Masked to Open-Label Study to Evaluate the S
 afety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
DESCRIPTION:A Multicenter\, Randomized\, Vehicle-Controlled\, Double-Masked
  to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Su
 bjects With Neurotrophic Keratitis\nNCT07568730 | PHASE2 | RECRUITING | sp
 onsor: TearSolutions\, Inc.\nPrimary completion date (ESTIMATED)\; top-lin
 e results usually follow later.\nDate precision: month (shown on the first
  day)\nSource: https://clinicaltrials.gov/study/NCT07568730\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07568730
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f00648ee1b4a9de3a51f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ENLV P2 readout (est.): Intra-Articular Allocetra in Patients With 
 Primary Knee Osteoarthritis
DESCRIPTION:Intra-Articular Allocetra in Patients With Primary Knee Osteoar
 thritis\nNCT07580716 | PHASE2 | RECRUITING | sponsor: Enlivex Therapeutics
  Ltd.\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nDate precision: month (shown on the first day)\nTicker ENLV (co
 nfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07580716\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07580716
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d6e058050ff20b939f30@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:TriGemX Bio\, Inc. P3 readout (est.): A Study to Evaluate the Effic
 acy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Elismetrep (K-30
 4) in the Acute Treatment of Migraine\nNCT07645924 | PHASE3 | RECRUITING |
  sponsor: TriGemX Bio\, Inc.\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nDate precision: month (shown on the firs
 t day)\nSource: https://clinicaltrials.gov/study/NCT07645924\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07645924
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:41f7d7090aaf7a36f202@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Hangzhou Gensciences Biopharmaceutical Co.\, Ltd. P3 readout (est.)
 : Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FR
 SW107) On-Demand Treatment
DESCRIPTION:Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Pr
 otein (FRSW107) On-Demand Treatment\nNCT07663903 | PHASE3 | ACTIVE_NOT_REC
 RUITING | sponsor: Hangzhou Gensciences Biopharmaceutical Co.\, Ltd.\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Date precision: month (shown on the first day)\nSource: https://clinicaltr
 ials.gov/study/NCT07663903\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07663903
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a23b384898ef71e02ba4@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Clarent Biopharma\, Inc. P2 readout (est.): Oral CBP-0276 or Placeb
 o in Adults With Active Psoriatic Arthritis (PsA)
DESCRIPTION:Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthri
 tis (PsA)\nNCT07706530 | PHASE2 | NOT_YET_RECRUITING | sponsor: Clarent Bi
 opharma\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nDate precision: month (shown on the first day)\nSource
 : https://clinicaltrials.gov/study/NCT07706530\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07706530
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9464090aa128036e8e84@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Shanghai RAAS Blood Products Co.\, Ltd. P2 readout (est.): A Phase 
 II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy
  in the Treatment of Congenital Coagulation Factor VII Deficiency
DESCRIPTION:A Phase II Exploratory Study of SR604 Injection Evaluating the 
 Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII 
 Deficiency\nNCT07711158 | PHASE2 | NOT_YET_RECRUITING | sponsor: Shanghai 
 RAAS Blood Products Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nDate precision: month (shown on the fi
 rst day)\nSource: https://clinicaltrials.gov/study/NCT07711158\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07711158
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:efb03d141738d7daf74f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Antag Therapeutics P2 readout (est.): A Study to Assess the Efficac
 y\, Safety and Tolerability of AT673 Co-administered With Semaglutide in A
 dult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
DESCRIPTION:A Study to Assess the Efficacy\, Safety and Tolerability of AT6
 73 Co-administered With Semaglutide in Adult Participants With Type 2 Diab
 etes (T2D) and Overweight or Obesity\nNCT07724340 | PHASE2 | ACTIVE_NOT_RE
 CRUITING | sponsor: Antag Therapeutics\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nDate precision: month (shown o
 n the first day)\nSource: https://clinicaltrials.gov/study/NCT07724340\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07724340
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b6097d56d8722bf8accd@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:LQDA P2 readout (est.): RE-WARM
DESCRIPTION:A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemi
 c Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks\nNCT07748000
  | PHASE2 | NOT_YET_RECRUITING | sponsor: Liquidia Technologies\, Inc.\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nDate precision: month (shown on the first day)\nTicker LQDA (confidence 
 0.6)\nSource: https://clinicaltrials.gov/study/NCT07748000\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07748000
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b39f9cefce4cb8583787@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Shandong Suncadia Medicine Co.\, Ltd. P2 readout (est.): Study of O
 ral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk 
 of Cardiovascular Events
DESCRIPTION:Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprot
 ein(a) and High Risk of Cardiovascular Events\nNCT07767513 | PHASE2 | RECR
 UITING | sponsor: Shandong Suncadia Medicine Co.\, Ltd.\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nDate precisio
 n: month (shown on the first day)\nSource: https://clinicaltrials.gov/stud
 y/NCT07767513\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07767513
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a232e5624dc0fdca6265@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:BLCO P2 readout (est.): BRIGHT
DESCRIPTION:BL1107 Response and Intensity Guided Dosing for Hyperemia Resol
 ution Trial\nNCT07778888 | PHASE2 | RECRUITING | sponsor: Bausch & Lomb In
 corporated\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nDate precision: month (shown on the first day)\nTicker BLC
 O (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07778888\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07778888
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4a74cbcfe5012d897cc1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:PT Bio Farma P3 readout (est.): Study Interchangeability Hep-B Vacc
 ine Administered at Birth Dose
DESCRIPTION:Study Interchangeability Hep-B Vaccine Administered at Birth Do
 se\nNCT07854847 | PHASE3 | NOT_YET_RECRUITING | sponsor: PT Bio Farma\nPri
 mary completion date (ESTIMATED)\; top-line results usually follow later.\
 nDate precision: month (shown on the first day)\nSource: https://clinicalt
 rials.gov/study/NCT07854847\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07854847
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0758cd3b56fc8b331362@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ScandiBio Therapeutics AB P3 readout (est.): Combined Metabolic Act
 ivator Supplementation in Subjects Diagnosed With Gout
DESCRIPTION:Combined Metabolic Activator Supplementation in Subjects Diagno
 sed With Gout\nNCT07889284 | PHASE3 | NOT_YET_RECRUITING | sponsor: Scandi
 Bio Therapeutics AB\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nS
 ource: https://clinicaltrials.gov/study/NCT07889284\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07889284
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:195c04d7bb3273ef73d6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:NVS P2 readout (est.): Ribociclib (LEE011) Rollover Study for Conti
 nued Access
DESCRIPTION:Ribociclib (LEE011) Rollover Study for Continued Access\nNCT029
 34568 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Novartis Pharmaceuticals
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nTicker NVS (confidence 0.9)\nSource: https://clinicaltrials.gov/stud
 y/NCT02934568\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT02934568
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:020672a0ca6d2af1ba4a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Amplia Therapeutics Limited P1/P2 readout (est.): ACCENT: AMP945 in
  Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreat
 ic Cancer
DESCRIPTION:ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabi
 ne for Treatment of Pancreatic Cancer\nNCT05355298 | PHASE1/PHASE2 | ACTIV
 E_NOT_RECRUITING | sponsor: Amplia Therapeutics Limited\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nSource: https
 ://clinicaltrials.gov/study/NCT05355298\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05355298
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1a8e577e34ee039c07e8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Gracell Biotechnologies (Shanghai) Co.\, Ltd. P1/P2 readout (est.):
  A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Er
 ythematosus
DESCRIPTION:A Study of GC012F Injection in Subjects With Refractory Systemi
 c Lupus Erythematosus\nNCT06530849 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING
  | sponsor: Gracell Biotechnologies (Shanghai) Co.\, Ltd.\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nSource: htt
 ps://clinicaltrials.gov/study/NCT06530849\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06530849
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f362fd150b28f43c9b45@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:AB Biotics\, SA P2 readout (est.): Investigation of the Efficacy of
  a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatoti
 c Liver Disease (MASLD): A Mechanistic Trial
DESCRIPTION:Investigation of the Efficacy of a Probiotic Mixture in Moderat
 e Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mech
 anistic Trial\nNCT07193927 | PHASE2 | RECRUITING | sponsor: AB Biotics\, S
 A\nPrimary completion date (ESTIMATED)\; top-line results usually follow l
 ater.\nSource: https://clinicaltrials.gov/study/NCT07193927\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07193927
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:11cb2b4e49398e4733a6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Boryung Pharmaceutical Co.\, Ltd P2 readout (est.): A Study of BR14
 00-1\, BR1400-2\, BR1400-3\, BR1400-4\, and BR1400-5 in Patients With Esse
 ntial Hypertension
DESCRIPTION:A Study of BR1400-1\, BR1400-2\, BR1400-3\, BR1400-4\, and BR14
 00-5 in Patients With Essential Hypertension\nNCT07373613 | PHASE2 | NOT_Y
 ET_RECRUITING | sponsor: Boryung Pharmaceutical Co.\, Ltd\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nSource: htt
 ps://clinicaltrials.gov/study/NCT07373613\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07373613
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:989f6de5256b93567a8a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:NVS P2 readout (est.): Study of Efficacy and Safety of LXH254 Combi
 nations in Patients With Previously Treated Unresectable or Metastatic Mel
 anoma
DESCRIPTION:Study of Efficacy and Safety of LXH254 Combinations in Patients
  With Previously Treated Unresectable or Metastatic Melanoma\nNCT04417621 
 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Novartis Pharmaceuticals\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Ticker NVS (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0
 4417621\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04417621
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3d4e2030df0fdc1a770c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Noema Pharma AG P2/P3 readout (est.): An Efficacy and Safety Study 
 of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
DESCRIPTION:An Efficacy and Safety Study of Basimglurant (NOE-101) in Patie
 nts With Trigeminal Neuralgia.\nNCT05217628 | PHASE2/PHASE3 | ACTIVE_NOT_R
 ECRUITING | sponsor: Noema Pharma AG\nPrimary completion date (ESTIMATED)\
 ; top-line results usually follow later.\nSource: https://clinicaltrials.g
 ov/study/NCT05217628\nScheduling/reference data from public records\; date
 s can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05217628
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e5a2f26c8e246efd6128@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:VERX P1/P2 readout (est.): Galileo
DESCRIPTION:A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic
  Dystrophy 1 (DM1)\nNCT06185764 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | 
 sponsor: Vertex Pharmaceuticals Incorporated\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker VERX (confidence 
 0.9)\nSource: https://clinicaltrials.gov/study/NCT06185764\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06185764
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ad9963e10f5b4856683a@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Cellvax Therapeutics Inc P2 readout (est.): FK-PC101 as Adjuvant Th
 erapy for Men With High-Risk Prostate Cancer
DESCRIPTION:FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Ca
 ncer\nNCT06636682 | PHASE2 | RECRUITING | sponsor: Cellvax Therapeutics In
 c\nPrimary completion date (ESTIMATED)\; top-line results usually follow l
 ater.\nSource: https://clinicaltrials.gov/study/NCT06636682\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06636682
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3019a25b45bf84abf356@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270203
DTEND;VALUE=DATE:20270204
SUMMARY:InventVacc Biologicals Inc. P2 readout (est.): Phase 2 Trial of a H
 aemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine
DESCRIPTION:Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glyc
 oconjugate Vaccine\nNCT07743008 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor
 : InventVacc Biologicals Inc.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nSource: https://clinicaltrials.gov/stud
 y/NCT07743008\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07743008
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:00a776ee339e00d2b0f7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:Hoffmann-La Roche P3 readout (est.): A Study of the Efficacy\, Safe
 ty\, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Deliver
 y System With Ranibizumab in Patients With Neovascular Age-Related Macular
  Degeneration (Velodrome)
DESCRIPTION:A Study of the Efficacy\, Safety\, and Pharmacokinetics of a 36
 -Week Refill Regimen for the Port Delivery System With Ranibizumab in Pati
 ents With Neovascular Age-Related Macular Degeneration (Velodrome)\nNCT046
 57289 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Hoffmann-La Roche\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nS
 ource: https://clinicaltrials.gov/study/NCT04657289\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04657289
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:76f3b18092c0da2807b1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:Janssen Research & Development\, LLC P3 readout (est.): DAFFODIL
DESCRIPTION:Nipocalimab in Moderate to Severe Sjogren's Disease\nNCT0674196
 9 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Janssen Research & Developme
 nt\, LLC\nPrimary completion date (ESTIMATED)\; top-line results usually f
 ollow later.\nSource: https://clinicaltrials.gov/study/NCT06741969\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06741969
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:18ce3e3995106005eceb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:Hangzhou Zhongmei Huadong Pharmaceutical Co.\, Ltd. P2 readout (est
 .): Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults
  Without Diabetes
DESCRIPTION:Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese
  Adults Without Diabetes\nNCT07521631 | PHASE2 | RECRUITING | sponsor: Han
 gzhou Zhongmei Huadong Pharmaceutical Co.\, Ltd.\nPrimary completion date 
 (ESTIMATED)\; top-line results usually follow later.\nSource: https://clin
 icaltrials.gov/study/NCT07521631\nScheduling/reference data from public re
 cords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07521631
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f5f01c73af6a21e0d09d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:NVS P2 readout (est.): PLATINUM
DESCRIPTION:Platform Study to Evaluate the Efficacy and Safety of Anti-mala
 rial Agents in Participants With Uncomplicated Plasmodium Falciparum Malar
 ia (Cohort C2)\nNCT07811908 | PHASE2 | RECRUITING | sponsor: Novartis Phar
 maceuticals\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nTicker NVS (confidence 0.9)\nSource: https://clinicaltria
 ls.gov/study/NCT07811908\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07811908
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4b9ed9ca01ccf046e8f6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:BMY P2 readout (est.): CheckMate-1533
DESCRIPTION:A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolum
 ab in Combination With Intravenous Ipilimumab and Chemotherapy in Particip
 ants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung
  Cancer (NSCLC)\nNCT06946797 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: B
 ristol-Myers Squibb\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nTicker BMY (confidence 0.9)\nSource: https://clin
 icaltrials.gov/study/NCT06946797\nScheduling/reference data from public re
 cords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06946797
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6a4b33593894ecbcdad1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:TAK P2 readout (est.): A Study of Zasocitinib in Adults With Hidrad
 enitis Suppurativa
DESCRIPTION:A Study of Zasocitinib in Adults With Hidradenitis Suppurativa\
 nNCT07244263 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Takeda\nPrimary c
 ompletion date (ESTIMATED)\; top-line results usually follow later.\nTicke
 r TAK (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT072442
 63\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07244263
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:370f8d007a34636f6cec@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:Applied Biology\, Inc. P1/P2 readout (est.): Clinical Study of DA-0
 20 for the Treatment of Chemotherapy Induced Alopecia
DESCRIPTION:Clinical Study of DA-020 for the Treatment of Chemotherapy Indu
 ced Alopecia\nNCT07397325 | PHASE1/PHASE2 | RECRUITING | sponsor: Applied 
 Biology\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nSource: https://clinicaltrials.gov/study/NCT07397325\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07397325
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:bc447d0929fe86a321bd@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:EktaH P2 readout (est.): SERENITY-1
DESCRIPTION:A PHASE 2A\, EXPLORATORY\, RANDOMIZED\, SINGLE-BLIND\, PLACEBO-
 CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 
 IN OBESE ADULTS.\nNCT07882654 | PHASE2 | NOT_YET_RECRUITING | sponsor: Ekt
 aH\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nSource: https://clinicaltrials.gov/study/NCT07882654\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07882654
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:464d1bd9e0ad941b0809@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270207
DTEND;VALUE=DATE:20270208
SUMMARY:Intra-IMMUSG Pte Ltd P1/P2 readout (est.): A Study of PRL3-zumab in
  Neovascular Age-related Macular Degeneration (nAMD)
DESCRIPTION:A Study of PRL3-zumab in Neovascular Age-related Macular Degene
 ration (nAMD)\nNCT07547228 | PHASE1/PHASE2 | RECRUITING | sponsor: Intra-I
 MMUSG Pte Ltd\nPrimary completion date (ESTIMATED)\; top-line results usua
 lly follow later.\nSource: https://clinicaltrials.gov/study/NCT07547228\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07547228
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1edd39b2dbb7affda5bf@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270208
DTEND;VALUE=DATE:20270209
SUMMARY:Abcentra P2 readout (est.): FORTIFY
DESCRIPTION:Focused Orticumab Research for Treating Inflammation in Coronar
 y Arteries\nNCT06927739 | PHASE2 | RECRUITING | sponsor: Abcentra\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nSou
 rce: https://clinicaltrials.gov/study/NCT06927739\nScheduling/reference da
 ta from public records\; dates can move. Not investment\, legal or medical
  advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06927739
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a1dc8569568ce849aeb1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:Aston Sci. Inc. P2 readout (est.): Conerstone3
DESCRIPTION:Therapeutic Cancer Vaccine (AST-301\, pNGVL3-hICD) in Gastric C
 ancer\nNCT05771584 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Aston Sci. 
 Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually follo
 w later.\nSource: https://clinicaltrials.gov/study/NCT05771584\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05771584
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:eee39d78132f5a0ff5a6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:SNY P2 readout (est.): BRIGHTEN
DESCRIPTION:Brivekimig for the Treatment of Moderate to Severe Hidradenitis
  Suppurativa\nNCT07170917 | PHASE2 | RECRUITING | sponsor: Sanofi\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nTic
 ker SNY (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0717
 0917\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07170917
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f14de2a0e968ff92e7bd@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:REGN P2 readout (est.): ROXI-ATLAS
DESCRIPTION:Safety in Adult Participants With Atrial Fibrillation Who Are T
 reated With Anticoagulation\nNCT07175428 | PHASE2 | RECRUITING | sponsor: 
 Regeneron Pharmaceuticals\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nTicker REGN (confidence 0.9)\nSource: https
 ://clinicaltrials.gov/study/NCT07175428\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07175428
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e766c1465355fa5127a0@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Janssen Research & Development\, LLC P3 readout (est.): QUASAR Jr
DESCRIPTION:A Study of Guselkumab in Pediatric Participants With Moderately
  to Severely Active Ulcerative Colitis\nNCT06260163 | PHASE3 | ACTIVE_NOT_
 RECRUITING | sponsor: Janssen Research & Development\, LLC\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nSource: ht
 tps://clinicaltrials.gov/study/NCT06260163\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06260163
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f92c1283693a4b7dcd5c@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:AZN P2 readout (est.): A Study of T-DXd as Monotherapy or in Combin
 ation With Anti-cancer Agents in Patients With Selected HER2-expressing Tu
 mors
DESCRIPTION:A Study of T-DXd as Monotherapy or in Combination With Anti-can
 cer Agents in Patients With Selected HER2-expressing Tumors\nNCT06271837 |
  PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: AstraZeneca\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nTicker AZN (co
 nfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06271837\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06271837
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:216ee8449039dc7de92b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Shanghai Henlius Biotech P2 readout (est.): A Study to Explore the 
 Reasonable Dosage and Evaluate the Efficacy\, Safety and Tolerability of H
 LX10 and HLX04 with or Without HLX53 in Untreated\, Locally Advanced or Me
 tastatic Hepatocellular Carcinoma Patients.
DESCRIPTION:A Study to Explore the Reasonable Dosage and Evaluate the Effic
 acy\, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in 
 Untreated\, Locally Advanced or Metastatic Hepatocellular Carcinoma Patien
 ts.\nNCT06349980 | PHASE2 | RECRUITING | sponsor: Shanghai Henlius Biotech
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nSource: https://clinicaltrials.gov/study/NCT06349980\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06349980
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:90cbaf1c8824e4144245@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Janssen Research & Development\, LLC P3 readout (est.): ICONIC-PsA 
 2
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ
 -77242113) in Biologic-experienced and Biologic-naive Participants With Ac
 tive Psoriatic Arthritis\nNCT06807424 | PHASE3 | ACTIVE_NOT_RECRUITING | s
 ponsor: Janssen Research & Development\, LLC\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nSource: https://clinical
 trials.gov/study/NCT06807424\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06807424
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9daab703f82916dfc778@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:TAK P3 readout (est.): A Study of Teduglutide in Chinese Adults Wit
 h Short Bowel Syndrome
DESCRIPTION:A Study of Teduglutide in Chinese Adults With Short Bowel Syndr
 ome\nNCT06973304 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Takeda\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nT
 icker TAK (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06
 973304\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06973304
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:33e9b61fda0e4a12418d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:SNY P2 readout (est.): A Study to Investigate the Efficacy and Safe
 ty of Rilzabrutinib in Adult Participants With Graves' Disease
DESCRIPTION:A Study to Investigate the Efficacy and Safety of Rilzabrutinib
  in Adult Participants With Graves' Disease\nNCT06984627 | PHASE2 | RECRUI
 TING | sponsor: Sanofi\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nTicker SNY (confidence 0.9)\nSource: https://c
 linicaltrials.gov/study/NCT06984627\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06984627
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7248980a03b8eeee17c6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:AZN P2 readout (est.): SERENIA
DESCRIPTION:A Study to Investigate the Efficacy\, Safety\, and Tolerability
  of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.\nNC
 T07215702 | PHASE2 | RECRUITING | sponsor: AstraZeneca\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nTicker AZN (co
 nfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07215702\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07215702
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a101a1836494c0c708ed@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:Gan & Lee Pharmaceuticals. P2 readout (est.): Evaluate the Efficacy
  and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
DESCRIPTION:Evaluate the Efficacy and Safety of GZR101-80 Injection in Pati
 ents With Type 2 Diabetes\nNCT07387003 | PHASE2 | NOT_YET_RECRUITING | spo
 nsor: Gan & Lee Pharmaceuticals.\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nSource: https://clinicaltrials.gov/s
 tudy/NCT07387003\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07387003
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9732df1c46890ff99cbc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:MRK P2 readout (est.): Safety and Efficacy of Pembrolizumab (MK-347
 5) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-6
 67/KEYNOTE-667)
DESCRIPTION:Safety and Efficacy of Pembrolizumab (MK-3475) in Children and 
 Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)\nNC
 T03407144 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Merck Sharp & Dohme 
 LLC\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nTicker MRK (confidence 0.6)\nSource: https://clinicaltrials.gov/s
 tudy/NCT03407144\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03407144
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ddf08bfcdc4cb27e6e3d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:OCGN P3 readout (est.): liMeliGhT
DESCRIPTION:A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Ret
 initis Pigmentosa\nNCT06388200 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor:
  Ocugen\nPrimary completion date (ESTIMATED)\; top-line results usually fo
 llow later.\nTicker OCGN (confidence 0.9)\nSource: https://clinicaltrials.
 gov/study/NCT06388200\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06388200
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4ccf495b5a91abb5c0ea@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Jecho Biopharmaceuticals Co.\, Ltd. P1/P2 readout (est.): JL18008
DESCRIPTION:A Study to Evaluate JL18008 in Subject With HIV Immunological N
 on-Responders\nNCT07579741 | PHASE1/PHASE2 | RECRUITING | sponsor: Jecho B
 iopharmaceuticals Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nSource: https://clinicaltrials.gov/study
 /NCT07579741\nScheduling/reference data from public records\; dates can mo
 ve. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07579741
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5cec69c2410c60308fbb@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270213
DTEND;VALUE=DATE:20270214
SUMMARY:Epizyme\, Inc. P3 readout (est.): SYMPHONY-1
DESCRIPTION:A Study to Assess the Efficacy\, Safety\, Pharmacodynamics\, an
 d Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus R
 ituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in
  Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicul
 ar Lymphoma.\nNCT04224493 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Epiz
 yme\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nSource: https://clinicaltrials.gov/study/NCT04224493\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04224493
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:af831e8e87d8e206cb24@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270213
DTEND;VALUE=DATE:20270214
SUMMARY:SK Bioscience Co.\, Ltd. P3 readout (est.): SkyVaricella® (NBP608)
  Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Yea
 rs
DESCRIPTION:SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy
  Children Aged 12 Months to 12 Years\nNCT07415252 | PHASE3 | RECRUITING | 
 sponsor: SK Bioscience Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nSource: https://clinicaltrials.gov/
 study/NCT07415252\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07415252
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e1fc1839fefa0fe64e91@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Evopoint Biosciences Inc. P1/P2 readout (est.): A Study of PARG Inh
 ibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard
  Treatment
DESCRIPTION:A Study of PARG Inhibitor XNW29016 in Patients With Advanced So
 lid Tumors Who Failed Standard Treatment\nNCT06987500 | PHASE1/PHASE2 | RE
 CRUITING | sponsor: Evopoint Biosciences Inc.\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nSource: https://clinica
 ltrials.gov/study/NCT06987500\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06987500
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:150effab4f5acc34c153@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Hudson Biotech P2 readout (est.): BPC-HAMSTR
DESCRIPTION:BPC 157 for Acute Hamstring Muscle Strain Repair\nNCT07437547 |
  PHASE2 | RECRUITING | sponsor: Hudson Biotech\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nSource: https://clinic
 altrials.gov/study/NCT07437547\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07437547
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0b20d04668c667f00bdc@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Hudson Biotech P2 readout (est.): MTII-VIT
DESCRIPTION:Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for R
 epigmentation in Stable Nonsegmental Vitiligo\nNCT07437560 | PHASE2 | RECR
 UITING | sponsor: Hudson Biotech\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nSource: https://clinicaltrials.gov/s
 tudy/NCT07437560\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07437560
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7ecbcb2e3362d0ebe095@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Hudson Biotech P2 readout (est.): CuHeal
DESCRIPTION:Topical GHK-Cu Gel for Acute Skin Wound Healing\nNCT07437586 | 
 PHASE2 | RECRUITING | sponsor: Hudson Biotech\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nSource: https://clinica
 ltrials.gov/study/NCT07437586\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07437586
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1faff542189995c00e6d@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Beijing Biotech P1/P2 readout (est.): DUO-NK-NSCLC
DESCRIPTION:Dual-Target CAR-NK Cells Directed Against MSLN\, EGFR\, or HER2
  in Advanced NSCLC\nNCT07467863 | PHASE1/PHASE2 | RECRUITING | sponsor: Be
 ijing Biotech\nPrimary completion date (ESTIMATED)\; top-line results usua
 lly follow later.\nSource: https://clinicaltrials.gov/study/NCT07467863\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07467863
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5ee9a67c4af2dabdc2bd@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Beijing Biotech P1/P2 readout (est.): DART-NK-SCLC
DESCRIPTION:Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung
  Cancer (SCLC)\nNCT07480213 | PHASE1/PHASE2 | RECRUITING | sponsor: Beijin
 g Biotech\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nSource: https://clinicaltrials.gov/study/NCT07480213\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07480213
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:06acff4eb02baab0b067@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Beijing Biotech P1/P2 readout (est.): DUAL-NK-PDAC
DESCRIPTION:Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC
 1 in Advanced Pancreatic Ductal Adenocarcinoma\nNCT07480928 | PHASE1/PHASE
 2 | RECRUITING | sponsor: Beijing Biotech\nPrimary completion date (ESTIMA
 TED)\; top-line results usually follow later.\nSource: https://clinicaltri
 als.gov/study/NCT07480928\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07480928
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cb0450fe86e87eae1a73@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Hudson Biotech P2 readout (est.): TESA-LIVER
DESCRIPTION:Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liv
 er Disease\nNCT07481734 | PHASE2 | RECRUITING | sponsor: Hudson Biotech\nP
 rimary completion date (ESTIMATED)\; top-line results usually follow later
 .\nSource: https://clinicaltrials.gov/study/NCT07481734\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07481734
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fbcb475a6126d2e09ec3@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Hudson Biotech P3 readout (est.): SURMOUNT-1
DESCRIPTION:Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo i
 n Participants Who Are Either Obese or Overweight With Weight-Related Como
 rbidities (SURMOUNT-1)\nNCT07481747 | PHASE3 | RECRUITING | sponsor: Hudso
 n Biotech\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nSource: https://clinicaltrials.gov/study/NCT07481747\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07481747
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8a3874c593fecf17c40f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Beijing Biotech P1/P2 readout (est.): DUAL-NK-BC
DESCRIPTION:Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and 
 TNBC)\nNCT07486089 | PHASE1/PHASE2 | RECRUITING | sponsor: Beijing Biotech
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nSource: https://clinicaltrials.gov/study/NCT07486089\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07486089
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:281f527e61f2fdaf9b8f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Hudson Biotech P1/P2 readout (est.): TBRIDGE-CV
DESCRIPTION:TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biom
 arkers in Stable ASCVD\nNCT07487363 | PHASE1/PHASE2 | RECRUITING | sponsor
 : Hudson Biotech\nPrimary completion date (ESTIMATED)\; top-line results u
 sually follow later.\nSource: https://clinicaltrials.gov/study/NCT07487363
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07487363
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c335cf586b859f8255de@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Eisai Inc. P2 readout (est.): A Study to Evaluate the Efficacy and 
 Safety of E2086 in Adults With Narcolepsy
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of E2086 in Adults 
 With Narcolepsy\nNCT07493265 | PHASE2 | RECRUITING | sponsor: Eisai Inc.\n
 Primary completion date (ESTIMATED)\; top-line results usually follow late
 r.\nSource: https://clinicaltrials.gov/study/NCT07493265\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07493265
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c8bf55b6b5e236fc0917@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Hudson Biotech P2 readout (est.): MOTS-MET
DESCRIPTION:MOTS-c for Improving Insulin Sensitivity in Adults With Prediab
 etes and Overweight/Obesity\nNCT07505745 | PHASE2 | RECRUITING | sponsor: 
 Hudson Biotech\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nSource: https://clinicaltrials.gov/study/NCT07505745\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07505745
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:21fb8ee9439493ea5535@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Beijing Biotech P1/P2 readout (est.): SOLID-NK
DESCRIPTION:Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in
  Advanced TROP2-Expressing Solid Tumors\nNCT07589530 | PHASE1/PHASE2 | REC
 RUITING | sponsor: Beijing Biotech\nPrimary completion date (ESTIMATED)\; 
 top-line results usually follow later.\nSource: https://clinicaltrials.gov
 /study/NCT07589530\nScheduling/reference data from public records\; dates 
 can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07589530
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:987463fa7d547fbc44e1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Beijing Biotech P1/P2 readout (est.): Adaptive Phase 1/2 Study of D
 ual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCL
 C)
DESCRIPTION:Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapse
 d/Refractory Small Cell Lung Cancer (SCLC)\nNCT07744256 | PHASE1/PHASE2 | 
 RECRUITING | sponsor: Beijing Biotech\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nSource: https://clinicaltrials.
 gov/study/NCT07744256\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07744256
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:bffbb45a81d5a5fbea89@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Acerta Pharma BV P3 readout (est.): A Study of BR Alone Versus in C
 ombination With Acalabrutinib in Subjects With Previously Untreated MCL
DESCRIPTION:A Study of BR Alone Versus in Combination With Acalabrutinib in
  Subjects With Previously Untreated MCL\nNCT02972840 | PHASE3 | ACTIVE_NOT
 _RECRUITING | sponsor: Acerta Pharma BV\nPrimary completion date (ESTIMATE
 D)\; top-line results usually follow later.\nSource: https://clinicaltrial
 s.gov/study/NCT02972840\nScheduling/reference data from public records\; d
 ates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT02972840
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d4907eff92d843cb6e73@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Albireo\, an Ipsen Company P3 readout (est.): ASSERT-EXT
DESCRIPTION:Long-term Safety and Efficacy of Odevixibat in Patients With Al
 agille Syndrome\nNCT05035030 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: A
 lbireo\, an Ipsen Company\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nSource: https://clinicaltrials.gov/study/NC
 T05035030\nScheduling/reference data from public records\; dates can move.
  Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05035030
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1fa42300fe97acc018d7@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:ModernaTX\, Inc. P3 readout (est.): Nova 301
DESCRIPTION:A Study to Investigate the Safety and Efficacy of mRNA-1403 in 
 Participants ≥18 Years of Age for the Prevention of Acute Gastroenteriti
 s\nNCT06592794 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: ModernaTX\, Inc
 .\nPrimary completion date (ESTIMATED)\; top-line results usually follow l
 ater.\nSource: https://clinicaltrials.gov/study/NCT06592794\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06592794
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:da2961a7a139d0d3097b@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:CanSino Biologics Inc. P3 readout (est.): A Study to Evaluate the I
 mmunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV1
 3i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
DESCRIPTION:A Study to Evaluate the Immunogenicity and Safety of 13-valent 
 Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (
 Minimum 6 Weeks)\nNCT07017777 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: 
 CanSino Biologics Inc.\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nSource: https://clinicaltrials.gov/study/NCT07
 017777\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07017777
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:72611a5acbf66f5d4896@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Ikaria Bioscience Pty Ltd P1/P2 readout (est.): Phase 1/2a Study to
  Evaluate the Safety\, Tolerability\, Pharmacokinetics\, Pharmacodynamics 
 and Effect on Body Weight of RN3161 as Monotherapy and in Combination With
  Tirzepatide in Adults With Overweight and Obesity
DESCRIPTION:Phase 1/2a Study to Evaluate the Safety\, Tolerability\, Pharma
 cokinetics\, Pharmacodynamics and Effect on Body Weight of RN3161 as Monot
 herapy and in Combination With Tirzepatide in Adults With Overweight and O
 besity\nNCT07245771 | PHASE1/PHASE2 | RECRUITING | sponsor: Ikaria Bioscie
 nce Pty Ltd\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nSource: https://clinicaltrials.gov/study/NCT07245771\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07245771
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2bb3b5e18b1cded517a6@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:BMY P3 readout (est.): A Study of Repotrectinib Versus Crizotinib i
 n Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibit
 or (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-
 3)
DESCRIPTION:A Study of Repotrectinib Versus Crizotinib in Participants With
  Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS
 1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)\nNCT06140836 | P
 HASE3 | ACTIVE_NOT_RECRUITING | sponsor: Bristol-Myers Squibb\nPrimary com
 pletion date (ESTIMATED)\; top-line results usually follow later.\nTicker 
 BMY (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06140836
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06140836
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a5f40d091053b944311f@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:Hangzhou Zhongmei Huadong Pharmaceutical Co.\, Ltd. P3 readout (est
 .): A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in 
 Adults With Type 2 Diabetes Mellitus
DESCRIPTION:A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tabl
 ets in Adults With Type 2 Diabetes Mellitus\nNCT07082114 | PHASE3 | RECRUI
 TING | sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co.\, Ltd.\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nS
 ource: https://clinicaltrials.gov/study/NCT07082114\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07082114
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e4ba6eb5f7e8d50cfe63@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:TAK P2 readout (est.): A Study on the Safety of TAK-279 and Whether
  it Can Reduce Inflammation in the Bowel of Participants With Moderately t
 o Severely Active Crohn's Disease
DESCRIPTION:A Study on the Safety of TAK-279 and Whether it Can Reduce Infl
 ammation in the Bowel of Participants With Moderately to Severely Active C
 rohn's Disease\nNCT06233461 | PHASE2 | RECRUITING | sponsor: Takeda\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nT
 icker TAK (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06
 233461\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06233461
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ece23fd306cbd2d851de@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:SNY P3 readout (est.): CEREN-3
DESCRIPTION:An Extension Study to Investigate the Long-term Safety and Tole
 rability of Itepekimab in Adult Participants With Inadequately Controlled 
 Chronic Rhinosinusitis With Nasal Polyps\nNCT07424144 | PHASE3 | ACTIVE_NO
 T_RECRUITING | sponsor: Sanofi\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nTicker SNY (confidence 0.9)\nSource: h
 ttps://clinicaltrials.gov/study/NCT07424144\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07424144
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7c7230c4a33a67df36f1@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:Beijing Biotech P1/P2 readout (est.): DUAL-OV-CAR-NK
DESCRIPTION:Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN\
 , FRα\, MUC16)\nNCT07480954 | PHASE1/PHASE2 | RECRUITING | sponsor: Beiji
 ng Biotech\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nSource: https://clinicaltrials.gov/study/NCT07480954\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07480954
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ef28db6d51eff94c6fd8@biocat.ai
DTSTAMP:20261118T181352Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:MRK P2 readout (est.): Study to Evaluate Tulisokibart in Adults Wit
 h Psoriatic Arthritis (MK-7240-015)
DESCRIPTION:Study to Evaluate Tulisokibart in Adults With Psoriatic Arthrit
 is (MK-7240-015)\nNCT07486960 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: 
 Merck Sharp & Dohme LLC\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nTicker MRK (confidence 0.6)\nSource: https://
 clinicaltrials.gov/study/NCT07486960\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07486960
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
